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Abstract 
Varicella Zoster Virus (VZV) is responsible for two clinically distinct diseases; 
varicella (or chickenpox) during primary infection, and herpes zoster (or shingles) 
following reactivation. Herpes zoster involves active viral replication within the dorsal 
root ganglia (DRG), as well as in the innervated skin. Post-herpetic neuralgia (PHN) 
is the most common complication of herpes zoster. During PHN patients experience 
intense persisting pain generally in the same distribution as the original herpes zoster 
rash. There is very little known about the underlying pathology and pathogenesis of 
PHN.  
One of the main reasons underlying this lack of understanding is the high species-
specificity of VZV; animal and in vitro models are quite limited and study requires 
suitable human tissue. Previous studies involving limited histological examinations 
have revealed the presence of an immune infiltration and general cell loss within the 
DRG innervating the affected area. Our laboratory gained access to rare DRG 
samples that were surgically-excised from a PHN-affected patient in an attempt to 
control their pain. Additionally we have obtained DRG samples obtained at post-
mortem examination from herpes zoster-affected patients and normal control 
patients. This has provided a unique opportunity to perform a detailed 
characterisation of the immune response to the virus within human sensory ganglia, 
as well as investigate viral gene expression and viral genome levels within the 
samples. An immune infiltration was detected in the PHN-affected patient material, 
and was composed of both CD4+ and CD8+ T cells with cytolytic potential, as well as 
B cells. Immunofluorescent investigation did not demonstrate any viral gene 
expression within the tissue, however molecular techniques showed that the VZV 
genome was present in the PHN-affected ganglia material at a level approximately 
seven-fold greater than that seen in a ganglion obtained from a patient with an active 
herpes zoster rash at the time of death. 
In both primary infection and reactivation, VZV infection involves a similar 
exanthematous stage, and skin lesions are histopathologically indistinguishable from 
each other. However our understanding of the immune response in the skin during 
PHN is very limited. We obtained skin biopsy material from PHN-affected and control 
patients at least 6 months post-resolution of their herpes zoster-affected rash. This 
allowed the detailed examination of dendritic cell and T cell subsets present within 
the skin biopsy material of both patient types to identify any factors that may 
 The University of Sydney 
- iii - 
predispose an individual to ongoing pain or resolution. The skin material from the 
PHN-affected patients contained a greater number of the immune cell subsets 
examined. Yet, there was no VZV antigen expression detected within these tissue 
samples. 
We also gained access to an extensive tissue bank comprised of skin biopsies 
obtained from patients following diagnosis of herpes zoster. Each patient was 
followed for at least 6-12 months, and at each visit a biopsy was taken from the most 
painful area of skin and clinical details recorded. This tissue material was utilised in 
blinded immunofluorescent assays to identify different subsets of dendritic cells and 
T cells. There was no VZV antigen expression identified within this tissue material, 
however when biopsies were taken lesions were avoided. Different T cell and 
dendritic cell subsets were examined over time, and matched with the patients’ 
clinical histories in order to identify any factor that may correlate with reported pain 
quality and levels. Despite investigating multiple factors and cell types there was no 
marker identified that predisposed to ongoing pain or a prompt recovery. 
Overall this thesis provides the first evidence of an ongoing chronic inflammatory 
process consisting predominantly of both CD4+ and CD8+ T cells within DRG from a 
PHN-affected patient many years post resolution of the herpes zoster rash. Within 
this chronically inflamed tissue, there is a large amount of VZV-specific DNA. In stark 
contrast to this, there does not seem to be any ongoing immunohistological process 
within the skin of patients post-herpes zoster. These findings have increased our 
knowledge on the immune reaction within human ganglia and skin following herpes 
zoster and during PHN and suggest that the best immune correlates of VZV diseases 
arising from VZV reactivation in ganglia are those that occur within the affected DRG 
rather than those that occur at cutaneous sites. 
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Chapter 1 - Literature review 
1.1 The Herpesviridae family 
The Herpesviridae family is a large ubiquitous group of viruses, with most animal 
species serving as possible hosts for at least one Herpesviridae family member 
(Pellett and Roizman, 2007). Viruses in this family rarely infect more than one 
species, but cause a broad range of diseases in their hosts. To date there have been 
more than 130 members of this family identified (Pellett and Roizman, 2007), with 8 
known to infect humans. These are termed human herpesviruses (HHVs), and 
include Herpes Simplex virus 1 (HSV-1) or HHV-1, Herpes Simplex virus 2 (HSV-2) 
or HHV-2, Varicella Zoster virus (VZV) or HHV-3, Epstein-Barr virus (EBV) or HHV-4, 
Human Cytomegalovirus (HCMV) or HHV-5, HHV-6, HHV-7 and Kaposi’s sarcoma-
associated herpesvirus (KSHV) or HHV-8 (Pellett and Roizman, 2007). 
1.1.1 Properties of Herpesviridae 
All Herpesviridae family members share a common virion structure and a broad set 
of biological properties. Herpesviruses encode a wide range of viral enzymes 
involved in nucleic acid metabolism, DNA synthesis, and protein processing 
(Roizman and Baines, 1991). Viral DNA synthesis and capsid assembly occurs in the 
nucleus of infected cells, and virions are enveloped as they are released from the 
nucleus (Roizman and Baines, 1991, Pellett and Roizman, 2007). However it is not 
known whether there is an initial de-envelopment and re-envelopment as the virion 
moves through the cell, or if it remains enveloped throughout the process (Pellett and 
Roizman, 2007). Herpesviruses all have a lytic infection cycle, which includes the 
production of infectious progeny and the subsequent destruction of the infected cell. 
They also have the ability to establish a life-long latent infection in their natural hosts. 
Within latently infected cells the viral genome takes a closed circular structure, there 
is limited viral gene expression and the virus retains the capacity to reactivate (Pellett 
and Roizman, 2007).  
Viruses are included in this family based on the architecture of their virions. A typical 
herpesvirus virion consists of a linear double stranded DNA (dsDNA) core, 
surrounded by an icosadeltahedral capsid consisting of 162 capsomeres and is 
approximately ~110 nm in diameter (Figure 1.1). Between the envelope and capsid 
there is an amorphous protein layer known as the tegument. The tegument has no 
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distinctive features, but may appear fibrous in negative staining (Pellett and 
Roizman, 2007). The virus is enclosed in an envelope containing glycoprotein spikes, 
and viral particles are between 180-300 nm in diameter (Pellett and Roizman, 2007). 
1.1.2 Classification of Herpesviridae 
Herpesviridae family members are further classified into three subfamilies according 
to biological properties, replication efficiency, cytopathology and characteristics of 
latent infection (Roizman, 1979, Anonymous, 1973). These subfamilies are 
Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae. 
1.1.2.1 ALPHAHERPESVIRINAE 
Members of the Alphaherpesvirinae subfamily characteristically have a relatively 
short replication cycle, spread rapidly in cell culture, and efficiently destroy infected 
cells during lytic infection. These viruses have the ability to establish latency primarily 
in sensory ganglia (Croen et al., 1988, Roizman and Baines, 1991). Examples of 
human herpesviruses classified in this subfamily are the herpes simplex viruses and 
varicella zoster virus. 
1.1.2.2 BETAHERPESVIRINAE 
Viruses in the Betaherpesvirinae subfamily have a restricted host range, with a long 
replication cycle and slow spread in cell culture. Cells infected with these viruses 
frequently become enlarged due to cell-to-cell fusion (Pellett and Roizman, 2007). 
Latency is established in tissues such as secretory glands, kidneys, lymphoreticular 
cells and some myeloid progenitor cells (Bevan et al., 1993, Pellett and Roizman, 
2007, Slobedman et al., 2010). Examples of human herpesviruses in this subfamily 
are HCMV and HHV-7. 
1.1.2.3 GAMMAHERPESVIRINAE 
Members of the Gammaherpesvirinae are classified according to a tropism for 
replication and latency in lymphoblastoid cells. Although some members have a lytic 
cycle in epithelial and fibroblastic cell types, viruses in this group are generally 
specific for either T or B lymphocytes. This allows further classification of this 
subfamily into gamma-1 (γ-1) and gamma-2 (γ-2) subfamilies, depending on tropism 
for T or B lymphocytes respectively. Included in this subfamily are EBV and KSHV; 
EBV has the ability to immortalise infected cells in vitro, and has been associated 
with Hodgkin’s lymphoma and Burkitt’s lymphoma, while KSHV commonly causes 
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Kaposi’s sarcoma in immunocompromised individuals (Landais et al., 2005, 
Rickinson and Moss, 1997, Speck and Ganem, 2010).  
 
1.2 Varicella Zoster Virus 
Varicella Zoster Virus – also called HHV-3, is a human herpesvirus that belongs to 
the alphaherpesvirinae subfamily. It is the only member of the Varicellovirus genus 
known to infect humans (Arvin and Gilden, 2007). Primary infection causes varicella 
(or chickenpox), and reactivation from latency results in herpes zoster (shingles).  
1.2.1 The virion and viral genome 
The VZV virion structure follows the general characteristics of all herpesviruses. It 
consists of four main components; a linear dsDNA genome core enclosed within 
three layers: a nucleocapsid, a tegument, and outermost an envelope with protruding 
viral glycoprotein spikes (Figure 1.1).  
The VZV core consists of a linear dsDNA genome of around 125 000 base pairs (bp) 
in length (Arvin and Gilden, 2007). The complete sequence was published in 1986 by 
Davison and Scott, and was found to consist of two joined segments known as Long 
(L) and Short (S) (Figure 1.2) (Davison and Scott, 1986). The L segment is 
comprised of a unique long region (UL) (around 105 000 bp) which is flanked by two 
inverted repeat regions; terminal repeat long (TRL) and internal repeat long (IRL) 
(both 88.5 bp in length). The S segment is comprised of a unique short region (US) 
(around 5 232 bp) flanked by two internal repeat regions; terminal repeat short (TRS) 
and inverted repeat short (IRS) (each 7 319.5 bp in length) (Arvin and Gilden, 2007, 
Davison and Scott, 1986, Ecker and Hyman, 1982). The VZV genome contains at 
least 71 unique open reading frames (ORFs), three of which are present as 
duplicates in the IRS and TRS regions (Arvin and Gilden, 2007). The duplicated genes 
are ORF62, ORF63 and ORF64, which are also present as ORF71, ORF70 and 
ORF69 respectively (Arvin and Gilden, 2007). 
The VZV nucleocapsid contains the viral genome, and is indistinguishable in 
appearance from that of other herpesviruses. Electron micrographs have shown a 
structure of 162 capsomeres with a 5:3:2 axial symmetry. In this icosohedron 
structure of 80-120 nm, pentameric proteins form the vertices and hexameric 
elements comprise its facets (Arvin and Gilden, 2007). 

 The University of Sydney 
- 4 - 
The nucleocapsid is surrounded by the tegument; an amorphous material with no 
distinctive features. It does contain several major transcriptional regulatory proteins, 
including proteins encoded by ORFs 4, 47, 62 and 63 (Kinchington et al., 1995, 
Kinchington et al., 1992, Stevenson et al., 1994). 
Enveloped VZV virions are usually spherical in shape, and range from 180-200 nm in 
diameter (Arvin and Gilden, 2007) (Figure 1.3). The viral envelope consists of 
patches of host cell membranes modified to display virally encoded glycoproteins 
(Arvin and Gilden, 2007). The virus passes through various cellular organelles during 
maturation and consequently the exact origin of this envelope is unknown (Achong 
and Meurisse, 1968, Wang et al., 2001, Zhu et al., 1995b). The displayed 
glycoproteins each have a homologous glycoprotein on the HSV-1 virion (Litwin et 
al., 1992), and are the major antigenic determinants of the VZV virion in antibody 
responses (Arvin and Gilden, 2007). 
1.2.2 Replication of Varicella Zoster Virus  
1.2.2.1 VIRION ATTACHMENT AND ENTRY 
The VZV replication cycle begins with attachment of the virion to the host cell. Like 
other herpesviruses this is thought to occur by fusion of the viral envelope with the 
cytoplasmic membrane (Arvin and Gilden, 2007). Initial contact between the virion 
and host cell occurs via non-specific electrostatic interactions between viral 
glycoproteins present in the virion envelope and cellular glycosaminoglycans (such 
as heparin sulphate) (Zhu et al., 1995a). VZV glycoprotein B (gB) has been 
implicated in this stage of viral entry (Jacquet et al., 1998). Following these initial low-
affinity interactions, the VZV virion engages specific cell-surface receptors, two of 
which have been potentially identified, to strengthen virion attachment to the host 
cell. The cation-independent mannose-6-phosphate receptor (MPRci) has been found 
to interact with phosphorylated N-linked complex oligosaccharides, which are present 
on some viral glycoproteins, and works to facilitate infection of stable cell lines with 
cell-free VZV. However this receptor does not mediate cell-to-cell spread of the virus 
(Arvin and Gilden, 2007, Zhu et al., 1995a).  
The second proposed VZV-specific cell-surface receptor is the insulin degrading 
enzyme (IDE), which has been shown to facilitate both cell-associated and cell-free 
VZV infection in a range of cell types (Li et al., 2006). This is thought to occur 
through IDE interacting with glycoprotein E (gE), which has been found to be an 
essential glycoprotein in VZV infection (Li et al., 2006). Furthermore gE residues 24-
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71 were shown to be required for IDE binding, and the native secondary structure is 
also important (Li et al., 2007). However more recently it was found that IDE bound 
the precursor form of the gE protein rather than the mature membrane-associated 
form. Consequently the IDE:gE interaction is more likely an interaction that occurs 
within the cytosol of already infected cells rather than a receptor/ligand interaction 
that occurs during virion attachment (Carpenter et al., 2010). In a cell-free VZV 
model of infection virion entry occurs in a cholesterol-dependent manner, and may 
undergo receptor-mediated endocytosis (Hambleton et al., 2007). 
1.2.2.2 VIRAL GENE EXPRESSION  
Following VZV entry into the host cell, the virion uncoats and the nucleocapsid and 
tegument proteins are transported into the nucleus. This results in the release of the 
viral genome, and the initiation of VZV gene expression. This is presumed, like other 
herpesviruses, to occur in a highly regulated and ordered cascade. The 71 ORFs 
encoded in the VZV genome can be divided into three distinct groups based on their 
expression patterns and timing requirements (Honess and Roizman, 1974). These 
groups are the immediate early (IE or α), early (E or β) and late (L or γ) genes.  
The first viral proteins to be expressed are the IE proteins. These act as major 
transcription regulators for both the early and late genes (Hambleton and Gershon, 
2005). Three different IE proteins that are present in the viral tegument are encoded 
by ORF4, ORF62 and ORF63 (Debrus et al., 1995, Defechereux et al., 1997, 
Forghani et al., 1990b), and are homologous to the HSV-1 IE genes infected cell 
protein (ICP) 27, ICP4 and ICP22 respectively (Arvin and Gilden, 2007). A fourth, 
ORF61, is not a component of the viral tegument, but is homologous to the HSV-1 IE 
gene ICP0 (Arvin and Gilden, 2007), and newly synthesised IE61 protein can be 
detected along with IE62 as early as 1 hour post-infection (Reichelt et al., 2009).  
The predominant IE protein is IE62, which is the major transcriptional regulatory 
protein. IE62 is derived from transcripts of both ORF62 and ORF71, which are 
located in the inverted repeat section of the US region (Davison and Scott, 1986). 
During infection of a permissive host cell, IE62 localises primarily within the nucleus. 
However co-expression with ORF66 protein results in cytoplasmic accumulation, 
which is observed late in the VZV infection cycle (Kinchington et al., 2000). IE62 has 
the capacity to transactivate many VZV genes from all three kinetic classes 
(Kinchington et al., 1992), and is required for both cell-to-cell spread in vivo, as 
shown in the human skin tissue xenografts in the severe combined 
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immunodeficiency (SCID) mouse model (or SCID-hu model), and for VZV replication 
in vitro (Sato et al., 2003a). 
The exact function of IE63 is less clear although it has been shown to be important in 
maintaining viral virulence. ORF63 is required for growth in cell culture and ORF63 
mutants were either non-virulent or had reduced virulence in the SCID-hu skin 
model, but mutations had no effect on replication in the SCID-hu T cell model (Baiker 
et al., 2004a, Sommer et al., 2001). IE63 has been shown to be part of the viral 
tegument (Kinchington et al., 1995). IE63 is located primarily within the nucleus 
during productive infection, however early in the infection it is found in both the 
nucleus and cytoplasm (Arvin and Gilden, 2007). IE63 has been shown to interact 
with IE62 to upregulate the transactivation of the VZV glycoprotein promoter, and 
may also interact with the cellular RNA polymerase (Lynch et al., 2002). ORF63 may 
also encode an anti-apoptotic factor and has been shown to protect neurons from 
apoptosis in vitro (Hood et al., 2006). Furthermore IE63 is the most prevalent and 
abundant transcript observed in latently infected human ganglia (Cohrs and Gilden, 
2007).  
ORF4 encodes another IE protein, which is predominantly located in the cytoplasm 
of infected cells, however on co-expression with IE62, it is primarily located within the 
nucleus (Defechereux et al., 1996). ORF4 protein has also been shown to be part of 
the viral tegument (Kinchington et al., 1995). ORF4 is an essential viral gene, as 
deletion has been shown to result in the loss of infectious virus (Sato et al., 2003b), 
and the protein product has also been shown to dimerise and transactivate other viral 
genes (Defechereux et al., 1997, Sato et al., 2003b).  
Following the expression of functional IE proteins, E genes are expressed, and 
traditionally peak expression is thought to occur 5-7 hours post-infection (Honess 
and Roizman, 1974), however more recent work has shown it occurs much earlier 
(Reichelt et al., 2009). E genes primarily encode enzymes and transcription factors 
important for viral DNA replication and phosphorylation, and nucleotide metabolism 
(Kinchington and Cohen, 2000). The E gene ORF28 encodes the large subunit of the 
viral DNA polymerase, and ORF16 is believed to encode the small subunit (Arvin and 
Gilden, 2007, Davison and Scott, 1986). This enzyme complex is required for viral 
DNA replication (Arvin and Gilden, 2007). Other viral enzymes essential for 
replication are the single-stranded DNA binding protein (encoded by ORF29) and the 
origin binding protein (encoded by ORF51) (Kinchington et al., 1988, Stow et al., 
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1990). The protein encoded by ORF29 has a predominantly nuclear localisation 
within productively infected cells (Kinchington et al., 1988).  
Other important E proteins are encoded by ORF36 (viral thymidine kinase); ORF18 
and ORF19 (ribonucleotide reductase); and ORF47 and ORF66 (two different 
serine/threonine protein kinases) (Davison and Scott, 1986, Mahalingam et al., 1990, 
Smith and Smith, 1989).  
The protein product of ORF47 has a cytoplasmic localisation in VZV-infected cells, 
and is a component of the virion capsid and tegument (Stevenson et al., 1994). 
ORF47 is essential for virus replication in human dendritic cells and human T cells, 
and for spread to other cells in vitro (Hu and Cohen, 2005, Sato et al., 2003c). 
ORF47 is also required for replication in human skin (Moffat et al., 1998b). Targeted 
ORF47 mutations have shown that a functional ORF47 protein kinase is required for 
replication and cell-to-cell spread in human skin in vivo, however this may involve 
some interaction between the ORF47 and IE62 proteins (Besser et al., 2003). More 
recently, ORF47 protein has been shown to interfere with innate immune responses 
by inhibiting the activation of the interferon regulatory factor 3, and functions to 
regulate many viral proteins throughout the infection cycle (Vandevenne et al., 2011, 
Kenyon and Grose, 2009). 
Another component of the virion capsid and tegument is the ORF66 protein, which is 
also located within the cytoplasm of virally infected cells (Stevenson et al., 1994). 
The protein product of ORF66 can phosphorylate IE62, which inhibits its 
translocation to the nucleus (Kinchington et al., 2000). ORF66 protein has also been 
implicated in the downregulation of the major histocompatibility complex (MHC) class 
I expression in VZV-infected human fibroblasts (Abendroth et al., 2001a, Eisfeld et 
al., 2007), suggesting the gene product plays a central role in immune evasion 
strategies employed by the virus. ORF66 protein expression is required for 
phosphorylation of the essential nuclear matrix protein matrin 3 at a unique site, 
affecting its cellular localisation throughout the infection cycle (Erazo et al., 2011). 
The final class of viral genes to be expressed in the VZV replication cycle are the L 
genes. L gene expression depends on prior protein expression from the IE and E 
genes (Honess and Roizman, 1974). L genes predominantly encode major structural 
proteins, including components of the tegument and nucleocapsid, as well as the 
viral glycoproteins. Examples of L genes include ORF33.5, ORF33, ORF40, ORF21 
and ORF10, as well as the glycoproteins (Arvin and Gilden, 2007). 
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ORF33.5 encodes an assembly protein which is thought to act as a scaffolding 
protein for nucleocapsid assembly, and is located in the 3’ region of ORF33 
(McMillan et al., 1997). The major constituents of the nucleocapsid are encoded by 
the ORF21 and ORF40 genes (Mahalingam et al., 1998, Vafai et al., 1990). The 
ORF10 gene product forms part of the viral tegument (Kinchington et al., 1992), and 
is important for viral virulence (Moriuchi et al., 1993). 
There have been 8 VZV glycoproteins identified to date (Storlie et al., 2008b). The 
most abundant is gE, which is encoded by ORF68 (Montalvo et al., 1985). gE is 
required for VZV replication, and has been shown to induce tight junction formation in 
epithelial cells, and hence increase cell-to-cell contact (Mo et al., 2002, Mo et al., 
2000). As well as the monomeric and dimeric forms, gE is also found as a 
heterodimer with either glycoprotein I (gI) on infected cells (Kimura et al., 1997) or 
glycoprotein H (gH) on VZV virions (Maresova et al., 2005). The gE:gI complex is 
formed through a cysteine rich region, the loss of which has been shown to 
differentially affect cell-to-cell spread and viral entry (Berarducci et al., 2009). 
Although generally considered a L gene product, one recent study found that gE 
accumulated in the Golgi apparatus as early as 4 hours post-infection (Reichelt et al., 
2009). Unlike the HSV homologue, VZV gE appears to play an important role in 
regulating membrane fusion and syncytial formation (Reviewed in Cole and Grose, 
2003, Pasieka et al., 2004). Interestingly there have been gE-mutant viruses isolated 
from clinical cases (Santos et al., 1998, Tipples et al., 2002), and these viruses show 
accelerated spread in both cell culture and the SCID-hu mouse model (Santos et al., 
2000). The N-terminal region of gE has been shown to be important for infection in 
skin and T cell models (Berarducci et al., 2010). 
While gE is indispensable for VZV replication in vitro, gI, encoded by ORF67, has 
been shown to be dispensable in some cell types (Mallory et al., 1997). However 
mutations in or deletions of gI resulted in disrupted syncytium formation, and altered 
conformation and distribution of gE in infected cells, which may indicate that gI 
assists in the cell-to-cell spread of the virus in vitro (Mallory et al., 1997). While gI is 
dispensable for viral infection of human melanoma cells (Cohen and Nguyen, 1997), 
it is essential for viral replication in human skin and T lymphocytes as shown in the 
SCID-hu mouse model (Moffat et al., 2002). Other investigations using the SCID-hu 
mouse model have shown a gI-deletion mutant virus failed to establish a persistent 
infection in human dorsal root ganglia (DRG) xenografts in the SCID-hu mouse 
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model, suggesting that gI is required for the establishment of latency in vivo (Zerboni 
et al., 2007).  
Glycoproteins C (gC) and K (gK), encoded by ORF14 and ORF5 respectively, have 
also been shown to be important in viral replication (Mo et al., 1999, Moffat et al., 
1998a). gC is dispensable for growth in cell culture (Cohen and Seidel, 1994). 
However it is important for virus growth in skin implants in the SCID-hu mouse model 
(Moffat et al., 1998a). gC expression levels on VZV-infected cells varies between 
different viral strains (Kinchington et al., 1990). Interestingly limited gC expression 
occurs within the first 48 hours of infection, while other glycoproteins are easily 
detectable within 24-48 hours (Storlie et al., 2008a). Partial and full deletions in gK 
using the VZV cosmid system were shown to prevent viral replication in melanoma 
cell lines (Mo et al., 1999). 
gB, encoded by ORF31, is the second most abundant viral glycoprotein (Arvin and 
Gilden, 2007), and an epitope within gB induces a neutralising antibody response 
(Forghani et al., 1990a). Recombinant gB has the ability to bind cellular heparin 
sulfate proteoglycans, and the recombinant protein delays the virion entry into cells 
(Jacquet et al., 1998). Consequently it is thought to be important in virion attachment 
and entry into host cells (Vafai et al., 1984).  
gH is encoded by ORF37, and is the third most abundant glycoprotein (Arvin and 
Gilden, 2007). Neutralisation of gH via a monoclonal antibody obstructs VZV entry, 
cell-to-cell spread, and the transport of virions out of infected cells (Ito et al., 1993, 
Rodriguez et al., 1993). In addition, prophylaxis treatment with an anti-gH antibody in 
the SCID-hu mouse skin xenograft model results in significantly reduced VZV 
replication in skin (Vleck et al., 2010). Endocytosis induced by gH has been shown to 
play an important role in facilitating fusion of virally infected cells (Pasieka et al., 
2004). Treatment of VZV-infected human embryonic lung cell cultures with an anti-
gH neutralising antibody prevented the spread of virus within the cultures, and 
resulted in a latent-like state with restricted viral gene expression within infected cells 
(Shiraki et al., 2011). Specific domains of gH have been shown to play critical roles in 
viral fusion and skin tropism (Vleck et al., 2011). 
When co-expressed with gH, glycoprotein L (gL), encoded by ORF60, has the ability 
to facilitate syncytia formation (Cole and Grose, 2003, Duus et al., 1995), and gL 
may act as a chaperone for gH allowing for complete maturation and expression on 
the cell surface (Duus and Grose, 1996). 
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Glycoprotein M (gM), encoded by ORF50, has only recently been characterised, and 
although it is dispensable for viral growth, it is important for efficient cell-to-cell 
spread in cell culture (Yamagishi et al., 2008, Sadaoka et al., 2010).  
1.2.2.3 VIRION ASSEMBLY AND RELEASE 
The L genes are the final class to be expressed in the VZV infection cycle, and the 
replication cycle within a cell is completed within 9-12 hours (Reichelt et al., 2009). At 
this stage in the infection cycle, VZV DNA that has been previously replicated is 
packaged into capsids, transported out of the nucleus, and acquires an envelope. 
The origin of this envelope is unknown, as virions progress through various cellular 
organelles during maturation and egress from the cell (Achong and Meurisse, 1968, 
Wang et al., 2001, Zhu et al., 1995b). It appears that there is an initial envelopment 
at the nuclear membrane and subsequent de-envelopment in the cytoplasm, with the 
final envelopment occurring in the trans Golgi network (Gershon et al., 1994). The 
glycoproteins produced during L gene synthesis are incorporated into the virion 
envelope during maturation, and assembled virions are released from the cell (Cook 
and Stevens, 1970).  
The assembly and release of virions has not been well characterised in vivo, 
however infectious progeny virions are released into aerosols and vesicular fluids, 
serving to facilitate infection of other susceptible hosts (Ozaki et al., 1996). In 
contrast, VZV infection in cultured cells is highly cell-associated (Taylor and Moffat, 
2005). To date, there are only two cell types known to release infectious progeny in 
vitro when infected with VZV – explanted human fetal dorsal root ganglia (DRG) 
(Gowrishankar et al., 2007) and human embryonic stem cell-derived neuron cultures 
(Markus et al., 2011). 
VZV infection of cells in vitro results in relatively low titres compared to other 
alphaherpesviruses such as the herpes simplex viruses. Early examinations of VZV-
infection cell cultures suggested that VZV virions featured an envelope that broke 
down on virion exit from the nucleus (Cook and Stevens, 1968). More recent work 
has examined the egress of VZV virions within infected cells in culture (Carpenter et 
al., 2008), and found that there may be a large dissociation between capsid 
development and viral envelopment, which could result in these relatively low viral 
titres. 
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1.2.3 Clinical features of VZV infection 
Primary VZV infection manifests as the generalised exanthematous disease of 
varicella (chickenpox) (Figure 1.4). Early symptoms which can precede the 
appearance of the rash by up to 48 hours include fever, malaise, headache and 
abdominal pain (Arvin and Gilden, 2007). The rash begins as maculopapular lesions 
that quickly become fluid-filled vesicles, and then become pustular and crust over 
within 2-3 days (LaGuardia and Gilden, 2001). Typically the rash first appears on the 
face and scalp, followed by the trunk and extremities (Cohen et al., 1999).The fluid 
within the vesicles contains infectious virus, which may serve as a source of viral 
transmission to other susceptible hosts who come in direct contact (Weller, 1953). 
After the appearance of the rash, common symptoms include fever, anorexia and 
listlessness. Varicella in the immunocompetent host is a mild disease, with lesion 
formation ceasing within 7 days (LaGuardia and Gilden, 2001). However 
complications can include secondary bacterial infections – particularly by 
Streptococcus pyogenes and Staphylococcus aureus, as well as pneumonia and 
central nervous system involvement, resulting in a more severe and potentially life-
threatening condition (Fleisher et al., 1981, Heininger and Seward, 2006). 
Immunocompromised patients are also more susceptible to prolonged lesion 
formation and other more severe forms of secondary infections, including 
pneumonia, encephalitis and even death (Balfour, 1988, Jantsch et al., 2011). 
Herpes zoster (shingles) is a clinically distinct disease caused by VZV. It is an 
exanthematous condition which results from the reactivation of endogenous latent 
VZV (Figure 1.5). Although the lesions are histopathologically indistinguishable from 
varicella (Oxman, 2000), the restricted distribution of the rash seen in herpes zoster 
distinguishes it from primary VZV infection. The herpes zoster rash is generally 
restricted to one dermatome, although it may spread up to three (one above and one 
below the affected area) in the immunocompetent host (Cohen et al., 1999). This 
reflects the intraneural spread of virus to the skin, rather than the general viremia that 
occurs in varicella (Oxman, 2000). The herpes zoster rash is usually preceded by 
and always accompanied with severe neuropathic pain within the same distribution 
(Cohen et al., 1999, Haanpaa et al., 1999), while other symptoms include fever, 
chills, malaise and gastrointestinal disturbances (Arvin and Gilden, 2007). Greater 
prodromal pain has been associated with a high viral load (Quinlivan et al., 2007). In 
some cases the severe pain persists for months to years following the resolution of 
the herpes zoster rash (Cohen et al., 1999, Steiner et al., 2007). This is called post-
herpetic neuralgia (PHN), and is the most common and debilitating complication 
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associated with herpes zoster (Hope-Simpson, 1965, Hope-Simpson, 1975, Steiner 
et al., 2007). PHN will be discussed in more detail in section 1.5. 
Other common conditions which may result from VZV reactivation include Ramsay 
Hunt Syndrome (RHS) and Bell’s palsy (or idiopathic peripheral facial palsy). RHS is 
a peripheral facial nerve palsy and is usually accompanied by a vesicular rash on the 
ear or in the mouth (Gilden et al., 2010), and has been associated in some patients 
with a rise in VZV-specific antibody titres and the presence of VZV DNA in skin, 
saliva and blood mononuclear cells (MNCs) (Hato et al., 2000, Murakami et al., 
1998). Similarly it has been found that some cases of Bell’s palsy are also 
accompanied with seroconversion to VZV and the presence of VZV DNA in blood 
MNCs (Morgan and Nathwani, 1992, Terada et al., 1998). 
There are other less common complications of VZV infection. For example VZV can 
productively infect the large and small cerebral arteries resulting in vasculopathy, 
where the virus is detectable within the affected arteries (Gilden et al., 1996, Salazar 
et al., 2011). Patients commonly present with headache, fever, and change in mental 
status, and the condition may ultimately result in stroke (Mueller et al., 2008).  
VZV can also cause myelitis, with two distinct clinical presentations. The first is a 
self-limiting condition known as “postinfectious myelitis”. This usually occurs in 
immunocompetent individuals days to weeks after primary VZV infection or 
reactivation (Gilden et al., 1994a, Rosenfeld et al., 1993). The second is a 
progressive and sometimes fatal myelitis which is often seen in immunocompromised 
individuals, and is most commonly associated with acquired immunodeficiency 
syndrome (AIDS) (Chang et al., 2009, Lionnet et al., 1996, Manian et al., 1995). 
VZV is also associated with two common clinical forms of necrotising retinitis: acute 
retinal necrosis (ARN) and progressive outer retinal necrosis (PORN). ARN is more 
likely to be HSV-related (Tan et al., 2001, Thompson et al., 1994, Soushi et al., 
1988), and can occur in both immunocompetent and immunocompromised 
individuals, while PORN is caused almost exclusively by VZV (Engstrom et al., 1994) 
and is most common in AIDS patients with very low CD4+ T cell counts (Guex-
Crosier et al., 1997). VZV is also the main pathogen that is associated with many 
atypical necrotising retinopathies (Garweg and Bohnke, 1997). 
Other complications include intractable itching, often complicated by the lack of other 
feeling within the affected area, termed post-herpetic itch (Oaklander, 2008, 
Oaklander et al., 2002, Oaklander et al., 2003, Semionov and Shvartzman, 2008). 
 The University of Sydney 
- 13 - 
Another complication is poliosis, or the depigmentation of hair, which has also been 
described in other inflammatory conditions (Wu et al., 2006).  
Other clinical diseases caused by VZV include varicella in pregnancy, disease in the 
immunocompromised and newborn, congenital infections, varicella encephalitis and 
varicella vasculitis (Arvin and Gilden, 2007). 
1.2.4 Epidemiology 
VZV is a ubiquitous human pathogen, and has a world-wide geographic distribution. 
Restriction enzyme digests of VZV DNA isolated from unrelated clinical patients have 
shown epidemiologically related and unrelated isolates (Quinlivan et al., 2002), with 
comparative genome analysis showing polymorphisms within the glycoproteins that 
differentiate between strains present in different regions of the world (Storlie et al., 
2008b). These different viral strains have very similar virulence and prevalence 
(Takayama et al., 1989).  
In most temperate climates more than 90% of the population are infected with VZV 
before adolescence (Fairley and Miller, 1996), while in tropical climates only half of 
those under 24 years old have been exposed (Mandal et al., 1998). This may be due 
to climate, social conditions, or a combination of factors, but the varicella infection 
rate is very high when susceptible individuals move from tropical to temperate zones 
(Ooi et al., 1992). The annual incidence of varicella in the United States has been 
estimated at 3.5 million cases per year (Arvin, 1996), however due to the introduction 
of a widespread vaccination program the incidence in some areas has decreased by 
up to 90% (Guris et al., 2008). In Australia, there are 0.19 cases of congenital 
varicella per 100 000 live births per annum (Khandaker et al., 2011). Although 
varicella is usually a benign disease, it has been estimated that in Australia, there 
was an average of 7 deaths and 1100 hospitalisations due to varicella per year 
(McIntyre et al., 2002). VZV causes annual epidemics of varicella, especially in 
temperate regions during the late winter and spring. These probably begin with 
sporadic cases in children exposed to reactivated VZV in adults. Years of higher 
incidence of varicella are generally followed by periods where few cases occur (Choo 
et al., 1995, Wharton, 1996). 
There is an estimated 1 million cases of herpes zoster per year in the United States 
(Weaver, 2007). In Australia the incidence of herpes zoster disease and 
complications are comparable to that seen in the United States (Araujo et al., 2007). 
Specifically, it is estimated to be up to 8.3 cases per 1000 people, with around      
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159 000 cases of herpes zoster in 1999 alone (MacIntyre et al., 2003). Susceptibility 
to herpes zoster is governed by a previous varicella infection. Thus given the high 
percentage of the population who have had varicella, most people are at risk of VZV 
reactivation and herpes zoster. Herpes zoster is very rare in childhood – occurring at 
a rate of 1.6 cases per 1000 people per year in children and adolescents up to 19 
years old (Petursson et al., 1998). In Australia, neonatal herpes zoster occurs at a 
rate of 2.0 cases per 100 000 lives births per annum (Khandaker et al., 2011). One 
risk factor for the development of herpes zoster at an early age is a primary varicella 
infection during the first year of life or intrauterine infection with varicella (Baba et al., 
1986, Guess et al., 1985, Takayama et al., 2000). Herpes zoster is more common in 
individuals older that 45 years, with the risk of virus reactivation increasing with the 
individual’s age (Brisson et al., 2001, Hope-Simpson, 1965, Ragozzino et al., 1982). 
It has been estimated that by age 70, the risk of developing herpes zoster is around 
five times that of middle age, and twelve times that of a child under 10 years old 
(Hope-Simpson, 1967). Rates of herpes zoster recurrence have been shown to be 
comparable to the incidence of initial herpes zoster reactivation, however recurrence 
is higher in women and anyone aged over 50 (Yawn et al., 2011). New cases of 
herpes zoster are diagnosed evenly throughout the year, with no seasonal variation 
at all (Hope-Simpson, 1965). The incidence of herpes zoster is increased in 
immunocompromised patients such as those with HIV, leukaemia or following bone 
marrow or renal transplants (Balfour, 1988). These clinical observations suggest that 
VZV reactivation and herpes zoster is associated with a decrease in cell-mediated 
immunity. 
The most common neurological complication of herpes zoster is PHN (Kost and 
Straus, 1996), and is reported to be the third most common cause of neuropathic 
pain in the United States (Bennett, 1998). Despite regional differences, the 
epidemiology of PHN in Australia are comparable with those seen in the United 
States (Araujo et al., 2007). PHN lasting between 4 weeks to 10 years occurs in 
around 10% of all herpes zoster patients (Ragozzino et al., 1982). Pain lasting longer 
than 1 month accounts for up to 10% of all herpes zoster encounters with primary 
care physicians, with over 90% requiring prescribed treatment (Conway et al., 2006). 
Another more recent study found that 19.5% and 13.7% of patients experienced PHN 
to some degree at 1 and 3 months after diagnosis with herpes zoster (Gauthier et al., 
2009). The age of onset of herpes zoster closely correlates with the incidence of 
PHN (Arvin, 1996). Studies have shown the risk of herpes zoster developing into 
PHN ranges from 43 to 47.5% in patients over 50 years (Brown, 1976, De Moragas 
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and Kierland, 1957), while for patients 30-49 years of age the risk is under 4% 
(Hope-Simpson, 1965). The incidence increases dramatically with age, and more 
than one third of the herpes zoster patients over 80 years will experience PHN 
(Hope-Simpson, 1975, Johnson et al., 2010). Children who experience herpes zoster 
are not at risk of PHN (Hope-Simpson, 1965, Petursson et al., 1998). In older 
patients, over 20% of PHN-affected patient experience symptoms for more than one 
year (Arvin and Gilden, 2007, Johnson et al., 2010). 
 
1.3 The human nervous system 
The human nervous system is divided into the central nervous system (CNS), 
consisting of the brain and spinal cord, and the peripheral nervous systems (PNS), 
consisting of sensory branches of cranial, spinal and peripheral nerves, and 
specialised nerve endings (Moore and Dalley, 1999). Collections of nerve cell bodies 
outside the CNS are called ganglia, for example a cranial ganglion or spinal ganglia 
(Ross and Pawlina, 2003).  
1.3.1 Components of the human nervous system 
The functional unit of the nervous system is the neuron. These are polarised cells 
which consist of cell bodies, axons, dendrites and terminals (Kandel et al., 2000). 
Neurons are arranged as an integrated communication network, and are able to 
receive stimuli from other cells, and in response conduct electrical impulses to other 
parts of the nervous system via their processes (Ross and Pawlina, 2003). 
Another important component of nervous tissue are the supporting cells. These are 
non-conducting cells which surround individual neurons. These non-neuronal, non-
excitable cells serve to physically support, electrically insulate, and provide nutrients 
for their associated neurons (Ross and Pawlina, 2003). In the CNS these cells are 
called neuroglia, or simply glia, while in the PNS they are called Schwann cells and 
satellite cells (Moore and Dalley, 1999). 
1.3.1.1 THE PERIPHERAL NERVOUS SYSTEM 
The PNS consists mainly of nerve fibres and their supporting Schwann cells (Ross 
and Pawlina, 2003), which are held together by three distinct types of connective 
tissue. From the inner-most outwards these connective tissue layers are the 
endoneurium, which surrounds each individual nerve fibre; the perineurium, which 
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surrounds each bundle of nerves, or fascicles; and the epineurium, which surrounds 
the entire peripheral nerve and fills the space between fascicles (Ross and Pawlina, 
2003). These tissues serve to protect, insulate and isolate each peripheral nerve. 
Nerves are also encased within Schwann cells, which function to insulate and 
provide nutrients for each nerve fibre. The junctions between Schwann cells are 
termed the nodes of Ranvier. At these gaps the plasma membrane of the neuron is 
exposed to the extracellular environment, which enables efficient conduction of 
neural impulses along the axon (Kandel et al., 2000). Schwann cells also secrete 
essential nutrients and growth factors, and along with fibroblasts within the 
endoneurium and epineurium, help maintain the structure of the PNS (Moore and 
Dalley, 1999). 
Each bundle of nerves, or axons, originate within the cell body from an area known 
as the axon hillock. This can be distinguished from the cell body as it usually lacks 
both Golgi apparatus and rough endoplasmic reticulum, as well as other large 
cytoplasmic vesicles (Ross and Pawlina, 2003). Each axon can either project locally, 
or extend from a cell body in one area of the nervous system to a nerve cell in a 
completely different section of the nervous system (Carpenter, 1983). The distal 
portion of each axon divides into extensive networks of nerve termini, which form 
synapses within the spinal cord (Carpenter, 1983). 
1.3.1.2 THE DORSAL ROOT GANGLIA 
In the PNS the cell bodies of sensory neurons are situated in the DRG or trigeminal 
ganglia (TG). These are bundles of neurons located immediately adjacent to the 
spinal cord (see Figure 1.6), and covered in a capsule of connective tissue which 
forms part of the epineurium and perineurium of the spinal nerves (Moore and Dalley, 
1999). Unlike other neurons the DRG neurons do not possess dendrites, but instead 
have a unipolar axon consisting of peripheral and central branches. These axonal 
branches are the conducting units, and are utilised to convey impulses from 
receptors in the periphery into the CNS (Ross and Pawlina, 2003).  
Neurons are post-mitotic cells and consequently do not undergo a replication cycle, 
however the internal structures do undergo regular turnover (Ross and Pawlina, 
2003). The neuronal cell bodies correspond to the dilated section of the neuron. This 
section has a globular or pear-like shape with a diameter of between 60 to 120 µm 
(Kandel et al., 2000). The neuronal cell bodies contain a central or paracentral 
nucleus with a prominent nucleolus, surrounded by a perinuclear cytoplasm (Ross 
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and Pawlina, 2003). Within the neuronal cytoplasm there is rough endoplasmic 
reticulum (called Nissl bodies when seen under light microscopy), smooth 
endoplasmic reticulum, ribosomes, mitochondria, Golgi apparatus, lysosomes, 
microtubules, neurofilaments and transport vesicles (Ross and Pawlina, 2003). 
Surrounding the neuron is a layer of satellite cells that tightly encapsulate the cell 
body (see Figure 1.7). 
1.3.1.3 THE TRIGEMINAL GANGLIA (TG)  
The TG is located in a cavity in the temporal bone, and is the sensory ganglion that 
generates most of the information from the orofacial complex in humans (Drake et 
al., 2009). There are three major divisions in the TG, each resulting in a branch 
which innervates a separate dermatome, and exits the cranium at a different site. 
The first division – the ophthalmic branch – (V1) innervates the area of skin above 
the eyes and forehead. The second division – the maxillary branch – (V2) innervates 
the region of skin below the eyes and above the mouth. The third division – the 
mandibular branch – (V3) innervates the skin over the jaw but sparring the angle of 
the mandible. The TG is made up of large and small unipolar neurons, their 
associated satellite cells and fibres (Drake et al., 2009).  
 
1.4 Pathogenesis of VZV infection 
The pathogenesis of VZV infection is comprised of three unique phases: inoculation 
with VZV leads to primary infection or varicella (chickenpox). During this phase a 
latent infection is established within sensory ganglia and maintained throughout the 
life of the host. The virus may reactivate from latency to cause a clinically distinct 
disease, herpes zoster (shingles) (Figure 1.8). 
1.4.1 Primary infection 
VZV infection occurs via the mucosa of the upper respiratory tract or conjunctiva 
when a susceptible individual comes into contact with aerosols containing infectious 
virus, although it can also occur from direct contact with infectious fluid from the 
vesicles of an infected individual (Grose, 1981, LaGuardia and Gilden, 2001) (Figure 
1.6). Following inoculation there is an incubation period that lasts for 10-21 days, 
during which the infected host is asymptomatic and the virus moves from the 
infection site to the skin where viral replication occurs (Arvin and Gilden, 2007, Ku et 
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al., 2004). It has been proposed that dendritic cells (DCs) within the respiratory 
mucosa are the first cell type to be infected with VZV and may be responsible for the 
transport of VZV from the infection site to draining lymph nodes, and the subsequent 
infection of T lymphocytes (Abendroth et al., 2001b). This is thought to be followed 
by a primary viremia, during which the virus is transported to the liver and other 
reticuloendothelial cells (Arvin and Gilden, 2007). Initial symptoms develop around 
14 to 16 days post infection, and during the final days of the incubation period a 
second viremia occurs. It has been hypothesised that the different phases of viremia 
during varicella are accompanied by the migration of VZV-infected T lymphocytes 
from the capillaries into the tissues (Moffat et al., 2007). Once here, VZV quickly 
invades cutaneous epithelial cells, resulting in the characteristic varicella rash (Asano 
et al., 1990). VZV has been shown to display a tropism for both CD4+ and CD8+ T 
lymphocytes in the SCID-hu mouse model (Moffat et al., 1995), and in particular for T 
lymphocytes that display skin homing markers (Ku et al., 2002).  
The first varicella lesions become apparent 24 to 48 hours after initial symptoms 
(Moffat et al., 2007). Viral DNA, proteins and intact virions can be detected in cells of 
the dermis and epidermis of VZV lesions (Annunziato et al., 2000, Nikkels et al., 
1993). As epidermal cells within lesions deteriorate, a fluid develops and fills the 
vesicle. This fluid contains cell-free virus, and can provide another transmission route 
on direct contact with a susceptible individual (Weller, 1953). 
Varicella is normally resolved within 7 days, and requires the development of VZV-
specific immunity. This is covered in more detail in subsequent section 1.6. 
Complications can arise during varicella, the most common of which is secondary 
bacterial infection, which can lead to a severe and life-threatening disease (Fleisher 
et al., 1981, Heininger and Seward, 2006). 
1.4.2 Latency 
At some stage during primary infection, VZV is transported to the sensory ganglia, 
primarily the DRG (Figure 1.7), where a latent infection is established and maintained 
throughout the life-time of the host (Gilden et al., 1983). Currently the method of virus 
transport to the ganglia, the exact cell-type infected during latency, and the 
underlying mechanisms by which the virus establishes and maintains latency are not 
fully understood. There have been two proposed models by which the virus gains 
access to sensory ganglia. The first is direct transmission through the bloodstream 
via infected T lymphocytes. This model is supported by recent work in the human 
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DRG xenograft SCID-hu mouse model, where VZV-infected T cells were shown to be 
capable of infecting DRG tissues (Zerboni et al., 2005). The second model, 
analogous to the establishment of HSV latency, involves retrograde axonal transport 
of virions from infected dermal and epidermal tissues (Abendroth et al., 2001a). This 
is favoured by immunohistochemical analysis which have shown the presence of 
VZV antigens in both Schwann cells and nerve termini (Silverstein and Straus, 2000). 
The exact cell-type in which latent VZV infection occurs has been the source of some 
controversy. Many studies, utilising different techniques, have shown neurons to be 
the exclusive site of latency (Hyman et al., 1983, Gilden et al., 1987), while others 
have identified latent VZV infection of satellite cells (Croen et al., 1988, Meier et al., 
1993). Other studies have shown that VZV establishes a latent infection 
predominantly in neurons, but also in some satellite cells (Dueland et al., 1995, 
Kennedy et al., 1998, Kennedy et al., 1999, Lungu et al., 1995). Another study 
utilised highly sensitive laser capture microdissection (LCM) and real time 
polymerase chain reaction (PCR) and found that latent VZV resides primarily, if not 
exclusively, within neurons (Wang et al., 2005). Other studies have utilised very 
specific nucleic acid separation techniques to show VZV latency almost exclusively 
within neurons (LaGuardia et al., 1999, Levin et al., 2003). 
The VZV genome is thought to be maintained within latently infected cells in a non-
integrated circular concatameric form, as PCR analysis has revealed that the 
genome termini are adjacent (Clarke et al., 1995). The exact amount of VZV DNA 
maintained within latently infected sensory ganglia is unknown, and studies have 
measured from between 6-31 copies of VZV DNA per 105 ganglionic cells 
(Mahalingam et al., 1993) to up to 9046 copies per 105 ganglionic cells (Cohrs et al., 
2000). Wang and co-workers in the LCM study calculated that around 1.0-6.9% of 
neurons harbour latent VZV, with around 6.9 viral genomes per infected cell (Wang 
et al., 2005). 
Although latency is characterised by the cessation of viral DNA synthesis, late gene 
expression, and production of infectious progeny (Silverstein and Straus, 2000), the 
virus retains the ability to reactivate to cause a productive infection. In HSV-1 latent 
infection of sensory neurons, viral gene expression is restricted to latency-associated 
transcripts (LATs) (Kent et al., 2003). VZV does not contain any known LAT 
homologues, however there is restricted VZV gene transcription in latent infection of 
sensory ganglia (Cohen, 2007). In contrast to HSV-1, VZV does not encode any viral 
microRNAs in latently infected cells (Umbach et al., 2009). Also there have been a 
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range of VZV ORFs detected in latently infected human sensory ganglia in various 
studies, with ORF4, ORF18, ORF21, ORF29, ORF62, ORF63 and ORF66 
consistently detected as RNA transcripts (Cohrs et al., 1996, Cohrs et al., 2003, 
Kennedy et al., 2000, Kennedy et al., 1999, Lungu et al., 1998, Mahalingam et al., 
1996, Theil et al., 2003, Inoue et al., 2010). These genes products are located within 
the cytoplasm of latently infected cells – contrasting with a predominantly nuclear 
localisation during productive infection of permissive cells (Lungu et al., 1998). It has 
been suggested that these proteins are sequestered from the nucleus to prevent 
their transcriptional function and preserve the virus in a latent state (Lungu et al., 
1998).  
One study demonstrated that ORF63 is the most prevalent transcript in latently 
infected human ganglia, suggesting it has an important role in maintaining viral 
latency (Cohrs and Gilden, 2007). However there is controversy about these latency 
associated proteins, with more recent papers detecting very low expression levels, 
and one in particular showing that IE63 protein expression was a very rare 
occurrence, and may actually indicate a pending or subclinical reactivation rather 
than a latent infection (Zerboni et al., 2010). This recent study also provided 
evidence that the previous reports of higher expression levels may in fact be due to 
inherent background present in the formalin-fixed and paraffin-embedded ganglionic 
tissue samples used. 
More recently Nagel and co-workers used a highly sensitive multiplex reverse 
transcription PCR (RT-PCR) approach previously developed (Nagel et al., 2009) 
which was able to detect transcripts from all 68 unique VZV ORFs to study the viral 
transcriptome during latency in human ganglia (Nagel et al., 2011). This recent study 
was able to detect transcripts mapping to VZV ORF4, ORF40, ORF29, ORF62 and 
ORF63 which had been previously identified during VZV latency. Additionally, 
transcripts mapping to VZV ORF11, ORF41, ORF43, ORF57 and ORF68 were also 
detected – none of which had been previously reported (Nagel et al., 2011). ORF63 
remained the most prevalent transcript detected (Nagel et al., 2011). Consequently 
the VZV transcripts that have been detected by multiplex RT-PCR during latency 
come from all kinetic classes of the virus life cycle – challenging the classical belief 
that early and late genes require a productive infection for transcription to occur. 
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1.4.3 VZV Reactivation 
Reactivation from latency results in herpes zoster, which can occur months to years 
following the resolution of primary VZV infection. It has been suggested that like 
other herpesviruses there are periodic episodes of subclinical reactivations which 
may help maintain the VZV latent infection (Arvin, 1996). This is supported by the 
detection of asymptomatic VZV viremia in both bone marrow transplant recipients, 
elderly adults and healthy asymptomatic blood donors (Devlin et al., 1992, Quinlivan 
et al., 2007, Wilson et al., 1992). 
Current information on the cellular and viral events responsible for VZV reactivation 
is quite limited. The underlying cause(s) of reactivation and reversion to productive 
infection is not yet known. The risk of herpes zoster increases with age (Hope-
Simpson, 1965), and it has been suggested that the age-related reduction in cell-
mediated immunity may allow VZV reactivation to occur (Schmader, 2007). This 
assertion is also supported by the higher incidence and greater severity of 
reactivation that occurs in immunocompromised and elderly patients (Alessi et al., 
1988, Balfour, 1988). Interestingly it has been reported that VZV DNA and viral 
shedding occurs in astronauts following their return from spaceflight, and spaceflight 
is known to reduce cell-mediated immunity (Cohrs et al., 2008). Other noted triggers 
for viral reactivation include immunosuppression, trauma, x-irradiation, malignancy, 
and other infections (Kennedy, 2002, Strangfeld et al., 2009).  
During VZV reactivation the full repertoire of viral genes is expressed, infectious 
virions are formed and are believed to be transported from the sensory ganglia to the 
nerve termini in the skin via anterograde axonal movement (Arvin and Gilden, 2007). 
This transport is believed to be along myelinated nerves which terminate within the 
epidermis near hair follicles and sebaceous glands (Muraki et al., 1996), and results 
in the infection of epithelial cells, causing the characteristic herpes zoster rash. 
Within the immunocompetent individual this takes the form of a unilateral vesicular 
rash usually localised to one dermatome (Abendroth et al., 2001a). This axonal 
movement model is supported by the detection of VZV proteins and inclusion bodies 
within small nerves in the dermis beneath the site of the vesicles (Annunziato et al., 
2000). The appearance of the rash is sometimes preceded by a prodrome of 
unilateral dermatomal pain (Haanpaa et al., 1999). As accurate diagnosis of herpes 
zoster depends on the appearance of the characteristic rash, this prodrome is often 
mistaken for other conditions such as angina, HSV infection and lumbar 
radiculopathy (Dworkin et al., 2008a). Some episodes of VZV reactivation do not 
 The University of Sydney 
- 22 - 
produce a rash at all, but rather pain with a dermatomal distribution accompanied by 
a rise in VZV antibody titres (Gilden et al., 1994b). This condition is called zoster sine 
herperte (Murata et al., 2010). 
VZV DNA has been detected in 20% of saliva samples taken from herpes zoster-
affected patients 15 days post-rash onset (Mehta et al., 2008). The same study 
showed that a higher level of viral DNA detectable by PCR in the saliva correlated 
with a higher amount of pain reported by the patient (Mehta et al., 2008). VZV DNA 
has been reported to remain in the blood of 80% of patients with herpes zoster, and 
higher viral load seems to correlate with higher reported pain levels (Personal 
communication by J. Breuer noted in Gershon et al., 2010). Interestingly, VZV DNA 
has been shown to persist in the blood for up to 6 months following the resolution of 
the herpes zoster-associated rash (Quinlivan et al., 2010). 
Herpes zoster has been shown to decrease the level of cutaneous innervation at the 
site of the cutaneous rash (Oaklander et al., 1998, Rowbotham et al., 1996). 
Interestingly, during the most common complication of herpes zoster, PHN, the level 
of cutaneous innervation at the site of the previous herpes zoster rash remains low, 
as well as a smaller reduction at an unaffected contralateral site (Oaklander et al., 
1998, Rowbotham et al., 1996). PHN also causes significant morbidity in affected 
individuals, and is dealt with in more detail in the subsequent section.  
 
1.5  Post-herpetic neuralgia 
1.5.1 Post-herpetic neuralgia  
PHN is the most common complication following herpes zoster (Kost and Straus, 
1996). It is defined as pain within the distribution of the herpes zoster rash that 
continues beyond a 4-6 week period following the resolution of the herpes zoster 
rash (Steiner et al., 2007), however the sensitive area often exceeds the area 
affected by the herpes zoster rash (Watson et al., 1988a). This pain substantially 
interferes with the affected individual’s physical, emotional and social functioning 
(Coplan et al., 2004), and results in significantly increased health care costs (Davies 
et al., 1994, Dworkin et al., 2007b). One study found treatment for PHN-affected 
patients could cost up to $9000 US each year (Dworkin et al., 2008b). The prognosis 
for affected patients is poor, with some patients suffering for many years, sometimes 
right up until death (Watson, 1998). Although in many cases the pain naturally 
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resolves, some experience a gradual increase in the severity of the condition over 
time (Watson, 1998). There are a range of different treatments available, 
pharmacological, interventional and surgical, however the efficacy of these vary, and 
in many cases the pain is intractable (Volmink et al., 1996, Wu and Raja, 2008). 
However a new treatment method involving the application of a liquid nitrogen cloud 
in order to cool the affected area has shown potential in relieving the pain associated 
with PHN (Calandria, 2011). 
1.5.1.1 CLINICAL FEATURES 
Clinical findings from PHN-affected patients indicate there is altered nervous system 
function, including areas of sensory loss and sensory gain (Watson, 1998). Patients 
affected with PHN experience a combination of three different types of pain: the first 
is a steady burning; the second is sharp, often lancinating, shock-like episodes of 
pain; and the third is pain on non-painful stimuli of the affected area, also called 
allodynia (Schmader, 2007). Allodynia can result from a cold wind or piece of clothing 
brushing across the affected area. This condition is generally less severe in the 
morning, and progressively worsens throughout the day (Ragozzino et al., 1982). 
Patients may also have altered pain and thermal sensitivity which extends beyond 
the pain-affected area (Alvarez et al., 2007). 
1.5.1.2  PATHOGENESIS 
The cause and pathogenesis of PHN is not known. As a neuropathic pain (a 
neuralgia), one hypothesis is that PHN may result from damage to the sensorineural 
pain pathway (Steiner et al., 2007). The sensorineural pain pathway is involved in 
protecting against tissue damage, as pain triggers a behavioural response such as 
withdrawing from harm or resting to allow adequate time for healing (Oaklander, 
2008). Characteristics of this type of pain include a discrepancy between the 
patient’s complaint of pain and the lack of a corresponding tissue injury, as well as a 
progressive worsening of pain during the day (Oaklander, 2008). Neuralgias are 
closely linked to the malfunctioning of sensory neurons that transmit pain signals 
(Oaklander, 2008). Neurons transmit signals using a electrochemical gradient via a 
coordinated cycle of polarisation, depolarisation and repolarisation of the cell 
membranes. Damage to neuronal cells can result in incorrect initiation of this cycle, 
leading to pathologic signalling (Bennett, 1994). 
In PHN, it is thought the structure of neurons within the reactivated ganglia may be 
altered during herpes zoster (Bennett, 1994). This may be due to different factors, 
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including direct cell death caused by virus infection and neuronal cell damage due to 
the inflammatory response (Bennett, 1994). In surviving nerve fibres, the population 
may shift from a balance between large inhibitory and small excitatory fibres towards 
a preponderance of smaller fibres (Watson, 1998). This may lead to pathologic 
signalling, either spontaneously or in response to the lightest of tactile stimulation. 
An alternative explanation for the pathogenesis of PHN is the presence of a 
persistent viral infection and ongoing replication within the sensory neurons following 
the resolution of the herpes zoster rash (Steiner et al., 2007). During the productive 
phase of viral replication, viral antigens are produced. These viral antigen expressing 
neuronal cells may produce an immune reaction resulting in a general inflammation 
within the affected sensory ganglia. This inflammation would include virus-specific T 
lymphocytes that could recognise VZV antigens presented in association with MHC 
molecules. Infected cells may include neurons or the supporting satellite cells, 
resulting in a depolarisation of the neuronal cell membrane and the initiation of a pain 
signal (Bennett, 1994). Evidence that PHN may be produced by low-level ganglionitis 
due to VZV infection of ganglionic cells includes the detection of viral proteins within 
MNCs in the blood of PHN-affected patients for months to years following the 
resolution of the herpes zoster rash (Gilden et al., 2003), but only for a period of 
months in uncomplicated cases of herpes zoster or varicella (Gilden et al., 1989, 
Vafai et al., 1988). Alternatively it has been suggested that persistent viral infection 
within the sensory ganglia could lead to abnormal nerve impulses (Schon et al., 
1987), and not be dependent on immune-cell mediated killing of VZV infected cells.  
While at this point it is unclear what mechanisms are responsible for the clinical 
manifestations of PHN, it has been suggested that there are multiple mechanisms 
that contribute to the different aspects of the syndrome due to the different types of 
pain and the large variability in severity between patients (Pappagallo et al., 2000). 
One such mechanism, which has been suggested to be the cause of the allodynia 
related pain, is the cross-reactivity between antibodies for VZV IE62 and the cellular 
protein brain derived neurotropic factor (BDNF) (Hama et al., 2010) – an important 
neuronal protein in pain hypersensitivity. Alternatively it may be caused by aberrant 
immune cell function; in a rat model of another neuropathic pain – graded chronic 
constriction injury – it was found that adoptive transfer of splenocytes from high pain 
to low pain individuals also increases the likelihood and severity of allodynia 
occurring in the recipient (Grace et al., 2011). VZV has been shown to induce 
neuropathic changes in rat dorsal root ganglia during chronic infection, inducing 
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behavioural changes that may be due to pain, and is relieved through the use of 
analgesic drugs (Hasnie et al., 2007, Garry et al., 2005). 
1.5.1.3 PATHOLOGY 
There is very little known about the underlying pathology of PHN. Previous studies 
involving PHN and the assessment of DRG have been limited to general and brief 
histological examinations of human ganglia. One early post-mortem study of an 
individual who experienced PHN for several months prior to death found diffuse and 
focal infiltrations of inflammatory cells (Smith, 1978). Another study found a general 
loss of both axons and myelin within the affected area (Watson et al., 1988b). A 
follow-up study on post-mortem DRG samples confirmed these findings, and noted 
evidence of a general inflammatory process occurring in some PHN-affected 
individuals, but not all cases studied (Watson et al., 1991). This study also noted 
atrophy of the spinal dorsal horn, as well as cell, axon, and myelin loss only in 
patients with persistent PHN. Persistent inflammation and lymphocytic infiltrate within 
the affected areas in long-term herpes zoster survivors has been previously noted, 
but these cases had alternate causes of death and no clear pain at time of death, 
and as such this inflammation cannot be directly attributed to PHN (Head and 
Campbell, 1900). The major limitation in studying the pathogenesis of PHN is the 
dearth of appropriate human ganglia samples. 
Other studies have focused on studying skin biopsies from both herpes zoster and 
PHN-affected patients. One study of skin samples from herpes zoster-affected 
patients revealed that there were significantly lower numbers of infiltrating cells 
present in the skin of patients who later went on to develop PHN compared to those 
that experienced no complications, despite the systemic cytokine and antibody 
responses showing no differences between the two groups (Zak-Prelich et al., 2003). 
Studies comparing skin samples from PHN and non-PHN-affected patients found 
that PHN-affected patients featured large-scale loss of epidermal neurites at the site 
of pain (Oaklander et al., 1998, Rowbotham et al., 1996). Interestingly, one of these 
studies utilised multiple biopsies from different sites to show that while the level of 
innervation at a distal site was similar between PHN-affected and non-PHN-affected 
patients, subjects with PHN had lost about 80% of their epidermal neurites at the 
shingles-affected site and about 30% at the contralateral site (Oaklander et al., 
1998). This generalised loss of neurites within the epidermis has also been seen in a 
patient with severe post-herpetic itch (Oaklander et al., 2002). Another study 
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compared the amount of sensory nerves present in the skin tissue of both the PHN-
affected and contralateral sites of PHN-affected individuals, and found that 
substantially different pattern of innervation at the PHN-affected site (Petersen et al., 
2002).  
Clinical human tissue samples are relatively difficult to obtain, and consequently 
other studies have looked at the expression of viral DNA and proteins within the 
blood of PHN-affected individuals. VZV-specific proteins (gE and gB) were detected 
within MNCs of patients affected with PHN 1-4 years following acute herpes zoster, 
but not in cases of uncomplicated herpes zoster (Vafai et al., 1988). Viral DNA 
present in MNCs within the blood of patients following varicella persists for very 
limited periods following the resolution of the varicella rash (Gilden et al., 1989). 
1.5.2 Epidemiology and risk factors 
PHN is the third most common cause of neuropathic pain in the United States 
(Bennett, 1998). The incidence of PHN rapidly rises with age (Hope-Simpson, 1975). 
It is very rare in patients under the age of 30 (Hope-Simpson, 1975), and around half 
of all herpes zoster patients from age 60 on will experience PHN to some extent (De 
Moragas and Kierland, 1957). The incidence continues to increase with advancing 
age, as generally does the duration of PHN (De Moragas and Kierland, 1957, Hope-
Simpson, 1975, Watson et al., 1988a). 
Besides increased age, other risk factors for PHN include immunosuppression, 
female gender, the presence of a prodrome to herpes zoster, and the occurrence of 
a more severe episode of herpes zoster (Balfour, 1988, Jung et al., 2004, 
McKendrick et al., 2009). Although no one of these risk factors can accurately predict 
the occurrence of PHN, patients with multiple factors have a substantially increased 
risk of developing the condition. A Japanese study found three HLA alleles were 
significantly associated with PHN, but not herpes zoster, when compared to normal 
controls (Sumiyama et al., 2008). One study found that long-term pain was 
associated with certain characteristics that could be identified during acute illness 
such as moderate to severe acute pain, severity of rash and prodromal pain 
(McKendrick et al., 2009). On the other hand, PHN develops in around 5-10% of 
patients who exhibited none of these risk factors (Jung et al., 2004). Although in an 
early study there was no correlation between viral loads during herpes zoster and the 
development of PHN (Quinlivan et al., 2007), another more recent study from the 
same group performed over a longer time frame found the opposite (Quinlivan et al., 
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2010). Thus the relevance of viral loads during herpes zoster and the incidence of 
PHN remains unclear. In most cases the pain resolves naturally and spontaneously 
(Volmink et al., 1996), however pain persists in many cases for longer than three 
months post-herpes zoster, and in around half of all cases for greater than a year 
(De Moragas and Kierland, 1957, Hope-Simpson, 1975, Ragozzino et al., 1982).  
1.5.3 Treatment and Prevention 
Treatment of PHN is quite challenging. It is made more difficult as the underlying 
cause and pathogenesis are unknown. Like many other types of neuropathic pain, 
PHN can be resistant to many therapies (Wu and Raja, 2008). There are many 
different therapies available, including pharmacological, interventional and surgical 
approaches. Although prevention strategies have been complicated by the lack of 
understanding of the events leading to PHN, a novel vaccine has the capacity to 
reduce the occurrence of PHN in herpes zoster patients by up to two thirds (Oxman 
et al., 2005). The implementation of the varicella zoster vaccine is discussed in more 
detail in section 1.8. 
There are many different pharmacologic agents that are used in the treatment of 
PHN. These include various systemic agents such as tricyclic anti-depressants, anti-
epileptics, analgesics and opioids, as well as topical therapies including local 
anaesthetics and capsaicin (Wu and Raja, 2008). The most common of these is 
tricyclic antidepressants, which are widely used for the symptomatic treatment of 
many neuropathic pains (Reviewed in Zin et al., 2008), however these therapies 
cause significant adverse effects particularly among the elderly (Collins et al., 2000, 
Sindrup and Jensen, 1999, Volmink et al., 1996). Anti-epileptics have also 
demonstrated some efficacy with side-effects less detrimental to a patient’s quality of 
life (Dworkin et al., 2003, Rice et al., 2001, Rowbotham et al., 1998, Sabatowski et 
al., 2004, Stacey et al., 2008), however the methodologies of some of these studies 
have been called into question (Gehling and Tryba, 2002, Bowsher, 2002, Low and 
Dotson, 1998). To compound this, many anti-epileptics can produce undesirable side 
effects such as delirium and dependence (Kruszewski et al., 2009). 
The use of opioids in the treatment of neuropathic pains has also been quite 
controversial (Arner and Meyerson, 1988). One study has shown opioids provide 
rapid and stable pain relief during PHN (Fan and OxyContin Tablets Postmarketing 
Surveillance Study Group, 2008). Other studies have investigated local, non-
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systemic agents such as capsaicin-impregnated patches or lidocaine-medicated 
plasters, both with promising results (Backonja et al., 2008, Liedgens et al., 2008).  
However the aforementioned therapies generally provide unsatisfactory results when 
used as the only treatment strategy (Dworkin et al., 2007a). Consequently a 
combinatorial treatment regime which combines first, second, and third-line options 
of pharmacotherapies is the normal course of treatment (Dworkin et al., 2007a). 
These treatment regimes are decided upon on a case-by-case basis, and changes to 
therapy are common before a successful and stable treatment regime is reached 
(Hall et al., 2008). 
A recent paper reported the use of a liquid nitrogen spray applied so as to cool the 
skin along the affected dermatome at weekly sessions for 30 seconds each 
treatment (Calandria, 2011). This approach resulted in a good or excellent 
improvement in 97% of the 47 PHN-affected patients before the sixth treatment. The 
author suggests it is a very efficient way of calming the pain associated with PHN, 
however does concede that the mechanism behind this treatment is currently 
unknown (Calandria, 2011). 
Despite the large amount of pharmacologic agents available, there is no one 
established and effective treatment strategy available for PHN (Wu and Raja, 2008), 
and many patients experience little relief from pain despite considerable side effects 
of treatments (Watson, 1995). 
There have been some reports of anti-viral treatment relieving the pain of PHN 
(Gilden et al., 2003). In one study a patient diagnosed with PHN had detectable 
levels of VZV DNA within blood MNCs, and she was treated with an anti-viral agent 
(famciclovir). This resulted in a complete relief of her pain within 1 month. The patient 
was followed over an 11 year period, and voluntarily ceased treatment on 5 separate 
occasions. Each time pain returned within a few days, accompanied by detectable 
levels of viral DNA within blood MNCs (Gilden et al., 2003).  
In another small clinical study of anti-viral treatment of PHN 15 patients with PHN 
lasting for more than 3 months (an average of 12 months) were treated with 
intravenous acyclovir for 14 days, followed by oral valacyclovir for 1 month (Quan et 
al., 2006). At the end of the study 53% of the patients had experienced a clinically 
meaningful reduction in the pain. However more large-scale controlled studies of the 
use of anti-viral treatment in PHN have not shown the same dramatic success 
(Reviewed in Li et al., 2009, McKendrick et al., 2009), and consequently anti-virals 
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are not currently a recommended therapy for PHN following the disappearance of the 
herpes zoster rash.  
Alternative therapies have also been trialled in the treatment of PHN. These include 
the effect of pulse radiofrequency (Kim et al., 2008), treatment using botulinum toxin 
A (Sotiriou et al., 2009), and acupuncture (Valaskatgis et al., 2008). These have 
mostly shown positive results, with successful reduction in the burden of pain. 
Another study found that PHN patients had significantly lower plasma concentrations 
of vitamin C when compared to healthy volunteers, and restoring the vitamin C level 
to normal brought about a decrease in episodes of pain (Chen et al., 2009). However 
this only affected spontaneous episodes of pain, and vitamin C treatment did not 
reduce episodes of burning or allodynia (Chen et al., 2009). Overall these alternate 
therapies have only been trialled in small scale studies or case reports, and each 
study requires larger clinical trials and more investigation into the underlying 
mechanisms of action. 
A wide variety of interventional strategies have been examined as potential PHN 
treatments. These include the use of sympathetic nerve blocks, which can provide 
transient pain relief (Wu et al., 2000). Other approaches include epidural and 
intercostal nerve blocks. Overall the long-term effectiveness of these in PHN 
treatment is unknown (Wu and Raja, 2008). PHN greatly reduces the sufferer’s 
quality of life, thus psychological interventions may be important for the emotional 
and mental health of the affected individual (Wu and Raja, 2008). 
Surgical approaches to PHN treatment are quite limited. One option that has been 
used in a clinical trial on a PHN-affected patient involved the removal of the top layer 
of skin from the pain-affected area (Petersen et al., 2002). This resulted in a 
temporary relief of pain and a reduction in the use of medication, but on its return 
both the severity of pain and size of the affected area increased, and the required 
pharmacological intake also increased, and consequently is not recommended as a 
therapeutic strategy for PHN (Petersen and Rowbotham, 2007). Other possible 
approaches include the use of a pump to deliver a continuous supply of an analgesic 
to the area (Angel et al., 1998), or the complete removal of the affected sensory 
ganglia via a dorsal root ganglionectomy (Colli et al., 2008). Efficacy of these 
interventions has yet to be evaluated for use in the treatment of PHN. 
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1.6 Immune responses to Varicella Zoster Virus 
Primary VZV infection initiates responses from both the innate and adaptive arms of 
the immune system. Early involvement of the innate immune system is likely to be 
responsible for restricting viral replication and spread of infection. This non-specific 
response involves both natural killer (NK) cells and interferon (IFN) production. NK 
cells are able to directly lyse VZV-infected fibroblasts in vitro (Ihara et al., 1984), and 
synthesise granulysin, a cytolytic protein which enhances target cell death (Hata et 
al., 2001), and have been shown to play some role during acute primary varicella 
infection (Malavige et al., 2010). In fact complete NK cell deficiency causes fatal 
primary varicella infection (Etzioni et al., 2005). 
The humoral response against VZV consists of antibodies specific for viral proteins 
and neutralising antibodies. Antibodies lyse infected cells by either activating the 
complement pathway or in conjunction with NK cells through antibody-dependent 
cellular cytotoxicity (ADCC) (Abendroth and Arvin, 2000, Arvin and Abendroth, 2007). 
VZV specific antibody isotypes consist of IgM, IgG and IgA antibodies, which are 
detectable within the serum of a host during varicella (Arvin, 1996). These VZV 
specific antibodies recognise a variety of different epitopes, mostly viral 
glycoproteins, as well as other regulatory and structural proteins and viral enzymes 
(Arvin, 2001, Dubey et al., 1988, Giller et al., 1989, LaRussa et al., 1990). Although 
these antibodies may assist in limiting viral spread within the first 72 hours post 
infection, as shown by the effectiveness of passive immunoglobulin transfer directly 
after VZV exposure (Arvin and Gilden, 2007), humoral immunity appears to play a 
limited role in controlling VZV infection. This is evident in the similar severity of 
varicella in immunocompromised and healthy children, and the occurrence of 
uncomplicated varicella in children with congenital agammaglobulinemia (Arvin, 
1987). Antibodies, along with cell-mediated immunity, are involved in preventing re-
infection from exogenous VZV at mucosal sites (Bogger-Goren et al., 1982, Bogger-
Goren et al., 1984). It has been suggested that humoral immunity may also play a 
role in the initial blocking of viral reactivation (Arvin, 1996), but is not the only barrier 
as declining antibody titres have been shown to have no effect on the rate of viral 
reactivation (Gershon and Steinberg, 1981). 
In contrast to humoral responses, VZV-specific cell-mediated immunity is critical in 
containing and resolving primary infection (Arvin, 1992). This is supported by clinical 
observations of patients unable to acquire cellular immunity through 
immunosuppression. These individuals are at a higher risk of persistent viremia and 
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life-threatening dissemination during varicella (Arvin, 1987). The required T 
lymphocyte response against VZV includes both CD4+ and CD8+ T cells (Abendroth 
and Arvin, 1999). This response is accompanied by the secretion of T helper 1-like 
cytokines, including interleukin (IL)-2, IL-10, IL-12, and IFN-γ, which direct the clonal 
expansion of viral-specific lymphocytes and the production of different antibody 
isotypes (Arvin et al., 1986, Jenkins et al., 1998, Zhang et al., 1994, Zhang et al., 
1995). In the classic model of cell-mediated immunity the cytotoxic T lymphocyte 
(CTL) response involves MHC class I restricted CD8+ T lymphocyte killing of virally 
infected cells (Abbas and Lichtman, 1991). However in VZV and other herpesvirus 
infections, both MHC class I-restricted CD8+ and MHC class II-restricted CD4+ CTLs 
are involved in the recognition and lysis of infected cells (Diaz et al., 1989, Hickling et 
al., 1987, Huang et al., 1992). 
A recent genome-wide analysis of T cell responses utilising the simian varicella virus 
(SVV) model to specific VZV ORFs (Haberthur et al., 2013). This study demonstrated 
that during acute SVV infection both CD4+ and CD8+ T cells responded to both IE 
and E proteins, with a trend towards higher CD8+ responses. CD4+ T cell responses 
were predominantly towards the structural proteins during acute infection, while CD8+ 
T cells responded to L proteins during latency (Haberthur et al., 2013). While these 
findings generally correlated with previous work in human disease, a similar analysis 
is yet to be performed using human samples. 
Although the adaptive immune system is central to the control of primary infection 
and prevention of re-infection, it is unable to prevent the establishment of latency or 
eradicate the latent virus from the host (Abendroth and Arvin, 2000). However it is 
predicted to play an important role in the prevention of viral reactivation. Clinical 
evidence for this includes a higher incidence of herpes zoster in the 
immunosuppressed and elderly, as increased age corresponds with a decline in T 
lymphocyte activity (Arvin, 1987). However declining cellular immunity may not be 
the only factor that leads to viral reactivation, as herpes zoster does not occur in all 
seropositive elderly individuals.  
The immune response against herpes zoster is very similar to that seen during 
primary infection. The main difference is a more rapid response in herpes zoster, due 
to the pre-existing VZV-specific memory lymphocytes which were primed during 
primary infection (Vossen et al., 2004). This leads to prolonged VZV-specific 
immunity, and this subsequent exposure and resulting increase in immunity may help 
explain why the occurrence of a second episode of herpes zoster is rare. 
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1.6.1 Varicella Zoster Virus encoded immune evasion 
VZV has evolved several different immune evasion strategies in order to persist in 
the human population. These are aimed towards avoiding immune detection and 
promoting viral spread (Arvin and Abendroth, 2007). The virus appears to evade host 
recognition during the initial incubation period of up to 21 days following VZV 
inoculation (Arvin et al., 1996), and so must encode some immunomodulatory 
proteins responsible for this transient evasion of T lymphocytes. VZV has been 
shown in vitro to specifically block the IFN-γ-induced upregulation of MHC class II 
(Abendroth et al., 2000), and to downregulate the cell-surface expression of MHC 
class I (Abendroth et al., 2001a). MHC class II surface expression is blocked through 
interference with the Jak/Stat signalling pathway, while the MHC class I molecules 
are retained within the Golgi apparatus of infected cells (Reviewed in Arvin and 
Abendroth, 2007). These effects may allow the virus to evade CD4+ T lymphocyte 
and CD8+ T lymphocyte responses (Abendroth et al., 2000, Arvin, 2001). VZV has 
also been shown to downregulate surface expression of the intercellular adhesion 
molecule 1 (ICAM-1) in infected cells (Nikkels et al., 2004). ICAM-1 is important in 
recruitment of inflammatory cells, and downregulation of this molecule may provide 
another means of virally encoded immune evasion. 
VZV has the ability to infect T lymphocytes directly (Ku et al., 2002) and through 
transfer from VZV-infected immature DCs (Abendroth et al., 2001b), and is thought to 
utilise these cell types for the initial dissemination of virus during varicella. 
Experiments in the SCID-hu mouse model have shown that VZV-infected T cells, and 
predominantly memory CD4+ T cells, can mediate the transfer of infectious virus to 
skin (Ku et al., 2004). During VZV skin infection, expression of IFN-α is 
downregulated in infected cells, allowing the formation of vesicles on the skin surface 
(Ku et al., 2004).  
VZV infection of human DCs results in the selective downregulation of functionally 
important cell-surface molecules, namely CD80, CD83 and CD86 (Morrow et al., 
2003). Low cell-surface expression of these costimulatory molecules corresponds to 
an impaired ability to stimulate T cell proliferation (Abendroth et al., 2001b). This 
impact of VZV infection on DCs, an important class of antigen presenting cells, may 
also delay immunosurveillance (Arvin and Abendroth, 2007), and may be due to 
modulation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) signalling pathway by ORF66 (Sloan et al., 2012). 
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It has been shown that ORF63, the most prevalent VZV transcript in latently infected 
ganglia, blocks the effects of IFN-α (Ambagala and Cohen, 2007). IFN-α is known to 
limit VZV replication within human skin xenografts in the SCID-hu mouse model, and 
consequently the ability of ORF63 to block this cytokine may play a central role in the 
establishment and maintenance of a latent infection (Ku et al., 2004). Another more 
recent study found that IE62 blocks the function of the interferon regulatory factor 3 
(IRF3) by interfering with its phosphorylation (Sen et al., 2010). VZV has been shown 
to interfere with NF-κB pathway, which is an integral part of the induction of the “anti-
viral state” (Jones and Arvin, 2006), while ORF66 has been shown to be important in 
downregulating the IFN-γ signalling pathway (Schaap et al., 2005). Consequently 
VZV encodes many different immunomodulatory gene products that are likely to 
greatly inhibits the anti-viral immune response in infected cells. 
 
1.7 Immune responses in chronic pain states 
Historically inflammation and neuropathic pain syndrome have been considered 
distinct conditions, however there is more and more evidence that they may be 
related. Inflammation is a well-characterised and studied process involving a 
cascade of different immune cell types such as mast cells, neutrophils, macrophages 
and T cells. These cells have all been shown to release compounds that can both 
contribute to and ameliorate pain (Reviewed in Machelska, 2011). A common 
underlying mechanism of neuropathic pain is the presence of inflammation at the 
damaged or affected site (Vallejo et al., 2010) and evidence suggests that these 
immune cells contribute to neuropathic pain in the periphery (Reviewed in Thacker et 
al., 2007) 
In the peripheral nervous system, tissue resident macrophages have been shown to 
migrate immediately following nerve injury to the site of injury, and display an active 
phenotype (Mueller et al., 2001). Further inflammation is promoted by the secretion 
of chemokines, matrix metalloproteases, and vasoactive mediators from activated 
macrophages, Schwann cells/satellite glial cells, and injured nerve axons to attract 
immune cells, increase blood flow to the area and cause swelling (Perrin et al., 2005, 
Shubayev et al., 2006, Zochodne et al., 1999). These changes result in a dense 
cellular infiltrate, mainly composed of macrophages, T lymphocytes and mast cells, 
which forms within 2 days of injury. 
 The University of Sydney 
- 34 - 
Immune cells have been shown to both ameliorate and contribute to pain. In a mouse 
model it was shown that CD4+ T lymphocytes were responsible for endogenous 
opioid-mediated analgesia in an antigen-specific manner (Boue et al., 2011). 
Peripheral immune cells have also been shown to actively contribute to nociceptor 
hypersensitivity and the resulting allodynia in a rat model of central nervous system 
chronic pain (Grace et al., 2011). Chemokines also have been implicated in the 
pathogenesis of pain states in the DRG. In addition, the upregulation of cytokine 
and/or chemokines within the nervous system, combined with tissue damage and 
infection has been proposed as a mechanism for hyperexcitability of neurons, 
causing pain (Miller et al., 2009, Abbadie et al., 2009). Characterisation of the host 
immune response within the ganglia and the skin during PHN has yet to be 
elucidated, and is the focus of this study. 
 
1.8 Varicella zoster virus vaccines 
The current varicella vaccine is a live attenuated virus using the Oka virus vaccine 
strain (vOka). The parental strain (pOka) was isolated from varicella skin lesions on a 
3 year old boy (Takahashi et al., 2008), and then passaged 11 times in human 
embryonic lung fibroblasts at 34oC, and then 12 times in guinea pig embryo 
fibroblasts at 37oC (Takahashi et al., 2008, Takahashi et al., 1975). The exact 
genetic basis of attenuation has not been determined, however the vaccine and 
parental viral genomes have nucleotide differences which cause amino acids 
changes in all classes of viral proteins (Argaw et al., 2000, Arvin and Gilden, 2007, 
Gomi et al., 2002, Quinlivan et al., 2011). This vaccine strain has a lower efficiency of 
replication in human skin (Moffat et al., 1998a), however it remains unattenuated in 
both T cells and neural cells in vivo (Baiker et al., 2004b, Moffat et al., 1998a). 
The current varicella vaccine was also expected to decrease the occurrence of 
herpes zoster. Although vOka still establishes a latent infection within sensory 
ganglia, it seems to have a lower rate of clinical reactivation (Edmunds and Brisson, 
2002). This is likely due to the lower efficiency of vOka to replicate in human skin, 
leading to either lower initial access to neuronal cells following vaccination, or lower 
probability of causing a clinical reactivation (Baiker et al., 2004b). However general 
vaccination may lead to a higher occurrence of herpes zoster due to a loss of 
vaccine-induced immunity over time (Chaves et al., 2007). A recent study has found 
that the incidence of herpes zoster in the United States has increased over the years 
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1993-2006 despite the introduction of the varicella vaccine, but there was no 
evidence to attribute this increase to the vaccine program (Leung et al., 2011). The 
Australian national varicella vaccination program has lead to a reduction in both 
congenital and neonatal varicella since its introduction in 2005 (Khandaker et al., 
2011). Additionally, although rare, the vaccine strain can still reactivate and result is 
severe illness in both the immunocompromised and immunocompetent host (Han et 
al., 2011, Tseng et al., 2010, Iyer et al., 2009, Bryan et al., 2008). 
Another vaccine formation has been developed for herpes zoster, and was shown to 
reduce the incidence of both herpes zoster and PHN in at-risk groups by up to a half 
and two thirds respectively (Oxman et al., 2005). This vaccine consists of the same 
viral strain at a fourteen times higher dose (Oxman et al., 2005). Viral DNA of the 
vaccine strain is detectable within the saliva of many recipients for over 28 days 
(Pierson et al., 2011). This vaccine provides a cost-effective and efficient 
preventative measure to prevent both herpes zoster and PHN, however does not 
always prevent either condition (Johnson, 2009, Najafzadeh et al., 2009). The 
duration of protective immunity provided, and the effects of vaccinating younger or 
at-risk groups is unknown.  
 
1.9 The human skin 
The skin is a highly complex organ, and at around 2 m2 is the largest in the human 
body – comprising of around 6% of the total body weight (Tobin, 2006). It is 
constantly in a process of regeneration and has many important immunologic and 
metabolic functions. 
1.9.1 Structure and function 
There are two distinct layers within the human skin: the epidermis and the dermis.  
1.9.1.1 THE EPIDERMIS 
The epidermis is the outermost layer of the skin. It is typically around 50 – 100 µm 
thick (Rees, 2004), and consists of hardening epithelium that terminates at 
mucocutaneous junctions (such as the mouth), and is disrupted by pores of glands 
and hair fibres (Tobin, 2006). The primary cell type within the epidermis is 
keratinocytes, with smaller numbers of both Langerhans cells and melanocytes 
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(Jackson et al., 1993). This layer is undergoing constant renewal, with cells gradually 
progressing from the innermost to outer levels, and it is estimated that the 
keratinocyte population within the epidermis is completely replaced around every 30 
days (Farage et al., 2007). Within the epidermis there are four main “strata”, or 
layers, with different cell types restricted to the different layers (Nestle et al., 2009, 
Narayan, 2009) (Figure 1.9).  
1.9.1.2 THE DERMIS 
The dermis lies directly below the epidermis. Despite it’s greater volume when 
compared to the epidermis, the dermis contains far fewer cells (Ross and Pawlina, 
2003). It can be roughly divided into two areas: a thin superficial area directly 
adjacent to the epidermis called the papillary region, and a thicker and deeper region 
known as the reticular region (Farage et al., 2007). The papillary region contains thin 
projections that interdigitate with the epidermis, strengthening the connection 
between the two (Farage et al., 2007). The reticular region consists mainly of a 
fibrous and amorphous extracellular matrix surrounding nerves, blood vessels, hair 
follicles, sebaceous and sweat glands, receptors and dermal cells (Tobin, 2006).  
1.9.2 Skin immune function and surveillance 
The epidermis is home to several important immune cell types, including 
macrophages and mast cells, as well as DCs and different subtypes of T cells 
(Nestle et al., 2009). The main resident immune cell in the epidermis is the 
Langerhans cell (Nestle et al., 2009). These are immature dendritic cells that are 
present at high levels in the epidermis, and perform an important immune 
surveillance function (Valladeau and Saeland, 2005). In addition, there are also T 
cells, mainly CD8+ lymphocytes, present in the lower layers of the epidermis (Krueger 
and Stingl, 1989). 
In comparison to the rather simple histology of the epidermis, the dermis features a 
much greater cellular diversity with a more complicated anatomy. Cells present 
include macrophages, mast cells, fibroblasts and nerve endings, as well as many 
specialised immune cell types including dermal DCs, and both conventional (CD4+ T 
helper lymphocytes) and unconventional (γδ T cells and natural killer) T lymphocytes 
(Nestle et al., 2009). Another important immune cell, the plasmacytoid dendritic cell 
(pDC), is normally rare in healthy human skin however has an important role in 
inflammatory conditions (Cella et al., 1999, Colonna et al., 2004, Valladeau and 
Saeland, 2005), as well as in the acute phases of innate and adaptive immune 
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responses, such as in herpesvirus infections (Donaghy et al., 2009, Huch et al., 
2010).  
1.9.3 VZV infection of human skin 
VZV is thought to spread to the skin during primary infection using a tropism for 
human tonsillar CD4+ T lymphocytes which express skin homing markers (Ku et al., 
2002, Ku et al., 2004). Once in the skin, VZV is able to replicate within all layers of 
the skin, causing typical lesions and resulting in the release of virions from infected 
cells with infectious virus present within the vesicular fluid and resulting scab 
(Annunziato et al., 1996, Annunziato et al., 2000, Nikkels et al., 1993, Nikkels et al., 
1995a, Taylor and Moffat, 2005). 
Previous studies have shown that there is a dramatic shift in the numbers of 
important immune cells within the skin during herpes zoster, with a reduction in 
tissue resident Langerhans cells within the epidermis, and an increase in pDCs – 
highly inflammatory dendritic cells (Colonna et al., 2004) – within herpes zoster-
affected skin (Gutzeit et al., 2010, Huch et al., 2010). VZV antigen has been 
observed in skin biopsies during both varicella and herpes zoster, and has been 
shown to inhibit the ability of pDCs to express IFN-α, and consequently delay the 
immune response within the skin (Huch et al., 2010). 
There have also been several studies comparing PHN-affected and normal skin 
material, which have been dealt with in more detail in section 1.4. Characterisation of 
human skin and specifically persistence of VZV antigen expression and immune cell 
composition in the skin of PHN-affected versus non-PHN-affected individuals has yet 
to be elucidated, and forms a large part of this study. 
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1.10 Aims and Hypotheses 
Remarkably, despite the pivotal role of ganglionic infection to PHN, a survey of the 
literature over the past 100 years reveals few studies that have reported any 
examination of ganglia following herpes zoster and PHN, and many of those that 
have are restricted to basic histological observations of post-mortem material. This 
PhD project involves a detailed immunohistological assessment of VZV infection and 
immune cell infiltration in human ganglia and skin biopsy samples obtained following 
natural reactivation and subsequent development of PHN. There is a critical need for 
this work to further our understanding of the involvement of the cause and 
pathogenesis of PHN. 
Currently it is not known whether there is a factor which predisposes some herpes 
zoster-affected individuals to developing PHN. There has yet to be a detailed study 
into any underlying immune cell involvement and persistence of VZV antigen 
expression during herpes zoster or PHN. It is also important to compare data from 
herpes zoster patients who developed PHN and those that experienced an 
uncomplicated recovery in an effort to find any distinguishing factor(s) between the 
two outcomes. 
In order to further our understanding of the underlying cause and pathogenesis of 
PHN, this PhD study sought to focus on two critical sites of VZV infection during 
natural VZV reactivation – the ganglia and the skin. The specific aims were to: 
1a Perform a detailed immunohistological analysis of human ganglionic material 
 surgically excised from a PHN-affected individual years following resolution of 
 the herpes zoster-associated rash, and compare and contrast with post 
 mortem material taken from herpes zoster-affected patients and control 
 patients in order to: 
 • Characterise any difference in local immune response and  cellular 
  immune infiltrate in the DRG and the spinal nerves. 
 • Identify and characterise VZV antigen expression within the  
  ganglia material. 
1b Perform a molecular analysis VZV-specific nucleic acid levels in order to 
 assess the VZV nucleic acid levels within the material. 
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2a Perform an immunohistological analysis of skin biopsy samples obtained from 
 patients who suffered from PHN-affected and control patients in order to: 
 • Characterise the cellular immune infiltrate in the skin of PHN-affected 
  and control patients, at different sites within the same individuals 
 • Identify and characterise VZV antigen expression within the skin  
  biopsy material. 
2b Perform a molecular analysis of VZV-specific nucleic acid levels within the 
 human skin biopsy material. 
3 Perform an immunohistological analysis of skin biopsy samples obtained from 
 patients suffering from herpes zoster over time in order to 
 • Identify VZV antigen expression within the skin biopsy material 
 • Compare and contrast immune cell phenotype over time in human 
  skin biopsies from herpes zoster-affected patients who experienced 
  uncomplicated herpes zoster and herpes zoster resulting in PHN.  
 • To identify any relation between the frequency or phenotype of  
  immune cells, the presence or absence of VZV antigen expression, 
  and the clinical level of pain reported by the patient. 
So in regards to these aims, I hypothesise that: 
• VZV reactivation in human ganglia and human skin during herpes zoster and 
 PHN is defined by unique cellular infiltrates comprised of subsets of 
 inflammatory cells. 
• VZV gene expression in human ganglia and human skin during PHN results 
 in productive viral antigen expression in a small subset of cells. 
• The dynamics of the immune infiltration in the skin of herpes zoster patients 
 will differ between those that develop PHN and those that experience an 
 uncomplicated recovery. 
• The presence of VZV antigen expression will correlate with greater clinically 
 reported pain levels. 
• The immune cell phenotype will differ between patients who report higher or 
 lower clinical pain levels. 
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1.11 Research plan 
One major difficulty in studying PHN is that the DRG samples used in many studies 
are taken from post-mortem examinations of patients, which can take place up to 
days after death. This raises the possibility that they may not be a true representation 
of the situation in vivo. Recently our lab came into possession of DRG samples that 
were surgically removed from a live patient suffering from PHN in order to relieve 
pain. These precious and rare samples will form the basis for some of the 
experiments in this project, and will be compared to a ganglia sample surgically 
excised from a patient with no evidence of PHN or herpes zoster, and post-mortem 
ganglia samples taken from both herpes zoster-affected and control patients. 
While skin biopsy samples are relatively easier to obtain than DRG samples as the 
procedure is less intrusive, there has been relatively limited work into herpes zoster 
and PHN involving skin samples. Currently it is not known whether there is an 
ongoing factor which predisposes some herpes zoster-affected individuals to 
developing PHN. Nor has there been a study which correlates clinical data with any 
underlying immune involvement during herpes zoster or PHN.  
Through a collaboration with the University of California, San Francisco (UCSF) we 
have access to skin biopsy samples taken over time from herpes zoster-affected 
patients who later went on to either develop PHN or had a complete recovery, along 
with clinical questionnaires which examine the patient’s experience of pain and other 
related details. This offers a unique opportunity to perform a detailed 
immunohistological assessment of VZV infection and immune infiltration in skin 
biopsy samples taken from single patients over time. By correlating the 
immunohistological findings with the clinical data, it may shed light on the potential 
mechanisms which cause one herpes zoster-affected patient to develop PHN, while 
another experiences no complications and makes a complete recovery. 
All of the included ganglia samples have been formalin fixed, paraffin embedded, cut 
into consecutive sections and mounted on microscope slides. This allows the use of 
consecutive mirror image 5 µm sections to link together examination of basic 
histology, identification of the phenotype of infiltrating cells, and assessment of the 
extent of viral antigen expression via immunofluorescent assay (IFA) and 
immunohistochemistry (IHC) as described below. 
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The skin biopsy samples have been formalin fixed, snap frozen, and cut in 
consecutive 14 µm sections. These sections will also be used in IFAs to identify 
immune cells and viral antigen positive cells. Although these sections are also 
consecutive mirror images, due to the thicker nature of the sections it is more difficult 
to compare the same regions across different slides. 
To characterise any immune infiltration in DRG and skin samples from patients 
suffering from herpes zoster and PHN, IFA and/or IHC will be performed on the 
paraffin-embedded and frozen sections utilising a variety of antibodies specific for 
different immune cells (such as different T cell subsets, B cell and dendritic cell 
specific cell markers). Assuming this is successful, their proximity to VZV-infected 
cells and other cells will be assessed by performing dual IFA stains for VZV antigens 
and immune cells within the same section, and comparing the corresponding 
locations of different markers examined over consecutive sections.  
To assess viral gene expression during PHN, IFA will initially be performed on 
paraffin-embedded DRG and skin samples from patients suffering from PHN using 
antibodies specific for the VZV protein IE63, and the protein complex between gE 
and gI (a marker of productive infection). In addition to this, reverse transcriptase real 
time PCR analysis will be performed to check for any viral transcripts present in the 
tissue. 
This study will further our understanding of the pathogenesis of VZV infection of 
human ganglia and skin in vivo, and has the potential to greatly enhance our limited 
understanding of PHN. 
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Chapter 2: Materials and Methods 
2.1   Buffers and Solutions 
2.1.1 General reagents 
1% Agarose (low melting point) for paraffin-embedded cell pellets  
0.5 g low gelling temperature agarose powder (Sigma, USA) was dissolved in 50 mL 
1x phosphate buffered saline (PBS) by heating. 
 
100% Ethanol 
Undenatured ethanol 100% (Fronine Laboratory Supplies, Australia). 
 
95% Ethanol 
Undenatured ethanol 100% (Fronine Laboratory Supplies, Australia) was added to 
distilled H2O (dH2O) to give a final concentration of 95% v/v. 
 
90% Ethanol 
Undenatured ethanol 100% (Fronine Laboratory Supplies, Australia) was added to 
dH2O to give a final concentration of 90% v/v. 
 
70% Ethanol 
Undenatured absolute ethanol (Fronine Laboratory Supplies, Australia) was added to 
dH2O to give a final concentration of 70% v/v. 
 
Histolene 
Dipentene 100% (Fronine Laboratory Supplies, Australia). 
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10 M NaOH 
Prepared by dissolving 80 g NaOH pellets (Sigma-Aldrich, Australia) in 200 mL ultra 
pure H2O. 
 
25x PBS 
Prepared by dissolving 200 g NaCl (Sigma-Aldrich, Australia), 28.7 Na2HPO4 (Sigma-
Aldrich, Australia), 5 g KCl (Sigma, USA) and 5 g KH2PO4 (Sigma, USA) in 300 mL 
ultrapure H2O. The pH was adjusted to approximately 7.4 using concentrated 
hydrochloric acid solution (37%) (Sigma-Aldrich, Australia) before being made up to 
1 L final volume with ultra pure H2O (Sigma-Aldrich, Australia). 
 
1x PBS 
Prepared by diluting 80 mL 25x PBS stock with 1920 mL dH2O to a final volume    of 
2 L. 
 
Proteinase K 
Prepared by resuspending Proteinase K powder (Amresco, USA) in ultra pure H2O to 
a final concentration of 20 mg/mL. Solution was stored at -20oC in 1 mL aliquots. 
 
Xylene 
Dimethylbenzines (Fronine Laboratory Supplies, Australia). 
 
2.1.2 Cell culture reagents 
Dulbecco’s Modified Eagle’s Media (DMEM) 
DMEM (Gibco, USA) contains 4.5 g/L D-glucose, L-glutamine and sodium pyruvate. 
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Heat inactivated foetal bovine serum (FBS) 
FBS (JRH Biosciences, USA) was heat inactivated at 56oC for 30 minutes, and then 
stored at -20oC until needed. 
 
MACS buffer 
Prepared by diluting human AB serum (Invitrogen, USA) and 0.5 M EDTA (pH 8.0) 
(Gibco, USA) to final concentrations of 1% v/v and 5 mM respectively in 1x PBS. 
 
Supplemented DMEM 
DMEM was supplemented with 10% v/v heat inactivated FBS and 50 IU/mL penicillin 
streptomycin (Gibco, USA) and was stored at 4oC until needed. 
 
Trypsin Versene 
Concentrated 10x Trypsin (0.12% v/v) /versene (0.05% v/v) (Gibco, USA) was diluted 
1:4 in 1x PBS. Solution was stored at -20oC until needed. 
 
2.1.3 Molecular biology reagents 
1% Agarose gel 
2 g of UltraPure Agarose (Invitrogen, USA) was dissolved in 100 mL 1x TAE by 
heating. Volume was then made up to 200 mL. Gel mix was allowed to cool. When 
gel had almost set 1 µL ethidium bromide solution was added to a final concentration 
of 50 ng/mL, mixed well by swirling and gel was poured into gel tank (Bio-Rad 
Laboratories, Australia) with end formers in place, well comb was then set in place 
and gel allowed to set. Prior to loading of samples, end formers and well comb were 
removed and gel tank was filled with 1x TAE to cover the gel. 
 
Ammonium Acetate solution 
5 M ammonium acetate solution in dH2O (Fluka, Australia) 
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Ampicillin stock solution 
Prepared by dissolving 0.5 g ampicillin powder (Sigma, USA) in 10 mL dH2O to a 
final concentration of 50 mg/mL. Stock solution was stored at -20oC in 1 mL aliquots. 
 
100x BSA 
1 mg/mL bovine serum albumin (New England Biolabs, USA) 
 
DNA ladder mixture 
GeneRuler DNA ladder mix (100-10000bp) (Fermentas, Canada). 
 
DNA loading buffer 
Blue/Orange 6x loading dye (Promega, USA). 
 
10 mM dNTP mix 
PCR Nucleotide Mix. Contains the sodium salts of dATP, dCTP, dGTP, dTTP, each 
at a concentration of 10 mM in water (Invitrogen, USA). 
 
25 mM dNTP mix 
PCR Nucleotide Mix. Contains the sodium salts of dATP, dCTP, dGTP, dTTP, each 
at a concentration of 25 mM in water (Promega, USA). 
 
Ethidium Bromide solution 
3,8-Diamino-5-ethyl-6-phenylphenanthridinium bromide, 10 mg/mL (Sigma, USA). 
 
GoTaq Flexi DNA Polymerase 
500 U, 5 U/µL with 5x green reaction buffer (Promega, USA). 
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Isopropanol 
2-Propanol (Sigma, USA). 
 
Kanamycin stock solution 
Prepared by dissolving 0.5 g kanamycin sulfate (Sigma, USA) in 10 mL dH2O to a 
final concentration of 50 mg/mL. Stock solution was stored at -20oC in 1 mL aliquots. 
 
Luria Bertani (LB) agar 
Prepared by dissolving 35 g LB agar powder (Sigma, USA) in 1 L of ultra pure H2O 
and autoclaved for 15 minutes at 121oC. Agar was allowed to cool and then mixed 
with appropriate antibiotic (ampicillin or kanamycin, to 50 µg/mL) before being poured 
into plates (BD Biosciences, Australia) and allowed to set. Plates were stored at 4oC 
until required.  
 
LB broth 
Prepared by dissolving 20 g LB broth powder (Sigma, USA) in 1 L of ultra pure H2O 
and autoclaved for 15 minutes at 121oC. Broth was stored at 4oC until required. 
 
Magnesium Chloride Solution 
25 mM MgCl2 solution (Promega, USA). 
 
10x NEBuffer 1 
Solution containing 10 mM Bis-Tris-Propane-HCL, 10 mM MgCl2, 1 mM Dithiothreitol 
(New England Biolabs, USA). 
 
SacI 
Restriction enzyme (20 000 units/mL) (New England Biolabs, USA)  
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SOC media 
S.O.C. medium (Invitrogen, USA) consisting of 2% tryptone, 0.5% yeast extract, 10 
mM sodium chloride, 2.5 mM potassium chloride, 10 mM magnesium chloride, 10 
mM magnesium sulfate and 20 mM glucose. 
 
25x TAE buffer 
Prepared by dissolving 242 g Tris, 57.1 mL glacial acetic acid (Sigma-Aldrich, 
Australia) and 100 mL 0.5 M EDTA (pH 8.0) (Gibco, USA) in 1 L distilled H2O. 
Distilled H2O was added to make volume up to 2 L. 
 
1x TAE buffer 
Prepared by diluting 40 mL 25x TAE buffer in 960 mL dH2O. 
 
2.1.4 Immunohistochemistry reagents 
Acid alcohol differentiator solution 
Prepared by mixing 4 L 70% ethanol solution with 10 mL concentrated hydrochloric 
acid solution (37%) (Sigma-Aldrich, Australia). 
 
Azure B solution 
Prepared by dissolving azure B powder (Sigma-Aldrich, Australia) in ultrapure dH2O 
to a final concentration of 1%. 
 
Biotin blocking system 
Endogenous biotin blocking system (Dako, Australia) consisting of avidin solution 
and biotin solution. 
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Diaminobenzidine (DAB) working solution 
Liquid DAB+ Substrate Chromogen System (Dako, Australia). Prepared immediately 
prior to use by mixing DAB+ chromogen solution and DAB+ substrate buffer in the 
ratio of 1 drop to 1 mL respectively. 
 
DPX 
DePeX Mounting Media (Electron Microscopy Science, USA). 
 
Eosin counter-stain 
Alcoholic eosin (Fronine Laboratory Supplies, Australia). 
 
3% H2O2 solution 
Prepared by diluting 45 mL hydrogen peroxide solution (30%) (Sigma-Aldrich, 
Australia) in 405 mL dH2O. 
 
Haematoxylin stain 
Haematoxylin solution (Fronine Laboratory Supplies, Australia). 
 
IHC antibody dilution buffer 
10% (v/v) rabbit or goat serum (depending on the primary antibody) (Sigma, USA) in 
1x TBS. 
 
IHC blocking solution 
20% (v/v) rabbit or goat serum (depending on the primary antibody) (Sigma, USA) in 
1x TBS.  
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Scott’s blueing solution 
Prepared by dissolving 14 g NaHCO3 (Sigma-Aldrich, Australia) in 2 L dH2O, and 80 
g MgSO4 (Sigma-Aldrich, Australia) in 2 L dH2O, and then mixing the two solutions to 
make a 4 L solution. 
 
2.1.5 Immunofluorescent assay (IFA) reagents 
10x (0.1 M) citrate buffer pH 6.0 
Prepared by dissolving 42.02 g citric acid (anhydrous) (Univar, USA) in 1.8 L dH2O, 
and the pH was adjusted to pH 6.0 using concentrated 10 M NaOH (Sigma-Aldrich, 
Australia). Distilled H2O was added to produce a final volume of 2 L. 
 
1x (0.01 M) citrate buffer pH 6.0 
Prepared by diluting 10x (0.1 M) citrate buffer in dH2O to a final concentration or 1x 
(0.01 M). 
 
Cryochrome freezing compound 
Shandon cryochrome compound sampler – containing red, yellow, green and blue-
coloured cryo-preservation compound (Thermo Fisher Scientific, USA). 
 
EDTA unmasking solution 
Prepared by diluting 1 mL 0.5 M EDTA (pH 8.0) (Gibco, USA) in 500 mL dH2O to a 
final concentration of 1 mM. 
 
Gelatin slide coating 
Prepared by dissolving 1% w/v gelatin (Sigma, USA) and 0.1% chromium (III) 
potassium sulfate (Sigma-Aldrich, Australia) in dH2O  
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IFA antibody dilution buffer 
10% v/v normal donkey serum (NDS) (Sigma, USA) in 1x tris buffered saline (TBS) 
or 1x PBS. 
 
IFA blocking buffer 
20% v/v NDS (Sigma, USA) in 1x TBS or 1x PBS. 
 
IFA blocking and dilution buffer (cryopreserved sample material) 
Prepared by dissolving 10 g bovine serum albumin (BSA) (Sigma, USA) and 2 mL 
Triton X-100 (Sigma-Aldrich, Australia) in 1 L 1x PBS to final concentrations of 1% 
and 0.2% respectively. 
 
Neutral Buffered Formalin (NBF) (10%) 
Neutral buffered solution containing 10% formalin (approximately 4% formaldehyde) 
(Sigma, USA). 
 
Prolong Gold with 4’,6-diamidino-2-phenylindole (DAPI) 
Prolong Gold antifade reagent with DAPI (Molecular Probes, USA). 
 
10x Sudan black stock solution 
Prepared by dissolving 6 g Sudan black B (Sigma-Aldrich, Australia) in 200 mL 70% 
ethanol. Solution was stored at room temperature and protected from light . 
 
Sudan black autofluorescence eliminator 
Prepared by diluting 10 mL 10x Sudan black stock solution in 90 mL 70% ethanol. 
Solution was then syringe filtered through a 0.22 µm filter (Millipore, USA) and 
protected from light. 
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10x TBS 
Prepared by dissolving 121.14 g Tris (Sigma-Aldrich, Australia) and 175 g NaCl 
(Sigma-Aldrich, Australia) in 1.5 L ultra pure H2O. The pH was adjusted to 
approximately 7.6 using concentrated hydrochloric acid solution (37%) (Sigma-
Aldrich, Australia) before being made up to 2 L final volume with ultra pure H2O. 
 
1x TBS 
Prepared by diluting 200 mL 10x TBS stock with 1800 mL dH2O to a final volume   of 
2 L. 
 
2.2   Antibodies 
Primary antibodies used for single and dual immunofluorescent staining are listed in 
Table 2.1. Primary antibodies used for immunohistochemistry are listed in Table 2.2. 
Isotype control antibodies for staining experiments are listed in Table 2.3. 
Fluorochrome-conjugated secondary antibodies used for immunofluorescent staining 
are listed in Table 2.4. Secondary enzyme-labelled antibodies utilised in 
immunohistochemistry are listed in Table 2.5. 
 
2.3   Primers 
Primer sets and sequences for PCR are shown in Table 2.6. Primers specific for VZV 
amplify a small sequence in the untranslated region between VZV ORF8 and 
ORF9a. Primers specific for the UL-42 region of HSV-1 were taken from a previously 
published paper (Cassinotti and Siegl, 1998). Primers for glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) were from an in-house design kindly provided 
by Dr Megan Steain. 
Primers used in the creation of plasmid constructs and to check the sensitivity of real 
time PCR reactions are also listed in Table 2.6. Primers specific for VZV ORF31 
(also known as VZV glycoprotein B) amplify a 853 bp fragment including the region 
detected by the gB-specific real time primer set, and were designed using the online 
tool provided by the National Centre for Biotechnology Information (NCBI). Primers 
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specific for VZV ORF63 amplify a 544 bp fragment, including the region detected by 
the IE63-specific real time primer set, and were also designed using the online tool 
provided by the NCBI. Primers specific for VZV ORF68 (also known as VZV 
glycoprotein E) amplify a 721 bp fragment including the region detected by the gE-
specific real time primer set, and were previously designed by Dr Chantelle Hood 
(Westmead Millennium Institute). 
 
Table 2.1: Primary antibodies used in IFA 
Antibody Company 
Optimal 
Dilution 
Optimal 
concentration 
Mouse anti-human CD3 
Leica Microsystems Inc, 
Germany 1:10 20 µg/mL 
Goat anti-human CD4 R&D Systems, USA 1:10 10 µg/mL 
Rabbit anti-human CD8 Abcam, USA 1:100 2 µg/mL 
Mouse anti-human CD20 
Leica Microsystems Inc, 
Germany 1:10 18 µg/mL 
Mouse anti-human CD45RO 
Santa Cruz Biotechnology, 
USA 1:100 1 µg/mL 
Mouse anti-human CD45RA 
Santa Cruz Biotechnology, 
USA 1:100 1 µg/mL 
Mouse anti-human TIA-1 Abcam, USA 
1:50 2 µg/mL 
Rabbit anti-cow S100 Dako, Denmark Predilute (unknown*) 
Mouse anti-human S100 Millipore, USA 1:200 1:200 
Mouse anti-human HLA-DR 
Leica Microsystems Inc, 
Germany 1:50 (unknown*) 
Goat anti-human DLEC 
(BDCA-2) R&D Systems, USA 1:50 2 µg/mL 
Rabbit anti-human DC-SIGN Abcam, USA 1:250 2 µg/mL 
Mouse anti-human Langerin 
Leica Microsystems Inc, 
Germany 1:200 (unknown*) 
Mouse anti-VZV 
glycoprotein E Millipore, USA 1:10 100 µg/mL 
Mouse anti-VZV 
glycoprotein E:glycoprotein 
I complex Meridian Life Science, USA 1:250 4 µg/mL 
Rabbit anti-VZV ORF63 
Provided by Professor R. 
Mahalingam, University of 
Colorado School of 
Medicine 1:1000 (unknown**) 
* - Concentration unknown as not provided by manufacturer. Isotype matched to antibody dilution 
** - Concentration unknown as provided as serum. Isotype serum matched to antibody dilution 
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Table 2.2: Primary antibodies used in IHC 
Antibody Company 
Optimal 
Dilution 
Optimal 
concentration 
Mouse anti-VZV 
glycoprotein E Millipore, USA 1:10 100 ug/mL 
Mouse anti-VZV 
glycoprotein 
E:glycoprotein I complex Meridian Life Science, USA 1:250 4 ug/mL 
Rabbit anti-VZV ORF63 
Provided by Professor R. 
Mahalingam, University of 
Colorado School of Medicine 1:1000 (unknown*) 
Mouse anti-VZV 
glycoprotein B 
Dr C. Grose, University of 
Iowa 1:10 (unknown*) 
Rabbit anti-VZV ORF29 
Dr P.R. Kinchington, 
University of Pittsburgh 1:250 (unknown*) 
Mouse anti-CD68 
Leica Microsystems Inc, 
Germany 1:10 (unknown**) 
* - Concentration unknown as provided as serum. Isotype serum matched to antibody dilution 
** - Concentration unknown as not provided by manufacturer. Isotype matched to antibody dilution 
 
 
Table 2.3: Isotype controls used in IFA and IHC 
Isotypes Company Dilution 
Mouse IgG 1 Invitrogen, USA 
Mouse IgG 2a Invitrogen, USA 
Mouse IgG 2b Invitrogen, USA 
Normal Rabbit IgG R&D Systems, USA 
Normal Rabbit Serum Sigma, USA 
Normal Goat IgG R&D Systems, USA 
As required to match 
primary antibody 
concentration 
 
 
Table 2.4: Secondary antibodies used for IFA 
Antibody Company 
Optimal 
Dilution 
Alexa Fluor 546 donkey anti-mouse IgG Molecular Probes, USA 1:200 
Alexa Fluor 594 donkey anti-mouse IgG Molecular Probes, USA 1:200 
Alexa Fluor 488 donkey anti-rabbit IgG Molecular Probes, USA 1:200 
Alexa Fluor 647 donkey anti-rabbit IgG Molecular Probes, USA 1:200 
Alexa Fluor 488 donkey anti-goat IgG Molecular Probes, USA 1:200 
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Table 2.5: Secondary antibodies used for IHC 
Antibody Company 
Optimal 
Dilution 
Polyclonal rabbit anti-mouse immunoglobulin. 
Biotin. Affinity-isolated F(ab')2 
Dako, 
Australia 1:200 
Polyclonal goat anti-rabbit immunoglobulin. Biotin. 
Affinity isolated 
Dako, 
Australia 1:200 
 
 
Table 2.6: PCR primer specificities and sequences  
Specificity Direction Sequence (5’-3’) 
Product 
Size (bp) 
Forward TCG GAT TCG GAA TAG TTT GGC TAC A VZV ORF9a 
Reverse ACA CGG CAG ACC GCG TAT TAA AC 
365 
Forward CGA GAT CCC TCC AAA ATC AA GAPDH 
Reverse GTC TTC TGG GTG GCA GTG AT 
350 
Forward GCT TTG TGG TGC TGG TT HSV-1 UL-42 
Reverse CTG GTG CTG GAC GAC AC 
208 
Forward GGA ACC TGC AGC GCG GAA CT VZV ORF31 
fragment Reverse CTC CAC CGT CCC GGA CCC AT 
853 
Forward GCG GCG CAT ATG CCT CGA CT VZV ORF63 
fragment Reverse GGC TTC GTG TCG ACG TCG CTT 
544 
Forward TTT CAA GAC ACC CGG TTC AAT CTC G VZV ORF68 
fragment Reverse GAT ACA AAC TCC GTA TAT GAG CCT T 
721 
 
Primer sets and sequences for real time PCR reactions are shown in Table 2.7. The 
GAPDH-specific primer pair was previously designed and kindly provided by Dr 
Kavitha Gowrishankar (Westmead Millennium Institute). VZV-specific primers 
detecting VZV gB (ORF31), VZV IE63 and VZV gE (ORF68) were previously 
designed and kindly provided by Dr Joshua Bowles (Westmead Millennium Institute). 
The albumin-specific primer pair used in quantitative real time PCR reactions has 
been previously published (Douek et al., 2002). Information regarding the VZV 
ORF28-specific primer pair and probe was generously provided by Prof. Randall 
Cohrs of the University of Colorado, Denver. 
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Table 2.7: Real time PCR primer specificities and sequences 
Specificity Direction Sequence (5'-3') 
Forward TCA CCA GGG CTG CTT TTA AC 
GAPDH 
Reverse GAC AAG CTT CCC GTT CTC AG 
Foward CCA GAC CTA CCT TGC CAG AG 
VZV gB (ORF31) 
Reverse TCG TCG GGA TCT GGT ATT TC 
Forward GAG GAG AGC ACC GAT TCT TG 
VZV ORF63 
Reverse CTT TCG CGG CTG TAT ATT CC 
Foward CCG AGA CTT GGA GCT TTT TG 
VZV gE (ORF68) 
Reverse CGG CCA ACT GAT CCT CTT TA 
Foward TGC ATG AGA AAA CGC CAG TAA 
Albumin 
Reverse TTG GTG AAC A-G GCG ACC AT 
Foward CGA ACA CGT TCC CCA TCA A 
VZV ORF28 
Reverse CCC GGC TTT GTT AGT TTT GG 
VZV probe (Iowa) Forward (FAM)-CCA GGT TTT AGT TGA TAC CA 
Note: (FAM) signifies the fluorophor 6-carboxyfluorescein 
 
Primers utilised in sequencing reactions are shown in Table 2.8. These primers were 
designed and kindly provided for use by Bin Wang (Westmead Millennium Institute), 
and are specific for regions either side of the insert site of the pGEM-T-Easy vector 
(Promega, USA). 
 
Table 2.8: Primers used in plasmid sequencing 
Specificity Name Sequence 
pGEMTa TCT CCC ATA TGG TCG ACC T 
pGEM-T-Easy vector pGEMTb TCA CGA CGT TGT AAA ACG AC 
 
2.4  Commercial Kits 
RecoverALL Total Nucleic Acid Isolation kit (Applied Biosystems, USA) 
QIAquick PCR purification kit (Qiagen, Australia) 
pGEM-T Easy Vector System (Promega, USA) 
QIAprep Spin Miniprep Kit (Qiagen, Australia) 
QIAfilter Plasmid Maxi (Qiagen, Australia) 
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2.5 Cells 
2.5.1 Cell culture techniques 
2.5.1.1 RESUSCITATING CELLS 
Cells were removed from -80oC and then immediately thawed in water at room 
temperature, and subsequently transferred to a falcon tube (BD Biosciences, 
Australia) containing 9 mL of appropriate culture media. Cells were centrifuged at 
524 x g for 5 minutes at room temperature and supernatant aspirated and discarded. 
Cells were rinsed once in 1x PBS, centrifuged at 524 x g for 5 minutes at room 
temperature and supernatant aspirated and discarded. Cells were resuspended in 
tissue culture media and transferred to a tissue culture flask of the appropriate area. 
Flasks were incubated at 37oC and 5% CO2. 
2.5.1.2 HARVESTING CELLS  
Cell media was aspirated and discarded to remove residual media. Cells were 
washed with 1x PBS, which was aspirated and discarded. To remove cells from flask 
1.5 mL trypsin versene was added to each 150 mL tissue culture flask, and flasks 
were incubated at 37oC for 5 minutes. Media was then added and flasks were 
agitated to remove cells from the tissue culture flask surface. Cells were then used to 
create paraffin-embedded or frozen control cell blocks or for molecular analysis.  
2.5.1.3 SPLITTING CELLS 
Cells were harvested as previously described, and then seeded into new tissue 
culture flasks at a lower density. Flasks were incubated at 37oC and 5% CO2. 
2.5.1.4 INFECTING CELLS 
When a cytopathic effect (CPE) of 2+ to 3+ was achieved by the virus, where 1+ 
represents 10% of cells infected and 4+ represents 100% of cells infected as 
demonstrated by plaque formation, the cells were harvested as previously described. 
The VZV-infected cells were seeded onto uninfected cells to achieve a cell-
associated infection at the desired ratio. 
2.5.1.5 CREATION OF CONTROL CELL BLOCKS 
To harvest cells for the creation of paraffin-embedded or frozen control cell blocks, 
cells were harvested from culture as previously described (Section 2.5.1.2) and the 
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cell suspension was transferred to a 15 mL Falcon tube (BD Biosciences, USA). 
Cells were pelleted by centrifugation at 524 x g for 5 minutes at room temperature 
and supernatant aspirated and discarded. Cell pellet was rinsed once in 1x PBS, and 
centrifuged at 524 x g for 5 minutes at room temperature and supernatant aspirated 
and discarded. Cell pellet was then mixed well with 10 mL neutral buffered formalin 
and fixed at 4oC overnight. Cell were centrifuged at 524 x g for 5 minutes at room 
temperature, and the cell pellet was rinsed twice with 1x PBS, centrifuged at 524 x g 
for 5 minutes at room temperature and supernatant aspirated and discarded. 
2.5.1.5.1 Paraffin-embedded cell block creation 
For the creation of paraffin-embedded cell blocks the cell pellet was resuspended in 
0.8% agarose (low gelling temperature) and allowed to set. Agarose cell pellets were 
then transferred to a histopathology tissue cassette (ProSciTech, Australia) and 
transferred to the University of Sydney Histopathology laboratory for overnight 
processing and paraffin-embedding. Sectioning was performed on a microtome 
(Thermo Fisher Scientific, USA) and 5 µm sections were placed on Superfrost Plus 
microscope slides (Thermo Fisher Scientific, USA). Slides were stored at room 
temperature until required. 
2.5.1.5.2 Frozen cell block creation 
For the creation of frozen cell blocks the cell pellet was resuspended in cryochrome 
freezing compound, transferred to a plastic cryoembedding mould (Fisher Scientific, 
USA) containing a contrasting colour of cryochrome freezing compound and snap 
frozen in liquid nitrogen. Blocks were stored at -80oC until sectioning. Sectioning was 
performed on a Shandon cryostat (Thermo Fisher Scientific, USA), and sections 
were placed on gelatin-coated microscope slides. Slides were stored at -80oC until 
required. 
2.5.2 Cell types 
2.5.2.1 HUMAN FORESKIN FIBROBLASTS (HFFS) 
Human foreskin fibroblasts (HFFs) were derived from surgically removed normal 
human foreskin tissue. In culture, HFFs were grown in DMEM supplemented with 
10% FBS and 50 IU/mL penicillin streptomycin (Gibco, USA) at 37oC 5% CO2. HFFs 
were passaged up to 25 times. 
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2.5.2.2 VZV-INFECTED HFFS 
VZV rOka strain was propagated in HFF monolayers in supplemented DMEM and 
incubated at 37oC and 5% CO2. When a CPE of 2+ to 3+ was achieved by the virus, 
the cells were harvested seeded onto uninfected HFFs (uniHFFs) to achieve a cell-
associated infection at the desired ratio. 
2.5.2.3 CD14- IMMUNE CELL ISOLATION 
CD14- peripheral blood mononuclear cells (PBMCs) were kindly provided by Rodney 
Henriquez (VZV Research Laboratory, The University of Sydney). Unscreened 
human donor blood was provided under University of Sydney Ethics approval by the 
Australia Red Cross and PBMCs were isolated via density gradient sedimentation 
using endotoxin free Ficoll Hypaque (GE Healthcare, USA) at 430 x g with no brake 
at room temperature for 20 minutes. Buffy coats were collected and washed 3 times 
with 1x PBS at 270 x g at 4oC for 5 minutes. Buffy coats were washed once in ice 
cold MACS buffer at 270 x g at 4oC for 5 minutes. PBMCs were then incubated in 
300 µL MACS buffer and 150 µL magnetically labelled anti-human CD14 microbeads 
(Miltenyi Biotec, USA) at 4oC for 30 minutes. PBMCs were then washed in MACS 
buffer at 270 x g at 4oC for 5 minutes then filtered through a MACS LS column 
attached to a Quadro MACS separator (Miltenyi Biotec, USA). The column was then 
washed twice with 5 mL MACS buffer and the positive fraction discarded. The 
remaining immune cells were used in the creation of paraffin-embedded and 
cryopreserved cell blocks. 
 
2.6  Molecular biology techniques 
2.6.1 Nucleic acid extraction 
To recover DNA and RNA from paraffin-embedded tissue sections, the RecoverALL 
total nucleic acid isolation kit (Applied Biosystems, USA) was used as per the 
manufacturer’s instructions. Paraffin-embedded sections were dissolved in xylene 
and physically scraped off the slides and placed in a 2 mL microcentrifuge tube. To 
remove all paraffin, 1 mL xylene was added to the samples, vortexed briefly and then 
heated to 50oC for 3 minutes. Samples were then centrifuged at 20 800 x g for 2 
minutes to pellet the tissue. Supernatants were removed and discarded. Pellets were 
washed twice in 100% ethanol, vortexed to mix, then centrifuged at 20 800 x g for 2 
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minutes to pellet and supernatants discarded. Samples were then centrifuged for a 
further 2 minutes to remove any residual ethanol, and then allowed to air dry.  
Digestion buffer and protease solutions were added to samples according to 
manufacturer instructions and samples were mixed gently. Samples were incubated 
at 50oC for 3 hours, and 400 µL was removed for RNA extraction. Remaining 
samples were incubated at 50oC for a total of 48 hours for DNA extraction. After 
incubation, isolation additive was added to each sample and vortexed briefly to mix. 
100% ethanol was then added to each sample and pipetted gently to mix. Portions of 
samples were transferred to a filter cartridge within a clean collection tube and 
centrifuged at 10 600 x g for 1 minute, and flow through was discarded. This was 
repeated until the entire sample had passed through the filter. Wash 1 was then 
added to the filter cartridge and then centrifuged at 10 600 x g for 30 seconds, and 
flow through was discarded. Wash 2/3 was added to the filter cartridge and then 
centrifuged at 10 600 x g for 30 seconds, and flow through was discarded. Samples 
were centrifuged for an additional 30 seconds to remove residual fluid from the filters. 
DNase or RNase was added to filters as described in the manufacturer’s instructions, 
depending on DNA or RNA isolation, and samples were incubated as required (30 
minutes at room temperature for RNA isolation, 30 minutes at 37oC for DNA 
isolation). Wash 1 was added to filter cartridges, and samples were incubated for 60 
seconds at room temperature and then centrifuged at 10 600 x g for 30 seconds. 
Flow through was discarded. Two washes of wash 2/3 were added to each filter 
cartridge and samples were centrifuged at 10 600 x g for 30 seconds and flow 
through discarded after each wash. Samples were centrifuged at 10 600 x g for an 
additional 60 seconds to remove any residual fluid from filters. Elution solution was 
preheated to 95oC. Filter cartridges were placed in clean collection tubes and 50 µL 
preheated elution solution was applied to the centre of the filter. Samples were 
allowed to sit at room temperature for 60 seconds, and then centrifuged at 20 800 x g 
for 60 seconds to collect eluant. The process was repeated with a second volume of 
preheated elution solution to ensure complete elution of isolated nucleic acid. 
Samples were quantitated on a Nanodrop spectrophotometer (Thermo-Scientific, 
USA) to check nucleic acid concentration and purity. DNA samples were stored at -
20oC until required. RNA samples were stored at -80oC until required.  
2.6.2 Polymerase chain reaction (PCR) 
Primers used for PCR reactions are shown in Table 2.6. 
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2.6.2.1 PCR REACTION CREATION  
Master mix was prepared, and reactions were set up for 30 µL total volume. 
Approximately 10 µL template DNA and 2.5 U GoTaq Flexi DNA polymerase were 
added to each reaction, with final concentrations of 1x Green GoTaq Flexi Buffer, 
100 nM MgCl2, 5 nM nucleotide mix, 20 pM of each primer, with reaction volume 
made up to 50 µL using ultra pure H2O.  
2.6.2.2 PCR MACHINE CYCLING PARAMETERS 
Cycling parameters for all gene specific primers were as follows: initial denaturation 
step at 94oC for 4 minutes followed by 35 cycles of 94oC for 30 seconds, 55oC for 30 
seconds and 72oC for 1 minute per kilobase of expected product. A final extension of 
72oC for 10 minutes was included after cycling to ensure full elongation of the final 
product. 
2.6.3 DNA separation via agarose gel electrophoresis 
DNA samples were mixed with gel loading buffer in a 6:1 ratio. PCR reaction 
mixtures using Green GoTaq Flexi Buffer already contained gel loading buffer. DNA 
ladder was mixed with loading buffer in a 1:1 ratio. Samples were loaded onto a 1% 
TAE agarose gel and run at 100 volts for 60 minutes. Gel was imaged via EC3 
imaging system (UVP Biomedicals, USA). 
2.6.4 Purification of PCR products 
Protocol involved the use of the QIAquick PCR purification kit (Qiagen, Australia) 
according to the manufacturer’s instructions. After checking PCR reactions were 
successful via agarose gel electrophoresis as described earlier, remaining PCR 
reaction mixtures were mixed with Buffer PBI in a ratio of 5 volumes buffer to 1 
volume reaction mixture and mixed well. This was transferred to a QIAquick spin 
column in a 2 mL collection tube and centrifuged at 17 900 x g for 1 minute at room 
temperature, and flow-through discarded. QIAquick spin column was washed with 
750 µL Buffer PE and centrifuged at 17 900 x g for 1 minute at room temperature, 
and flow-through discarded. QIAquick spin column was centrifuged at 17 900 x g for 
1 minute at room temperature to remove any residual solution, and spin column was 
transferred to a new collection tube. DNA was eluted by adding 30 µL Buffer EB to 
the centre of the QIAquick membrane, incubating for 1 minute, and then centrifuged 
 The University of Sydney 
- 61 - 
at 17900 x g for 1 minute at room temperature. Purified DNA was stored at -20oC 
until required. 
2.6.5 DNA Ligation for plasmid creation  
DNA ligation reactions were performed utilising the pGEM-T Easy vector system 
(Promega, USA). Briefly: 3 µL purified insert DNA were mixed with 2x Rapid Ligation 
Buffer, pGEM-T Easy Vector and T4 DNA ligase to final concentrations of 1x, 50 ng, 
and 3 Weiss units respectively. Optimal insert concentration was around 8 ng, 
however if unsuccessful reactions using different molar ratios were utilised. Reaction 
mixtures were incubated overnight at 4oC, and then utilised in bacterial 
transformations, as described in Section 2.6.10.1. 
2.6.6 DNA sequencing  
Primers used for sequencing reactions are shown in Table 2.8. 
DNA sequencing reactions were created by mixing 600-1500 ng template DNA and 
10 pmol primer in a total volume of 12 µL. Sequencing was performed by the 
Australian Genome Research Facility at the Westmead Millennium Institute. 
2.6.7 DNase treatment and cDNA synthesis 
Nucleic acid extracts were initially treated with DNase to ensure the complete 
removal of genomic DNA. This was performed by mixing 1-5 µg of total RNA with 
DNase I (amplification grade) (Ambion, USA) and 10x DNase I buffer (Ambion, USA) 
to final concentrations of 1 unit and 1x respectively. Solutions were incubated at 37oC 
for 15 minutes, and then 1 µL DNase I stop solution (Invitrogen, USA) was added 
and mixed well. DNase enzyme was then inactivated by incubating the solution at 
65oC for 10 minutes, and transferred to ice. 
DNase treated mixture was placed on ice, and reverse transcription was performed 
by mixing template RNA with dNTP mix (Invitrogen, USA) and random primers 
(Invitrogen, USA) and incubating at 65oC for 5 minutes. Reaction mix was then 
placed on ice and 5x RT buffer (Invitrogen, USA), DTT (Invitrogen, USA), 
RNaseOUT (Invitrogen, USA) and Superscript III Reverse Transcriptase were added. 
Final reaction mixture concentrations were 0.5 mM dNTP mix, 150 ng random 
primers, 1x RT buffer, 5 mM DTT, 40 Units RNaseOUT and 200 Units Superscript III 
Reverse Transcriptase. Mixture was mixed well via pipette, and then incubated at 
25oC for 5 minutes, 50oC for 1 hour and then 70oC for 15 minutes. Reaction mix was 
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then transferred to 37oC, and treated with 2 Units RNase H (Invitrogen, USA) for 30 
minutes to remove residual RNA. Resulting cDNA was stored at -20oC until required. 
2.6.8 Real time PCR analysis of cDNA samples 
Primers used for real time PCR reactions are shown in Table 2.7. 
2.6.8.1 REAL TIME PCR REACTION CREATION 
Real time PCR was performed using the SYBR green system (Invitrogen, USA). 
Master mix containing 0.54% (v/v) SYBR green, primers and RNase/DNase free 
water to a volume of 9.5 µL was added to each sample containing 3 µL cDNA. 
Positive control samples consisted of cDNA obtained from VZV-infected and 
uninfected cell cultures, and was kindly provided by Jenna Christensen (VZV 
Research Laboratory, The University of Sydney). Negative control samples consisted 
of master mix only with RNase/DNase free water. In addition, corresponding reverse 
transcriptase negative samples were included for all samples.  
2.6.8.2 REAL TIME PCR CYCLING PARAMETERS 
All samples were processed using a Rotorgene 6000 qRT-PCR machine (Qiagen, 
Australia). Real time PCR cycling conditions were as follows: a single 2 minute 
denaturation step at 50oC followed by incubation at 95oC for 2 minutes. 50 cycles 
were then carried out with denaturation at 95oC, annealing and extension at 60oC for 
30 seconds. During this annealing/extension step fluorescence levels were acquired. 
Following cycling, a step-wise increase in temperature from 60 – 90oC as performed 
to generate a melt curve. Data was analysed using Rotogene 6000 Software 
(Qiagen, Australia). 
2.6.9  Quantitative real time PCR analysis of DNA levels 
Primers and probes used in quantitative real time PCR reactions are shown in Table 
2.9. 
Plasmid constructs for use as standards had been previously created and were 
kindly provided for use by Dr Megan Steain. Plasmids consisted of pGEM-T Easy 
backbone with a small coding section for human albumin or VZV ORF28 inserted 
which contained the region detected by the corresponding real time primers. 
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2.6.9.1 STANDARD CURVE CREATION  
Plasmid constructs were linearised to improve detection efficiency. Restriction digest 
was performed by mixing a known quantity or plasmid with SacI, NEB buffer 1 and 
BSA to final concentrations of 50 units, 1x and 1x respectively. Reaction was 
incubated at 37oC for 2 hours, and then incubated at 65oC for 20 minutes to heat 
inactivate the enzyme. Digests were checked by running on a gel to check compete 
digestion.  
A standard curve was created by calculating the copy number of plasmid included in 
the restriction digestion, and then performing tenfold serial dilutions of this reaction. 
Diluted and digested plasmid standards were then used in a real time PCR analysis 
to check that the standard curve was acceptable, before being used for quantitative 
real time PCR analysis of sample material. 
2.6.9.2 QUANTITATIVE REAL TIME PCR ANALYSIS OF HUMAN ALBUMIN DNA  
Quantitative real time PCR analysis of human albumin DNA levels was perform using 
the SYBR green system (Invitrogen, USA). Master mix containing 0.54% (v/v) SYBR 
green buffer, primers and RNase/DNase free water to a volume of 8.5 µL was added 
to each sample containing 4 µL DNA. A standard curve which had been previously 
created and tested as described earlier was included in each PCR run, and all 
samples were run in duplicate to ensure reliability. Negative control samples 
consisted of master mix mixed with RNase/DNase free water.  
All samples were processed using a Rotorgene 6000 qRT-PCR machine (Qiagen, 
Australia). Real time PCR cycling conditions were as follows: a single 2 minute 
denaturation step at 50oC followed by incubation at 95oC for 2 minutes. 45 cycles 
were then carried out with denaturation at 95oC for 10 seconds, annealing at 62oC for 
15 seconds and extension at 72oC for 20 seconds. During these annealing and 
extension steps fluorescence levels were acquired. Following cycling, a step-wise 
increase in temperature from 60 – 90oC as performed to generate a melt curve. Data 
was analysed using Rotorgene 6000 Software (Qiagen, Australia). 
2.6.9.3 QUANTITATIVE REAL TIME PCR ANALYSIS OF VZV ORF28 DNA 
Quantitative real time PCR analysis of VZV ORF28 DNA levels was perform using 
the Rotor-Gene Probe PCR Kit (Qiagen, USA). Master mix containing reaction buffer, 
primers, probe and RNase/DNase free water to a volume of 8.5 µL was added to 
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each sample containing 4 µL DNA. A standard curve which had been previously 
created and tested as described earlier was included in each PCR run, and all 
samples were run in duplicate to ensure reliability. Negative control samples 
consisted of master mix mixed with RNase/DNase free water.  
All samples were processed using a Rotorgene 6000 qRT-PCR machine (Qiagen, 
Australia). Real time PCR cycling conditions were as follows: a single 3 minute 
denaturation step at 95oC. 50 cycles were then carried out with denaturation at 95oC 
for 3 seconds, annealing and extension at 60oC for 10 seconds. During this 
annealing/extension step fluorescence levels were acquired. Data was analysed 
using Rotogene 6000 Software (Qiagen, Australia). 
2.6.10 Bacterial cultures 
2.6.10.1 BACTERIAL TRANSFORMATION (HEAT SHOCK METHOD) 
Plasmid or ligation mix was stored on ice. JM109 competent cells (Promega, USA) 
were defrosted on ice. Plasmid and competent cells were then mixed in a ratio of 
1:10. Plasmids were mixed gently through competent cells by gentle stirring of 
pipette tip only. Mixtures were placed in a water bath at 42oC for 30 seconds, and 
then incubated on ice for 2 minutes. SOC media (Invitrogen, USA) was then mixed 
with bacterial mixture and tubes were incubated at 37oC and 225 rpm for 60 minutes. 
Cells were then transferred to agar plates as described below. 
2.6.10.2 BACTERIAL GROWTH 
2.6.10.2.1 Agar plate growth 
Bacterial cells were transferred from previous culture to LB agar plates. If from LB 
broth culture, plates were allowed to dry on bench for 45 minutes. Plates were 
transferred to 37oC incubator for overnight growth. 
2.6.10.2.2 Broth growth 
Cultures were set up using large conical flasks. LB broth and appropriate antibiotic 
(ampicillin or kanamycin) solution were pre-warmed and mixed well, and then 
cultures were inoculated with bacterial cells from previous culture. Bacterial cultures 
were grown in shaking incubators at 37oC overnight. 
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2.6.10.3 BACTERIAL COLONY PCR 
Bacterial colony PCR was utilised to check that the colony in question contained the 
desired plasmid construct. It was performed as described earlier, and bacterial 
colonies were scraped from plate growth and transferred to PCR tube directly before 
reactions were placed in PCR machine for cycling. PCR cycling conditions were 
performed as described earlier. 
2.6.10.4 PLASMID MINIPREP  
Plasmid minipreps were performed using the QIAprep Spin Miniprep Kit (Qiagen, 
Australia). Briefly bacterial cells from overnight culture were harvested by 
centrifugation at 6000 x g for 10 minutes at room temperature, and supernatant was 
discarded. Bacterial pellet was resuspended in 250 µL Buffer P1. 250 µL Buffer P2 
was added to bacterial mixture and mixed well by inversion. 350 µL Buffer N3 was 
added to bacterial mixture and mixed immediately by inversion. Mixture was then 
centrifuged at 17 900 x g for 10 minutes to form a compact white pellet. Supernatants 
were then transferred to a QIAprep spin column and centrifuged at 17 900 x g for 1 
minute, and flow through discarded. The QIAprep spin column was then washed by 
adding 0.5 mL Buffer PB and then centrifuged at 17 900 x g for 1 minute, and flow 
through discarded. QIAprep spin column was then washed with 0.75 mL Buffer PE 
and centrifuged at 17 900 x g for 1 minute, and flow through discarded. QIAprep spin 
column was centrifuged for an additional minute at 17 900 x g to remove any residual 
wash buffer. QIAprep spin column was then transferred to a clean microcentrifuge 
tube, and plasmid DNA eluted by adding 30 µL Buffer EB to the centre of the spin 
column, incubated at room temperature for 1 minute, and centrifuged at 17 900 x g 
for 1 minute. Plasmid DNA was then stored at -20oC until required. 
2.6.10.5 PLASMID MAXIPREP 
Plasmid maxipreps were performed using the QIAfilter Plasmid Maxi Kit (Qiagen, 
Australia) Briefly bacterial cells from overnight culture were harvested by 
centrifugation at 6000 x g for 15 minutes at 4oC, and supernatant was discarded. 
Bacterial pellet was resuspended in 10 mL Buffer P1 and mixed well. 10 mL Buffer 
P2 was added to mixture and mixed tubes inverted 6-8 times, and then incubated at 
room temperature for 5 minutes. 10 mL pre-chilled Buffer P3 was then added to 
tubes, mixed well by inverting, and the bacterial cell lysate was then transferred to a 
QIAfilter cartridge and incubated at room temperature for 10 minutes. During this 
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incubation a QIAGEN-tip 500 was prepared by adding 10 mL Buffer QBT and 
allowing the column to empty by gravity flow. The bacterial cell lysate was then 
filtered through the QIAfilter Cartridge into the QIAGEN-tip, and allowed to flow 
through the column by gravity flow. The QIAGEN-tip was then washed with two lots 
of 30 mL Buffer QC. Plasmid DNA was then eluted from QIAGEN-tip with 15 mL 
Buffer QF. DNA was precipitated by adding 10.5 mL isopropanol to the mixture, 
mixed well by inverting and centrifuged at 15 000 x g and 4oC for 30 minutes. 
Supernatant was carefully decanted, and pellets washed with room temperature 70% 
ethanol, and the centrifuged at 15 000 x g and 4oC for 30 minutes. Supernatant was 
carefully decanted and pellets air-dried. Pellet was resuspended in TE buffer. 
Plasmid DNA concentration and purity was checked using a Nanodrop 
spectrophotometer (Thermo-Fisher Scientific, USA) and plasmid was stored at -20oC 
until required.  
2.6.10.6 LONG TERM BACTERIAL STORAGE 
To store bacterial cells for longer periods 200 µL of overnight cultures were mixed 
well with 800 µL of glycerol (Sigma, USA), and then tubes were stored in -80oC. Cells 
were checked for viability at least 1 month after storage by streaking cells on to LB 
agar plates and growing overnight. 
 
2.7 Immunohistochemistry (IHC) 
2.7.1 Haematoxylin and eosin stain 
Slides were deparaffinised by washing in two changes of Xylene for 10 minutes 
each. Slides were re-hydrated by successively washing twice in 100% ethanol, twice 
in 95% ethanol, and once in 70% ethanol for 3 minutes each, and were then rinsed in 
running H2O for 3 minutes. Slides were incubated in haematoxylin solution for 2 
minutes and then rinsed quickly in running H2O. Slides were dipped in acid alcohol 
solution three times to remove excess stain and then rinsed quickly in running H2O. 
Slides were incubated in Scott’s Blueing solution for 30 seconds and then rinsed in 
running H2O. Slides were examined under a microscope to ensure adequate staining 
levels. If extra staining was required slides were re-immersed in haematoxylin and 
subsequent steps were followed. If staining was adequate, slides were washed in 
running H2O for 3 minutes. Slides were then washed in 70% ethanol for 30 seconds, 
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before being counterstained in eosin for 20 seconds. Slides were then dehydrated 
rapidly through graded ethanol (from 70% to 100%) and cleared in two washes in 
histolene of 2 minutes each. Slides were then coverslipped with DPX and allowed to 
dry overnight. 
2.7.2 Immunohistochemistry (IHC) 
Primary and secondary antibodies utilised in IHC procedures are listed in Table 2.2 
and Table 2.5 respectively. Isotype control antibodies are shown in Table 2.3. 
2.7.2.1 SINGLE IHC STAINING WITH HIGH TEMPERATURE ANTIGEN UNMASKING 
Slides were deparaffinised and rehydrated as in Section 2.7.1. Slides were then 
dipped in running H2O and washed in 1x TBS for 5 minutes. Endogenous 
peroxidases were blocked by incubating sections in 3% H2O2 solution for 10 minutes, 
and then slides were rinsed in distilled H2O. Sections were unmasked by incubating 
slides in 1x citrate buffer for 13 minutes at 93oC. Slides were left in 1x citrate buffer, 
taken off the heat and allowed to cool for 20 minutes. Slides were washed in 1x TBS 
for 5 minutes. Biotin blocking was then performed using the Biotin-blocking system 
(Dako, Australia). Avidin solution was applied to sections and slides were incubated 
for 10 minutes. Slides were then rinsed in 1x TBS. Biotin solution was applied to 
sections and slides were incubated for 10 minutes. Slides were then rinsed in 1x TBS 
for 2 minutes. Sections were circled using a Dako pen (Dako, Australia) and IHC 
blocking solution was applied to the sections, then incubated in a humidified chamber 
for 30 minutes at room temperature. Primary antibody diluted in IHC antibody dilution 
buffer was applied to the sections, then incubated in a humidified chamber for 2 
hours at room temperature. Slides were washed in three changes of 1x TBS for 3 
minutes each. IHC secondary antibody solution – containing biotinylated secondary 
antibody diluted in IHC antibody dilution buffer – was then applied to the sections, 
and incubated in a humidified chamber for 30 minutes at room temperature. Slides 
were then washed in three changes of 1x TBS for 3 minutes each. IHC enzyme 
solution – containing Streptavidin-HRP (Dako, Australia) diluted in IHC antibody 
dilution buffer – was then applied to the sections, which were incubated in a 
humidified chamber for 30 minutes at room temperature. Slides were then washed in 
three changes of 1x TBS for 3 minutes each. DAB working solution was mixed 
immediately prior to use, added to the sections and incubated for 5 minutes at room 
temperature. DAB working solution was removed from sections and the reaction was 
stopped by rinsing sections with dH2O for 5 minutes. Slides were then transferred to 
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running H2O for at least 10 minutes. Sections were then counterstained with azure 
blue or haematoxylin and mounted using DPX. 
2.7.3 Azure Blue counterstain 
Slides were counterstained in azure B solution for 4 minutes, before being washed in 
running H2O for 5 mins. Slides were then dehydrated by washing subsequently in 
70% ethanol for 30 seconds, 95% ethanol for 40 seconds, 95% ethanol for 50 
seconds, and in two changes of 100% ethanol for 1 minute each. Slides were then 
washed in two changes of histolene for 2 minutes each before being coverslipped 
(ProSciTech, Australia) with DPX and allowed to dry overnight. 
2.7.4 Haematoxylin counterstain 
Slides to be counterstained in haematoxylin for 10 seconds, before being washed in 
running H2O for at least 10 minutes. Slides were dehydrated by washing 
subsequently in 70% ethanol once, twice in 95% ethanol, and then twice in 100% 
ethanol for 3 minutes each. Slides were then washed in two changes of histolene for 
2 minutes each before being coverslipped (ProSciTech, Australia) with DPX and 
allowed to dry overnight. 
 
2.8  Immunofluorescent assay (IFA) 
Primary and secondary antibodies utilised in immunofluorescent assays are shown in 
Table 2.1 and Table 2.4 respectively. Isotype control antibodies are shown in Table 
2.3. 
2.8.1 Immunofluorescence staining of paraffin embedded sections 
with high temperature antigen unmasking 
Slides were deparaffinised and re-hydrated as per Section 2.7.1. Antigen retrieval 
was performed as per Section 2.7.2.1. Following this, slides were washed in 1x TBS 
for 5 minutes. Sections were circled using a Dako pen (Dako, Australia), and 
blocking solution (20% NDS in 1x TBS or 1x PBS) was applied to the sections which 
were then incubated in a humidified chamber for 30 minutes at room temperature. 
Blocking solution was discarded by tapping slides, and primary antibody solution 
(either single primary antibody for single stain or mix of primary antibodies for dual 
and triple stains) diluted in IFA antibody dilution buffer (10% NDS in 1x TBS) was 
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applied to the sections, which were then incubated in a humidified chamber for 2 
hours at room temperature. Slides were washed in three changes of 1x TBS for 3 
minutes each. Secondary antibody solution (either single or multiple antibody mix) 
diluted in IFA antibody dilution buffer was applied directly to the sections, which were 
then incubated in a humidified chamber for 60 minutes at room temperature. 
Samples were protected from light as much as possible for the remaining steps. 
Slides were washed in three changes of 1x TBS for 3 minutes each, and were 
coverslipped (ProSciTech, Australia) using Prolong Gold with DAPI, and then sealed 
with nail polish. Slides were stored at 4oC and protected from light. 
2.8.2 Autofluorescence masking 
This protocol was utilised to mask autofluorescence in sections during 
immunofluorescence assays where necessary. 
Slides were stained according to immunofluorescence protocols. After primary 
antibody incubation and subsequent rinses 1x sudan black solution was applied to 
sections and slides were incubated at room temperature for 5 minutes. Excess 
solution was tipped off slides, slides were dipped briefly in 70% ethanol and then 
excess solution was allowed to drain off. Slides were then rinsed in 1x PBS, and 
normal staining protocol continued. 
2.8.3 Gelatin coating of slides 
Gelatin coating solution was made fresh and placed into a large container. Plain 
uncoated microscope slides (Mikro-Glass, Australia) to be used for collection of cryo-
preserved material were loaded into slide carriers, and then dipped briefly into warm 
gelatin solution. Slide carrier was gently shaken to ensure no air bubbles remained. 
Slide carriers were then removed, excess solution drained back into container, and 
then slide carrier was banged on the bench to ensure that no air bubbles or droplets 
of solutions remained on the slides. Slides were left in the carrier to dry overnight, 
and gelatin coating solution was stored in the fridge. Protocol was repeated on slides 
the following day  
Slides were then transferred to slide boxes on the third day, and stored in a cool, 
dark and dry place and were used within a month from coating. 
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2.8.4 Immunofluorescence staining of frozen samples with low  
  temperature antigen unmasking 
2.8.4.1 SINGLE IMMUNOFLUORESCENCE STAINING 
Unfixed tissue sections were fixed in 10% neutral buffered formalin for 4 hours prior 
to being used. Slides were rinsed twice in 1x PBS for 20 minutes each before being 
unmasked in 1 mM EDTA at 60oC for 3 hours. Slides were allowed to cool at room 
temperature for 30 minutes, and rinsed in 1x PBS for 30 minutes. Slides were then 
incubated in blocking buffer for 2 hours. Sections were circled using a Dako pen 
(Dako, Australia), primary antibody mix (in blocking buffer) was applied to sections 
and then incubated overnight in a sealed humidified chamber at room temperature. 
Slides were then washed three times in 1x PBS for 20 minutes each. Secondary 
antibody mix (in blocking buffer) was then applied and slides incubated for 3 hours in 
a humidified chamber at room temperature. Slides were protected from light for the 
remainder of the protocol. Slides were washed 4 times in 1x PBS for 25 minutes 
each. Slides were then coverslipped with 5 µL Prolong Gold with DAPI applied to 
each section. Slides were sealed with nail polish and stored at 4oC. 
2.8.4.2 DUAL IMMUNOFLUORESCENCE STAINING 
Fixation (if required), unmasking and initial primary antibody were performed as with 
single immunofluorescence. Following initial primary antibody incubation slides were 
rinsed in 1x PBS for 6-8 hours. The second primary antibody mix (in blocking buffer) 
was then applied to sections and slides were incubated overnight in a sealed 
humidified chamber at room temperature. Slides were then washed three times in 1x 
PBS for 20 minutes each. Secondary antibodies specific for the relevant primary 
antibodies were applied as a mix (in blocking buffer) and slides incubated for 3 hours 
in a humidified chamber at room temperature. Slides were protected from light for the 
remainder of the protocol. Slides were washed 4 times in 1x PBS for 25 minutes 
each. Slides were then coverslipped with 5 µL Prolong Gold with DAPI applied to 
each section. Slides were sealed with nail polish and stored at 4oC. 
2.8.4.3 TRIPLE IMMUNOFLUORESCENCE STAINING 
Fixation (if required), unmasking and initial and second primary antibodies were 
performed as with dual immunofluorescence. Following initial primary antibody 
incubation slides were rinsed in 1x PBS for 6-8 hours. The third primary antibody mix 
(in blocking buffer) was then applied to sections and slides were incubated overnight 
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in a sealed humidified chamber at room temperature. Slides were washed three 
times in 1x PBS for 20 minutes each. Secondary antibodies specific for relevant 
primary antibodies were applied as a mix (in blocking buffer) and slides incubated for 
3 hours in a humidified chamber at room temperature. Slides were protected from 
light for the remainder of the protocol. Slides were washed 4 times in 1x PBS for 25 
minutes each. Slides were then coverslipped with 5 µL Prolong Gold with DAPI 
applied to each section. Slides were sealed with nail polish and stored at 4oC. 
 
2.9  Microscopy and analysis 
 
All microscopes, cameras and analysis software utilised were from the Advanced 
Microscopy Facility of the Bosch Institute (University of Sydney, Australia).  
Confocal microscopy was performed utilising a Zeiss LSM 510 Meta Spectral 
confocal microscope (Carl Zeiss, Australia). 
Bright field microscopy was performed utilising a Zeiss AxioPlan 2 upright 
microscope with an AxioCam HR digital monochrome CCD camera (Carl Zeiss, 
Australia) for images of immunofluorescent stains, or an AxioCam HR digital colour 
CCD camera (Carl Zeiss, Australia) for images of immunohistochemical stains.  
Cell counts, tissue area and cell frequencies were calculated with the aid of the Zeiss 
AxioVision LE software (Carl Zeiss Pty Ltd, Australia). 
Each results chapter contains specific information on the methods utilised to 
visualise stained tissue material and counting methods utilised. 
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Chapter 3 – Characterisation of immune cell 
phenotype in human dorsal root ganglia 
obtained from a patient with post-herpetic 
neuralgia, and comparison with other human 
ganglia samples obtained from patients at 
different stages post-herpes zoster. 
3.1 Introduction 
VZV is an ubiquitous human pathogen that causes two similar yet clinically distinct 
diseases – varicella and herpes zoster. Although the lesions are histopathologically 
indistinguishable in the two syndromes (Oxman, 2000), the general rash location 
differs considerably. The most common complication of herpes zoster is PHN - a 
severe neuropathic pain which can persist for months to years after the resolution of 
the herpes zoster-associated rash (Cohen et al., 1999, Steiner et al., 2007, Hope-
Simpson, 1965, Hope-Simpson, 1975). To date there is very limited information 
about both the host immune response and the extent of viral replication within the 
ganglia during PHN. 
This study aims to address this lack of knowledge through an immunofluorescent 
examination of rare human ganglia material obtained surgically from a PHN-affected 
patient, in comparison with other valuable post-mortem herpes zoster-affected and 
control ganglia material. Additionally nucleic acids were extracted from this material 
to assess the extent of viral infection within these samples. 
The underlying pathology and pathogenesis of PHN is relatively unknown. Multiple 
theories have been offered as explanation. However research to date has been 
restricted due to the lack of a suitable animal model of PHN, and the very rare nature 
of clinical sample material. There have been very few studies into clinical PHN 
samples, and even fewer have utilised human ganglia material.  
Previous studies involving PHN and the assessment of DRG have been limited to 
general and brief histological examinations of human ganglia. One histological study 
of ganglia obtained post-mortem from an individual who experienced PHN for several 
months prior to death found diffuse and focal infiltrations of inflammatory cells (Smith, 
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1978). Another study found a general loss of both axons and myelin within the 
affected area of a single patient suffering from PHN (Watson et al., 1988b). A follow-
up study on post-mortem DRG samples confirmed these findings, and noted 
evidence of a general inflammatory process occurring in some PHN-affected 
individuals (Watson et al., 1991). This study also noted atrophy of the spinal dorsal 
horn, and cell, axon, and myelin loss were only found in patients with persistent PHN. 
Persistent inflammation and lymphocytic infiltrate within the affected areas in long-
term herpes zoster survivors had been previously noted, but these cases had other 
causes of death and no clear pain at time of death, and as such this inflammation 
cannot be directly attributed to PHN (Head and Campbell, 1900). 
Overall these earlier histological based studies have been quite limited in their scope. 
This is most likely due to the experimental limitations at the time of publication, as 
well as the very limited number of samples available. Given the importance of the 
ganglia and the cellular and virological events that may be occurring during PHN, we 
sought to source ganglia from PHN-affected individuals. In this respect, we have 
obtained sample material surgically excised from a PHN-affected patient, as well as 
very valuable herpes zoster-affected and control material. This naturally infected 
ganglia material obtained post-herpes zoster and many months later during PHN is 
enough to allow a detailed examination of VZV DNA levels, the presence of active 
VZV gene transcription and antigen expression, and the constitution of infiltrating 
immune cells within this naturally infected material. 
 
3.2 Patient material 
3.2.1 Human ganglionic material used in this study 
A major limiting factor in advancing our understanding of the interaction of VZV with 
cells within human ganglia and the role the immune response may play during 
reactivation and PHN in vivo has been obtaining suitable human ganglia material. 
This study utilises precious PHN-affected ganglia material that was surgically excised 
from a PHN-affected patient. Also included are rare post-mortem material recovered 
from herpes zoster-affected patients and control material for comparison. 
All tissue specimens were obtained in accordance with ethics guidelines of the 
University of Sydney, and informed consent of the donors was obtained where 
required. 
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3.2.1.1 PHN PATIENT MATERIAL 
PHN-affected patient material was obtained from Dr Michael Buckland, originally of 
St Vincent’s Hospital, and now of the Department of Pathology, University of Sydney. 
This patient was diagnosed with acute myeloid leukaemia in 2001, and consequently 
underwent a bone marrow transplant in 2002. During recovery from this procedure 
the patient experienced herpes zoster in the right thoracic region from T9 to T12. 
Following this the patient experienced prolonged PHN at levels T10 to T12. 
After all other treatments options failed the patient was offered a ganglionectomy in 
an attempt to control the pain. This was performed in November 2006 – and material 
was removed from the patient’s right T11 region. PHN re-occurred, and in June 2007 
a second ganglionectomy was performed – this time removing both the right T10 and 
T12 ganglia. The three ganglia samples obtained were cut into smaller parts, 
formaldehyde fixed and embedded in paraffin blocks. Figure 3.1 shows the locations 
of the removed ganglia. 
The T11 ganglion obtained from the first surgery (PHN1) was made into three 
separate paraffin blocks containing tissue from different parts of the affected ganglion 
– one from the perikaryon region of the DRG (referred to as the neuronal area) 
(PHN1a) and two from the region of nerve bundles (PHN1b and PHN1c). Only the 
first block from this sample had been stained previously during my final year’s 
undergraduate honours work (Sutherland, 2008). However replicate stains, new IFA 
and IHC staining combinations, counts and frequency analyses were performed on 
all three paraffin embedded blocks during this study. 
There were two ganglia obtained at the second surgery. The first (PHN2) from T10 
level was made into two blocks – one each from the neuronal area (PHN2a) and 
nerve bundle region (PHN2b). The first block from this sample had mainly been 
stained previously during my honours work (Sutherland, 2008). Replicate stains, new 
IFA and IHC staining combinations, counts and frequency analyses were performed 
during this study. Sections from the second paraffin embedded block were 
immunostained for the first time in this study. 
The second ganglion from this surgery (PHN3) from the T12 level and only one block 
was deemed suitable for this study and contained tissue located in the nerve bundle 
region (PHN3a). Another block was available, but following sectioning was found to 
contain very little tissue (PHN3b). 
Figure 3.1 - Location of ganglia samples from the PHN-aected patient
PHN-aected ganglia material used in this study were obtained from the right thoracic region. PHN1 was the 
right T10 ganglion, PHN2 was the right T11 ganglion and PHN3 was the right T12 ganglion.
Ganglia diagram adapted from: http://www.backpain-guide.com/Chapter_Fig_folders/Ch06_Path_Folder/4Radiculopathy.html (accessed 29/2/12)
PHN2
PHN1
PHN3
 The University of Sydney 
- 75 - 
All herpes zoster patient material was generously provided by Dr Michael Buckland 
from the Department of Pathology, University of Sydney. Samples were supplied as 
formalin-fixed paraffin-embedded blocks, which were sectioned into consecutive 5 
µm sections and mounted on Superfrost plus microscope slides (Thermo Fisher 
Scientific, USA) by Dr Jane Radford formerly of the Histopathology Laboratory of the 
University of Sydney. Off cuts from each block were also collected in clean 
eppendorf tubes to be utilised for nucleic acid extraction and subsequent molecular 
analysis. 
3.2.1.2 HERPES-ZOSTER-AFFECTED PATIENT MATERIAL 
Also included for comparison are rare post-mortem samples obtained from patients 
who had an active VZV reactivation event at or near the time of death. In this study 
ganglia from three different patients were included. Figure 3.2 shows the location of 
ganglia samples from the herpes zoster-affected patient material. 
The first herpes zoster ganglion sample (HZ1) was obtained post-mortem. The 
patient was a 31 year old female who had been on immunosuppressive therapy 
(prednisone and mycophenolate) for five years following a renal transplant which was 
the result of preeclampsia which lead to end-stage renal failure. Past medical history 
also noted cardiomyopathy diabetes mellitus and hypertension. Six months prior to 
death the patient developed disseminated herpes zoster secondary to 
immunosuppression and EBV-associated post-transplant lymphoproliferative 
disorder (lymphomatoid granulomatosis grade 3). The patient also had complicating 
hepatitis and pneumonia. One month later she had recurrent herpes zoster 
complicated by thrombotic thrombocytopenic purpura and splenic vein thrombosis 
requiring splenectomy. Secondary transverse myelitis and demyelinating neuropathy 
was also diagnosed 4 months prior to death. One week prior to death the patient 
presented with headaches and confusion, and an MRI demonstrated multiple lesions 
on both cerebral hemispheres consistent with acute encephalitis. Multiple pulmonary 
emboli and deep vein thromboses were noted post-mortem. Cerebrospinal fluid 
taken at autopsy was PCR positive for VZV and EBV. The ganglion utilised in this 
study was a TG, which at autopsy tested PCR positive for VZV but negative for EBV 
and other infectious agents (Rodriguez, 2010). This ganglion sample contained 
tissue from the neuronal region of the TG. Sections from this ganglion were used in 
new IFA staining combinations, and all counts and frequency analyses were 
performed during this study. 
Figure 3.2 - Location of ganglia samples obtained from HZ-aected patients
(A) The HZ1 ganglion sample was from the trigeminal region, however side was unknown.
(B) The HZ2 ganglion sample was from the upper left cervical region. Other ganglia included in the analysis 
were the HZ2 SOR (right trigeminal ganglia) and HZ2 contra (left trigeminal).
(C) The HZ3 ganglion sample was from the right lumbar region. The HZ3 SOR ganglion sample was from 
the tenth lumbar ganglion on the left side.
Ganglia diagrams adapted from: http://www.uihealthcare.org/Adam/?/HIE%20Multimedia/2/18069 (accessed 29/2/12)
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The second herpes zoster ganglia sample (HZ2) was obtained post-mortem from a 
patient who at the time of death had active herpes zoster. The patient was a 62 year 
old male with acute myeloid leukaemia, which was diagnosed at autopsy. The patient 
had begun experiencing herpes zoster approximately 3 weeks prior to death in the 
right ophthalmic division of the TG. The rash was still evident at autopsy and there 
was some dissemination to the thoracic region (Rodriguez, 2010). Ganglionitis was 
observed in both TG and cervical DRG. The ganglion from this case utilised in this 
study was from the left cervical region (HZ2), and contained tissue from the nerve 
bundle region of the DRG. The site of reactivation (SOR) – the right TG (HZ2 SOR) 
and left TG (contralateral to SOR) (HZ2 contra) had been previously stained by Dr 
Megan Steain in a study which focused on the neuronal regions of the tissue (Steain 
et al., 2013) and these slides were utilised in this study to examine regions of nerve 
bundles within the ganglia material. 
The third herpes zoster ganglion sample (HZ3) was obtained post-mortem from a 
patient with an active case of herpes zoster at the time of death. The patient was a 
93 year old male with frontotemporal dementia who died due to aspiration 
pneumonia. Medical records indicated that this patient developed a herpes zoster 
rash approximately 17 days prior to death, which was treated with antibiotics 
(according to clinical notes) (Rodriguez, 2010). At autopsy there was a haemorrhagic 
vesicular and ulcerated rash in a left lumbar dermatome. The innervating ganglion 
was noted to be inflamed. The ganglion utilised in this study was a right lumbar DRG, 
not noted at autopsy to be inflamed, and contained tissue from the nerve bundle 
region of the DRG. As with HZ2, the SOR – the left lumbar ganglion (HZ3 SOR) had 
been previously stained by Dr Megan Steain in a study which had focused on the 
neuronal regions of the tissue (Steain et al., 2013), and these slides were utilised in 
this study to examine the regions of nerve bundles within the tissue. 
All herpes zoster-affected patient material was generously provided by Dr Michael 
Rodriguez from the Department of Forensic Medicine, University of Sydney. Samples 
were supplied as formalin-fixed paraffin-embedded blocks, which were sectioned into 
consecutive 5 µm sections and mounted on Superfrost plus microscope slides 
(Thermo Fisher Scientific, USA) by Dr Jane Radford formerly of the Histopathology 
Laboratory of the University of Sydney. Off cuts from each tissue block collected as 
above for nucleic acid extraction and subsequent molecular analysis. 
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3.2.1.3 CONTROL PATIENT MATERIAL 
Post-mortem ganglia samples from two patients who did not present with herpes 
zoster were included as controls. The first control patient ganglia material (CON1) 
was obtained post-mortem from a 73 year old female who died from metastatic 
adenocarcinoma. This ganglion was from the lower thoracic area, and contained 
tissue from the neuronal area of the DRG. This sample had been stained previously 
during my honours work (Sutherland, 2008). New IFA and IHC staining 
combinations, replicate stains, all counts and frequency analyses were performed 
during this study. 
The second control patient material (CON2) was obtained post-mortem from a 73 
year old female who died from a head injury and previously suffered from 
cardiovascular disease. This sample contained tissue from the nerve bundle region 
of the DRG. This study is the first use of this sample material. 
VZV sero-status of control patients is unknown. 
All control patient material was generously provided by Dr Michael Rodriguez from 
the Department of Forensic Medicine, University of Sydney. Samples were supplied 
as paraffin-embedded blocks, consecutive 5 µm sections were collected onto 
Superfrost plus microscope slides (Thermo Fisher Scientific, USA) by Dr Jane 
Radford formerly of the Histopathology Laboratory of the University of Sydney. Off 
cuts from each tissue block collected as above for nucleic acid extraction and 
subsequent molecular analysis. 
3.2.2 Control material 
Normal tonsil samples had been previously provided by Dr. Tony Henwood (The 
Children’s Hospital at Westmead, Australia). These were supplied as formaldehyde-
fixed tissue blocks embedded in paraffin as described earlier. 
Control cell blocks were created from both uninfected and VZV-infected human 
foreskin fibroblasts, and CD14- depleted human PBMCs as described in Section 
2.5.2.3. CD14- human PBMCs were generously donated by Rodney Henriquez 
(Varicella Zoster Virus Research Group, University of Sydney). 
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3.3 Results 
3.3.1 Histology of patient ganglia samples 
Previous reports have found extensive cellular infiltration in human ganglia obtained 
via autopsy from PHN-affected individuals (Head and Campbell, 1900, Watson et al., 
1991). Thus, my initial examination of patient DRG material was a haematoxylin and 
eosin stain (H&E) of 5 µm paraffin-embedded ganglionic sections shown in Figures 
3.3 and 3.4. 
In all ganglionic sections there is the presence of lipofuscin, seen as a brown 
pigment within neurons. This a normal feature of human ganglionic material, and is 
made up of lipid containing residues of lysosomal degradation that builds up within 
neurons throughout the normal ageing process (Ross and Pawlina, 2003). 
There were three separate tissue blocks obtained from PHN ganglia 1. The first 
(PHN1a) showed limited areas containing neurons, with an infiltration of immune 
cells concentrated within the outer capsule which surrounds the ganglia. The second 
(PHN1b) featured a cross-sectional view of the nerve bundles with an infiltration of 
immune cells concentrated around one nerve bundle and throughout the capsule. 
The third block (PHN1c) contained a longitudinal view of nerve fibres with a small 
infiltration of immune cells throughout the tissue. Representative images of H&E 
staining on ganglionic material from PHN1a, PHN1b and PHN1c are shown in 
Figures 3.3 A, B and C respectively. 
There were 2 separate tissue blocks from PHN ganglia 2. The first (PHN2a) showed 
areas of neurons, along with an infiltration of immune-like cells throughout the entire 
ganglia with some focal points of immune infiltrations within the ganglia. The second 
(PHN2b) featured tissue containing a cross-sectional view of many smaller nerve 
bundles with limited immune-like cells. Representative images of H&E staining of 
ganglionic material from PHN2a and PHN2b are shown in Figures 3.3 D and E 
respectively. 
There were 2 separate tissue blocks available from PHN ganglia 3. The first (PHN3a) 
consisted of a longitudinal view of nerve fibres without obvious infiltration of immune-
like cells, and a representative image of H&E staining on this sample is shown in 
Figure 3.3 F. The second block (PHN3b) contained a very limited tissue region and 
was not utilised in subsequent experiments. 
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Interestingly, within PHN ganglia 2 there was also an area of altered morphology 
which was not observed in any of the other ganglia samples studied. This area also 
showed general loss of neuronal profiles via H&E staining (Fig. 3.5 A). Neuronal cell 
death has been shown to lead to a proliferation of satellite cells in place of the 
adjacent neuron in a formation known as a Nodule of Nageotte (Ramon y Cajal, 
1959). To identify if this PHN ganglia sample contain regions of proliferating satellite 
cells caused by neuronal cell death an IFA was performed using a primary antibody 
specific for S100B – a satellite cell and myelin marker. The resulting staining pattern 
is shown in Figure 3.5 B. S100B+ cells were readily detected around neurons, 
however there were no S100B+ cells observed within the region of altered 
morphology. Consequently the altered morphology observed in the PHN ganglia 2 
sample does not appear to correlate with any detectable satellite cell proliferation 
and may be a region of fibrosis. Alternatively the altered morphology observed within 
PHN2 could simply be due to an infolding of the outer capsule of the DRG – thus 
giving rise to an abnormal appearance within an otherwise normal histology. 
Overall the PHN-affected ganglionic material featured prominent infiltrations of 
immune-like cells, with PHN ganglia 2 containing the largest infiltration, along with a 
region of altered cellular morphology. Smaller infiltrations of small round cells that 
bear the characteristics of immune cells were also identified in PHN ganglia 1. There 
were no obvious immune-like infiltrations in PHN ganglia 3.  
The histology of the herpes zoster-affected ganglia sample HZ1 showed normal 
neuronal regions of ganglia with no obvious immune infiltration. A representative 
image of H&E staining on this sample is shown in Figure 3.4 A. 
The block available from HZ2 showed several distinct regions of tissue, each 
featuring cross-sectional views of large nerve fibre bundles with no obvious 
infiltrations of immune-like cells. A representative image of H&E staining on this 
sample is shown in Figure 3.4 B. Of the two other blocks previously stained by Dr 
Megan Steain the SOR and contralateral site both featured neuronal and nerve 
bundle regions with small areas of immune infiltration spread evenly throughout the 
ganglia samples (Steain et al., 2013).  
The tissue sample utilised from HZ3 showed a small area of tissue which featured a 
cross-sectional view of several nerve fibre bundles with limited infiltrations of 
immune-like cells. A representative image of H&E staining on this sample is shown in 
Figure 3.4 C. The SOR – previously stained by Dr Megan Steain - featured both 
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neuronal and nerve bundle areas with a large and extensive immune infiltration 
within the ganglia sections (Steain et al., 2013).  
The histology of the control ganglia sample (CON1) showed normal neuronal regions 
of ganglia with no immune infiltration, and the presence of large and small neurons 
each surrounded by satellite cells. A representative image of H&E staining on this 
sample is shown in Figure 3.4 D. 
The second control tissue sample (CON2) featured two distinct areas of tissue that 
both had cross-sectional views of nerve fibre bundles with no obvious infiltrations of 
immune-like cells. A representative image of H&E staining on this sample is shown in 
Figure 3.4 E. 
There were infiltrations of immune-like cells in both herpes zoster-affected tissue and 
PHN-affected tissue, but not in control material. The infiltrations within the PHN-
affected material was present in both PHN ganglia 2 and to a lesser extent PHN 
ganglia 1. The infiltrations of small round cells observed in herpes zoster-affected 
tissue were mainly restricted to the ganglia innervating the rash area (Data presented 
in Steain et al., 2013). There was no infiltration of small round immune-like cells in 
control ganglia material. 
3.3.2 Detection of VZV DNA in human ganglia following herpes zoster 
and PHN 
In order to check for the presence of viable cellular DNA, and identify the presence of 
VZV DNA nucleic acid extraction and PCR amplification was performed. PCR 
amplification provides a convenient method for amplifying DNA fragments, and by 
using a specific primer pair this technique is able to detect sequences of DNA with 
high sensitivity and specificity. DNA extraction was performed on all ganglia samples 
except the ganglia region from PHN1 as there was not enough tissue available. 
Controls included DNA extracted from VZV-infected HFFs (infHFFs) in culture, as 
well from HSV-1 cell culture supernatant. A no template negative control was also 
included. Primers used in PCR to amplify GAPDH, VZV and HSV DNA regions are 
listed in Section 2.3. 
As the material used in this study was paraffin-embedded, initially it was important to 
show the presence of amplifiable DNA within the sections. This was done using 
primers specific for the housekeeping gene GAPDH predicted to give a PCR product 
of 350 bp. The resulting PCR product were run on a 1% TAE agarose gel with a 
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suitable DNA ladder mix, shown in Figure 3.6 A. A band of the expected size was 
detected in PHN1a, PHN1b, PHN2a, PHN2b and PHN3a. There was no band 
detected in PHN3b. A band of the expected size was detected in HZ1 and CON1, but 
not in HZ2, HZ3 or CON2. This shows successful extraction of intact DNA from the 
PHN1a, PHN1b, PHN2a, PHN2b, PHN3a, HZ1 and CON1 ganglia samples. 
Although there was no GAPDH detection in PHN3b, HZ2, HZ3 and CON2 samples, 
corresponding with no viable DNA from each of these samples they were included in 
subsequent PCRs for consistency. 
Using the same primer set, a product was detected in the infHFF culture DNA 
sample at the expected size (350 bp). There was no PCR product detected in the 
HSV-1 culture supernatant, but this is to be expected as it should contain HSV-1 
virions only without any cellular DNA. There was no PCR product present in the no-
template control, showing no contamination of the PCR. 
To detect the presence of VZV DNA in each of the samples, a PCR was performed 
using primers specific for VZV ORF9a, which amplifies a product of 365 bp. The 
resulting PCR products were run on a 1% agarose gel, shown in Figure 3.6 B. The 
positive control infHFF featured a band at the expected fragment size. A band of the 
expected size was detected in PHN1a, PHN2a, PHN2b and PHN3a. No band was 
detected in PHN1b or PHN3b. A band of the expected size was also detected in 
HZ1. No bands were detected in HZ2, HZ3, CON1 or CON2. This shows successful 
PCR detection of VZV-specific DNA in the PHN1a, PHN2a, PHN2b, PHN3a and HZ1 
ganglia samples, but not in PHN1b, PHN3b, HZ2, HZ3, CON1 or CON2.  
HSV-1 is a highly related alphaherpesvirus, which unlike VZV has been shown to 
cause an immune infiltration in latently infected human ganglia (Verjans et al., 2007). 
In order to detect any HSV-1-specific DNA in the ganglia samples a PCR was 
performed using previously published HSV-1-specific primers (Cassinotti and Siegl, 
1998) which produce a amplified PCR product of 208 bp. The resulting PCR products 
were run on a 1% agarose gel, shown in Figure 3.6 C. The positive control HSV-1 
infected culture supernatant featured a band at the expected fragment size. A PCR 
product of the expected size was also observed in the HZ1 ganglia sample. No other 
ganglia sample showed detectable HSV-1 DNA. No PCR product was detected in the 
infHFF culture DNA samples, as expected. There was no PCR product present in the 
no-template controls, showing no contamination of the PCR mixture. 
Consequently it was possible to isolate viable DNA from all PHN1 and PHN2 
samples, and from PHN3, as well as from the HZ1 and CON1 samples. Significantly 
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Figure 3.6 - Detection of GAPDH and VZV DNA, but not HSV DNA in patient ganglia samples
DNA isolated from all PHN, HZ and Control ganglia samples was utilised in PCR reactions and then loaded onto 1%  TAE 
agarose gels. PCR reactions used primers specic for the housekeeping gene GAPDH (A), VZV ORF9a (B) and a HSV-1-
specic fragment (C), with band sizes shown above. 
Each PCR reaction included control DNA extracted from infected HFF in cell culture, as well as the supernatant 
(containined HSV-1 virions) from an HSV-1 infected culture. Gels also included a DNA ladder (Fermentas GeneRuler 
DNA Ladder Mix) containing bands from 100 bp to 100 00 bp, with major band sizes labelled.
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VZV DNA and not HSV-1 DNA was also detected by PCR in the PHN1a, all PHN2 
and the PHN3a samples, demonstrating any immune cell infiltrate present in these 
ganglia was not due to an HSV-1 infection. VZV DNA was also detected in the HZ1 
ganglia sample. HSV-1 DNA was only detected in the HZ1 ganglia sample. 
3.3.3 Quantitation of VZV DNA in human ganglia samples 
As VZV DNA was detected in several PHN-affected ganglia samples it was decided 
to investigate the relative amounts of VZV DNA present in each sample. This was 
carried out by performing two independent quantitative real time PCR analyses to 
detect human albumin and VZV ORF28. Human albumin is present as a single copy 
in each cell and is suitable as a standard in quantitative real time PCR (Douek et al., 
2002), while VZV ORF28 contains a region unique to VZV – not present in any other 
related herpesviruses, allowing the specific detection of only VZV DNA. Reaction 
conditions, primer and probe sequences were kindly provided Prof Randall Cohrs of 
the University of Colorado, Denver. 
To compare ganglia samples the number of copies of VZV ORF28 DNA was 
normalised against the number of copies of human albumin. Results are shown as 
“VZV DNA load per 105 cells” to allow easy comparison between these results and 
previously published work (Eshleman et al., 2011). The relative results (from 2 
replicates) are in shown in Figure 3.7. On average there was 6.9 times more VZV-
specific DNA present in the ganglionic sample from a PHN-affected individual 
(PHN2a) than in the site of an active herpes zoster reactivation (HZ3 SOR).  
Unfortunately there was insufficient DNA material to perform a full analysis on all 
ganglia samples, consequently only material from the neuronal region of PHN2 
(PHN2a), HZ3 SOR and CON2 samples were completely analysed in two 
independent experiments. 
This data suggests that there may be a higher viral DNA burden in PHN-affected 
ganglia than in ganglia following active herpes zoster reactivation. 
3.3.4 RNA analysis of VZV-specific transcripts in human ganglia 
samples 
As the viral DNA load in one of the PHN-affected ganglionic samples was found to be 
much higher than that detected in the ganglion at the site of reactivation, it 
investigated whether any active viral replication was present within the ganglia 
samples. This was assessed using reverse transcriptase real time PCR analysis of 
Figure 3.7 - Quantitation of VZV DNA in human ganglia samples
VZV-specic DNA levels were measured via quantitative real time PCR utilising a primer specic for a unique VZV 
coding region.  Results were normalised to human albumin (present in 1 copy per each cell), and then the number of 
copies per 105 cells calculated.
DNA from the neuronal area of PHN2 (PHN2a), the site of reactivation from HZ3 (HZ3 SOR) and CON2 were fully 
analysed. Unfortunately analysis of other ganglia samples was not possible as there was insucient DNA to perform all 
experiments.
On average there was 6.9x more copies of VZV present in the neuronal region of PHN2 than in the HZ3 site of 
reactivation.
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VZV-specific mRNA transcripts of three viral genes: gB, gE and IE63. IE63 is an 
immediate early gene, and may also be expressed during latent infection however 
VZV gB and gE are both late genes, only expressed during in productively infected 
cells (Reichelt et al., 2009). 
3.3.4.1 PLASMID CONSTRUCTS 
Initially it was important to measure the sensitivity of the primer pairs used. To this 
end, plasmid constructs were created containing the coding region detected by the 
real time PCR primer pairs. Plasmid construction was performed using the pGEM-T 
Easy vector system (Promega, USA). Regions of interest were amplified in PCR 
reactions (Section 2.6.2), confirmed via gel electrophoresis (Section 2.6.3), purified 
(Section 2.6.4) and utilised in ligation reactions (Section 2.6.5). Bacterial cells were 
transformed via heat shock (Section 2.6.10.1), and then amplified via bacterial 
cultures (Section 2.6.10.2). Constructs were screened for the region of interest via 
bacterial colony PCR (Section 2.6.10.3), before plasmid isolation (Section 2.6.10.4), 
and sending the resulting purified DNA for sequencing at the Australian Genome 
Research Facility (Section 2.6.6). The resulting plasmids constructs are called 
pGEM-gB-RT, pGEM-gE-RT and pGEM-IE63-RT and plasmid maps are shown in 
Figure 3.8 were created utilising PlasMapper (Dong et al., 2004). 
3.3.4.2 PRIMER SENSITIVITY TESTING 
Utilising the plasmid constructs from above, plasmids were linearised by restriction 
enzyme digestion and serial dilutions of plasmid stocks were created and using the 
molecular weight of the plasmids the copy number of each dilution calculated. These 
serial dilutions were then utilised as templates in real time PCR reactions to measure 
the primer sensitivity of each primer pair. The IE63 and gB-specific primer pairs 
reliably and reproducibly amplified a product from 100 copies of their target 
sequences per reaction, while the gE-specific primer pair reliably and reproducibly 
amplified a product from 1000 copies of target sequence per reaction. Detection 
below this level was possible, however serial dilutions were less precise, and 
consequently it could not be reliably detected. Data is shown in Appendix 1.  
3.3.4.3 REAL TIME PCR ANALYSIS OF VZV-SPECIFIC GENE EXPRESSION IN 
HUMAN GANGLIA SAMPLES 
After checking sensitivity of the primers, RNA was extracted from human ganglia 
samples, and utilised in reverse transcription reaction to create cDNA. This cDNA 
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was utilised as templates in real time PCR analysis in order to detect VZV-specific 
transcripts, with real time analysis performed using primers for both a viral transcript 
(either gB or gE) and the house keeping gene GAPDH concurrently. Unfortunately 
analysis using an NanoDrop spectrophotometer (Thermo Scientific, USA) indicated 
that the RNA extracted from all ganglia samples was degraded (likely due to the 
heavy fixation process each ganglia was subjected to), and consequently the cDNA 
was not of sufficient quality and detection of both VZV and house keeping transcripts 
was not possible, despite the positive control (cDNA obtained from RNA infected cell 
culture material) working well. The IE63-specific primer pair was not able to be used 
as there was insufficient template material to continue. Therefore we were not able to 
use RNA to establish VZV-specific gene expression in human ganglia samples. 
3.3.5 Presence and distribution of viral antigen expression in human 
ganglia following herpes zoster and during PHN 
Although there is very little known about the underlying pathology and pathogenesis 
of PHN one of the main hypotheses offered is the presence of ongoing active viral 
infection within the ganglia (Steiner et al., 2007). VZV reactivation within the ganglia 
leads to herpes zoster, however PHN can be present months to years following the 
resolution of the zoster rash (Watson, 1998). Our laboratory has previously shown 
the presence of VZV antigen positive cells within post mortem ganglia samples taken 
from herpes zoster-affected patients (Gowrishankar, 2008, Gowrishankar et al., 
2010), however a more recent study has shown that this may due to cross-reactivity 
between components of the antibody solution with human blood group proteins 
rather than viral antigen expression (Zerboni et al., 2012). More recently we have 
been able to demonstrate the presence of multiple VZV antigens in post mortem 
ganglia samples from another herpes zoster-affected patient, however at a much 
lower level and with a different cellular distribution than previously reported (Steain et 
al., 2013). In this study VZV IE63 antigen positive cells were observed within the 
ganglia of one herpes zoster-affected patient, and in another herpes zoster-affected 
patient anti-VZV gE and anti-VZV gE:gI complex antibody staining was observed 
within neuron-satellite cell units, along with some small infiltrating cells also staining 
positive for VZV gE. To date there has been no reported direct demonstration of 
productively infected cells or VZV antigen staining in PHN-affected ganglia material, 
despite detection of VZV-specific proteins within mononuclear cells in the blood of 
PHN-affected patients (Gilden et al., 2003).  
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VZV antigen detection within human ganglionic samples from a PHN-affected sample 
was attempted with the VZV-specific antibodies listed below in Table 3.1. Both 
immunofluorescent staining with sudan black autofluorescence masking and 
immunohistochemical staining with azure blue counterstain methods (see Sections 
2.8.2 and 2.7.3) were attempted. In each experiment staining was successful on 
positive control infHFF cell blocks and VZV-infected fetal explant ganglia material. 
Control stains were performed in parallel by applying a matched antibody isotype at 
the same concentration to ganglia material. Negative controls included uniHFF and 
uninfected fetal explant ganglia material, as well as control human ganglia material. 
There was no VZV antigen detection in the PHN patient material with any method 
attempted. There was no VZV antigen expression detected in the herpes zoster or 
control patient material. In total, 5 different markers were utilised a minimum of 3 
times each. Some of these experiments were attempted simultaneously and in 
conjunction with those reported in Steain et al. (2013), which successfully 
demonstrated the presence of low level VZV antigen (IE63, gE and gE:gI) expression 
in both ganglia and infiltrating cells in post-mortem material from patients with active 
herpes zoster. 
Therefore despite the higher viral DNA burden demonstrated in PHN-affected ganglia 
by quantitative real-time PCR we were not able to confirm the presence of any active 
viral replication by IFA staining. 
 
Table 3.1 - Primary antibodies utilised in staining experiments 
investigating VZV antigen expression in patient ganglia samples. 
Antibody Specificity Source 
Mouse anti-glycoprotein E  (Millipore) 
Mouse anti-glycoprotein E:glycoprotein I complex (Meridian Life Sciences) 
Mouse anti-glycoprotein B 
(Dr C. Grose, University of 
Iowa) 
Rabbit anti-ORF29  
(Prof P. R. Kinchington, 
University of Pittsburgh) 
Rabbit anti-IE63  
(Dr R. Mahalingam, University  
of Colorado) 
 
 The University of Sydney 
- 86 - 
3.3.6 Constitution and distribution of infiltrating immune cells in 
human ganglia in vivo 
Previously during my undergraduate honours work I performed an analysis of the 
constitution and distribution of immune cells present in one ganglion sample each 
from PHN1 and PHN2, as well as in the HZ1 and CON1 samples. To do this ganglia 
sections were stained for a variety of immune markers including CD3, CD4, CD8 (for 
T cell subsets), CD20 (for B cells), CD68 (for macrophages and other large cells), 
CD57 (for NK cells), CD1a (for dendritic cells), CD45RA (for naive T cells), CD45RO 
(for memory T cells), TIA-1 (T cell intracytoplamic antigen) and granzyme B 
(cytotoxic T cells and NK cell marker). All of these samples contained tissue from the 
neuronal region of the DRG. 
Following on from this work we gained access to additional PHN patient ganglionic 
material which consisted mainly of regions of nerve bundles from the various ganglia. 
As there has not been to date an analysis of the infiltrate within the different regions 
of the ganglia, this project encompassed a detailed comparison of the immune cell 
infiltrate in PHN, herpes zoster and control material for both the neuronal and nerve 
bundle areas. There has also been no analysis of immune cell infiltration and viral 
antigen expression across the different phases of VZV infection of ganglia in vivo. To 
this end, ganglia and nerve bundle samples from individuals with active viral 
reactivation (HZ2 and HZ3), 6 months post-herpes zoster (HZ1) as well as years 
post-herpes zoster during PHN were all immunostained and examined by fluorescent 
microscopy. 
All samples were IFA stained and analysed for CD3, CD4, CD8, CD20, CD68, 
CD45RA, CD45RO and TIA-1. Sensory neurons typically lack expression of MHC 
molecules, however is has been reported that HSV-1 infection of mouse sensory 
neurons causes an upregulation of these functionally important immune molecules 
(Pereira et al., 1994). All ganglia samples were also consequently used to examine 
the expression of HLA-DR to check for any upregulation of MHC class II on 
professional antigen-presenting cells. 
To ensure accurate interpretation of IFA staining experiments a number of controls 
were included. The positive control material used was either human tonsil tissue or 
the CD14- PBMC cell block. Negative control material was uniHFF sections. Isotype 
controls were also performed to confirm the specificity of antibody staining, and 
included applying the appropriate isotype control antibody to matched ganglionic 
 The University of Sydney 
- 87 - 
sections. A representative panel of microscope images for each of the successful 
immune cell markers is shown for each IFA stain. 
3.3.6.1 IMMUNE CELL ANALYSIS 
Initial analysis during honours of the number of each cell type detected was 
performed by calculating the number of each cell marker detected as a percent of all 
small round cells (Sutherland, 2008). This was investigated to compare results with 
another study performed in our lab that was being performed at around the same 
time (Gowrishankar, 2008, Gowrishankar et al., 2010). However as the process was 
laborious and at times imprecise due to the subjective issue of what constitutes a 
“small round cell”, for this study cell marker numbers were analysed as frequency of 
positive cells per unit area – and more specifically number of positive cells per 100 
000 µm2. This allows for a more robust analysis that is more easily performed on new 
samples, and is more feasible to compare between samples stained and counted at 
different times. 
Following IFA staining of sections, microscope images were captured using the Zeiss 
AxioPlan 2 upright microscope with an AxioCam HR digital monochrome CCD 
camera (Carl Zeiss, Australia) for images of immunofluorescent stains, or an 
AxioCam HR digital colour CCD camera (Carl Zeiss, Australia) for images of 
immunohistochemical stains. Microscope and cameras were part of the Bosch 
Advanced Microscopy Unit (University of Sydney, Australia). Cell counts and cell 
frequencies were calculated by counting the number of positive cells for each cell 
specific marker in 8-20 random images per section (limited only by the size and 
condition of the section). The total surface area examined in each micrograph was 
then calculated with the aid of the Zeiss AxioVision LE software (Carl Zeiss Pty Ltd, 
Australia). The frequency of positive cells was obtained by dividing the number of 
positive cells by the total area of the tissue which was then expressed as “positive 
cells per 100 000 µm2”. This analysis was performed for the cell markers CD3, CD4, 
CD8, CD20 and TIA-1. In addition, all IFA slides previously stained during honours 
were re-analysed using this method to allow a direct comparison. 
An alternate method was utilised for HLA-DR and CD45RA/RO analysis as individual 
cell expression was difficult to identify, instead regions of expression were analysed. 
These markers were investigated in terms of relative expression: HLA-DR expression 
was compared across the various ganglia samples taken during active zoster, many 
months post herpes zoster and in a PHN-affected individual. This enabled the 
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comparison in HLA-DR expression levels between the difference disease states 
following natural VZV reactivation in vivo. CD45RA expression was compared to 
CD45RO expression within the same ganglia to identify the prominent immune cell 
type present – naive (CD45RA+) or memory (CD45RO+). 
3.3.6.2 DETECTION OF CD3+ T CELLS 
T cells are an important effector cell type in the body’s immune system, especially in 
viral infections (Abbas and Lichtman, 1991), and during VZV infection T cell 
mediated immune responses have been shown to be crucial in the control of primary 
VZV infection (Arvin, 1992). To determine whether T cells were present within the 
PHN sample material and compare the relative cell numbers and distribution with 
that seen in herpes zoster and control ganglia samples, dual IFA was performed 
using the rabbit anti-S100B and mouse anti-CD3 primary antibodies specific for 
satellite cells/myelin and T cells respectively. The S100B marker allowed for further 
distinction between infiltrating cells and satellite cells. The secondary antibodies used 
to detect antibody binding were the Alexa Fluor 488 donkey anti-rabbit (green) and 
Alexa Fluor 594 donkey anti-mouse (red). 
Representative images of CD3+ T cells staining (red) on each ganglia samples are 
shown in Figure 3.9. CD3 is a cell surface marker on T cells, and the staining for the 
anti-CD3 antibody shows a cell membrane-associated pattern. S100B is a calcium 
binding protein, and staining for S100B (green) is present within the cytoplasm and 
nucleus of satellite cells and myelin bundles. Specificity of the staining was confirmed 
by staining ganglia with isotype control antibodies (Fig 3.9 O). 
The neuronal area of PHN1 (Fig. 3.9 A) had an infiltration of CD3+ T cells within the 
capsule region, and a smaller number of T cells in close proximity to neurons. The 
nerve areas of PHN1 (Fig. 3.9 B and C) showed a marked infiltration of CD3+ cells 
surrounding one nerve bundle, and a diffuse infiltration throughout the remaining 
tissue. The neuronal area of PHN2 (Fig. 3.9 D) had the largest infiltration of T cells, 
with cells spread throughout the ganglia within neuronal regions. The nerve bundles 
of PHN2 (Fig. 3.9 E) showed a very limited number of CD3+ cells. The nerve region 
of PHN3 (Fig. 3.9 F) showed a diffuse infiltration of CD3+ cells throughout the ganglia 
with two small areas of high infiltration.  
HZ1 (Fig. 3.9 G) featured a CD3+ T cell infiltration mainly restricted to the capsule 
and outer edges of the neuronal regions. The nerve bundles of HZ2 (Fig. 3.9 H) 
showed limited CD3+ infiltrate spread throughout the tissue section. There was a 
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diffuse infiltrate of CD3+ T cells restricted to the nerve bundles of both HZ2 SOR and 
HZ2 contra, with some small foci (Fig. 3.9 I and J). The nerve bundles of HZ3 (Fig. 
3.9 K) featured a diffuse infiltration of CD3+ cells throughout the tissue section. The 
HZ3 SOR featured a large infiltration of CD3+ T cells spread throughout the nerve cell 
bundles and to a lesser degree within the capsule region (Fig. 3.9 L). 
CON1 (Fig. 3.9 M) and CON2 (Fig. 3.9 N) contained only a few sporadic CD3+ T cells 
spread randomly within the section. CD3+ T cell staining was clearly observed in the 
positive control human tonsil material (data not shown) while background and non-
specific staining on the negative control (uniHFF) and isotype control stained 
sections was minimal (Fig. 3.9 O).  
The frequency of CD3+ T cells in human ganglia samples is shown in Figure 3.10. 
Each cell count is in “Positive cells per 100 000 µm2”. The average value for the 
neuronal regions (Fig. 3.10 A) was 35.81 for PHN1, 14.33 for PHN2, 7.20 for HZ1 
and 2.74 for CON1. The average value for the nerve bundle areas (Fig. 3.10 B) was 
18.24 for PHN1, 1.51 for PHN2, 5.19 for PHN3, 0.71 for HZ2, 5.04 for HZ2 SOR, 
7.04 for HZ2 contra, 12.74 for HZ3, 23.99 for HZ3 SOR and 1.62 for CON2. 
The greatest infiltration of CD3+ T cells was seen in the ganglia obtained from the site 
of reactivation of HZ3, (rash began 17 days prior to and was present at death). CD3+ 
T cell frequencies in the PHN-affected ganglia were greater than those seen in HZ2 
and HZ1 – reactivation occurring 3 weeks prior to death (and still present at death) 
and occurring 6 months prior to death. Significantly all the PHN-affected ganglia 
material showed the presence of infiltrating CD3+ T cells greater than that observed 
in normal control ganglia. 
3.3.6.3 DETECTION OF CD4+ T HELPER CELLS 
Different subsets of T cells perform different functions within the human immune 
system. CD4+ T helper cells are important in mediating humoral immune 
mechanisms (Abbas and Lichtman, 1991), and VZV-specific CD4+ T cells are 
essential for the resolution of varicella (Abendroth and Arvin, 1999). In many 
herpesvirus infections (including VZV) CD4+ T cells have been shown to perform 
cytolytic functions (Arvin et al., 1991). To detect the presence of CD4+ T cells within 
the PHN sample material and compare the relative amounts and distribution with that 
seen in herpes zoster and control ganglia samples, immunofluorescence was 
performed using the goat anti-CD4 primary antibodies specific for cell markers on T 
helper cells. The secondary antibody used was Alexa Fluor 594 donkey anti-goat 
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Figure 3.10 - Frequency of CD3+ T cells in human ganglia samples
Human ganglia samples were stained by immunuorescence, imaged and the number of positive cells per eld of 
view counted. The total surface area of each eld of view was calculated, cell counts averaged, and the frequency of 
positive cells per 100 000 um2 for both the neuronal (A) and nerve bundle (B) regions of the ganglia samples are 
shown. For each sample stains were performed in duplicate, with 8-20 random elds of view examined per stain 
limited only by the size and condition of each tissue sample. Columns display the mean cell count for each sample, 
with the minumum and maximum shown by the square and triangle respectively. 
 The University of Sydney 
- 90 - 
(red). Sections were also stained with rabbit anti-S100B and Alexa Fluor 488 donkey 
anti-rabbit (green) to allow better distinction between infiltrating cells and satellite 
cells. 
Representative images of CD4+ T cell staining for each ganglia sample are shown in 
Figure 3.11. CD4 is a cell surface marker on T helper cells, and successful staining 
shows a membrane-associated pattern (red staining). CD4+ cells were found 
distributed throughout all human ganglia samples assessed. S100B is a calcium 
binding protein, and staining for S100B (green) is present within the cytoplasm and 
nucleus of satellite cells and myelin bundles. Specificity of the staining was confirmed 
by staining ganglia with isotype control antibodies (Fig 3.11 O). 
The neuronal region of PHN1 (Fig. 3.11 A) featured a low frequency of CD4+ T cells 
within the ganglia as well as an infiltration in the capsule region. The nerve areas of 
PHN1 (Fig. 3.11 B and C) featured an infiltration of CD4+ cells very similar to that 
seen with the CD3 staining of these sections - a marked infiltration of CD4+ cells 
surrounding one nerve bundle, and a diffuse infiltration throughout the remaining 
tissue. The neuronal region of PHN2 (Fig. 3.11 D) featured infiltrations of CD4+ T 
cells found throughout the ganglia. The nerve bundles of PHN2 and PHN3 (Fig. 3.11 
E and F) showed a very limited number of CD4+ cells. 
The neuronal region in HZ1 (Fig. 3.11 G) showed CD4+ T cells generally restricted to 
the outer regions of the neuronal areas of the ganglia and capsule region. The nerve 
bundle regions in HZ2 (Fig. 3.11 H) featured a very limited number of CD4+ T cells. 
There was some diffuse CD4+ T cells spread throughout the nerve bundles of HZ2 
SOR, with two separate foci in one bundle of nerves and the capsule region (Fig. 
3.11 I). HZ2 contra featured a limited infiltration of CD4+ T cells throughout the nerve 
bundle regions (Fig. 3.11 J). The nerve bundle regions in HZ3 (Fig. 3.11 K) featured 
a diffuse infiltrate of CD4+ T cells spread throughout the tissue section. The HZ3 
SOR featured a large infiltration of CD4+ T cells spread throughout the nerve cell 
bundles and to a lesser degree within the capsule region (Fig. 3.11 L). 
The neuronal region of CON1 (Fig. 3.11 M) and CON2 (Fig. 3.11N) showed sporadic 
CD4+ T cells spread throughout the ganglia. Specific CD4+ staining was observed in 
the positive control human tonsil sections (tonsil not shown), while background and 
non-specific staining on the negative control (uniHFF) and isotype antibody control 
sections was minimal (Fig. 3.11 O).  
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The frequency of infiltrating CD4+ T cells in human ganglia samples is shown in 
Figure 3.12. Each cell count is in “Positive cells per 100 000 µm2”. The average 
count for the neuronal regions (Fig. 3.12 A) was 10.98 for PHN1, 1.96 for PHN2, 3.63 
for PHN3 and 0.64 for CON1. The average count for the nerve bundle areas (Fig. 
3.12 B) was 6.12 for PHN1, 1.29 for PHN2, 1.65 for PHN3, 0.48 for HZ2, 4.92 for 
HZ2 SOR, 1.31 for HZ2 contra, 3.13 for HZ3, 24.45 for HZ3 SOR and 1.84 for CON2. 
The highest frequency of infiltrating CD4+ T cells was observed in the HZ3 SOR 
ganglia sample, while the PHN1 and HZ2 samples had similar levels. Higher levels of 
CD4+ T cells were observed in all PHN ganglia samples, above that observed in the 
controls. Control neuronal areas showed a very limited CD4+ T cell infiltration, 
however there was a similar frequency of CD4+ T cells in the control nerve bundle 
regions (CON2) compared to other VZV-affected ganglia samples. 
3.3.6.4 DETECTION OF CD8+ T CYTOTOXIC CELLS 
Cytotoxic T cells are the principle cells involved in direct cell-mediated immune 
responses against viral infection, and are important for the control of primary VZV 
infection (Abbas and Lichtman, 1991, Abendroth and Arvin, 1999). CD8 is a 
characteristic marker of this subset of T cells (Abbas and Lichtman, 1991). To detect 
the presence of CD8+ cytotoxic T cells within the PHN sample material and compare 
the relative frequency and distribution of these cells with that seen in herpes zoster 
and control ganglia samples, immunofluorescence was performed using a rabbit anti-
CD8 primary antibody specific for cell markers on cytotoxic T cells. The secondary 
antibody used to detect binding of the primary antibody was the Alexa Fluor 594 
donkey anti-rabbit (red). 
Representative images of CD8+ T cell staining on each ganglia sample are shown in 
Figure 3.13. CD8 is a cell surface marker on T cytotoxic cells, and successful 
staining showed a membrane-associated pattern. CD8+ T cells were readily detected 
and found distributed throughout all PHN ganglia samples, HZ1 and HZ3. Specificity 
of the staining was confirmed by staining of ganglionic sections with isotype control 
antibodies (Fig 3.13 O) 
The neuronal area of PHN1 (Fig. 3.13 A) featured a relatively small number of CD8+ 
T cells within neuronal regions in the ganglia as well as a sizeable infiltration in the 
capsule region. The nerve bundle regions of PHN1 (Fig. 3.13 B and C) showed an 
infiltration of CD8+ cells very similar to that seen with CD3+ and CD4+ cells - a 
marked infiltration of CD8+ cells surrounding one nerve bundle, and a diffuse 
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Figure 3.12 - Frequency of CD4+ T cells in human ganglia samples
Human ganglia samples were stained by immunuorescence, imaged and the number of positive cells per eld of 
view counted. The total surface area of each eld of view was calculated, cell counts averaged, and the frequency of 
positive cells per 100 000 um2 for both the neuronal (A) and nerve bundle (B) regions of the ganglia samples are 
shown. For each sample stains were performed in duplicate, with 8-20 random elds of view examined per stain 
limited only by the size and condition of each tissue sample. Columns display the mean cell count for each sample, 
with the minumum and maximum shown by the square and triangle respectively. 
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infiltration throughout the remaining tissue. The neuronal region of PHN2 (Fig. 3.13 
D) featured relatively large infiltrations of CD8+ T cells found throughout the neuronal 
regions of the ganglia.  
Limited numbers of CD8+ T cells were observed within the nerve bundle region of 
PHN2 (Fig. 3.13 E). The nerve bundle region of PHN3 (Fig. 3.13 F) showed a diffuse 
infiltrate spread throughout the tissue region.  
The neuronal region of HZ1 (Fig. 3.13 G) showed CD8+ T cells generally restricted to 
the outer regions of the ganglia and capsule region. There were no CD8+ cells 
detected in the nerve bundle region of HZ2 (Fig 3.13 H). There was one focus of 
CD8+ cells within one nerve bundle in HZ2 SOR, with limited detection throughout the 
rest of the nerve tissue (Fig. 3.13 I), and limited detection within the nerve bundles of 
HZ2 contra (Fig. 3.13 J). There was a diffuse CD8+ infiltrate detected throughout the 
nerve bundles of HZ3 (Fig. 3.13 K), and a large infiltration of CD8+ cells within the 
nerve bundle regions of HZ3 SOR (Fig. 3.13 L). 
No CD8+ T cells were observed in the neuronal regions CON1 (Fig. 3.13 M) or the 
nerve bundle regions of CON2 (Fig. 3.13 N). Specific staining was observed in the 
positive human tonsil material (data not shown), while background and non-specific 
staining on the negative control (uniHFF) and isotype control sections was minimal 
(Fig. 3.13 O).  
The frequency of CD8+ T cells in human ganglia samples is shown in Figure 3.14. 
Each cell count is in “Positive cells per 100 000 µm2”. The average count for the 
neuronal regions (Fig. 3.14 A) was 8.44 for PHN1, 2.74 for PHN2, 0.21 for HZ1 and 
0.00 for CON1. The average counts for the nerve bundle areas (Fig. 3.14 B) was 
7.33 for PHN1, 0.77 for PHN2, 3.02 for PHN3, 0.41 for HZ2, 0.27 for HZ2 SOR, 0.55 
for HZ2 contra, 4.32 for HZ3, 6,86 for HZ3 SOR and 0.10 for CON1. 
CD8+ T cells were detected in comparable frequencies in all PHN1 samples and in 
the HZ3 SOR (17 days post reactivation with rash still present). However other than 
this sample, CD8+ T cells were generally present in greater abundance in the PHN-
affected material compared to the other herpes zoster-affected and control ganglionic 
material. 
3.3.6.5 DETECTION OF TIA-1+ CELLS 
As CD8+ T cells were readily observed within the immune infiltration in herpes zoster 
and PHN-affected ganglia, I sought to determine the cytolytic nature of these cells. T-
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Figure 3.14 - Frequency of CD8+ T cells in human ganglia samples
Human ganglia samples were stained by immunuorescence, imaged and the number of positive cells per eld of 
view counted. The total surface area of each eld of view was calculated, cell counts averaged, and the frequency of 
positive cells per 100 000 um2 for both the neuronal (A) and nerve bundle (B) regions of the ganglia samples are 
shown. For each sample stains were performed in duplicate, with 8-20 random elds of view examined per stain 
limited only by the size and condition of each tissue sample. Columns display the mean cell count for each sample, 
with the minumum and maximum shown by the square and triangle respectively. 
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cell intracytoplasmic antigen 1 (TIA-1) is a marker found in cytolytic granules, and 
was detected using a mouse anti-TIA-1 antibody.  
Representative images of TIA-1 immunofluorescent staining on each of the human 
ganglia samples are shown in Figure 3.15. TIA-1 is confined to cytoplasmic granules, 
and positive staining appears as small punctate areas (red staining). S100B is a 
calcium binding protein, and staining for S100B (green) is present within the 
cytoplasm and nucleus of satellite cells and myelin bundles. Specificity of the staining 
was confirmed by staining ganglia with isotype control antibodies (Fig 3.15 O). 
There was staining of TIA-1+ cells observed within both the neuronal and nerve 
bundles regions of PHN 1 (Fig. 3.15 A, B and C) and PHN2 (Fig. 3.15 D and E), and 
more limited detection seen in the nerve bundles of PHN3 (Fig. 3.15 F). 
TIA-1 expression was also clearly observed in the neuronal regions of HZ1 (Fig. 3.15 
G), and the nerve bundles of HZ2 and HZ3 (Fig. 3.15 H and K respectively). No TIA-
1 expressing cells were detected in the nerve bundles of HZ2 SOR and HZ2 contra 
(Fig. 3.15 I and J respectively), or HZ3 SOR (Fig. 3.15 L). Furthermore, no TIA-1 
expressing cells were observed within the CON1 and CON2 samples (Fig. 3.15 M 
and N respectively). 
The frequency of TIA-1+ cells in human ganglia samples is shown in Figure 3.16. 
Each cell count is in “Positive cells per 100 000 µm2”. The average count for the 
neuronal regions (Fig. 3.16 A) was 5.32 for PHN1, 2.57 for PHN2, 2.74 for HZ1 and 
1.33 for CON1. The average count for the nerve bundle areas (Fig. 3.16 B) was 4.76 
for PHN1, 3.23 for PHN2, 0.34 for PHN3, 0.08 for HZ2, 0.00 for HZ2 SOR, 0.00 for 
HZ2 contra, 0.80 for HZ3, 0.00 for HZ3 SOR and 0.00 for CON2. 
These results demonstrate that within the PHN-affected sample material there were 
TIA-1+ cells spread throughout both neuronal and nerve bundle regions, and these 
were observed at a much greater frequency than that seen in the herpes zoster-
affected and control material. 
3.3.6.6 DETECTION OF CD20+ B CELLS 
B cells are an important effector cell type in the humoral immune system (Abbas and 
Lichtman, 1991). During VZV infection antibodies specific for viral proteins and 
neutralising antibodies are both important in activating the complement pathway or 
antibody dependent cellular cytotoxicity (Abendroth and Arvin, 2000, Arvin and 
Abendroth, 2007). B cells have also been previously detected in human ganglia 
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Figure 3.16 - Frequency of TIA-1+ cytolytic T cells in human ganglia samples
Human ganglia samples were stained by immunuorescence, imaged and the number of positive cells per eld of 
view counted. The total surface area of each eld of view was calculated, cell counts averaged, and the frequency of 
positive cells per 100 000 um2 for both the neuronal (A) and nerve bundle (B) regions of the ganglia samples are 
shown. For each sample stains were performed in duplicate, with 8-20 random elds of view examined per stain 
limited only by the size and condition of each tissue sample. Columns display the mean cell count for each sample, 
with the minumum and maximum shown by the square and triangle respectively. 
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many weeks to months following herpes zoster (Gowrishankar, 2008, Gowrishankar 
et al., 2010). CD20 is a cell surface marker expressed exclusively on B cells. In order 
to determine whether B cells are present during PHN and compare the relative 
frequency and distribution of B cells with that seen in herpes zoster and control 
ganglia samples, IFA was performed using the mouse anti-CD20 primary antibodies 
followed by the Alexa Fluor 594 donkey anti-mouse secondary antibody (red). 
Sections were co-stained with rabbit anti-cow S100B to labelled satellite cells and 
nerves, detected with the Alexa Fluor 488 donkey anti-rabbit secondary antibody 
(green). 
Representative images of CD20 staining from PHN-affected, herpes zoster-affected 
and control ganglia sample are shown in Figure 3.17. CD20 is a cell surface marker 
of B cells, and successful staining shows a membrane-associated pattern. S100B is 
a calcium binding protein, and staining for S100B (green) is present within the 
cytoplasm and nucleus of satellite cells and myelin bundles. Specific detection of 
CD20 was observed in human tonsil material (data not shown), while background 
and non-specific staining on the negative control (uniHFF) and isotype control 
sections was minimal (Fig. 3.17 O). 
B cells were readily detected within the neuronal region of PHN1 (Fig. 3.17 A) and 
had a sizeable infiltration of B cells within the ganglia capsule, while the nerve bundle 
region of PHN1 (Fig. 3.17 B and C) showed a marked infiltrate centred around one 
nerve bundle with a diffuse infiltrate throughout the rest of the tissue section. 
However there was less CD20+ B cells detected in both the neuronal and nerve 
bundle regions of PHN2 (Fig. 3.17 D and E), and PHN3 (Fig. 3.17 F).  
A limited number of CD20+ B cells were detected in the neuronal region of HZ1 (Fig. 
3.17 G), and within the nerve bundles of the SORs for HZ2 and HZ3 (Fig 3.17 I and L 
respectively). Limited CD20+ B cells were detected in HZ2 contra and HZ3 (Fig. 3.17 
J and K respectively) and the neuronal area of CON1 (Fig 3.17 M), while no positive 
staining cells were observed in HZ2 (Fig. 3.17 H) or in the nerve bundle region of 
CON2 (Fig. 3.17 N).  
The frequency of CD20+ B cells in human ganglia samples is shown in Figure 3.18. 
Each cell count is in “Positive cells per 100 000 µm2”. The average count for the 
neuronal regions (Fig. 3.18 A) was 5.71 for PHN1, 0.75 for PHN2, 0.07 for HZ1 and 
0.00 for CON1. The average count for the nerve bundle areas (Fig. 3.18 B) was 5.20 
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Figure 3.18 - Frequency of CD20+ B cells in human ganglia samples
Human ganglia samples were stained by immunuorescence, imaged and the number of positive cells per eld of 
view counted. The total surface area of each eld of view was calculated, cell counts averaged, and the frequency of 
positive cells per 100 000 um2 for both the neuronal (A) and nerve bundle (B) regions of the ganglia samples are 
shown. For each sample stains were performed in duplicate, with 8-20 random elds of view examined per stain 
limited only by the size and condition of each tissue sample. Columns display the mean cell count for each sample, 
with the minumum and maximum shown by the square and triangle respectively. 
 The University of Sydney 
- 95 - 
for PHN1, 0.00 for PHN2, 0.13 for PHN3, 0.00 for HZ2, 0.11 for HZ2 SOR, 0.00 for 
HZ2 contra, 0.00 for HZ3, 0.17 for HZ3 SOR and 0.00 for CON2. 
These data demonstrates that CD20+ B cells are present in the greatest number in 
the PHN ganglia material when compared to all herpes zoster-affected and control 
ganglia material. In PHN sample 1 CD20+ B cells are present in a similar frequency 
throughout the different regions of the ganglion sample, in both neuronal and nerve 
bundle regions. No CD20+ B cells were detected in either of the control ganglia 
samples. 
3.3.6.7 DETECTION OF CD45RA AND CD45RO EXPRESSING CELLS 
Naive cells are immune cells that have not been exposed to antigen, while memory 
cells are immune cells that persist long after initial exposure to antigen (Abbas and 
Lichtman, 1991). Responses against herpes zoster have been shown to consist 
mainly of memory T cells (Vossen et al., 2004), and previous work on herpes zoster-
affected ganglia material has confirmed the predominance of memory cells 
(Gowrishankar, 2008, Gowrishankar et al., 2010). The RA isoform of CD45 is a cell 
marker expressed on naive immune cells, included B cells, T cells and monocytes, 
while the RO isoform of CD45 is expressed on memory lymphocytes. To determine 
whether naive and memory cells are present within ganglia samples during PHN and 
to compare the relative frequency and distribution to that seen in herpes zoster, 
immunofluorescence was performed separately using mouse anti-CD45RA and 
mouse anti-CD45RO primary antibodies. The secondary antibody used to detect 
primary antibody binding was the Alexa Fluor 594 donkey anti-mouse (red). 
Unfortunately due to the limited number of sections provided, staining for CD45RA 
and CD45RO was not performed on the HZ2 SOR and HZ2 contra samples. 
Representative images of CD45RA and CD45RO immunofluorescent staining on the 
various human ganglia samples are shown in Figure 3.19 and Figure 3.20 
respectively. CD45RA and RO are cell surface markers of naive and memory 
immune cells respectively, and successful staining shows a membrane-associated 
pattern (red).  
PHN1 showed CD45RA+ naive and CD45RO+ memory immune cells present within 
both the neuronal and nerve bundle areas of the ganglia as well as in an infiltration in 
the capsule region (Fig. 3.19 A, B and C, and Fig. 3.20 A, B and C respectively). 
PHN2 showed a small infiltrate of CD45RA+ naive and CD45RO+ memory immune 
cells spread within neuronal and nerve bundle areas (Fig. 3.19 D and E, and Fig. 
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3.20 D and E respectively). PHN3 showed a very limited infiltrate of CD45RA naive 
immune cells and a diffuse infiltration of CD45RO+ memory immune cells within the 
nerve bundle areas (Fig. 3.19 F and Fig. 3.20 F respectively). 
HZ1 showed limited naive immune cell infiltration restricted to the outer edges of 
neuronal and capsule regions (Fig 3.19 G). There was a very limited infiltration of 
CD45RA+ naive immune cells detected in the neuronal areas of HZ2 and HZ3 (Fig. 
3.19 H and I respectively), and the nerve bundle areas of HZ3 SOR (Fig. 3.19 J). 
There was not enough tissue available from HZ2 SOR and contra to perform this 
stain. HZ1 and HZ2 (Fig. 3.20 G and H respectively) showed CD45RO memory cell 
detection limited to the outer edges of the neuronal and nerve bundle areas, and the 
capsule region. There was a marked infiltration of CD45RO memory cells observed 
throughout the HZ3 and HZ3 SOR samples (Fig. 3.20 I and J respectively). 
CON1 and CON2 both showed a low level of CD45RA+ naive immune cells and 
CD45RO+ memory immune cells spread throughout the ganglia (Fig. 3.19 K and L, 
and Fig 3.20 K and L respectively). Staining was successful on the positive human 
tonsil material (data not shown), while background and non-specific staining on the 
negative control (uniHFF) and isotype control sections was minimal (Fig. 3.19 M and 
Fig. 3.20 M).  
PHN-affected sample material showed comparable levels of both CD45RA and 
CD45RO+ cells. However, all ganglia samples had more CD45RO+ cells present 
within the tissue samples. 
3.3.6.8 DETECTION OF MHC CLASS II ISOFORM HLA-DR 
Although normally sensory neurons do not express MHC class I or class II 
molecules, it has been previously shown that MHC-II (via human leukocyte antigen 
DR (HLA-DR)) is upregulated on satellite cells within ganglia during herpes zoster 
and in the recovery from a recent reactivation (Gowrishankar, 2008, Gowrishankar et 
al., 2010, Steain et al.). Consequently it was of interest to study whether this 
upregulation was maintained in human ganglionic material long after herpes zoster 
rash resolution and during PHN.  
Representative images of HLA-DR (green) and CD4 (red) staining of each human 
ganglia sample are shown in Figure 3.21. In PHN1 there was a single region of HLA-
DR upregulation in the small neuronal region of the tissue (Fig. 3.21 A). In the nerve 
bundle region of PHN1 there were areas of high HLA-DR expression generally 
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accompanied by an infiltration of CD4+ T cells (Fig. 3.21 B and C). In PHN2 there 
was limited upregulation of HLA-DR in both the neuronal (Fig. 3.21 D) and nerve 
bundle regions (Fig. 3.21 E), which also occurred in conjunction with CD4+ T cell 
infiltration. In the nerve bundle regions of PHN3 there was some HLA-DR 
expression, which at times corresponded with CD4+ T cell infiltration (Fig. 3.21 F). 
In the neuronal regions of HZ1 there was some HLA-DR expression, which occurred 
with CD4+ T cells in close proximity (Fig. 3.21 G). HLA-DR expression was low in the 
nerve bundle regions of HZ2 (Fig. 3.21 H). There was small areas of detectable HLA-
DR expression in the nerve bundles of HZ2 SOR (Fig. 3.21 I) and HZ2 contra (Fig. 
3.21 J), often accompanied by an infiltration of CD4+ T cells. In the nerve bundles of 
HZ3 there was some strong HLA-DR expression throughout the nerve bundles, often 
with CD4+ T cells in close proximity (Fig. 3.21 K). In the nerve bundles of HZ3 SOR 
there is diffuse HLA-DR expression accompanied by a large infiltrate of CD4+ T cells 
(Fig. 3.21 L). 
In CON1 there was low level HLA-DR expression observed throughout the ganglion 
sample, although it is not associated with a CD4+ T cell infiltration (Fig. 3.21 M). In 
CON2 HLA-DR expression was limited to one area in the capsule of the nerve 
bundle regions, and accompanied by a CD4+ T cell infiltration (Fig. 3.21 N). Specific 
HLA-DR staining was observed in the positive control human tonsil and CD14- cell 
block sections, while background and non-specific staining on the negative control 
(uniHFF) and isotype control sections was minimal (Fig. 3.21 O). 
This data demonstrates there are areas of HLA-DR upregulation in many of the VZV-
affected ganglia samples. The PHN-affected ganglia material showed large 
upregulation of HLA-DR in very small regions mainly restricted to the nerve bundles. 
There was no HLA-DR expression observed on neurons within the PHN-affected 
material. herpes zoster-affected material featured diffuse HLA-DR expression 
throughout the tissue. One of the control samples showed a small region of very high 
HLA-DR expression within the capsule of the ganglion sample.  
 
3.4 Discussion 
The focus of this study was to characterise the immune cell infiltration and viral gene 
expression in human ganglia samples that were surgically excised from an individual 
suffering from PHN, and to compare these samples to ganglia obtained post-mortem 
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from patients who are suffering from or have recently suffered from herpes zoster 
and normal control ganglia samples. PHN is a very painful complication of herpes 
zoster, which results from VZV reactivation within human ganglia. 
PHN is a relatively unstudied condition, and very little is known about the underlying 
pathology and pathogenesis. Due to the high species-specificity of VZV, studies must 
be done using cells and samples of human or simian origin (Arvin and Gilden, 2007). 
Animal models to study VZV disease are very limited, and in particular there is no 
current animal model for VZV reactivation and development of PHN. Consequently 
the very limited previous studies have utilised post-mortem material taken from 
herpes zoster-affected and PHN-affected individuals. These have reported both 
widespread cell loss and the presence of infiltrating immune-like cells (Head and 
Campbell, 1900, Watson et al., 1991, Watson et al., 1988b). However these studies 
were limited to basic histological examination, with no attempt to characterise the 
immune cell types involved in the infiltration or the extent and spread of active VZV 
infection. 
Previously our lab has undertaken a detailed analysis of human ganglia obtained 
from individuals who presented with herpes zoster 1-5 months prior to death 
(Gowrishankar, 2008, Gowrishankar et al., 2010), with respect to characterising the 
different immune cells present as well as viral antigen expression in ganglionic cells. 
In these patients it was shown that the immune infiltration consisted predominantly of 
macrophages and non-cytolytic CD8+ T cells.  
More recently, another study by our research group examined ganglia samples from 
two patients who had experienced herpes zoster (ie. zoster rash present) at the time 
of death (Steain et al., 2013). A details IFA analysis of ganglionic sections revealed a 
large inflammatory immune infiltrate present in both patient samples was comprised 
mainly of macrophages, natural killer cells, CD4+ T cells and cytolytic CD8+ T cells. 
Many of these T cells were closely associated with neurons within the reactivated 
ganglia. Both our laboratory’s previous studies mainly focused on the neuronal areas 
within the ganglia samples. This current PhD study has focused on neuronal areas 
and also examined in detail the nerve bundles, derived from these ganglia, but 
outside of the neuronal cell body areas. This is the first such study to characterise in 
detail the immune infiltration in the nerve bundles of patients at different stages of 
VZV reactivation. The HZ2 and HZ3 ganglia samples included in this study are the 
same samples utilised in Steain et al. (2013), however in the current study the nerve 
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bundle areas were examined, as the neuronal areas had previously been 
characterised. 
The PHN ganglia samples used in this study were surgically excised from a PHN-
affected patient from the lower thoracic level. This patient had suffered from herpes 
zoster, the rash had resolved and pain had continued for around 5 years. This offers 
an incredibly rare opportunity, and to the best of our knowledge there has been no 
previous study that has examined human ganglia material that has been surgically 
excised from a living patient suffering from PHN. 
The herpes zoster-affected material utilised in this study was obtained from three 
different patients. HZ1 experienced a VZV reactivation 6 months prior to death but 
did not have any evidence of ongoing VZV replication at the time of death. HZ2 and 
HZ3 both had a VZV reactivation within weeks of death, and both had a visible 
herpes zoster rash at the time of death. This offers the opportunity to study different 
stages of VZV reactivation: active reactivation (HZ2 and HZ3), the recovery from 
VZV reactivation (HZ1), and long term pathology following herpes zoster in a PHN-
affected individual (PHN samples). 
Most of the patient material utilised in this study was obtained from patients who had 
undergone or were undergoing some type of immunosuppressive therapy, or were 
suffering from some type of immune-altering disorder. The PHN-affected patient was 
diagnosed with acute myeloid leukaemia, and consequently underwent a bone 
marrow transplant. The HZ1 patient was diagnosed with a EBV-associated 
lymphoproliferative disorder following a period of 5 years on an immunosuppressive 
treatment regime. The HZ2 patient was not currently nor had previously been on any 
immunosuppressive therapy, however at death was diagnosed with acute myeloid 
leukaemia. The control patient CON1 could be expected to be immunocompromised 
at the time of death due to metastatic adenocarcinoma. The herpes zoster patient 
HZ3, and control patient CON2 were not diagnosed with any direct immune-altering 
disease, or treated with any immunosuppressive treatment regime. However HZ3 
was 93 years old at the time of death and therefore would be experiencing the 
normal decline in cell-mediated immune function which accompanies normal aging 
(Oxman, 2009). In an ideal case all patients would be immunocompetent and 
otherwise healthy, however realistically it is very rare to have access to the above 
post-mortem sample material and even more precious surgically-excised ganglia 
samples. VZV reactivation is also more likely to occur in patients who are 
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immunocompromised, or with age-related immune dysfunction (Hope-Simpson, 
1965). 
Post-mortem samples were obtained at time of autopsy. Fixation in formaldehyde 
would have commenced immediately on removal from the patient. Currently the time 
interval between time of death and commencement of autopsy is unknown, however 
generally is less than 1-2 days. 
Basic histological examination of H&E stained PHN-affected sample material 
revealed the presence of a readily detectable immune infiltration in all the PHN 
ganglia samples. This was spread generally throughout neuronal and nerve bundle 
regions with distinct focal infiltrations in all PHN ganglia samples. This is consistent 
with previous studies on human ganglia from PHN-affected individuals which found 
evidence of an ongoing inflammatory process (Head and Campbell, 1900, Watson et 
al., 1991, Watson et al., 1988b). One early study of PHN-affected ganglia also found 
both diffuse and focal infiltrations of inflammatory cells, although examination was 
limited to the neuronal areas of the ganglia (Smith, 1978). 
An extensive immune infiltration was also readily identified via basic histological 
examination of the neuronal regions of the sites of reactivation in active cases of VZV 
reactivation (HZ2 and HZ3), as identified in Steain et al. (2013). In this study on the 
neuronal areas from these same samples the immune infiltration was only present in 
the nerve bundles of HZ3 at the site of reactivation, and in a ganglion around the 
same region. Ganglia from HZ2 also featured a smaller but still significant immune 
infiltration in the neuronal regions.  
H&E examination of samples from the 6 month post-zoster sample did feature a 
more limited immune infiltration, however this was restricted to the outer edges of the 
ganglia and capsule region. This result is in contrast to previous work in which there 
were varying amounts of infiltrating cells found in different herpes zoster-affected 
patients, however they were found spread generally throughout the ganglionic 
sections (Gowrishankar, 2008, Gowrishankar et al., 2010). 
The PHN ganglionic samples used in this study were considerably smaller in size 
when compared to the herpes zoster and control samples. This may have been the 
result of the source of tissue. The PHN patient samples were removed from a live 
patient, and the priority of the surgeon is the well-being of the patient over removal of 
the intact ganglia samples, whereas the herpes zoster samples were removed during 
post-mortem examinations. 
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Interestingly one of the PHN-affected ganglia samples also featured altered 
morphology, with the loss of both neuronal profiles and no resulting proliferation of 
satellite cells. This is characteristic of fibrosis, and has been previously reported in 
studies of ganglia from PHN-affected patients (Smith, 1978, Watson et al., 1991, 
Watson et al., 1988b). One study also noted atrophy of the dorsal horn (Watson et 
al., 1991). The dorsal horn is directly innervated by sensory neurons which proceed 
from cell bodies contained within the DRG (Kandel et al., 2000). It is quite possible 
that the areas of fibrosis within the ganglia and the atrophy of the dorsal horn may be 
caused by the same pathological process. However on consultation with a 
neuropathologist the possibility was raised that this area of altered morphology may 
in fact be due to an infolding of the ganglion capsule itself (Professor M. Buckland, 
Personal interview, August 2011), and not any type of pathology. Unfortunately given 
the limited availability of the sample material we were not able to distinguish between 
these two scenarios. 
In order to demonstrate the presence of DNA within the sections DNA was extracted 
from all available ganglia material. DNA extraction from the PHN1, PHN2 and PHN3a 
samples were successful, shown by the detection of a PCR product corresponding to 
the housekeeping gene GAPDH. DNA extraction was also successful for the HZ1 
and CON1 samples. Unfortunately there was no GAPDH-specific product detected in 
the PHN3b, HZ2, HZ3 and CON2 samples, corresponding to no intact DNA extracted 
from these samples. This is likely due to degradation of cellular DNA due to the 
heavy fixation process. All samples used in this study were provided as formalin-
fixed paraffin-embedded tissue blocks, and I had no choice in the fixation method. 
In order to demonstrate the presence of VZV-specific DNA, PCR was performed 
using primers specific for VZV ORF9a. VZV specific DNA was detected in PHN1a, 
PHN2, and PHN3a. VZV specific DNA was also detected in the HZ1 sample. No VZV 
specific DNA was detected in PHN1b or CON1 despite successful DNA extraction. 
No VZV specific DNA was detected in PHN3b, HZ2, HZ3, or CON2, however DNA 
extraction was not successful on these samples. 
Of the samples which showed successful extraction of DNA from the paraffin-
embedded material, PCR using primers specific for the HSV-1 gene UL-42 showed 
no detectable HSV-1 within any PHN ganglia samples or the CON1 sample. 
Unfortunately the HSV-1 primers utilised in this study were highly specific to HSV-1, 
and do not cross-react with HSV-2 (Cassinotti and Siegl, 1998), and consequently 
we do not know the HSV-2 infection status of the patient samples utilised. However 
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given that the ganglia samples are not derived from the sacral region, it is less likely 
they would contain any HSV-2.  
The HZ1 ganglia sample did show a detectable presence of HSV-1 DNA. As HSV-1 
latency is almost ubiquitous within the human population (Smith and Robinson, 2002) 
and this sample was a trigeminal ganglia, it was expected to harbour a latent HSV-1 
infection. HSV-1 latency has been previously shown to attract immune cells which 
surround latently infected cells within human ganglia. This process does not occur in 
response to VZV latency (Theil et al., 2003, Verjans et al., 2007). This ganglia 
sample displayed no foci for immune cells within any of the neuronal regions 
examined. The immune infiltration within this sample was limited to the outer regions 
of the ganglia. Thus it is unlikely that the main body of the infiltrating cells was in 
response to a latent HSV-1 infection. 
Although PCR is useful in providing a qualitative result, and identifying the presence 
or absence of a specific DNA sequence, due to any potential differences in tissue 
fixation and processing, and the different lengths of time stored post-fixation it can 
not provide a reliable estimation on relative amounts of DNA. Consequently a 
quantitative real time PCR method was utilised to allow the calculation of the number 
of copies of VZV DNA per cell in each ganglia. Due to the very limited amount of 
DNA originally obtained from each ganglia sample, and the failure to isolate any 
viable DNA from some samples, complete analysis using this quantitative real time 
PCR approach was only possible on three ganglia samples: PHN2a, HZ3 SOR and 
CON2. 
Interestingly the CON2 ganglia samples did not show any amplification of GAPDH, 
VZV or HSV-1 DNA utilising the conventional PCR approach. Conversely there was 
a detectable amount of β-actin within this sample via the quantitative real time PCR 
method. In both cases, similar amounts of input template were utilised, and 
consequently the real time PCR approach appears to be more sensitive. 
It was also of great interest that this quantitative real-time PCR analysis showed that 
there was approximately seven-fold more copies of VZV DNA present in the PHN2a 
sample compared to that observed in the HZ3 SOR. Both of these samples feature a 
predominantly neuronal area, consisting mainly of the cell bodies of DRG neurons. 
The HZ3 patient experienced a reactivation of VZV within this ganglia just 17 days 
prior to death, with potential ongoing VZV replication occurring as shown by the 
presence of a rash at the time of death and the detection of VZV proteins within 
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several neurons (Steain et al., 2013). This patient was an immunocompetent patient 
suffering from dementia who died due to aspiration pneumonia. The PHN-affected 
patient did not show any clinical signs of VZV reactivation at the time of 
ganglionectomy. This could indicate an ongoing virological process within this PHN-
affected patient which is confined to the DRG, giving rise to a greater VZV DNA load 
per cell than that seen in a herpes zoster-affected patient with a current and relatively 
extensive reactivation, and possibly contributing to the ongoing pathogenesis of 
PHN. Alternatively it may indicate that during herpes zoster a greater amount of viral 
replication occurred in this ganglia, increasing the latent virus burden, and may be a 
risk factor in the development of PHN. 
Given the relatively high level of VZV DNA present in one of the PHN-affected, and 
one of the herpes zoster-affected samples, it was of interest to look for the 
expression of VZV-specific proteins from the different viral kinetic classes. 
Unfortunately all attempts to detect viral protein expression were unsuccessful 
despite the positive control material showing successful immunofluorescent detection 
of VZV antigens. In the same staining experiment HZ3 showed detectable VZV 
antigen expression using the same method, reported in Steain et al (Steain et al., 
2013). This could be due to a low level of antigen expression – which seems unlikely 
due to the high viral load and presence of active replication in two of the herpes 
zoster-affected samples. Alternatively our current experimental approaches or 
antibodies may not be sensitive enough to detect viral protein expression in the 
human ganglia samples.  
In fact to date, taking into account the many difficulties in performing 
immunohistochemistry on human formaldehyde-fixed paraffin-embedded material 
(Zerboni et al., 2012) there is only one recent reported detection of VZV-specific 
protein expression in human ganglia, and this was utilising the neuronal regions from 
the HZ3 SOR as reported in Steain et al. (2013). All attempts to detect VZV-
expression in PHN-affected ganglia material performed during this current study 
were performed in tandem with the experiments reported in this paper. Thus despite 
VZV antigens being readily detected in the herpes zoster ganglia directed innervating 
active herpes zoster rash, no antigens were observed in the PHN-affected material. 
It was also of interest to study any VZV-specific mRNA expression within the human 
ganglia samples. Previously during my honours work I was able to demonstrate the 
presence of viable mRNA specific to HLA-DRα (work not shown) via in-situ 
hybridisation (ISH) in satellite cells within the neuronal areas of PHN1, PHN2 and 
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HZ1. Unfortunately all attempts to detect a VZV-specific gene product via ISH were 
unsuccessful. In addition, RNA extraction from all ganglia samples was attempted. A 
real time PCR system was established, plasmid standards were created and the 
sensitivity of each primer pair was measured to ensure sensitivity was sufficient to 
ensure detection of low level mRNA copy numbers. Unfortunately there was little to 
no viable mRNA extracted from ganglia samples, and consequently VZV transcript 
analysis was not possible. 
Significantly, the immunohistochemical analysis of PHN-affected ganglia samples 
revealed a large infiltration of immune cells, predominantly comprised of both CD4+ T 
cell and CD8+ T cells, as well as a large proportion of B cells and cytolytic cells. This 
immune cell infiltration appeared to be spread throughout the affected ganglia, in 
both the neuronal and nerve bundle areas. This immune cell infiltration was more 
comparable to that observed in the active herpes zoster samples rather than the 
samples isolated months post-herpes zoster.  
There was considerable variability seen between the total number of CD3+ T cells, 
and the sum of CD4+ and CD8+ T cells. The counts for each stain were performed on 
random non-overlapping images of individual sections from different parts of the 
tissue block. For some of the larger tissue samples (the herpes zoster and control 
samples) the tissue area was considerably larger than the imaged regions. To control 
for this images areas were selected randomly, and multiple counts obtained and 
averaged to ensure a representative quantity was obtained overall. The difference in 
counts is most likely due to biological variability rather than the presence of rarer T 
cell types (NKT cells and γδ T cells). 
The infiltration seen in the PHN-affected material which was obtained many years 
post occurrence of clinical VZV reactivation was much greater than that seen in 
herpes zoster-affected patient material just 6 months post-herpes zoster. The 
immune infiltration in the PHN-affected patient material was comparable to that seen 
in another immunosuppressed patient who experienced an acute VZV reactivation 
just 3 weeks prior to death with a rash still present at death. However the level of 
infiltration in the PHN-affected patient material was less than that seen in material 
obtained from an immunocompetent patient who experienced VZV reaction 17 days 
prior to death with rash still present at death. 
Interestingly only the PHN-affected patient material (many years post VZV-
reactivation) and the herpes zoster-affected material from the immunocompetent 
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patient (active VZV reactivation) showed the presence of B cells. IgG secreting B 
cells are known to be recruited to sites of chronic inflammation (Kunkel and Butcher, 
2003). The lymphocytes (both B and T cells) in the PHN-affected material provides 
evidence of an ongoing inflammation in these samples, possibly a chronic 
inflammatory process.  
This study included the first examination of the immune cell phenotype within the 
nerve bundles in the ganglia from a PHN-affected and herpes zoster-affected 
patients. The DRG is located in close proximity to multiple bundles of nerves. It is 
continuous with the dorsal root of the spinal cord, and in close proximity to the ventral 
root and the spinal nerve (previously identified in Figure 1.7). Unfortunately we 
cannot identify the exact origin of the nerve bundles that were examined during this 
study, nor can we ensure that the nerve bundles from the PHN-affected and herpes 
zoster-affected patients were from the same anatomical location.  
Previous detailed immunohistochemical analysis of herpes zoster-affected ganglia 
samples have shown an immune infiltration consisting predominantly of 
macrophages, NK cells, CD4+ T cells and CD8+ T cells (Gowrishankar, 2008, 
Gowrishankar et al., 2010, Steain et al., 2013). Although staining for NK cells using 
antibodies specific for both CD56 and CD16 was attempted on patient samples in 
this study, neither was successful in providing clear identification of NK cells within 
the ganglia due to the expression of these markers by satellite cells, nerve sheaths 
and many other cell types. A similar problem was experienced when using an 
antibody specific for CD68 – a marker on macrophages, monocytes and other large 
cells which is also expressed on some satellite cells and nerve sheaths (van Velzen 
et al., 2009). 
In all ganglia samples examined the immune cell infiltrate consisted mainly of a 
memory cell phenotype, shown through expression of the CD45RO antigen and 
lower expression of CD45RA. This predominance was to be expected due to the 
prior exposure to VZV antigens during primary infection and the subsequent 
development of memory cells. Only the PHN-affected patient samples also contained 
a significant proportion of CD45RA+ naive immune cells, and could be a result of 
some ongoing chronic inflammatory process. 
There was also a significant proportion of TIA-1 expression in infiltrating immune 
cells. TIA-1 is a cytolytic marker present in T cells, as well as NK cells. TIA-1 is an 
mRNA binding protein which possesses nucleolytic activity against target cells when 
released from cytotoxic cells, resulting in apoptosis of the target cell (NCBI, 2013). 
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TIA-1 is expressed in cytotoxic cells irrespective of activation states. Staining for 
another cytolytic marker granzyme B was unsuccessful on this tissue. Granzyme B is 
a cytolytic marker that is upregulated on activated cytolytic cells, and would have 
both confirmed the cytolytic and activation state of the infiltrating cells. Cytotoxic 
CD4+ T cells have been described (Appay et al., 2002), and CD4+ T cells with 
cytolytic function have been shown to play an important role in the immune response 
to herpesvirus infections (Reviewed in Heller et al., 2006).  
Steain et al. (2013) identified T cells in close proximity to neurons in post-mortem 
herpes zoster-affected ganglia material. These T cells appeared to have penetrated 
the satellite cell barrier surrounding the neurons. Despite CD4+ T cells being the 
predominant T cell subset detected in the herpes zoster reactivated ganglia samples, 
CD8+ T cells were far more likely to be interacting with the neuron-satellite cell barrier 
(Steain et al., 2013). These findings suggest that direct contact between neurons and 
T cells may occur in human ganglia during active herpes zoster. Although a 
significant amount of time was utilised examining the PHN-affected ganglia material, 
there were no observed instances where T cell or other immune cells appeared to 
have breached the satellite cell barrier and were in close proximity to neurons. 
The infiltrating immune cells present within the PHN-affected ganglia material were 
distributed throughout the ganglia, with small foci of infiltration within both neuronal 
and nerve bundle regions. Previous work has shown that during active VZV 
reactivation infiltrating immune cells, predominantly CD8+ cytolytic T cells, are spread 
throughout the ganglia (Steain et al., 2013), and many months post herpes zoster 
infiltrating immune cells, predominantly non-cytolytic CD8+ T cells are spread 
throughout neuronal regions of the ganglia samples (Gowrishankar et al., 2010). 
Sensory neurons do not normally express MHC molecules, however they can be 
expressed in response to viral infection (Redwine et al., 2001). Previous studies have 
shown an upregulation of both MHC I (via β2m expression) and MHC II (via HLA-DR 
expression) on satellite cells in human ganglia following VZV reactivation 
(Gowrishankar et al., 2010, Steain et al., 2013). In this current study HLA-DR 
expression was seen in areas throughout all patient samples, however expression 
appeared to be restricted to satellite cells. Satellite cells have been shown to have 
phagocytic capacity (van Velzen et al., 2009), and may play the role of professional 
antigen presenting cells within the ganglia (Verjans et al., 2007). HLA-DR expression 
varies significantly between patients, and comparison between patient samples is not 
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possible. β2m staining was attempted, but was unsuccessful on the PHN-affected 
patient material. 
The PHN-affected patient material appears to be a site of chronic inflammation. 
Clinically the patient has been on an immunosuppressive treatment regime for many 
years. Despite this, there is a significant immune infiltrate into the dorsal root ganglia 
many years following the resolution of clinical VZV reactivation. This study has 
shown significant numbers of T cells and B cells, spread throughout both the 
neuronal and nerve bundle regions of the ganglia tissue. Due to the prolonged period 
of time from the resolution of the rash and the surgical extraction and subsequent 
fixation of tissue, for inflammatory cells to remain in the tissue suggests some 
ongoing chronic process that may contribute to the pathogenesis of PHN. 
The immune infiltrate level seen in the PHN-affected material (from an 
immunosuppressed patient) was comparable to that seen in an immunocompetent 
herpes zoster-affected patient within 17 days of VZV reactivation who died with an 
extensive herpes zoster-associated rash at the time of death. The PHN-affected 
ganglia material also contained approximately 7 fold more VZV DNA than that seen 
in this currently herpes zoster-affected patient material. This provides some evidence 
that there may be some ongoing virological process present in the PHN-affected 
ganglia material that maybe important in maintaining a continued presence of 
infiltrating immune cells. 
There are many other immune cell types that remain be investigated. Neutrophils, 
NK cells, mast cells, macrophages and other monocytes all play important roles in 
inflammation, and their role in PHN-related infiltration has yet to be elucidated. The 
activation state of the immune cells has yet to be demonstrated. Aberrant chemokine 
expression has also been shown to play some role in chronic pain states (Reviewed 
in White et al., 2007), but has yet to be examined during PHN. Unfortunately such 
studies are hampered by the limited availability of appropriate clinical samples, and 
could not be performed as part of this work. 
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Chapter 4 – Phenotype of immune cells in skin 
biopsy samples from post-herpetic neuralgia-
affected and normal patients. 
4.1 Introduction 
VZV causes two clinically distinct diseases which both involve an exanthematous 
stage – the generalised rash seen in varicella and the more dermatomal restricted 
rash seen in herpes zoster. In both of these conditions the lesions are 
histopathologically indistinguishable from each other (Oxman, 2000). The most 
common complication of herpes zoster is PHN - a severe neuropathic pain which can 
persist for months to years after the resolution of the herpes zoster rash (Cohen et 
al., 1999, Steiner et al., 2007, Hope-Simpson, 1965, Hope-Simpson, 1975). To date 
there is limited information available about the host immune response in human skin 
during PHN, and whether there is any ongoing viral replication within the affected 
area.  
This chapter aims to address this lack of knowledge through an immunofluorescent 
examination of rare human skin biopsies from both the active and contralateral sides 
of PHN-affected patients, as well as left and right sides from normal healthy control 
patients. 
Previous studies have shown that there is a dramatic shift in the numbers of 
important immune cells within the skin during herpes zoster. In particular a reduction 
in tissue resident Langerhans cells within the epidermis, and an increase in 
plasmacytoid dendritic cells (pDCs), highly inflammatory DCs (Colonna et al., 2004) 
have been observed within herpes zoster-affected skin (Gutzeit et al., 2010, Huch et 
al., 2010).  
Another study found significantly lower numbers of infiltrating lymphocytes present in 
the skin biopsies of patients who later develop PHN compared to those that 
experience no complications, despite the systemic cytokine and antibody responses 
being at comparable levels (Zak-Prelich et al., 2003). However this study was 
performed with single biopsies from each individual, which does not take into account 
the variation between individuals. It also did not explore the immune response of 
patients during PHN itself, but focused on herpes zoster. 
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As PHN is regarded as a neuropathic pain (Steiner et al., 2007), several studies have 
focused on the level of epidermal innervation. Early studies indicated there was 
extensive damage to both the peripheral and central nervous system in PHN-affected 
patients (Watson et al., 1991, Watson et al., 1988b), and clinical findings indicate 
altered nervous system function, showing both areas of sensory loss and sensory 
gain (Watson, 1998). 
More detailed comparisons of skin biopsies obtained from both PHN and non-PHN-
affected patients have shown that PHN-affected individuals feature a large-scale loss 
of epidermal neurites at the site of pain (Oaklander et al., 1998, Rowbotham et al., 
1996). PHN patients show decreased innervation at both the affected and 
contralateral sites (Petersen et al., 2002, Oaklander et al., 1998). This is in contrast 
to patients who experience uncomplicated herpes zoster, who feature a decrease in 
the level of cutaneous innervation only at the site of the herpes zoster rash. The 
exact mechanism for this is unknown. However as VZV-infected neuronal cells are 
resistant to apoptosis (Hood et al., 2003), this difference in levels of innervation is 
unlikely to be due to direct virus killing of neuronal cells, but is more likely to be either 
through some effect of the host response or an indirect effect of the virus. 
The underlying pathogenesis of PHN is still unknown. In some patients it has been 
shown that there may be ongoing viral replication during PHN. Viral proteins have 
been detected within circulating blood mononuclear cells in PHN-affected patients for 
months to years following the resolution of the herpes zoster rash (Gilden et al., 
2003, Vafai et al., 1988). This prolonged period during which viral antigen expression 
can be detected does not occur in patients who experience an uncomplicated 
recovery from herpes zoster (Gilden et al., 1989). 
To date, there has not been an investigation of VZV antigen expression in skin 
samples from PHN-affected patients. Nor has a detailed immunofluorescent 
examination of the subsets of DCs and T cells present in PHN-affected skin been 
performed. The overall aim of this chapter is to address these important issues 
utilising valuable skin biopsies obtained from PHN-affected and control patients. 
This research is unique in that as well as being able to compare skin biopsy samples 
taken from both PHN-affected and non-PHN -affected patients, skin biopsy samples 
taken from the contralateral side of each patient were also available. This was 
possible through a collaboration with Albany Medical College and the UCSF. Using 
both a biopsy from the affected and the contralateral side for each patient (or left and 
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right for control patients) we can account for any variation in natural immunity that 
may occur between individuals. 
4.2 Patient and control material 
Where applicable; all tissue specimens were obtained in accordance with ethics 
guidelines of both the University of Sydney and Western Sydney Area Health 
Service, and informed consent of the donors was obtained where required. 
4.2.1  Control cell block material 
Initial protocol and antibody optimisations were performed on control cell blocks. 
Control cell blocks were generated using both uniHFFs and infHFFs, and CD14- 
sorted human PBMCs. HFFs were cultured, infected with VZV and harvested as 
described in section 2.5. CD14- human PBMCs were isolated as described in section 
2.5, and were generously donated by Rodney Henriquez (VZV research laboratory, 
University of Sydney). 
4.2.2 Control patient skin material  
Once antibody optimisation was successful on sections obtained from control cell 
blocks, antibodies were then trialled on human tissue material to ensure that the 
antibodies and staining technique were well established. Control human material 
consisted of cryopreserved human tonsil and skin tissue, kindly provided by Dr 
Heather Donaghy from the Westmead Millennium Institute in accordance with 
relevant ethics guidelines. 
4.2.3 Patient skin sample material 
Patient skin biopsies were very generously provided by Professor Frank Rice of the 
Albany Medical College and Professor Karen Petersen of UCSF. Skin biopsy 
material included in the study was formaldehyde-fixed and cryopreserved (Petersen 
and Rowbotham, 2007, Petersen et al., 2002). Frozen material had been 
cryosectioned into 14 µm sections and mounted on gelatin-coated microscope slides. 
Multiple sections taken from different regions of each patient skin biopsy had been 
mounted on each slide. Where possible each slide contained a section from the 
beginning, middle and end of the tissue biopsy, as represented in Figure 4.1. This 
allowed multiple replicates to be represented on the one microscope slide. 
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In this initial pilot study skin biopsy material obtained from 5 PHN-affected patients 
and 5 normal control patients was utilised. Patient details including sample number, 
diagnosis, age, sex and biopsy location are shown in Table 4.1. This information was 
provided by our collaborators Professor Frank Rice (Albany Medical College) and 
Professor Karen Petersen (UCSF). The PHN-affected patients consisted of three 
females and two males, with an age range of 26 to 71 years old, and an average of 
53.0 years. The normal control patients also consisted of three females and two 
males, with a similar age range of 22 to 68 years old, and an average of 52.4 years. 
 
Table 4.1 - Clinical data for patients used to obtain skin biopsy material 
this study. 
Patient Diagnosis Age Sex Biopsy Location 
PHN 1 PHN 66 F T8 Dermatome 
PHN 2 PHN 48 M T6 Dermatome 
PHN 3 PHN 54 F L1 Dermatome 
PHN 4 PHN 71 F C5 Dermatome 
PHN 5 PHN 26 M Shoulder 
Control 1 Normal control 61 F T8 Dermatome 
Control 2 Normal control 56 F L1 Dermatome 
Control 3 Normal control 55 M T8 Dermatome 
Control 4 Normal control 68 F Deltoid 
Control 5 Normal control 22 M C4 Dermatome 
 
Punch biopsy samples (3 mm) were taken from both the active (most painful area) 
and contralateral side (contra) for PHN patients or left and right sides for normal 
control patients. In total 3 slides containing 2-3 sections each from each biopsy 
sample were provided for use in this study.  
 
4.3 Results 
4.3.1 Immunofluorescent assay (IFA) development 
Given the inherent difficulty in detecting antigen expression in formaldehyde-fixed 
and snap frozen biopsy material, particularly by IFA, an important initial step was to 
develop new IFA staining protocols. In addition, suitable positive control material 
matching the fixation and preparation of the test samples needed to be generated. 
The patient sample material utilised in this chapter consisted of formaldehyde-fixed 
and snap frozen material – a type not previously used in our laboratory. Taking into 
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account the frozen nature of the samples, the previously established high 
temperature unmasking technique utilised in our laboratory with formaldehyde-fixed 
paraffin-embedded samples was unsuitable, and a new IFA protocol was required. 
To complicate this our laboratory had no available positive control material which 
adequately matched both the fixation and preservation methods of the test skin 
biopsy sample material with which to create and optimise the experimental 
procedure.  
4.3.1.1 CONTROL MATERIAL CREATION 
To overcome this initial hurdle a method of fixing and snap-freezing cell pellets was 
created. Control cell blocks were created using both uniHFFs and infHFFs, and 
CD14- sorted PBMCs. Cells were fixed in 10% NBF for 4 hours at 4oC to match the 
fixation method used with the sample material (Petersen et al., 2002, Petersen and 
Rowbotham, 2007). Cells were centrifuged and rinsed in 1x PBS and resuspended in 
coloured cryochrome freezing compound. A freezing mould was then filled with 
coloured cryochrome freezing compound of a contrasting colour, and the cell 
suspension transferred to the centre of the freezing mould. The mould was immersed 
in liquid nitrogen to snap freeze the block of cyrochrome freezing compound 
containing the cell suspension. The contrasting colours used allowed the 
differentiation between the supporting cryochrome compound and the suspended 
cells within the block, which enabled the cells to be easily cryosectioned and 
mounted on gelatin-coated slides. 
Due to the very limited quantity of formaldehyde-fixed and snap-frozen skin biopsy 
sample material, it unsuitable for initial use in determining antibody suitability and 
optimising antibody concentrations. Instead, unfixed cryopreserved human tissue 
was obtained in order to trial antibodies on control human tissue after initial 
optimisation on cell blocks. Unfortunately we did not have access to any known VZV 
skin material, and consequently human tonsil tissue and normal skin tissue were 
used to trial all antibodies in conjunction with the infHFFs. This material was 
cryosectioned and mounted on gelatin-coated microscope slides. While different 
post-sectioning fixation methods were trialled, including methanol/acetone fixation 
and formaldehyde fixation, in order to more closely match the fixation of both the 
control cell blocks (10% NBF) to that of the precious patient derived sample material 
(4% formaldehyde), this control material was post-fixed immediately prior to use in 
10% NBF for 30 min before continuing with the normal staining protocol. 
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4.3.1.2 IFA STAINING METHOD DEVELOPMENT 
Initial protocol optimisation focused on different antigen unmasking techniques. As 
the patient biopsy material was formaldehyde-fixed, it is first necessary to perform an 
antigen retrieval step (or unmasking step) for successful detection of many antigens. 
Proteinase K digestion was found to be unsuitable due to its tendency to destroy cell 
surface markers (especially CD markers) This occurred at all proteinase K 
concentrations tested (from 10 to 25 µg/mL). Furthermore, the high temperature 
antigen unmasking technique commonly utilised in our laboratory for paraffin-
embedded sections was found to be unsuitable as it melted the gelatin coating from 
the slide and destroyed the section at 95oC (data not shown). Instead of unmasking 
at high temperature, a range of lower temperatures were trialled (from 30oC to 80oC) 
for different lengths of time (from 20 min to 5 hours). Unmasking solutions of both 
citrate unmasking buffer and EDTA unmasking solution were tested. The optimal 
unmasking conditions were found to be EDTA unmasking solution at 55oC for 3 
hours, with 30 min at room temperature to allow the slides to cool down. This was 
found to provide adequate unmasking of epitopes within the tissue with minimal 
damage to the tissue section. 
Various blocking solutions were also trialled in the IFA staining method development. 
General blocking solution was 1x PBS containing between 1-20% serum (either NDS 
or BSA) with or without Tween 20 or Triton-X (0-0.5%). Blocking solution was applied 
for between 30 min to 3 hours. Optimal blocking conditions, which minimised both 
background staining levels and damage to the tissue material, were found to be 1% 
BSA and 0.2% Triton-X in 1x PBS for 2 hours. This solution was also used as an 
antibody dilution buffer. 
Various wash solutions were also trialled, including both 1x TBS or 1x PBS alone, or 
wash solutions containing either Tween 20 or Triton-X (0-0.5%) with or without 
agitation. Optimal wash conditions, which minimised damage to the tissue sections 
were found with three changes of 1x PBS for 20 min each without agitation.  
The final conditions employed were antigen unmasking at 55oC for 3 hours followed 
by a 30 min incubation at room temperature, blocking and antibody dilution buffer of 
1% BSA and 0.2% Triton-X in 1x PBS for 2 hours, and optimal washing conditions of 
3 changes of 1x PBS for 20 min each. This maintained suitable histology and 
enabled adequate detection of antigens within the tissue section. 
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4.3.2 Antibody optimisation 
All antibodies were optimised for use with formaldehyde-fixed and cryopreserved 
tissue and IFA staining protocol. All successful primary antibodies which showed a 
robust level of specific staining and minimal background fluorescence and matching 
isotype controls are listed in Table 4.2.  
Using the protocol outlined above, antibodies against specific cell surface markers 
were initially tested in single immunofluorescent stains on suitable control material 
(human skin, human tonsil tissue and CD14- immune cells from peripheral human 
blood) and where appropriate on UCSF skin biopsy sample material. In parallel all 
sections were incubated with matched isotype control antibodies. Example images of 
IFA staining using antibodies specific for the pan-T cell marker CD3, the T helper cell 
marker CD4, the cytotoxic T cell marker CD8, the NK cell and other monocyte 
marker CD16, the B cell marker CD20 and the macrophage, monocyte and other 
large cell marker (cells of macrophage lineage) CD68 are shown in Figures 4.2 and 
4.3. Specific staining with the antibodies against the cell surface markers CD3, CD4, 
CD8, CD16 and CD20 all showed the expected membrane-associated patterns. 
Staining with the antibody specific for CD68 showed the expected cytoplasmic 
staining pattern. No staining was observed in the sections incubated with isotype 
control antibodies (representative image shown in Figure 4.3E). 
Example images of antibodies specific for the dermal dendritic cell marker DC-SIGN, 
the pDC marker DLEC (also called BDCA-2), and the Langerhans cell marker 
langerin are shown in Figure 4.4. The specific staining patterns observed above the 
isotype control stained sections showed the expected cellular distribution: DC-SIGN 
is cell-surface associated, langerin is a cytoplasmic marker and DLEC is a cell 
surface marker. 
Example images of IFA staining of infHFFs with antibodies against VZV IE63, and 
the glycoprotein complex formed between gE and gI (gE:gI) are shown in Figure 4.5. 
Although these viral antigens normally display a cell membrane associated pattern in 
formaldehyde-fixed and paraffin-embedded material, in the formaldehyde-fixed and 
cryopreserved tissue they showed staining throughout infected cells. No specific 
staining was observed on uniHFFs incubated with VZV specific antibodies or 
sections incubated with isotype control antibodies. 
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Table 4.2 - Primary and isotype control antibodies optimised for IFA on 
formaldehyde-fixed cryopreserved skin biopsy material. Isotype control antibody 
dilutions were calculated to match the working concentration of the primary antibody 
solution. 
 
Antibody Company Optimal dilution 
Mouse anti-CD3 Leica Microsystems, Germany 1 in 10 
Goat anti-CD4 R&D systems, USA 1 in 10 
Rabbit anti-CD8 Abcam, USA 1 in 100 
Mouse anti-CD16 Leica Microsystems, Germany 1 in 40 
Mouse anti-CD20 Leica Microsystems, Germany 1 in 10 
Mouse anti-CD68 Leica Microsystems, Germany 1 in 10 
Rabbit anti-DC-SIGN Abcam, USA 1 in 500 
Goat anti-DLEC (BDCA-2) R&D systems, USA 1 in 50 
Mouse anti-Langerin Leica Microsystems, Germany 1 in 200 
Rabbit anti-VZV IE63 
Prof R Mahalingam, University of 
Colorado Medical school 
1 in 1000 
Mouse anti-VZV gE:gI 
complex Meridian Life Science, USA 1 in 250 
Mouse IgG 2a Invitrogen, USA (As required) 
Mouse IgG 2b Invitrogen, USA (As required) 
Rabbit IgG R&D systems, USA (As required) 
Goat IgG R&D systems, USA (As required) 
 
The patient material provided by collaborators was very limited in number, allowing 
for 2 repeats of 3 antibody combinations only. Consequently, to maximise the 
information obtained and gain information on the presence and localisation of more 
than one specific cell type in the skin biopsy sample, IFA with two or three specific 
antibodies was developed. Dual and triple IFAs allowing the co-detection of different 
antigens within the same sample, and provided valuable information about the 
relative positions of various immune cells and viral antigen expression. Thus 
antibody combinations were trialled on appropriate skin biopsy sample material from 
UCSF. The successful primary and secondary antibody combinations are described 
in Table 4.3.  
Sample IFA images of the various antibody combinations used in immunofluorescent 
staining on control material are shown in Figures 4.6, 4.7 and 4.8. The first antibody 
combination (Figure 4.6) consisted of anti-CD4, anti-CD8 and anti-VZV gE:gI specific 
antibodies. Antibodies against CD4 and CD8 detect T helper and T cytotoxic 
lymphocytes respectively, while an anti-VZV gE:gI antibody detects the viral 
glycoprotein E-glycoprotein I complex in VZV-infected cells. All antibody staining 
patterns were similar to those observed in single stains. 
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Table 4.3 - Combinations of primary antibodies, matching isotype controls 
and secondary antibodies utilised in IFAs on formaldehyde-fixed 
cryopreserved tissues 
 
 Order of antibody application to sections 
  First Second Third 
     
Anti-CD4 Anti-VZV gE:gI  Anti-CD8 Combination 1 
 Goat IgG  
 
Mouse IgG2a  
 
Rabbit IgG  
 
Secondary 
antibodies 
 
Alexa Fluor 488 
donkey anti-goat 
Alexa Fluor 546 
donkey anti-
mouse 
Alexa Fluor 647 
donkey anti-rabbit 
 
Anti-BDCA-2 Anti-Langerin Anti-CD8  
 
Combination 2 
 Goat IgG 
 
Mouse IgG2b  
 
Rabbit IgG  
 
Secondary 
antibodies  
 
Alexa Fluor 488 
donkey anti-goat 
Alexa Fluor 546 
donkey anti-
mouse 
Alexa Fluor 647 
donkey anti-rabbit 
 
Anti-CD68  Anti-VZV IE63  
 
Combination 3 
 Mouse IgG2a  
 
Matched NRS 
 (nil) 
Secondary 
antibodies 
 
Alexa Fluor 594 
donkey anti-
mouse 
Alexa Fluor 488 
donkey anti-rabbit  
 
The second antibody combination (Figure 4.7) consisted of anti-BDCA-2, anti-CD8 
and anti-langerin specific antibodies. The marker BDCA-2 is a marker of pDCs, 
langerin is a marker of tissue-resident dendritic cells Langerhans cells, and CD8 is a 
marker of CTLs. All antibody staining patterns were similar to those observed in 
single stains. 
The third and final antibody combination (Figure 4.8) consisted of anti-CD68 and 
anti-VZV IE63 specific antibodies. CD68 is a marker of macrophages, monocytes 
and other large cells (of macrophage lineage), while anti-VZV IE63 detects the IE63 
protein in VZV-infected cells. All antibody staining patterns were similar to those 
observed in single stains. No third antibody was used in this staining combination as 
there was none deemed suitable. 
The above dual and triple IFA antibody staining combinations allowed the detailed 
analysis of the immune cell profile in formaldehyde-fixed and cryopreserved tissue. 
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4.3.3 Immunofluorescent analysis of cells present in human skin 
 biopsies from PHN-affected and normal patients  
To establish the immune cell profile in human skin biopsy samples from the active 
and contralateral sides of five PHN -affected patients, and the left and right sides of 
five control patients, IFAs were performed utilising our newly developed and 
optimised antibody staining combinations as described above. 
The first antibody combination applied to human skin biopsy sections stained for 
CD4+ and CD8+ T cells in conjunction with VZV-infected cells by utilising the antibody 
specific for the viral proteins gE:gI. Representative images from two patients are 
shown in Figure 4.9. CD4+ and CD8+ T cells were detected in both PHN-affected and 
control tissue, as well as in control patients. Both subsets of T cells were detected 
throughout the dermis, generally within close proximity of the epidermis. Generally 
CD4+ T cells were detected at a greater frequency than CD8+ T cells in all skin 
biopsy samples. Positive staining for the VZV late gene marker gE:gI was not 
observed in either the PHN-affected patients or the control patients, despite the 
successful staining in the positive control infHFFs and low background staining levels 
on the isotype and negative controls. 
The second antibody combination stained for pDCs, CD8+ T cells and Langerhans 
cells. Representative images from two patients are shown in Figure 4.10. pDCs were 
detected at a very low frequency in two patient samples only, and did not correlate 
with the presence of PHN. CD8+ T cells were detected in all samples, and were 
included to obtain a relative position in regards to the DC subsets identified in this 
combination. Langerhans cells were detected at varying frequencies in all patients, 
and the location and frequency were analysed (data shown below). 
The third and final antibody combination stained for macrophages and VZV-infected 
cells by utilising an anti-VZV immediate-early protein IE63. The matched isotype 
staining for CD68 featured quite high background staining levels on the skin biopsy 
material, and no positive staining was observed above this. No IE63 staining was 
observed in any patient sample (data not shown). In these staining experiments, the 
positive controls showed clear positive staining, the isotype controls and negative 
controls showed low non-specific and background staining levels.  
In each of the above stains matched isotype control antibodies were applied to skin 
biopsy material. Due to the very limited amount of patient skin samples provided, 
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slides from control 5 were used, and consequently experimental data from this 
patient is limited. 
4.3.3.1 ANALYSIS OF CELL MARKER FREQUENCY AND DISTRIBUTION IN HUMAN 
 SKIN BIOPSY SAMPLES FROM PHN-AFFECTED AND CONTROL PATIENTS 
While IFA is useful to demonstrate the presence or absence of a specific expressed 
marker on cells, a quantitative analysis is required to better compare the frequency of 
a cell populations within the tissue. This requires enumeration of the number of 
positive IFA stained cells, and their relative position within the section. To allow 
proper analysis of the data obtained from the immunofluorescent assays performed 
on human biopsy samples from PHN-affected and control patients, two different 
quantitation methods were used.  
4.3.3.1.1 Analysis of the presence and distribution of immune cell subsets in human 
  skin biopsy samples 
To analyse the presence of a rare cell marker, and the distribution of these cells 
within the section a semi-quantitative approach was utilised. It involved the 
examination of antibody staining for specific cell surface markers within a 
representative microscope images from each section, and assigning a score to each 
based on the presence or location of cells within the sample. Three independent 
sections were analysed to examine the location of Langerhans cells within the tissue, 
and the presence of pDCs. As biopsy samples were sectioned to provide multiple 
replicates of each biopsy on a single slide, this analysis was performed on up to 
three sections per biopsy sample for each IFA staining combination.  
To analyse the location of Langerhans cells within the tissue samples, langerin 
staining was assessed according to presence of langerin+ cells in the dermis, and 
their proximity to CD8+ T cells. Results for langerin+ cell scoring is shown in Table 
4.4. Scoring was performed as follows: “norm” indicates tissue with langerin+ cells 
present in the epidermis, “+” indicates langerin+ cells within the dermis, while “+ TC” 
indicates langerin+ cells present in the dermis in close proximity to CD8+ T cells. This 
is illustrated in Figure 4.11. 
Migration of Langerhans cells from the epidermis (as shown by langerin+ cells 
present in the dermis) was seen more often in skin taken from PHN-affected patients 
(Langerhans cell migration present in 4/5 PHN-affected patients compared to 2/4 
control patients). However migration was not restricted to the active side in PHN-
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affected patients (Langerhans cell migration in 3/5 PHN patients on active side, and 
3/5 on contralateral side). 
 
Table 4.4 - Scoring of Langerhans cell presence in the dermis of patient skin biopsy 
samples. Scoring is as follows: “norm” indicates normal epidermal distribution of langerin+ 
cells, “+” indicates langerin+ cells within the dermis, while “+ TC” indicates langerin+ cells 
present in the dermis in close proximity to CD8+ T cells. The fraction in brackets is the number 
of sections in which the staining was observed followed by the total number of sections 
examined for each patient. Slides from patient Control 5 were used for isotype control (ND = 
staining not done). 
 
PHN-affected 
patients Active Contralateral  Control Patients Left Right 
PHN 1 norm + (1/2)  Control 1 norm 
+ TC 
(1/3) 
PHN 2 
+ TC 
(2/3) + (1/3)  Control 2 norm 
+ TC 
(1/3) 
PHN 3 
+ TC 
(1/3) norm  Control 3 norm norm 
 
PHN 4 norm norm  Control 4 norm norm 
PHN 5 
+TC 
(2/3) 
+TC (1/3), + 
(2/3) 
 Control 5 (ND) 
 
Langerhans cells were observed in close proximity to CD8+ T cells within the dermis 
in both PHN-affected and control material. There was no relationship between 
Langerhans cells in close proximity to T cells and the presence of PHN (Langerhans 
cells in close proximity to CD8+ T cells in 3/5 PHN-affect patients compared to 2/4 
control patients), nor any link within PHN-affected patients (3/5 active PHN biopsies 
showed Langerhans cells and CD8+ T cells in close proximity, compared to 3/5 
contralateral side).  
As it was a rare event, BDCA-2 staining was assessed to be either positive or 
negative based on presence or absence of positive staining within the tissue section. 
Results are shown below in Table 4.5. BDCA-2+ pDCs were detected in two sections 
from the contralateral side of one PHN patient (PHN 2), and in one section from a 
control patient (Control 3). There was no relationship with the presence of pDCs and 
PHN when comparing opposite sides within PHN-affected patients, and when 
comparing PHN-affected and control patients.  
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Table 4.5 - Scoring of BDCA-2+ cells present in patient skin biopsy samples. Samples 
were scored either "+" (present) or "-" (absent). The fraction in brackets is the number of 
sections in which the staining was observed followed by the total number of sections 
examined for each patient. Slides from patient Control 5 were used for isotype control (ND = 
staining not done). 
 
PHN-
affected 
patients Active Contralateral  
Control 
Patients Left Right 
PHN 1 - -  Control 1 - - 
PHN 2 - + (2/2)  Control 2 - - 
PHN 3 - -  Control 3 - + (1/3) 
PHN 4 - -  Control 4 - - 
PHN 5 - -  Control 5 (ND) 
 
4.3.3.1.2 Analysis of the frequency of immune cell subsets in human skin biopsy 
  material 
In order to gain a more complete understanding of the immune cell repertoire within 
the tissue samples, the frequency was calculated for the immune cell markers 
present in higher numbers: specifically Langerhans cells and T cell subsets. This 
involved counting the number of positive cells for each cell marker in up to three 
microscope images per section, for each section (limited only by the size and 
condition of the section). Three images per section were chosen as this covered a 
majority of the tissue area. The total surface area examined in each micrograph was 
then calculated with the aid of the Zeiss AxioVision LE software (Carl Zeiss Pty Ltd, 
Australia and New Zealand). The frequency of positive cells was then obtained by 
dividing the number of positive cells by the total area of the tissue. Fold changes 
were obtained by normalising patient values against the contralateral side (PHN-
affected material) or the right site (control material). This analysis was performed for 
analysis of Langerhans cells in the epidermis, and CD4+ and CD8+ T cell subsets 
within the tissue. The dermis was not examined, as it was not possible to differentiate 
between migrating cells and cells present within vessel walls. 
The frequency of Langerhans cells in the epidermis of patient skin biopsy samples is 
presented as fold change normalised to the contralateral or right side, shown in 
Figure 4.12. In 3/5 PHN-affected patients – patients PHN 1, PHN 4, PHN 5 – there 
was a reduction in the number of Langerhans cells in the epidermis of the PHN-
affected side when compared to the contralateral side. The largest fold change was 
1.4x seen in active side of patient PHN 2, and the smallest fold change was 0.6x 
seen in the active side of patient PHN 4. The average fold change in Langerhans 
cells in the epidermis of PHN-affected patient material was 0.9x. 
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In the control patient samples the frequency of Langerhans cells was considerably 
less varied between sides for each patient. The largest fold changes were 1.2x and 
0.8x for patients Control 1 and Control 2 respectively. Patients Control 3 and Control 
4 had similar levels of Langerhans cells staining in their left and right sides. The 
average fold change in Langerhans cells in the epidermis of all the control patient 
material was 1.0x. 
The frequency of CD4+ T cells present within the tissue of patient biopsy samples is 
presented as fold change normalised to the contralateral or right side, shown in 
Figure 4.13. CD4+ T cells were detected primarily within the dermis of the PHN-
affected skin biopsy samples, however there were rare CD4+ cells detected within the 
epidermis. Three out of five PHN-affected patients showed an increase in frequency 
of CD4+ T cells in their active side compared to the contralateral – patients PHN 1, 
PHN 2, PHN 4. The largest was an increase of 1.6x (PHN 2). The other two PHN-
affected patients showed a lower frequency of CD4+ T cells present in the active 
side, the lowest at 0.5x the contralateral side of patient PHN 3. Overall the average 
fold change in CD4+ T helper cells in PHN-affected patient material was 1.1x. 
In control patient samples there was overall less CD4+ T cells detected in normal 
skin, and a lower range seen between different patient samples. The largest increase 
was 1.3x (patient Control 2), and the largest reduction was 0.5x (patient Control 4). 
On average there was a slight decrease (0.9x) in the frequency of CD4+ T cells in 
skin biopsy material from the left compared to the right sides.  
CD8+ T cells were detected at a much lower frequency, with much greater variation 
within samples than CD4+ T cells in all skin biopsy samples examined. The frequency 
of CD8+ T cells within the tissue of patient biopsy samples is shown in Figure 4.14, 
and the variation within samples is shown through the greater range of minimum and 
maximum values as compared to previous results. Similar to CD4+ T cells, CD8+ T 
cells were primarily restricted to the dermis, with sporadic CD8+ cell visible within the 
epidermis. Three PHN-affected patients – PHN 2, PHN 3, and PHN 4 – showed an 
increase in CD8+ T cells on the active side, with the greatest increase – a 2.3 fold 
increase – seen in patient PHN 3. Patients PHN 1 and PHN 5 showed similar 
frequencies of CD8+ T cells on the active and contralateral sides. On average, skin 
biopsy material from PHN-affected patients had a 1.5 fold increase in CD8+ T cells on 
the pain side. 
The frequency of CD8+ T cells in the control patient material was also more varied 
than other immune cell types investigated. The greatest change was a 0.4 fold 


 The University of Sydney 
- 122 - 
decrease, seen in patient Control 1. On average the control patient material featured 
a limited increase of 1.1x more CD8+ T cells on the left side. 
Overall in all skin biopsy samples there was high variability in the frequency of 
Langerhans cells, and greater frequency of both CD4+ and CD8+ T cells in the skin 
biopsy samples from PHN-affected patients. 
4.3.3.1.3 Analysis of frequency of immune cell subsets according to patient 
While a comparison of the frequency of immune cells in each patient for the different 
cell markers is beneficial in showing a trend across patients, another useful analysis 
is the frequency of detection of each immune cell subset in each patient. This can be 
used to establish whether there is any difference in immune cell types in a specific 
patient. The fold changes of different immune cell markers are displayed for PHN-
affected patient material and control patient material in Figures 4.15 and 4.16 
respectively. While there are not any clear trends in the difference between cell 
marker frequencies, it is obvious that the frequencies of the cell markers investigated 
in this study are more variable in skin biopsies taken from PHN-affected patients 
compared to control patient biopsy material.  
 
4.4 Discussion 
This study has provided a detailed understanding of the numbers and type of 
dendritic cells and T cell subsets present in human skin during PHN. PHN is a very 
painful complication of herpes zoster, which results from VZV reactivation within 
human ganglia.  
As VZV is a highly species-specific human herpesvirus, experimentation is generally 
restricted to the use of tissues of human origin. To date there is no experimental 
model that replicates the complete VZV infection cycle seen in vivo. The modelling of 
latency and reactivation in particular has been challenging, and experimental 
modelling of PHN has so far been beyond our capabilities. 
Consequently studies into VZV reactivation and PHN in particular have required the 
use of clinical human tissue samples. This type of material has been difficult to 
acquire due to many different factors, and consequently studies performed previously 
have been quite limited in number and scope. 
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One particular study performed by Zak-Prelich et. al. took skin biopsy samples from 
herpes zoster-affected patients, and then monitored the same patients for 6 months 
following herpes zoster for the development of PHN (Zak-Prelich et al., 2003). This 
study examined CD3, CD4, CD8 and CD56 expression in skin biopsies of herpes 
zoster lesions taken from patients presenting to hospital with herpes zoster. They 
found that there were significantly lower numbers of infiltrating lymphocytes present 
in skin biopsy samples taken during herpes zoster of patients who went on to 
develop PHN. However whether the immune infiltration persisted or was present in 
the skin following rash resolution and during PHN was unknown. Also this study does 
not take into account the possibility of individual variation in the amount of immune 
cell infiltration between patients, and utilised single punch biopsy samples from each 
patient involved (Zak-Prelich et al., 2003). 
My study was made possible due to the provision of precious human biopsy material 
by collaborators at Albany Medical College and the UCSF. The skin material 
provided allows us to compare both between individuals – PHN-affected patient to 
control – and within individuals – PHN-affected side to contralateral side. This 
material allows us to account for any variation in immune response between 
individual patients. 
The two initial patient cohorts – PHN-affected and control – represent similar ages 
and sex distribution. The skin biopsies were obtained at least six months after the 
resolution of the herpes zoster rash. Currently clinical data is limited to this 
information. It is not known whether control patients represent recovered herpes 
zoster patients at least 6 months post rash, or were normal patients without any VZV 
reactivation.  
As with most clinical samples there was a very limited number available for use in 
this study. The work presented in this chapter was designed to form the foundation 
for a larger and more comprehensive study, using a larger patient cohort. This is the 
focus of Chapter 5 of this thesis. 
Due to the limitation in the amount of human skin biopsy sample material available 
for this study a significant amount of time and effort was spent on method 
development. This method development and optimisation stage involved both the 
development of suitable control material, and the creation of an IFA staining protocol 
that enabled the examination of multiple markers within the same section. The 
development of a dual and triple IFA detection system that maintained the integrity of 
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the tissue and provided adequate antigen unmasking was critical for this work to 
progress, 
Unfortunately there was no reproducible detection of VZV antigen positive cells 
within any of the PHN-affected skin patient material used in this study. Two different 
antibodies were utilised: one specific for a glycoprotein complex (gE:gI) and the other 
for an immediate early protein (IE63). These two viral antigens are normally present 
at relatively high levels during a productive infection (Reichelt et al., 2009). However 
at the start of my study both our laboratory and our colleagues did not have any 
fixation and preservation matched known VZV antigen positive tissue material. Thus 
we developed a suitable positive control for IFA staining, which was both fixation and 
preservation matched infHFF cell pellets, utilised as positive control material. 
Expression levels of VZV antigens in this productively infected material may be 
higher than that observed during clinical infection – especially if there is only a low 
level of persistent infection within the skin material, many months post-herpes zoster 
rash resolution. Consequently it is not known whether VZV antigen can be detected 
in patient sample material utilising our current protocol.  
Ideally, if possible it would be best to attempt to obtain a biopsy sample of a herpes 
zoster lesion within days of its appearance and match the fixation and 
cryopreservation in order to assess the suitability of this method. None the less, we 
have previously used the anti-gE:gI antibody readily detected these VZV antigens by 
immunohistochemistry and immunofluorescence several days post-herpes zoster 
rash onset (Huch et al., 2010). 
Another alternative explanation for the lack of VZV antigen detection in this tissue 
maybe that the VZV antigen expression is below the limit of the detection method. 
One of the VZV-specific antibodies utilised in this study (anti-VZV IE63) has been 
used by our laboratory to demonstrate the presence of very low level VZV infection in 
human ganglia samples (Steain et al., 2013). VZV antigen expression has also been 
demonstrated by previous work in our laboratory during active herpes zoster and 
many months following reactivation in both human skin biopsy and human ganglia 
samples (Gowrishankar et al., 2010, Huch et al., 2010). 
Anti-viral treatment also has the potential to affect the presence of replicating VZV 
within the skin of patients both during herpes zoster and during the associated 
recovery period. It is possible it could affect VZV antigen expression during PHN to a 
point below detectable levels. Unfortunately it is unknown whether the patients 
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included in this study were treated with any anti-viral medication during the acute 
infection period. 
Langerhans cells are the primary tissue resident dendritic cells present in the human 
epidermis (Ross and Pawlina, 2003). These cells are present in an immature 
phenotype in normal human skin and the upper respiratory tract. Upon exposure and 
capture of foreign antigen, Langerhans cells have the ability to migrate to draining 
lymph nodes and perform an important antigen presenting role through interaction 
with T lymphocytes (Valladeau and Saeland, 2005). Langerhans cells are not only 
restricted to the epithelial layer of the skin, but are also present in lymph nodes, hair 
follicles or other organs (Valladeau and Saeland, 2005).  
In this study Langerhans cells were identified through the surface expression of the 
marker langerin. There is a population of langerin+ DCs that reside within the dermis 
that are a distinct population of cells, and perform a different function to Langerhans 
cells (Bursch et al., 2007, Ginhoux et al., 2007, Poulin et al., 2007). Although these 
cells are at a very low frequency (Romani et al., 2010), they are indistinguishable 
from migrating Langerhans cells with the staining method utilised, and consequently 
Langerhans cells were counted when confined to the epidermis only. 
The frequency of Langerhans cells in human skin biopsy samples taken from PHN-
affected patients was quite varied when compared to control patient biopsy material. 
In general, control patients had similar frequencies of Langerhans cells when 
comparing biopsies taken from left and right, while PHN-affected patients showed 
quite different levels when comparing active and contralateral biopsy material.  
In 3 of the 5 PHN-affected patients, there was a greater frequency of Langerhans 
cells on the contralateral side compared to the active PHN-affected site. Whether this 
was an increase in the number of Langerhans cells on the contralateral side 
(proliferation of Langerhans cells), or a decrease in the number of Langerhans cells 
on the active side (migration of Langerhans cells out of the tissue) is unknown. In 
either case there is some factor that has caused a change in the dynamics of 
Langerhans cells from the normal steady state generally seen in the control patient 
biopsy material. The cause of this change from steady state dynamics observed in 
control patient material to the varied frequency seen in PHN-affected patient material 
is not known. 
pDCs play an important role in the innate anti-viral immune response (Donaghy et 
al., 2009, Huch et al., 2010, Valladeau and Saeland, 2005). They are recruited to 
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sites of inflammation, and are inflammatory cells themselves, secreting many 
cytokines and chemokines that promote effector cell activation – in particular IFN-α 
(Cella et al., 1999, Fitzgerald-Bocarsly, 1993, Siegal et al., 1999). pDCs have been 
shown to play an important role in the control herpes simplex virus reactivation 
(Donaghy et al., 2009), as well as during both active varicella and herpes zoster in 
the skin (Huch et al., 2010). 
pDCs were only detected in a single biopsy sample from two cases: the biopsy from 
contralateral side of PHN-affected patient PHN 2, and the biopsy from the right side 
of patient control 3. All samples from PHN-affected patients were obtained at least 6 
months following the resolution of the herpes zoster-associated rash. Thus at this 
late time post-rash resolution, it is unlikely that pDCs would still be involved unless 
there was still an active and ongoing acute inflammatory process. Overall this infers 
that these cells play a limited role in the pathogenesis or control of PHN, and these 
cells seem to play a limited role months post herpes zoster, which is in stark contrast 
to what is observed in the skin during active herpes zoster (Huch et al., 2010). This 
suggests it is important to examine the dynamics of both Langerhans cells and pDCs 
over several time points following the appearance of the herpes zoster-rash in 
patients with and without PHN. This will be performed in the next chapter. 
Dermal dendritic cells (dDCs) are another important subset of DCs present in human 
skin. These cells are present at high frequency throughout the human dermis. Cells 
expressing the dDC marker DC-SIGN have previously been shown to be present in 
similar frequencies in normal, varicella and herpes zoster-affected skin (Huch et al., 
2010). Although we were able to successfully optimise an antibody against the dDC 
marker DC-SIGN, due to the limited number of slides it was not possible to study 
dDC frequency in the current study. In future it would be worthwhile examining the 
frequency of dDC in human skin samples from PHN-affected versus normal patients.  
In the adaptive immune response again VZV infection, both CD4+ and CD8+ T cells 
are involved in control of viral replication through the destruction of infected cells 
(Abendroth and Arvin, 1999). Previous work done in our laboratory has shown that T 
cells are likely involved in the control of herpes zoster within the human ganglia 
(Gowrishankar et al., 2010, Steain et al., 2013), and despite the presence of T cells 
in close proximity with neurons in the reactivated ganglia there is no evidence of T 
cell induced neuronal apoptosis (Steain et al., 2013). Previous work done in this 
thesis (see Chapter 3) has shown that there is a large CD3+ T cell infiltrate within the 
ganglia of a PHN-affected patient many years post-resolution of the herpes zoster-
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associated rash, however in contrast to that observed in ganglia during herpes zoster 
there were comparable levels of both CD4+ and CD8+ T cell subsets.  
Based on the IFA staining of the skin biopsies, there was a greater number of T cells 
present in the skin biopsy tissue of PHN-affected patients, including both CD4+ and 
CD8+ T cells. As with the Langerhans cell frequency – there is no clear trend shown 
when comparing between the active and contralateral sides of PHN-affected 
individuals, or between the PHN-affected and control patient material. Previous work 
has found that lower numbers of infiltrating T cells within the skin may contribute to 
the development of PHN (Zak-Prelich et al., 2003). However that study examined 
biopsies of active herpes zoster lesions, while this current study avoided active 
lesions and concentrated on the painful area of skin only. 
Initially the IFA examination of the macrophage marker CD68 was also planned. This 
was mainly due to the significant level of macrophages that have been shown within 
human ganglia during herpes zoster (Gowrishankar et al., 2010). The antibody was 
successfully optimised and used on trial material, and subsequently utilised in the 
examination of the PHN-affected and control skin samples. Unfortunately the IFA 
staining was not successful and resulted in very high background staining levels with 
no specific staining identifiable above the background level seen in the isotype 
control stained sections, and consequently the frequency of CD68 positive cells 
within the skin biopsy material remains unknown. In future, an antibody specific for 
another macrophage-specific cell surface marker could be utilised to study the 
frequency of this immune cell subsets in the sample material. 
This study has utilised some very precious skin biopsy material comprising of 
matched biopsy samples taken from five PHN-affected and control patients. The 
biopsies were performed at least 6 months following the resolution of the herpes 
zoster rash. Biopsies were obtained from patients at a single time point only, 
providing a “snap shot” of immune cell subsets present during PHN. Although the two 
patient cohorts were generally matched in terms of median age and gender, it is 
unknown whether the control patients represent recovered herpes zoster patients 
matched to time post-rash, or normal patients who have not experienced herpes 
zoster. This could play a significant factor in the mechanics of immune infiltration and 
tissue resident immune cells. 
This study was restricted in the different markers accessed mainly due to the very 
limited number of slides available. Although there were multiple sections present 
from each biopsy sample on each slide, it was not feasible to stain each section for 
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different markers due to the close proximity of the sections. Ideally multiple slides 
from each biopsy sample would be available, which would allow the examination of 
other related immune markers to study the presence of T cell subsets (CD45RA and 
CD45RO), B cells (CD20), NK cells (CD16), and cytotoxic markers (TIA-1 and 
Granzyme B). Other interesting immune markers include neutrophil (Ly-6G/-6C), 
mast cell (mast cell tryptase) and other innate and adaptive immune markers that 
have been associated with neuropathic pain (Machelska, 2011, Zhou et al., 2010, 
Vallejo et al., 2010, Labuz et al., 2010, Hama et al., 2010). 
In future studies the kinetics of the different T cell and DC subsets (dDCs, 
Langerhans cells and pDCs) present within human skin could also be studied. This 
would require multiple biopsy samples taken from the one patient over time following 
diagnosis with herpes zoster, and is the focus of the next results chapter. While we 
have only looked at a single time point snapshot, the kinetics of immune cell 
infiltration over time would be interesting to examine. This is the focus of the study 
presented in the next chapter of this thesis. 
 The University of Sydney 
- 129 - 
Chapter 5 – Kinetics of immune cell infiltration 
over time in human skin biopsy samples 
obtained following herpes zoster. 
5.1 Introduction 
VZV is a common human infection that causes two clinical presentations – varicella 
and herpes zoster. PHN is the most common complication following herpes zoster 
(Cohen et al., 1999, Steiner et al., 2007, Hope-Simpson, 1965, Hope-Simpson, 
1975). To date there has been no investigation into the dynamics of the immune 
infiltration or viral antigen expression in the skin over time and the level of pain 
experienced by the patient following the resolution of the herpes zoster-associated 
rash and the development of PHN.  
This study aims to address this lack of knowledge through an immunofluorescent 
examination of rare sample material that includes biopsies obtained from multiple 
sites from patients during herpes zoster, and subsequent biopsies obtained from the 
same patients at intervals post-herpes zoster rash resolution along with matching 
detailed clinical data. This will enable a detailed examination of the subsets of 
immune cells present in the skin, the number and location of VZV antigen positive 
cells, and their relative location in regards to each other. The matching clinical data 
includes information on the size and severity of the painful and alloreactive areas of 
skin.  
Previous studies have shown that there is a dramatic shift in the numbers of 
important immune cells within the skin during herpes zoster, with a reduction in 
tissue resident Langerhans cells within the epidermis, and an increase in pDCs – 
highly inflammatory dendritic cells (Colonna et al., 2004) – within herpes zoster-
affected skin (Gutzeit et al., 2010, Huch et al., 2010). However whether this shift is 
maintained long-term post herpes zoster or in patients suffering PHN is unknown. 
Another study found significantly lower numbers of infiltrating lymphocytes present 
during herpes zoster in the skin of patients who later developed PHN compared to 
those that experienced no complications, despite the systemic cytokine and antibody 
responses being at comparable levels (Zak-Prelich et al., 2003). It would be 
interesting to investigate whether difference in important immune mediators is 
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maintained following the resolution of the herpes zoster-associated rash, or if there 
are any other immune cell changes that may predispose a patient towards PHN 
instead of an uncomplicated recovery. 
A common underlying mechanism of neuropathic pain is the presence of 
inflammation at the damaged or affected site (Vallejo et al., 2010) and evidence 
suggests that these immune cells contribute to neuropathic pain in the periphery 
(Reviewed in Thacker et al., 2007). In the peripheral nervous system, tissue resident 
macrophages have been shown to migrate immediately following nerve injury to the 
site of injury, and display an active phenotype (Mueller et al., 2001). Further 
inflammation is promoted by the secretion of chemokines, matrix metalloproteases, 
and vasoactive mediators from activated macrophages, Schwann cells/satellite glial 
cells, and injured nerve axons to attract immune cells, increase blood flow to the area 
and cause swelling (Perrin et al., 2005, Shubayev et al., 2006, Zochodne et al., 
1999). These changes result in a dense cellular infiltrate, mainly composed of 
macrophages, T lymphocytes and mast cells, forming within 2 days of injury at the 
injury site (Zochodne et al., 1999).  
While there have been studies into the location of VZV antigen expression in the skin 
during herpes zoster (Huch et al., 2010, Nikkels et al., 1995a, Nikkels et al., 1995b, 
Oxman, 2000), to date there has been no investigation of VZV antigen expression in 
human skin over time following herpes zoster. Furthermore, there have been no 
reported studies investigating the persistence of VZV antigen expression in human 
skin from patients with or without PHN following natural VZV reactivation. This study 
aims to address this important area by using two different viral markers, and 
investigate whether VZV antigen expression persists in the skin following herpes 
zoster, and whether there is any difference in dynamics of VZV antigen expression 
between patients who experience greater or lesser pain levels, or between patients 
who develop ongoing PHN compared to those who experience an uncomplicated 
recovery. 
This study is novel as it involves the analysis of skin samples from multiple patients 
from the time they presented with herpes zoster, throughout the rash and following 
rash-resolution, along with monitoring the patients’ associated clinical pain levels. 
This study is possible through access to a tissue bank created by collaborators at the 
UCSF and the Albany Medical College. Punch biopsy samples were collected from 
multiple sites from patients who presented with a herpes zoster-associated rash, and 
from the same patients over subsequent visits. At each visit clinical data was 
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obtained, including several pain measurements. This offers a rare opportunity to 
study in detail any possible link between herpes zoster-associated pain levels and 
any ongoing virological or immunological processes in the skin. 
 
5.2 Patient and control material 
Where applicable; all tissue specimens were obtained in accordance with ethics 
guidelines of both the University of Sydney and Western Sydney Area Health 
Service. 
5.2.1 Control cell block material 
Initial protocol and antibody optimisation were performed on control cell blocks. 
Control cell blocks were generated using both uninfected and infHFFs, and CD14- 
sorted human PBMCs. HFFs were cultured, infected and harvested as described in 
section 2.5. CD14- human PBMCs were isolated as described in section 2.5, and 
were generously donated by Rodney Henriquez (VZV research laboratory, University 
of Sydney). 
5.2.2 Control patient skin material 
Once antibody optimisation was successful on control cell sections, antibodies were 
then trialled on human tissue material to ensure that the antibodies and staining 
technique were established. Control human material consisted of cryopreserved skin 
tissue, kindly provided by Dr Heather Donaghy from the Westmead Millennium 
Institute in accordance with relevant ethics guidelines. 
5.2.3 Patient skin sample material 
Patient skin biopsies were generously provided by Professor Karen Petersen of 
UCSF and Professor Frank Rice of Albany Medical College. The subjects were 
immunocompetent, in stable health, over the age of 50, and had cervical, thoracic, 
lumbar, or sacral outbreaks of herpes zoster. The subjects were required to have an 
average daily pain of at least 20 on the 0–100 mm pain visual analogue scale (VAS) 
over the last 48 hours at the time of the study inclusion visit. No subjects with facial 
or ophthalmic herpes zoster were included to avoid collection of skin biopsies from 
the face. All subjects provided written informed consent (Petersen et al., 2010). 
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The VAS is psychometric scale used to measure subjective information. For the 
UCSF tissue bank, patients were shown a numerical pain scale that corresponded to 
a measure of 0 to 100 mm (Petersen et al., 2010). Patients were asked to rate the 
severity of their pain on the scale, with 0 corresponding to no pain, and 100 
corresponding to full pain. The VAS has been shown to be a reproducible measure of 
patient symptoms (Grant et al., 1999). 
At the initial visit each patient’s areas of abnormal sensation and allodynia were 
mapped, and various sensory function tests were performed. Four sites were 
selected as follows: site 1 was placed in the most painful area in herpes zoster-
affected skin, avoiding open lesions. Site 2 was placed in the second most painful 
area on the herpes zoster-affected skin. Site 3 was mirror-image to Site 1. Site 4 was 
a distant control site placed contralateral to and at least 2 dermatomes away from the 
level of the herpes zoster-affected dermatome; typically on the shoulder (Petersen et 
al., 2010). Sites studied are shown in Figure 5.1. Biopsies (3 mm punch biopsies) 
were obtained from all four sites on the first visit, and then from at least Site 1 and 
Site 3 on subsequent visits. Mostly full biopsy sets for each individual patient were 
provided for use in this study. 
Each biopsy sample was assigned a code number from a random number list to 
maintain blinding during tissue microscopy and analysis. The specimens were 
immediately placed into a solution of ice-cold 4% paraformaldehyde in 0.1 M PBS at 
pH 7.4 for 4 h to fix, and then transferred through 3 one hour rinses of cold PBS 
before storage in PBS under refrigeration. After overnight incubation in 30% sucrose 
in PBS, the biopsies were rapidly frozen with CO2 onto a chuck for sectioning by 
cryostat (Petersen et al., 2010). 
Slides were archived frozen under glycerol mounted coverslips. Multiple sections 
taken from different regions of each biopsy sample had been mounted on each slide. 
This allowed multiple replicates to be represented on the one microscope slide. For 
each biopsy sample, 3 slides containing 2-3 sections each were provided for use in 
this study. In total samples from 27 patients have been completely examined, 
numbering 283 biopsy samples. Patient details are summarised in Table 5.1. 
The average patient age was 67.8 years old, with a range of 46 to 85 years old. 
There were 13 male patients (average age 70.2, range 63 to 78 years old) and 14 
female patients (average age 65.6, range 46 to 85 years old). Patients were followed 
for an average of 160 days (range of 130 to 210 days). There were at least 4 visits 
for each patient. All visits were recorded as days post herpes zoster rash onset. On 
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average visit 1 was at 22 days (range 9 to 49 days), visit 2 was at 47 days (range 38 
to 63 days), visit 3 was at 93 days (range 80 to 113 days) and visit 4 was at 181 days 
(range 147 to 219 days).  
Information regarding co-morbidities and immune status was not available for each 
patient sample, however initial criteria for inclusion in the tissue bank required that 
subjects be immunocompetent, in stable health, over the age of 50, and have a 
cervical, thoracic, lumbar or sacral outbreak of herpes zoster (Petersen et al., 2010). 
Pain levels for each patient were recorded at each visit. Pain was measured using a 
VAS, with pain regarded as clinically significant when measured at a score of 30 or 
above (Thyregod et al., 2007). All patients had a VAS of at least 20 to be included in 
the study, however only fifteen patients had an average VAS of 30 or above, with 
VAS at visit 1 missing for one patient. Out of the twenty-seven patients in the study, 
seventeen patients’ pain resolved during the study period. Ten patients experienced 
continuing pain beyond the study duration, however all VAS were below clinically 
significant levels during the study period. Of these ten patients, four last had VAS ≥ 
30 at visit 1, five patients at visit 2, with one patient at visit 3. These patients are 
studied in further detail later in the chapter (see section 5.3.3.2). 
Following IFA staining of the skin sections, the tissue was imaged using the Zeiss 
LSM 510 Meta confocal microscope. Three images per section were taken, and the 
number of positive cells for each cell marker counted. The total surface area 
examined in each micrograph was then calculated with the aid of the Zeiss 
AxioVision LE software (Carl Zeiss Pty Ltd, Australia and New Zealand). The 
frequency of positive cells was then obtained by dividing the number of positive cells 
by the total area of the tissue, and then multiplying to give “Positive cells per          
100 000 µm2”. 
5.3 Results 
5.3.1 Antibody optimisation 
As with the previous chapter, the patient material provided by collaborators was very 
limited. Consequently, to maximise the information obtained and to gain information 
on the presence and localisation of more than one cell type in the skin biopsy 
sample, IFA using antibodies to two or three specific markers were examined 
concurrently on the sections provided. Dual and triple IFAs allowed the co-detection 
of different antigens within the same sample, and gave critical information about the 
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relative positions of various immune cells and viral antigen expression. Multiple 
sections on each slide allowed repeats to be performed within the one IFA 
experiment. Antibody combinations were established on appropriate control material 
as described in Chapter 4. The primary antibodies utilised are listed in Table 5.2. The 
successful primary and secondary antibody combinations are described below in 
Table 5.3. 
 
Table 5.2 - Primary and isotype control antibodies utilised in 
immunofluorescent assays on formaldehyde-fixed cryopreserved skin 
biopsy material.  
  
Antibody Company 
Mouse anti-CD3 Leica Microsystems, Germany 
Goat anti-CD4 R&D systems, USA 
Rabbit anti-CD8 Abcam, USA 
Mouse anti-langerin Leica Microsystems, Germany 
Goat anti-DLEC (BDCA-2) R&D systems, USA 
Rabbit anti-DC-SIGN Abcam, USA 
Mouse anti-VZV gE:gI Meridian Life Sciences, USA 
Rabbit anti-VZV IE63 
Prof R Mahalingam, University of Colorado Medical 
School 
Mouse IgG2a Invitrogen, USA 
Mouse IgG2b Invitrogen, USA 
Rabbit IgG R&D systems, USA 
Goat IgG R&D systems, USA 
 
Sample IFA images of the various antibody combinations used on control material 
are shown in Figures 5.2-5.4. The first antibody combination (Figure 5.2) consisted of 
anti-CD4, anti-CD8 and anti-VZV gE:gI. Antibodies against CD4 and CD8 detect T 
helper and cytotoxic T lymphocytes respectively, and anti-VZV gE:gI detects VZV-
infected cells. All antibody staining patterns were similar to those observed in single 
stains, background staining on negative controls and non-specific staining on isotype 
control sections were minimal. 
The second antibody combination (Figure 5.3) consisted of anti-CD3 and anti-VZV 
IE63. The marker CD3 is a pan T cell marker, and VZV IE63 is expressed early on in 
during the productive infection cycle in VZV-infected cells. All antibody staining 
patterns were similar to those observed in single stains, background staining on 
negative controls and non-specific staining on isotype control sections were minimal. 
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The third antibody combination (Figure 5.4) consisted of anti-BDCA-2, anti-DC-SIGN 
and anti-langerin specific antibodies. The marker BDCA-2 is a marker of pDCs, 
langerin is a marker of tissue-resident dendritic cells Langerhans cells, and DC-SIGN 
is a marker of dermal dendritic cells. All antibody staining patterns were similar to 
those observed in single stains, background staining on negative controls and non-
specific staining on isotype control sections were minimal. 
 
Table 5.3 – Proposed combinations of primary antibodies, matching isotype 
controls and secondary antibodies optimised for use in immunofluorescent 
assays on formaldehyde-fixed cryopreserved tissues. 
    
 Order of antibody application to sections 
  First Second Third 
     
Anti-CD4 Anti-VZV gE:gI Anti-CD8 Proposed 
combination 1 Goat IgG Mouse IgG2a  Rabbit IgG 
    
Secondary 
antibodies 
Alexa Fluor 488 
donkey anti-goat 
Alexa Fluor 546 
donkey anti-mouse 
Alexa Fluor 647 
donkey anti-rabbit 
        
     
Anti-CD3 Anti-VZV IE63 (nil) Proposed 
combination 2 Mouse IgG2a Matched NRS 
   
Secondary 
antibodies 
Alexa Fluor 594 
donkey anti-mouse 
Alexa Fluor 488 
donkey anti-rabbit  
        
     
Anti-BDCA-2 Anti-Langerin Anti-DC-SIGN Proposed 
combination 3 Goat IgG Mouse IgG2b Rabbit IgG 
    
Secondary 
antibodies 
Alexa Fluor 488 
donkey anti-goat 
Alexa Fluor 546 
donkey anti-mouse 
Alexa Fluor 647 
donkey anti-rabbit 
 
The antibody staining combinations shown in Table 5.3 were then applied to the 
formaldehyde-fixed and cryopreserved tissue to enable the detailed analysis of the 
immune cell profiles present in the skin biopsy tissue taken at various times post-
herpes zoster rash. 
5.3.2 Immunofluorescent analysis present in human biopsy samples 
Although initial antibody optimisation and staining trials on normal control material 
were successful, the combinations did not all transfer directly to the UCSF sample 
material. Of the optimised antibody combinations (seen above in Table 5.2), only 
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combination 3 (anti-BDCA-2/anti-langerin/anti-DC-SIGN primary antibodies) were 
successful. In combination 1 the anti-VZV gE:gI was unsuccessful, with significant 
non-specific background staining seen on the paraformaldehyde-fixed, 
cryopreserved and gelatin-mounted UCSF sample material. The staining for the anti-
CD4 and anti-CD8 combination was still deemed successful as positive staining 
above low non-specific background staining was observed and all control sections 
were successful. Combination 2 (anti-CD3 and anti-VZV IE63 primary antibodies) 
was entirely successful. The final staining combinations utilised on the UCSF sample 
material are shown in Table 5.4. 
 
Table 5.4 - Combinations of primary antibodies, matching isotype 
controls and secondary antibodies utilised in immunofluorescent assays 
on formaldehyde-fixed cryopreserved skin biopsy material. 
    
 Order of antibody application to sections 
  First Second Third 
     
Anti-CD4 Anti-CD8  Combination 1 
Goat IgG Rabbit IgG (nil) 
    
Secondary 
antibodies 
Alexa Fluor 488 
donkey anti-goat 
Alexa Fluor 647 
donkey anti-rabbit  
        
     
Anti-CD3 Anti-VZV IE63 (nil) Combination 2 
Mouse IgG2a Matched NRS 
   
Secondary 
antibodies 
Alexa Fluor 594 
donkey anti-mouse 
Alexa Fluor 488 
donkey anti-rabbit  
        
     
Anti-BDCA-2 Anti-Langerin Anti-DC-SIGN Combination 3 
Goat IgG Mouse IgG2b Rabbit IgG 
    
Secondary 
antibodies 
Alexa Fluor 488 
donkey anti-goat 
Alexa Fluor 546 
donkey anti-mouse 
Alexa Fluor 647 
donkey anti-rabbit 
 
5.3.2.1 IMMUNOFLUORESCENT ANALYSIS OF THE IMMUNE CELL SUBSETS IN 
HUMAN SKIN BIOPSY MATERIAL 
To characterise the immune cell profile in multiple skin biopsy samples from the 
same patients over time from the most painful sites in patients post-herpes zoster, 
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along with a contralateral site and a contralateral and distal control site, IFAs were 
performed utilising the antibody staining combinations as described above. 
In each of the IFAs, matched isotype control antibodies were applied to UCSF skin 
biopsy material. A biopsy sample was selected at random, and was utilised for 
application of isotype control antibodies for all staining experiments.  
5.3.2.1.1  Immunofluorescent assay: staining combination 1 
The first antibody combination applied to human skin biopsy sections stained for 
CD4+ and CD8+ T cells. Representative images from a single patient are shown in 
Figure 5.5. CD4+ and CD8+ T cells were detected in all biopsy samples examined.  
5.3.2.1.2 Anti-CD3 T cell and anti-VZV IE63 staining 
Immunofluorescent staining utilising the second combination – anti-CD3 and anti-
VZV IE63 – was attempted on the first patients to be analysed (consisting of 
approximately 80 slides and 240 individual sections). After microscopic analysis of 
these sections there was no identified VZV IE63 expression within the skin biopsy 
sample material (data not shown). Staining was successful on positive control 
material, and there was minimal non-specific background staining. Both the UCSF 
skin biopsy material and the anti-VZV IE63 primary antibody had been kindly 
provided to us by collaborators, and both were extremely valuable in their own right. 
The anti-CD3 primary antibody was present on all T cells, however both CD4+ and 
CD8+ T cells were successfully identified in the previous IFA staining combination. 
Consequently this immunofluorescent assay was not performed on the remaining 
patient material. The remaining patient skin biopsy sample material was conserved 
for use in the future for detection of another VZV antigen. 
5.3.2.1.3 Immunofluorescent assay: staining combination 3 
The final immunofluorescent assay performed on the UCSF skin biopsy material 
stained for Langerhans cells, dDCs and pDCs. A representative image is shown in 
Figure 5.6. Langerhans cells and dDCs were identified in all sections from all UCSF 
skin biopsy material. pDCs were identified through the expression of the marker 
BDCA-2, and were a rare event. BDCA-2 expression was detected in 10 sections 
only from 7 different patient samples (out of 283 individual patient samples).  
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5.3.2.1.4 Microscopic analysis of immunofluorescent assays; quantitation of results 
To elucidate the changes in immune cell subsets observed in the skin during the 
herpes zoster-associated rash and following resolution over time a quantitative 
analysis is required. This requires enumeration of the number of positive stained 
cells in each tissue sample. This involved counting the number of positive cells for 
each cell marker in up to three microscope images per section for each section 
stained. Three images per section was chosen as at the magnification utilised it 
covered a majority of the tissue area. The exact size of the surface area of each 
micrograph was calculated with the aid of the Zeiss AxioVision LE software (Carl 
Zeiss Pty Ltd, Australia and New Zealand). The frequency of positive cells was then 
obtained by dividing the number of positive cells by the total area of the tissue. This 
analysis was performed for all immune cells examined. T cell and pDC frequency 
was calculated using the entire surface area of the tissue – an example 
measurement shown for analysis of CD4 and CD8 expression is shown in Figure 5.7, 
and for dendritic cell subtypes in Figure 5.8. Langerhans cells frequency were 
calculated utilising the surface area of the epidermis only (Figure 5.8 A), while dDCs 
frequency was calculated utilising the surface area of the dermis only (Figure 5.8 B).  
Once all the cell counting and analyses had been performed on individual sections, 
data was provided by our collaborators which identified which patient each sample 
belonged to. Once all sections were organised into each patient type, and immune 
cell phenotype over time identified, clinical data for each patient was also provided. 
In this way the research was performed in a completely blinded fashion at each step.  
5.3.3 Patient analysis 
5.3.3.1 INDIVIDUAL PATIENT ANALYSIS 
To establish the immune cell repertoire in skin within single patients over time 
following the resolution of the herpes zoster-associated rash, the median frequency 
of each immune cell type was graphed for each visit. Graphs for a representative 
patient – patient 22 – are shown in Figure 5.9. Graphs for all immune markers 
examined for all patients are shown in Appendix 2. CD3+ T cells (Figure 5.9 A) were 
detected in all sections examined, and CD4+ helper T cells (Figure 5.9 B) and CD8+ 
cytotoxic T cells (Figure 5.9 C) were detected in all sections. All T cell markers were 
highly variable, and there were no general increases or decreases over time. 
Similarly Langerhans cells frequencies within the epidermis and dDC frequencies 
within the dermis were also highly variable (Figure 5.9 D and E).  
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pDC were rarely detected, and were not only restricted to the painful areas (Figure 
5.9 F). pDCs were detected in 25 biopsy samples from 13 different patients. Of the 
twenty-five detections, ten were in biopsy samples from visit 1, three from visit 2, five 
from visit 3, five from visit 4 and two from visit 5. pDCs were detected in biopsies 
from site 1 eleven times, from site 2 seven times, from site 3 five times, site 4 one 
time and from an unknown site one time (data not shown).  
5.3.3.2 PATIENT PAIN LEVELS 
At each visit the average, minimum and maximum pain level (as measured by VAS) 
were recorded (see Table 5.1). In order to perform further analyses, patients were 
divided into two different groups: those which continued to experience pain 
throughout the entire study period, and those in which the pain resolved before their 
final study visit. This information is shown in Table 5.5. Although PHN is defined as 
average daily pain ratings over the last 48 hrs of greater than zero at 6 months post-
herpes zoster-rash onset, clinically significant pain levels correspond to a VAS of 30 
or greater (Petersen et al., 2010). None of the patient group experienced clinically 
significant pain for the entire study period. Although measurements were recorded on 
just four different occasions, overall the median time for pain levels to reach sub-
clinical levels was 39 days post-rash onset (range of 9-92 days). The median time for 
pain levels to reach sub-clinical levels in the “Pain resolved” patient group was 25 
days post-rash onset (range 9-44 days), and in the “Pain continued” patient group 
was 41.5 days post-rash onset (range 16-92 days). The median time for pain to 
resolve in the “Pain resolved” patient group was 40 days post-rash onset (range 9-
113 days). 
5.3.3.3 FURTHER ANALYSES 
5.3.3.3.1 Immune cell frequency over time 
In order to examine any changes in the frequency of immune cells over time in skin 
biopsy material taken from the most painful area (biopsy site 1), the frequency of 
each immune marker was examined over time. Representative graphs displaying 
frequency of CD4+ T cells over time are shown in Figure 5.10. Values graphed are for 
each visit. Lines are only drawn for consecutive patient visits – when no biopsy from 
site 1 was provided then no value is available. Graphs for all immune markers 
examined are presented in Appendix 3.1. Overall there are no trends shown in the 
data, with highly varied distribution of immune cell frequencies observed in both the 


 The University of Sydney 
- 140 - 
patient in whom pain continued throughout the study, and in those that pain resolved 
within the study period. 
5.3.3.3.2 Immune cell ratio over time 
In order to control for any variation between individuals a ratio was calculated using 
the immune cell frequency measured at biopsy site 1 to biopsy site 3 within the one 
patient – that is the most painful site and the contralateral control site. 
Representative graphs displaying this ratio of CD4+ T cells at biopsy site 1 and site 3 
over time are shown in Figure 5.11. Lines are only drawn for consecutive patient 
visits – when no biopsy from site 1 or site 3 were provided then no value is available. 
Graphs for all immune markers examined are presented in Appendix 3.2. Overall 
ratios are quite varied, with no observed trend in data in either patient group. 
5.3.3.3.3 Immune cell frequency compared to reported pain levels 
In order to examine whether the frequency of immune cells present within the pain 
area of skin was related to the reported pain level, the immune cell frequency 
measured at biopsy site 1 (the most painful area) was graphed as a function of the 
reported pain level (VAS) from the 48 hours preceding the corresponding patient 
visit. Representative graphs for CD4+ T cells are shown in Figure 5.12. Graphs for all 
immune markers examined are shown in Appendix 3.3. There was no observed 
relationship between immune cell frequency and reported pain level for any immune 
cell marker examined. A similar analysis was performed comparing the immune cell 
frequencies measured at both biopsy sites 1 and 2 (the most painful and second 
most painful site) to the reported pain level (data not shown), and there was no 
observed relationship between immune cell frequency and reported pain level for any 
immune cell marker examined. 
5.3.3.3.4 Immune cell ratio compared to reported pain levels 
In order to control for any potential variation between individuals, a ratio of immune 
cell frequencies measured at biopsy sites 1 and 3 was calculated as above. 
Representative graphs for CD4+ T cells are shown in Figure 5.13. Graphs for all 
immune markers examined are shown in Appendix 3.4. There was no observed 
relationship between the ratio of immune cell frequencies at biopsy site 1 to biopsy 
site 3 and the reported pain level for any immune cell marker examined.  
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5.3.3.3.5 Other analyses 
A similar analysis was performed comparing the immune cell frequency calculated 
within the most painful and second most painful areas to the size of either the most 
painful area, or the size of the allo-reactive area. Graphs for all immune markers 
examined are shown in Appendices 3.5 and 3.6. There was no relationship observed 
between these variables. 
Overall there was no relationship observed between immune cell frequencies, report 
pain level, time, or size of the painful areas.  
5.3.3.4 SPECIFIC COMPARISONS 
An alternative to examining across patient cohorts is to focus on specific patient 
samples. Three different comparisons were selected from the patient cohort, and 
patients were selected to match age and sex. Patient details are shown in Table 5.6.  
 
Table 5.6 - Comparisons between specific patients. Patients who experienced pain throughout the 
study period were matched with age and sex matched patients for whom their pain resolved during the study 
period. There were three comparisons performed. 
            
   
Pain score  
(Average VAS in last 48 hr) 
Time (days post herpes  
zoster rash onset) 
  
Age/ 
Sex 
Site of 
herpes 
zoster rash V1 V2 V3 V4 V1 V2 V3 V4 
Time 
studied 
Comparison 1             
Patient 15 77M T4 right 21 33 0 0 11 40 88 169 158 
Patient 26 78M L1 left 63 82 32 6 15 43 92 184 169 
Comparison 2           
Patient 10 70M T10 left 22 6 9 0 27 54 113 181 154 
Patient 19 69M L4 left 50 44 23 2 14 44 93 182 168 
Comparison 3           
Patient 2 73M T4 right 26 11 0 0 13 59 99 178 165 
Patient 8 73M T10 right 21 0 0 0 12 42 96 184 172 
Patient 22 73M T4 left 35 20 28 18 44 51 92 187 143 
 
The first comparison was between patients 15 and 26. Patient 15 was a 77 year old 
male for whom pain resolved after his second visit. Patient 26 was a 78 year old 
male who experienced pain throughout the entire study, however his reported pain 
level dropped below clinically significant levels by his fourth visit. Both patient visits 
occurred at comparable intervals apart from visit 4. Immune cell frequency graphs for 
both patient 15 and patient 26 are shown in Figure 5.14. CD4+ T cell frequency in 
patient 15 was less on average less varied than that observed in patient 26. Patient 
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26 had a greater frequency of CD4+ T cells present in biopsies from the most painful 
site (site 1) on visits 1, 2 and 3. The highest median frequency was observed in 
patient 26 biopsy site 2 on the first visit. CD8+ T cell frequencies were comparable at 
all visits. Langerhans cells and dDC were comparable at all visits. pDCs were rare in 
both patient types. 
The second comparison was between patients 10 and 19. Patient 10 was a 70 year 
old male for whom pain resolved after his third visit. Patient 19 was a 69 year old 
male who experienced pain throughout the entire study, however his reported pain 
level dropped below clinically significant levels by his second visit. Both patient visits 
occurred at comparable intervals. Immune cell frequency graphs for both patient 10 
and patient 19 are shown in Figure 5.15. There were more biopsy samples available 
for patient 10 – no biopsy samples were available for patient 19 visit 2. Calculated 
frequencies or CD4+ and CD8+ T cells, Langerhans cells and dDCs were all 
comparable at the visits compared. There were no pDCs detected in patient 19, and 
a variable amount observed in patient 10. 
The final comparison was between patients 2, 8 and 22. Patient 2 was a 73 year old 
male for whom pain resolved after his second visit. Patient 8 was a 73 year old male 
for whom pain resolved after his first visit. Patient 22 was a 73 year old male who 
experienced pain throughout the entire study, however his reported pain level 
dropped below clinically significant levels by his first visit. All patient visits occurred at 
comparable intervals apart from visit 1 – patient 22 visited 30 days later than both 
patients 2 and 8. Immune cell frequency graphs for patients 2, 8 and 22 are shown in 
Figure 5.16. CD4+ and CD8+ T cell frequencies peaked in patient 8 at visit 1. CD4+ T 
cell frequencies were comparable in patients 2 and 22. CD8+ T cell frequency in 
patient 2 at visit 1 was double that observed in patient 22, however was comparable 
at all other visits. Langerhans cell and dDCs were present in comparable frequencies 
at all visits. On average, pDCs were only detected in patient 8, with very rare 
detection in both patient 2 and patient 22. 
Overall there was no major difference in the frequency of immune cells within skin 
biopsy samples taken from patients who experienced herpes zoster-associated pain 
throughout the study period and those for whom pain ceased within the study period 
when age and sex is matched. 
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5.4 Discussion 
The focus of this study was to characterise the immune infiltration within the skin of 
patients following the onset of the herpes zoster-associated rash over time. Patients 
presented at the clinica on at least 4 separate occasions, and punch biopsies were 
obtained from up to 4 different sites. At each visit various clinical observations were 
recorded, in an effort to identify any relation between immune cell presence or viral 
antigen expression and clinical features including the extent, severity and 
persistence of pain. 
This study was made possible due to the provision of precious human biopsy 
material by collaborators at UCSF and Albany Medical College. In total skin biopsy 
samples from 27 patients were completely examined by the IFA based approaches 
which were developed in Chapter 4. 
Due to the very limited amount of tissue sections available it was not always possible 
to obtain a full set of biopsy samples for each patient. This restricts the ability to fully 
analyse all patients. For example when either biopsy site 1 or site 3 was missing, a 
ratio of cell frequency at site 1 to site 3 was not possible, and consequently there are 
missing data points in this analysis. 
This study was carried out in a completely blinded fashion. At no point during the 
experimental process were any clinical details known. Each sample was labelled with 
a number only. Once the IFA staining, microscopic analysis and counting had been 
completed our collaborators provided the data matching biopsy sample number to 
the patients. Once biopsies had been sorted into patient groups, our collaborators 
provided the matching clinical information for each patient.  
Although PHN was defined as average daily pain ratings over the last 48 hours 
greater than zero on the VAS at 6 months post rash onset, clinically meaningful PHN 
was requires a VAS of 30 or greater (Thyregod et al., 2007). Unfortunately no patient 
sample from the study still experienced a VAS of 30 or greater as reported on visit 4, 
however there were 10 patients who did report continued pain throughout the entire 
study period, which would allow for a diagnosis of PHN. 
Despite considerable efforts there was no detection of VZV antigen positive cells 
within any of the skin biopsy material tested in this study. As with the last results 
chapter, the same two antibodies were utilised: one specific for a glycoprotein 
complex (gE:gI) and the other for an immediate early protein (IE63). These two 
 The University of Sydney 
- 144 - 
antibodies have been previously used successfully on a variety of different human 
tissue sections including human ganglia following natural VZV reactivation to detect 
VZV antigen positive cells (Steain et al., 2013). Along with this, the punch biopsy 
procedure utilised by our collaborators avoided any herpes zoster lesions, possibly 
decreasing the likelihood of detecting active viral gene expression within the painful 
area of skin. Although VZV antigens can be readily detected by 
immunohistochemistry and immunofluorescence within the skin days post herpes 
zoster rash onset (Huch et al., 2010), previous studies have focused on active 
lesions rather than surrounding skin. Consequently it is unknown whether viral 
antigen expression occurs in this area. Based on our findings there was no 
detectable VZV antigens present in the skin sites tested. 
Although peripheral immune cells, including CD4+ and CD8+ T cells, have been 
shown to both ameliorate and contribute to pain and allodynia in animal models 
(Boue et al., 2011, Grace et al., 2011), it remains unknown whether they contribute to 
PHN. During the initial skin work presented in Chapter 4 there seemed to be an 
association between PHN-affected material and a greater infiltration of immune cells 
(and specifically T cell subsets).  
The patient samples utilised in Chapter 4 were single biopsy samples from patients 
diagnosed with PHN at least 6 months post resolution of the herpes zoster-
associated rash, while those utilised in Chapter 5 were a series of biopsies over time 
from patients following diagnosis of herpes zoster. The amount of patient material 
examined in Chapter 5 was considerable more than in Chapter 4, and consequently 
overall this study showed no relationship between T cell frequencies and pain levels, 
there was no link between the number of T cells present within the skin and either 
the development or pain or allodynia, or a reduction in pain reported by the patient. 
The dendritic cell subsets examined in this study were Langerhans cells, dDCs and 
pDCs. All of these cells are major components of the body’s immunosurveillance 
system and play various roles in skin immunity. Langerhans cells are known to 
produce an important immune surveillance function and antigen presentation role 
(Valladeau and Saeland, 2005). Langerhans cells have also been shown to be 
permissible to VZV infection in vivo during both varicella and herpes zoster, and 
Langerhans cell frequency is significantly decreased in herpes zoster-affected skin 
and post-herpes zoster (Huch et al., 2010). In this study there was no observed 
difference in Langerhans cell number in skin biopsies taken from the painful area of 
skin around the herpes zoster rash and the contralateral side. In fact numbers were 
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also similar when compared to skin from a contralateral and distal biopsy site. 
Consequently the decrease in Langerhans cell numbers is possibly restricted to sites 
immediately surrounding herpes zoster-associated lesions. Alternatively it may be a 
phenotype only observed during early VZV lesion development, during which there is 
robust VZV infection of skin cells. 
Another subset of dendritic cells present within the skin are dDCs. While these cells 
are present at high frequencies throughout the human dermis (Valladeau and 
Saeland, 2005), there is no evidence they play a role in the ongoing pathogenesis of 
PHN or recovery from herpes zoster. These cells were identified through the 
expression of DC-SIGN, which is also present on other cells such as pre-
plasmacytoid dendritic cells, macrophages and a small subset of B cells (Kwan et al., 
2008, Rappocciolo et al., 2006). Consequently frequencies presented in this study 
may be an overestimation of the true number of dDCs present in the human skin 
samples. 
While pDCs are not present in normal human skin they are important mediators of 
the innate anti-viral immune response (Donaghy et al., 2009, Huch et al., 2010, 
Valladeau and Saeland, 2005), and have been shown to play important roles in 
immunity against herpesviruses in the skin (Donaghy et al., 2009, Huch et al., 2010). 
Of the dendritic cells examined, the pDCs were detected at the lowest frequency. 
They were not restricted to the area of painful skin. Nor were they present exclusively 
in patients whom pain continued or was resolved within the study time frame. 
Consequently it seems that pDCs play a limited role in the pathogenesis of VZV post-
herpes zoster in the skin not immediately associated with a lesion. 
This study has utilised some very rare skin biopsy material comprising of sequences 
of matched biopsy samples taken from patients following onset of a herpes zoster-
associated rash. It has allowed for the first investigation of the kinetics of CD4+ and 
CD8+ T cells, and different dendritic cells as well as viral antigen expression over 
time within the same patient.  
This study was limited in the number of sections available from each biopsy sample, 
and the number of biopsy samples provided from each patient. In an ideal situation 
there would be multiple sections from each biopsy sample that would allow the 
investigation of multiple immune markers with several repeats. Although there are no 
more sections available from the patients presented in this study, there may be more 
patient samples available in the future. Consequently it may be possible in the future 
to examine other related immune markers. It would be interesting to investigate 
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whether innate immune cells such as NK cells, neutrophils and mast cells play a role 
in the ongoing pathogenesis of PHN. As PHN is a neuropathic pain, it would also be 
interesting to investigate the location of any immune cells present within the tissue in 
relation to a nerve cell marker. 
Overall there does not seem to be any relation between any of the immune cells 
investigated and the clinical presentation of the patients. There was no distinct 
pattern to the immune cell phenotype over time, nor is there a link between immune 
cell numbers and the reported pain level, the size of the painful or allo-reactive areas 
of skin based on the parameters assessed. There was no factor identified that would 
predispose one patient to an uncomplicated recovery from herpes zoster or a 
prolonged experience of allodynia or painful skin. 
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Chapter 6 - Final summary and relevance 
Varicella zoster virus is an ubiquitous human herpesvirus that produces two distinct 
clinical conditions: varicella and herpes zoster. The most common complication of 
herpes zoster is the neuropathic pain syndrome called post-herpetic neuralgia (PHN) 
(Kost and Straus, 1996). Despite being the third most common cause of neuropathic 
pain in the United States (Bennett, 1998), resulting in significant negative impact on a 
person’s quality of life (Coplan et al., 2004, Davies et al., 1994, Dworkin et al., 2007b, 
Watson, 1998) our understanding of the underlying pathology and pathogenesis 
remains relatively limited.  
This study performed a detailed immunohistological analysis of human ganglionic 
material surgically excised from a PHN-affected individual following resolution of the 
herpes zoster-associated rash, and compared with post mortem material taken from 
herpes zoster-affected and normal patients. The immunohistochemical analysis of 
PHN-affected ganglia samples showed a large infiltration of immune cells comprised 
of both CD4+ and CD8+ T cells with cytolytic potential, as well as B cells. The immune 
infiltration observed in the PHN-affected patient material was comparable to those 
seen in acute herpes zoster-reactivations. There was no detection of VZV antigen 
expression within the PHN-affected ganglia material. A highly sensitive real time 
PCR method was utilised to show that the VZV genome was present at 
approximately seven-fold higher levels in one of the PHN-affected samples when 
compared to a post-mortem ganglion sample obtained from the site of an active 
herpes zoster reactivation. A new quantitative RT-PCR method for examining viral 
nucleic acid expression was also established for use on future samples with 
retrievable mRNA. 
This study also performed an immunohistological examination of skin biopsy samples 
obtained from patients suffering from PHN and normal control patients and 
characterised the cellular immune infiltrate in these samples. Overall there was a 
greater immune infiltrate present in the skin biopsy samples from PHN-affected 
patients, however there was no overall trend when comparing biopsies obtained from 
the painful and contralateral sides of PHN-affected patients. There was no VZV 
antigen expression detected within these tissue samples. 
Finally, this study performed an immunohistological analysis of the cellular immune 
infiltrate and VZV antigen expression in skin biopsy samples obtained from patients 
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diagnosed with herpes zoster over time. There was no VZV antigen expression 
identified in these skin biopsy samples. Different T cell and dendritic cell subsets 
were examined over time, and matched with the patients’ clinical history. There was 
no relationship between the frequency or phenotype of immune cells examined and 
the clinical level of pain reported by each patient. There was no difference in the level 
of examined immune cell subsets between patients who reported ongoing pain and 
those for whom pain resolved within the time of study. There was no difference in the 
immune cell phenotype between patients who reported higher or lower clinical pain 
levels. 
One major barrier to the study of PHN and VZV in general is the high species 
specificity of the virus, which imposes significant limitations on the use of animal 
models. To date there is no animal model for VZV reactivation or PHN. Consequently 
studies of PHN require access to appropriate human tissue samples, which are 
extremely difficult to obtain. This thesis has been possible through the generous 
provision of rare and precious clinical material, some of which has never been 
studied before. The PHN-affected ganglia material was surgically-excised from a 
PHN-affected patient in an effort to relieve their pain, after all other avenues of 
treatment had been exhausted. In addition, rare herpes zoster-affected and control 
post-mortem ganglia material formed the basis for the study and results presented in 
Chapter 3.  
Previous studies from our research group have shown a large infiltration of immune 
cells within herpes zoster-affected human DRG material, comprised mainly of 
macrophages, natural killer cells, CD4+ and CD8+ T cells (Gowrishankar, 2008, 
Gowrishankar et al., 2010, Steain et al., 2013). Immunofluorescence staining for a 
number of immune cell markers in the ganglia samples from the PHN-affected 
patient again demonstrated a large infiltration of immune cells predominantly 
consisting of CD4+ and CD8+ T cells. Infiltration levels observed in this study were 
comparable to those observed in these previous studies of herpes zoster-affected 
ganglia material, despite the significant time between the resolution of the PHN-
affected patient’s herpes zoster rash and subsequent ganglionectomy – a period of 
several years. This gives further evidence of an ongoing chronic inflammatory 
process within the DRG that may contribute to the pathogenesis of PHN.  
In regards to what is driving the ongoing inflammatory response, one possibility is the 
presence of ongoing viral replication. To this end I performed IHC and IFA to assess 
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VZV antigen expression utilising anti-VZV antibodies well established to detect VZV 
antigens in formalin-fixed paraffin-embedded sections. 
Although detection of VZV antigen expression and viral RNA transcripts within the 
DRG material was not possible in this study, VZV-specific DNA was detected in 
multiple DRG samples obtained from our PHN-affected patient. A VZV DNA 
quantitation method developed by our research group demonstrated a much higher 
VZV DNA load per cell in the PHN-associated ganglia than in material obtained from 
the site of reactivation in a patient who had a herpes zoster-associated rash at the 
time of death, as well as detectable VZV antigens present within the ganglia (Steain 
et al., 2013). Molecular studies also demonstrated that there was no HSV latent 
infection in the PHN-associated material, suggesting that any immune cells observed 
within the ganglia were due to the presence of VZV. 
This extremely rare ganglionic material has provided us with a unique insight into the 
inflammatory changes present within ganglia during PHN. Clearly further study is 
warranted in this area in order to determine the exact cause of the chronic 
inflammation observed, however access to other appropriate clinical samples 
remains a significant obstacle. 
Despite the critical role of infection of the ganglia to VZV and PHN, the skin is 
another important site for VZV disease. Also utilised in this thesis was rare human 
skin biopsy material obtained from two different patient cohorts, which were utilised 
for Chapters 4 and 5. The first study utilised a set of biopsies obtained from 10 
different patients at least 6 months following the resolution of their herpes zoster-
associated rash – 5 PHN-affected patients and 5 control patients. For each patient 
there was a biopsy from the affected and contralateral side.  
Utilising a newly developed immunofluorescence staining technique which I 
established in Chapter 4, it was shown that in general there was a greater number of 
T cells present in the skin biopsy tissue obtained from the PHN-affected patients, 
however there did not seem to be a predominance of either CD4+ or CD8+ T cells. In 
addition, there was no clear increase in T cell number or Langerhans cell frequency 
in biopsies from the PHN-affected side compared to the contralateral side in this 
single time point “snap-shot”. 
PHN-affected patients experience ongoing pain and altered sensation that can last 
for months to years following the resolution of the herpes zoster-affected rash 
(Alvarez et al., 2007, Schmader, 2007, Steiner et al., 2007, Watson, 1998). Thus in 
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order to determine if inflammatory infiltrates observed within skin samples from PHN-
affected patients changed over time from the onset of herpes zoster and associated 
pain through rash resolution with or without resolved pain, the second study of 
human skin biopsy samples, presented in Chapter 5, utilised a tissue bank of 
biopsies taken from multiple patients at multiple time points following diagnosis of 
herpes zoster. This patient material was unique in that the study examined samples 
taken from up to four different biopsy sites at different time points, along with detailed 
clinical assessments of type, extent and severity of pain for up to a year from the 
appearance of the herpes zoster rash. 
Biopsy samples from 27 different patients were examined in a completely blinded 
study - representing 283 individual biopsy samples. Biopsy samples were utilised in 
immunofluorescent assays and imaged via fluorescent microscope. Several 
thousand confocal and deconvolution microscope images were obtained, and then 
individually analysed by manually counting and measuring tissue surface area. To 
ensure consistency all microscopy and analysis was performed by a single person. 
To the best of our knowledge, to date this is the most extensive analysis of T cell and 
dendritic cell frequencies in skin and corresponding clinical data over time in patient 
samples following herpes zoster. 
There were large numbers of T cells – both CD4+ and CD8+ - detected in the skin 
biopsy samples, with a predominance of CD4+ T cells. Multiple dendritic cell subsets 
were examined; Langerhans cell and dDC numbers were found to be quite variable 
within and between patients, and pDCs were found to be a rare event in all biopsy 
samples. Despite extensive analysis examining and comparing cell frequency over 
time directly and indirectly, pain levels and the size of the painful and allo-reactive 
areas there was no obvious factors found to be specific to either the patients who 
experienced ongoing pain throughout the study or those in whom pain resolved 
before the final visit. Thus this data suggests that at the peripheral site (that is the 
skin) the cell types studied play a limited roll in the ongoing pathogenesis of PHN. 
While T cells may not be directly involved in PHN, there are still other immune 
mediators that remain to be investigated. Mast cells may contribute directly to the 
development of pain through histamine release in the skin (Baron et al., 2001). 
Additionally, mast cells along with macrophages and neutrophils may play a role in 
the generation of neuropathic pain through the release of pro-nociceptive mediators 
and enhance the recruitment of other immune cell types (Reviewed in Thacker et al., 
2007). 
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In all studies performed and presented in this thesis patient sample material was very 
limited. Because of this restriction, a significant amount of time was spent on 
optimising and organising the best methods for extracting the most information from 
the material available. Most of the DRG samples utilised in Chapter 3 are exhausted, 
and no slides remain of usable areas of tissue. Likewise, there is no more material 
available for study from the skin biopsy material utilised in Chapter 4. While for some 
skin biopsy samples utilised in Chapter 5 there is 1 slide remaining, many have been 
completely used. However unlike the ganglia samples, there are other skin biopsy 
samples from new patients available for both the patient types in Chapters 4 and 5. 
Thus any future directions for this work will be dependent on obtaining more suitable 
sample material. 
Overall there was a substantial amount of infiltrating immune cells present in all 
material from PHN-affected patients studied in this thesis. There were comparable 
numbers of immune cells present in both the DRG and skin samples from PHN-
affected patients, however there was a clear difference between PHN and control 
patients observed with the human DRG material. While there were infiltrating 
immune cells detected in skin biopsy samples obtained from PHN-affected patients, 
there was no clear difference between the affected and contralateral sites within the 
same patient, and between those patients who experienced prolonged pain and 
those who experienced a relatively uncomplicated recovery. 
There was a greater amount of VZV-specific DNA present in the PHN-associated 
ganglia material in comparison to an active case of herpes zoster. This is despite 
there being no clinical evidence of viral replication present in the PHN-affected 
patient other than the pain reported. In order to examine any VZV-specific RNA in the 
ganglia material, a quantitative method utilising real time RT-PCR was established. 
Unfortunately the ganglia material was not suitable for RNA analysis, and 
consequently levels of gene expression at the RNA level in these ganglia samples 
were not able to be analysed. This RT-PCR approach can be utilised with any 
suitable patient material that may be obtained in the future. 
Considerable effort in this thesis was devoted to the detection of VZV antigen 
expression in all sample material from the PHN-affected patients. While there has 
been previous reported detection of VZV antigen expression in human ganglia 
material, there has also been some recent complications identified when using an 
immunohistochemical approach (Zerboni et al., 2012). Our research group has 
recently demonstrated limited VZV antigen detection within herpes zoster-associated 
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DRG (Steain et al., 2013). All attempts to detect VZV antigen expression in ganglia 
material presented in Chapter 3 were performed in tandem with those reported in 
Steain et al. (2013). Despite considerable effort in this thesis, there is currently no 
evidence of detectable VZV antigen expression in ganglia sample material from 
PHN-affected patients. 
There was also no successful detection of VZV antigen expression in the skin biopsy 
material from both patient cohorts. In all skin material, the established biopsy 
protocol involved obtaining the biopsy from the painful area of skin while avoiding 
any active herpes zoster lesions. Previous studies of active lesions have shown VZV 
antigen expression from multiple kinetic classes (Huch et al., 2010). It is possible that 
VZV antigen expression is limited to areas immediately surrounding herpes zoster 
lesions. Alternatively, there may be a low level of VZV replication within the ganglia 
causing expression of either viral proteins or immune mediators in the skin. However 
it would be extremely difficult to identify the exact sites of herpes zoster lesions 
beyond the resolution of the herpes zoster-associated rash.  
During the research conducted in this thesis, every available antibody specific for a 
viral protein was trialled for use on any suitable control material. However in regards 
to the human skin material, biopsies were obtained from areas within painful regions, 
and any active herpes zoster-associated lesions were avoided. Consequently we 
have no current access to positive control material that was an exact fixation, 
cryopreservation and tissue type match. While the formaldehyde-fixed and 
cryopreserved infHFF cell pellet utilised was useful in showing which antibodies were 
unsuitable for use, final selection and optimisation of antibody and staining protocol 
would be assisted with exact matching control material. 
While this study has not been able to demonstrate VZV gene expression through 
viral antigen expression or RNA detection within any PHN-associated human tissue 
samples, there was a greater amount of VZV DNA present in one of the PHN-
affected ganglia samples when compared to an active case of VZV reactivation. This 
was despite no visible evidence of an active VZV infection and the absence of all 
clinical signs other than PHN. This high level of VZV genomic material present in the 
PHN-associated tissue gives some evidence for an ongoing viral process that may 
contribute to the underlying pathogenesis of PHN. 
Unfortunately there was no nucleic acid material available for skin biopsy samples, 
and consequently no way of examining whether higher viral DNA loads correlated 
with greater clinically reported pain levels, or prolonged pain. 
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This thesis has successfully established highly sensitive and specific molecular 
techniques useful in detecting the presence of VZV-specific DNA transcripts in 
nucleic acids from paraffin-embedded and formaldehyde-fixed ganglia material. 
Unfortunately the very limited amount of sample material available restricted the 
amount of DNA available, and the samples were not suitable for RNA analysis. 
However this study has established methods that can be utilised for any future 
sample material, and due to the quantitative nature of the analysis can be directly 
compared to results obtained in this study. At this point in time, nucleic acid 
extraction has not been attempted on any human skin material, although our current 
extraction protocol could be adapted if new material was provided. 
Although the demonstration of RNA transcripts via real time RT-PCR is useful for 
analysing samples as a whole, it provides no detail on which cell types are 
expressing the transcripts and their location within the tissue. Initially this thesis was 
to incorporate an in-situ hybridisation examination of mRNA transcripts within the 
tissue utilising DIG-labelled riboprobes. Plasmid constructs specific for cellular and 
viral RNA transcripts were created, however sample material was not deemed 
suitable and this approach was abandoned. 
Currently this study has revealed in the skin that there is no relationship between the 
number of infiltrating T cells, the type of dendritic cells present, the period of time in 
which pain is experienced, or the size of either the painful or allo-reactive areas of 
skin.  
In regards to my prior hypotheses this about the makeup of cellular infiltrate of 
inflammatory cells, this thesis has shown that there is a predominance of CD4+ and 
CD8+ T cells present in human ganglia material obtained from a PHN-affected 
patient. While there are substantial numbers of T cells of both subtypes present in 
the painful area of skin from PHN-affected patients, there are also higher levels in the 
contralateral sides in comparison to skin material obtained from unaffected patients. 
There was no difference in the immune cell phenotype in the skin of patients who 
report higher and lower clinical pain levels. However due to the very limited amount 
of sample material available from each patient, this thesis examined subsets of T 
cells and dendritic cells only. There are many other immune cells that may play an 
important role in the recovery from herpes zoster or the ongoing pathogenesis of 
PHN. Histamine release has been shown to induce a burning pain in the skin of 
patients suffering from PHN (Baron et al., 2001), and mast cells have been shown to 
be activated during peripheral nerve injury in animal models (Zuo et al., 2003). It 
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would be worthwhile to investigate if mast cells played any role in the underlying 
pathology and pathogenesis of PHN. 
While T cells and dendritic cells play important roles in the adaptive immune 
response, to date there is limited information available on other immune cells that 
may contribute to the ongoing inflammation during PHN in the ganglia and 
inflammation in the skin. In previous ganglia studies utilising herpes zoster-
associated material, macrophages and natural killer cells have been part of the 
infiltration identified within the tissue (Gowrishankar, 2008, Gowrishankar et al., 
2010, Steain and Sutherland, 2013). Macrophages have been shown to play an 
important immunomodulatory role immediately following nerve injuries (Mueller et al., 
2001), and NK cells play a vital role in the initial in the control of primary infection 
(Etzioni et al., 2005). To date their presence and number in PHN-associated material 
is yet to be investigated. 
One of the main barriers to continued study is the lack of suitable human sample 
material. This thesis has had access to rare, precious, and one-of-a-kind sample 
material in very limited amounts. The development of an in-vitro model would allow 
continued research without the additional limits. One possible model to study the 
acute development of herpes zoster and possible latency is the two chamber model, 
which has been previously utilised in the study of alphaherpesvirus interaction with 
trigeminal ganglion neurons (Smith et al., 2001, De Regge et al., 2006b, Geenen et 
al., 2005, De Regge et al., 2006a). This model utilises two chambers isolated by a 
gel barrier through, primary human fetal explant DRG are grown within the central 
chamber and allowed to grow through into the outer chamber. Communication 
between the two chambers takes place through the neuronal processes alone. 
Another model is the skin raft culture, which has been previous used to study the 
both HSV-1 and VZV (Andrei et al., 2005, Hukkanen et al., 1999). It may even be 
possible to combine the two model types to investigate the interaction between DRG 
and skin in vitro, and would be useful in characterising the innate immune response. 
This thesis has demonstrated the presence of a substantial amount of VZV DNA in 
the ganglia of a PHN-affected patient, at a greater level than that observed in the site 
of reactivation of a herpes zoster affected patient. It has also shown the presence of 
an ongoing chronic inflammation within the same ganglia, despite no identified 
stimulus or clinical presentation other than ongoing chronic pain. It was shown that 
there is no relationship between pain experienced, number of immune cells present 
in the skin or propensity to either experience prolonged pain or a speedy recovery. It 
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did show on average skin biopsies from PHN-affected patients had a greater 
frequency of immune cells present within their skin, however it was not only restricted 
to the painful side. 
Overall this thesis provides the first evidence of an ongoing chronic inflammatory 
process consisting predominantly of both CD4+ and CD8+ T cells within DRG from a 
PHN-affected patient many years post resolution of the herpes zoster rash. Within 
this chronically inflamed tissue, there is a large amount of VZV-specific DNA. In stark 
contrast to this, there does not seem to be any ongoing immunohistological process 
within the skin of patients post-herpes zoster. These findings have increased our 
knowledge on the immune reaction within human ganglia and skin following herpes 
zoster and during PHN. 
 The University of Sydney 
- 156 - 
Chapter 7 - References 
ABBADIE, C., BHANGOO, S., DE KONINCK, Y., MALCANGIO, M., MELIK-PARSADANIANTZ, S. & 
WHITE, F. A. (2009) Chemokines and pain mechanisms. Brain Research Reviews, 60, 125-34. 
ABBAS, A. K. & LICHTMAN, A. H. (1991) Cellular and Molecular Immunology, Philadelphia, Saunders. 
ABENDROTH, A. & ARVIN, A. (1999) Varicella-zoster virus immune evasion. Immunological Reviews, 
168, 143-56. 
ABENDROTH, A. & ARVIN, A. M. (2000) Host response to primary infection. IN ARVIN, A. M. & 
GERSHON, A. A. (Eds.) Varicella Zoster Virus: Virology and Clinical Management. Cambridge, 
Cambridge University Press. 
ABENDROTH, A., LIN, I., SLOBEDMAN, B., PLOEGH, H. & ARVIN, A. M. (2001a) Varicella-zoster virus 
retains major histocompatibility complex class I proteins in the Golgi compartment of infected 
cells. Journal of Virology, 75, 4878-88. 
ABENDROTH, A., MORROW, G., CUNNINGHAM, A. L. & SLOBEDMAN, B. (2001b) Varicella-zoster 
virus infection of human dendritic cells and transmission to T cells: implications for virus 
dissemination in the host. Journal of Virology, 75, 6183-92. 
ABENDROTH, A., SLOBEDMAN, B., LEE, E., MELLINS, E., WALLACE, M. & ARVIN, A. M. (2000) 
Modulation of major histocompatibility class II protein expression by varicella-zoster virus. 
Journal of Virology, 74, 1900-7. 
ACHONG, B. G. & MEURISSE, E. V. (1968) Observations on the fine structure and replication of 
varicella virus in cultivated human amnion cells. Journal of General Virology, 3, 305-8. 
ALESSI, E., CUSINI, M., ZERBONI, R., CAVICCHINI, S., UBERTI-FOPPA, C., GALLI, M. & MORONI, 
M. (1988) Unusual varicella zoster virus infection in patients with the acquired 
immunodeficiency syndrome. Archives of Dermatology, 124, 1011-3. 
ALVAREZ, F. K., TESSEROLI DE SIQUEIRA, S. R. D., OKADO, M., TEIXEIRA, M. J. & TESSEROLI 
DE SIQUEIRA, J. T. (2007) Evaluation of the sensation in patients with trigeminal post-herpetic 
neuralgia. Journal of Oral Pathology & Medicine, 36, 347-50. 
AMBAGALA, A. P. N. & COHEN, J. I. (2007) Varicella-Zoster virus IE63, a major viral latency protein, is 
required to inhibit the alpha interferon-induced antiviral response. Journal of Virology, 81, 
7844-51. 
ANDREI, G., VAN DEN OORD, J., FITEN, P., OPDENAKKER, G., DE WOLF-PEETERS, C., DE 
CLERCQ, E. & SNOECK, R. (2005) Organotypic epithelial raft cultures as a model for 
evaluating compounds against alphaherpesviruses. Antimicrobial Agents & Chemotherapy, 49, 
4671-80. 
ANGEL, I. F., GOULD, H. J., JR. & CAREY, M. E. (1998) Intrathecal morphine pump as a treatment 
option in chronic pain of nonmalignant origin. Surgical Neurology, 49, 92-8; discussion 98-9. 
ANNUNZIATO, P., LUNGU, O., GERSHON, A., SILVERS, D. N., LARUSSA, P. & SILVERSTEIN, S. J. 
(1996) In situ hybridization detection of varicella zoster virus in paraffin-embedded skin biopsy 
samples. Clinical and Diagnostic Virology, 7, 69-76. 
 The University of Sydney 
- 157 - 
ANNUNZIATO, P. W., LUNGU, O., PANAGIOTIDIS, C., ZHANG, J. H., SILVERS, D. N., GERSHON, A. 
A. & SILVERSTEIN, S. J. (2000) Varicella-zoster virus proteins in skin lesions: implications for 
a novel role of ORF29p in chickenpox. Journal of Virology, 74, 2005-10. 
ANONYMOUS (1973) Editorial: Provisional labels for herpesviruses. Journal of General Virology, 20, 
417-9. 
APPAY, V., ZAUNDERS, J. J., PAPAGNO, L., SUTTON, J., JARAMILLO, A., WATERS, A., 
EASTERBROOK, P., GREY, P., SMITH, D., MCMICHAEL, A. J., COOPER, D. A., ROWLAND-
JONES, S. L. & KELLEHER, A. D. (2002) Characterization of CD4(+) CTLs ex vivo. Journal of 
Immunology, 168, 5954-8. 
ARAUJO, L. Q., MACINTYRE, C. R. & VUJACICH, C. (2007) Epidemiology and burden of herpes zoster 
and post-herpetic neuralgia in Australia, Asia and South America. Herpes, 14 Suppl 2, 40-4. 
ARGAW, T., COHEN, J. I., KLUTCH, M., LEKSTROM, K., YOSHIKAWA, T., ASANO, Y. & KRAUSE, P. 
R. (2000) Nucleotide sequences that distinguish Oka vaccine from parental Oka and other 
varicella-zoster virus isolates. Journal of Infectious Diseases, 181, 1153-7. 
ARNER, S. & MEYERSON, B. A. (1988) Lack of analgesic effect of opioids on neuropathic and 
idiopathic forms of pain. Pain, 33, 11-23. 
ARVIN, A. & ABENDROTH, A. (2007) VZV immunobiology and host response. IN ARVIN, A., 
CAMPADELLI-FIUME, G., MOCARSKI, E., MOORE, P. S., ROIZMAN, B., WHITLEY, R. & 
YAMANISHI, K. (Eds.) Human Herpesviruses: Biology, Therapy and Immunoprophylaxis. 
Cambridge, Cambridge University Press. 
ARVIN, A. & GILDEN, D. (2007) Varicella-zoster virus. IN KNIPE, D. M. & HOWLEY, P. (Eds.) Fields 
Virology. Philadelphia, Lippincott Williams & Wilkins. 
ARVIN, A. M. (1987) Clinical manifestations of varicella and herpes zoster and the immune response to 
varicella-zoster virus. IN HYMAN, R. W. (Ed.) The natural history of varicella-zoster virus. New 
York, CRC Press. 
ARVIN, A. M. (1992) Cell-mediated immunity to varicella-zoster virus. Journal of Infectious Diseases, 
166 Suppl 1, S35-41. 
ARVIN, A. M. (1996) Varicella-zoster virus. Clinical Microbiology Reviews, 9, 361-81. 
ARVIN, A. M. (2001) Varicella-zoster virus: molecular virology and virus-host interactions. Current 
Opinion in Microbiology, 4, 442-9. 
ARVIN, A. M., KOROPCHAK, C. M., WILLIAMS, B. R., GRUMET, F. C. & FOUNG, S. K. (1986) Early 
immune response in healthy and immunocompromised subjects with primary varicella-zoster 
virus infection. Journal of Infectious Diseases, 154, 422-9. 
ARVIN, A. M., MOFFAT, J. F. & REDMAN, R. (1996) Varicella-zoster virus: aspects of pathogenesis 
and host response to natural infection and varicella vaccine. Advances in Virus Research, 46, 
263-309. 
ARVIN, A. M., SHARP, M., SMITH, S., KOROPCHAK, C. M., DIAZ, P. S., KINCHINGTON, P., 
RUYECHAN, W. & HAY, J. (1991) Equivalent recognition of a varicella-zoster virus immediate 
early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ 
phenotype. Journal of Immunology, 146, 257-64. 
ASANO, Y., ITAKURA, N., KAJITA, Y., SUGA, S., YOSHIKAWA, T., YAZAKI, T., OZAKI, T., 
YAMANISHI, K. & TAKAHASHI, M. (1990) Severity of viremia and clinical findings in children 
with varicella. Journal of Infectious Diseases, 161, 1095-8. 
 The University of Sydney 
- 158 - 
BABA, K., YABUUCHI, H., TAKAHASHI, M. & OGRA, P. L. (1986) Increased incidence of herpes zoster 
in normal children infected with varicella zoster virus during infancy: community-based follow-
up study. Journal of Pediatrics, 108, 372-7. 
BACKONJA, M., WALLACE, M. S., BLONSKY, E. R., CUTLER, B. J., MALAN, P., JR., RAUCK, R., 
TOBIAS, J. & GROUP, N.-C. S. (2008) NGX-4010, a high-concentration capsaicin patch, for 
the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurology, 
7, 1106-12. 
BAIKER, A., BAGOWSKI, C., ITO, H., SOMMER, M., ZERBONI, L., FABEL, K., HAY, J., RUYECHAN, 
W. & ARVIN, A. M. (2004a) The immediate-early 63 protein of Varicella-Zoster virus: analysis 
of functional domains required for replication in vitro and for T-cell and skin tropism in the 
SCIDhu model in vivo. Journal of Virology, 78, 1181-94. 
BAIKER, A., FABEL, K., COZZIO, A., ZERBONI, L., FABEL, K., SOMMER, M., UCHIDA, N., HE, D., 
WEISSMAN, I. & ARVIN, A. M. (2004b) Varicella-zoster virus infection of human neural cells in 
vivo. Proceedings of the National Academy of Sciences of the United States of America, 101, 
10792-7. 
BALFOUR, H. H., JR. (1988) Varicella zoster virus infections in immunocompromised hosts. A review of 
the natural history and management. American Journal of Medicine, 85, 68-73. 
BARON, R., SCHWARZ, K., KLEINERT, A., SCHATTSCHNEIDER, J. & WASNER, G. (2001) 
Histamine-induced itch converts into pain in neuropathic hyperalgesia. Neuroreport, 12, 3475-
8. 
BENNETT, G. J. (1994) Hypotheses on the pathogenesis of herpes zoster-associated pain. Annals of 
Neurology, 35 Suppl, S38-41. 
BENNETT, G. J. (1998) Neuropathic pain: new insights, new interventions. Hospital Practice, 33, 95-8, 
101-4, 107-10 passim. 
BERARDUCCI, B., RAJAMANI, J., REICHELT, M., SOMMER, M., ZERBONI, L. & ARVIN, A. M. (2009) 
Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain 
abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry. 
Journal of Virology, 83, 228-40. 
BERARDUCCI, B., RAJAMANI, J., ZERBONI, L., CHE, X., SOMMER, M. & ARVIN, A. M. (2010) 
Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-
zoster virus infection. Proceedings of the National Academy of Sciences of the United States of 
America, 107, 282-7. 
BESSER, J., SOMMER, M. H., ZERBONI, L., BAGOWSKI, C. P., ITO, H., MOFFAT, J., KU, C.-C. & 
ARVIN, A. M. (2003) Differentiation of varicella-zoster virus ORF47 protein kinase and IE62 
protein binding domains and their contributions to replication in human skin xenografts in the 
SCID-hu mouse. Journal of Virology, 77, 5964-74. 
BEVAN, I. S., WALKER, M. R. & DAW, R. A. (1993) Detection of human cytomegalovirus DNA in 
peripheral blood leukocytes by the polymerase chain reaction. Transfusion, 33, 783-4. 
BOGGER-GOREN, S., BABA, K., HURLEY, P., YABUUCHI, H., TAKAHASHI, M. & OGRA, P. L. (1982) 
Antibody response to varicella-zoster virus after natural or vaccine-induced infection. Journal of 
Infectious Diseases, 146, 260-5. 
BOGGER-GOREN, S., BERNSTEIN, J. M., GERSHON, A. A. & OGRA, P. L. (1984) Mucosal cell-
mediated immunity to varicella zoster virus: role in protection against disease. Journal of 
Pediatrics, 105, 195-9. 
 The University of Sydney 
- 159 - 
BOUE, J., BLANPIED, C., BROUSSET, P., VERGNOLLE, N. & DIETRICH, G. (2011) Endogenous 
opioid-mediated analgesia is dependent on adaptive T cell response in mice. Journal of 
Immunology, 186, 5078-84. 
BOWSHER, D. (2002) Comment on Rice ASC, Maton S, the Postherpetic Neuralgia Study Group (UK), 
gabapentin in postherpetic neuralgia: a randomized, double blind, placebo-controlled study. 
Pain, 96, 409-10; author reply 411-2. 
BRISSON, M., EDMUNDS, W. J., LAW, B., GAY, N. J., WALLD, R., BROWNELL, M., ROOS, L. & DE 
SERRES, G. (2001) Epidemiology of varicella zoster virus infection in Canada and the United 
Kingdom. Epidemiology & Infection, 127, 305-14. 
BROWN, G. R. (1976) Herpes zoster: correlation of age, sex, distribution, neuralgia, and associated 
disorders. Southern Medical Journal, 69, 576-8. 
BRYAN, C. J., PRICHARD, M. N., DAILY, S., JEFFERSON, G., HARTLINE, C., CASSADY, K. A., 
HILLIARD, L. & SHIMAMURA, M. (2008) Acyclovir-resistant chronic verrucous vaccine strain 
varicella in a patient with neuroblastoma. Pediatric Infectious Disease, 27, 946-8. 
BURSCH, L. S., WANG, L., IGYARTO, B., KISSENPFENNIG, A., MALISSEN, B., KAPLAN, D. H. & 
HOGQUIST, K. A. (2007) Identification of a novel population of Langerin+ dendritic cells. 
Journal of Experimental Medicine, 204, 3147-56. 
CALANDRIA, L. (2011) Cryoanalgesia for post-herpetic neuralgia: a new treatment. International 
Journal of Dermatology, 50, 746-50. 
CARPENTER, J. E., HUTCHINSON, J. A., JACKSON, W. & GROSE, C. (2008) Egress of light particles 
among filopodia on the surface of Varicella-Zoster virus-infected cells. Journal of Virology, 82, 
2821-35. 
CARPENTER, J. E., JACKSON, W., DE SOUZA, G. A., HAARR, L. & GROSE, C. (2010) Insulin-
degrading enzyme binds to the nonglycosylated precursor of varicella-zoster virus gE protein 
found in the endoplasmic reticulum. Journal of Virology, 84, 847-55. 
CARPENTER, M. B. (1983) The neuron. Human neuroanatomy. 8th ed. Baltimore, Lippincott Williams 
and Wilkins. 
CASSINOTTI, P. & SIEGL, G. (1998) A nested-PCR assay for the simultaneous amplification of HSV-1, 
HSV-2, and HCMV genomes in patients with presumed herpetic CNS infections. Journal of 
Virological Methods, 71, 105-14. 
CELLA, M., JARROSSAY, D., FACCHETTI, F., ALEBARDI, O., NAKAJIMA, H., LANZAVECCHIA, A. & 
COLONNA, M. (1999) Plasmacytoid monocytes migrate to inflamed lymph nodes and produce 
large amounts of type I interferon. Nature Medicine, 5, 919-23. 
CHANG, C. C., MCLEAN, C., VUJOVIC, O., JENNEY, A. J., SHORT, M., LYON, S., STOREY, E. & 
LEWIN, S. R. (2009) Fatal acute varicella-zoster virus hemorrhagic meningomyelitis with 
necrotizing vasculitis in an HIV-infected patient. Clinical Infectious Diseases, 48, 372-3. 
CHAVES, S. S., GARGIULLO, P., ZHANG, J. X., CIVEN, R., GURIS, D., MASCOLA, L. & SEWARD, J. 
F. (2007) Loss of vaccine-induced immunity to varicella over time. New England Journal of 
Medicine, 356, 1121-9. 
CHEN, J.-Y., CHANG, C.-Y., FENG, P.-H., CHU, C.-C., SO, E. C. & HU, M.-L. (2009) Plasma vitamin C 
is lower in postherpetic neuralgia patients and administration of vitamin C reduces 
spontaneous pain but not brush-evoked pain. Clinical Journal of Pain, 25, 562-9. 
CHOO, P. W., DONAHUE, J. G., MANSON, J. E. & PLATT, R. (1995) The epidemiology of varicella and 
its complications. Journal of Infectious Diseases, 172, 706-12. 
 The University of Sydney 
- 160 - 
CLARKE, P., BEER, T., COHRS, R. & GILDEN, D. H. (1995) Configuration of latent varicella-zoster 
virus DNA. Journal of Virology, 69, 8151-4. 
COHEN, J. (2007) Varicella Zoster Virus: molecular basis of persistence (latency and reactivation). IN 
ARVIN, A., CAMPADELLI-FIUME, G., MOCARSKI, E., MOORE, P. S., ROIZMAN, B., 
WHITLEY, R. & YAMANISHI, K. (Eds.) Human Herpesviruses: Biology, Therapy and 
Immunoprophylaxis. Cambridge, Cambridge University Press. 
COHEN, J. I., BRUNELL, P. A., STRAUS, S. E. & KRAUSE, P. R. (1999) Recent advances in varicella-
zoster virus infection. Annals of Internal Medicine, 130, 922-32. 
COHEN, J. I. & NGUYEN, H. (1997) Varicella-zoster virus glycoprotein I is essential for growth of virus 
in Vero cells. Journal of Virology, 71, 6913-20. 
COHEN, J. I. & SEIDEL, K. E. (1994) Absence of varicella-zoster virus (VZV) glycoprotein V does not 
alter growth of VZV in vitro or sensitivity to heparin. Journal of General Virology, 75, 3087-93. 
COHRS, R. J., BARBOUR, M. & GILDEN, D. H. (1996) Varicella-zoster virus (VZV) transcription during 
latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a 
cDNA library enriched for VZV RNA. Journal of Virology, 70, 2789-96. 
COHRS, R. J. & GILDEN, D. H. (2007) Prevalence and abundance of latently transcribed varicella-
zoster virus genes in human ganglia. Journal of Virology, 81, 2950-6. 
COHRS, R. J., GILDEN, D. H., KINCHINGTON, P. R., GRINFELD, E. & KENNEDY, P. G. E. (2003) 
Varicella-zoster virus gene 66 transcription and translation in latently infected human Ganglia. 
Journal of Virology, 77, 6660-5. 
COHRS, R. J., MEHTA, S. K., SCHMID, D. S., GILDEN, D. H. & PIERSON, D. L. (2008) Asymptomatic 
reactivation and shed of infectious varicella zoster virus in astronauts. Journal of Medical 
Virology, 80, 1116-22. 
COHRS, R. J., RANDALL, J., SMITH, J., GILDEN, D. H., DABROWSKI, C., VAN DER KEYL, H. & TAL-
SINGER, R. (2000) Analysis of individual human trigeminal ganglia for latent herpes simplex 
virus type 1 and varicella-zoster virus nucleic acids using real-time PCR. Journal of Virology, 
74, 11464-71. 
COLE, N. L. & GROSE, C. (2003) Membrane fusion mediated by herpesvirus glycoproteins: the 
paradigm of varicella-zoster virus. Reviews in Medical Virology, 13, 207-22. 
COLLI, B. O., CARLOTTI, C. G., JR., ASSIRATI, J. A., JR., LOPES, L. D. S., MARQUES, W., JR., 
CHIMELLI, L., NEDER, L. & BARREIRA, A. A. (2008) Dorsal root ganglionectomy for the 
diagnosis of sensory neuropathies. Surgical technique and results. Surgical Neurology, 69, 
266-73; dicussion 273. 
COLLINS, S. L., MOORE, R. A., MCQUAYHJ & WIFFEN, P. (2000) Antidepressants and 
anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic 
review. Journal of Pain and Symptom Management, 20, 449-58. 
COLONNA, M., TRINCHIERI, G. & LIU, Y.-J. (2004) Plasmacytoid dendritic cells in immunity. Nature 
Immunology, 5, 1219-26. 
CONWAY, E. L., LENKIC, C. & MACINTYRE, C. R. (2006) Herpes Zoster and Associated Health Care 
Use in General Practice in Australia. Public Health Associatedion of Australia 10th National 
Immunisation Conference. Sydney. 
COOK, M. L. & STEVENS, J. G. (1968) Labile Coat: Reason for Noninfectious Cell-free Varicella-Zoster 
Virus in Culture. Journal of Virology, 2, 1458-64. 
 The University of Sydney 
- 161 - 
COOK, M. L. & STEVENS, J. G. (1970) Replication of varicella-zoster virus in cell culture: an 
ultrastructural study. Journal of Ultrastructural Research, 32, 334-350. 
COPLAN, P. M., SCHMADER, K., NIKAS, A., CHAN, I. S. F., CHOO, P., LEVIN, M. J., JOHNSON, G., 
BAUER, M., WILLIAMS, H. M., KAPLAN, K. M., GUESS, H. A. & OXMAN, M. N. (2004) 
Development of a measure of the burden of pain due to herpes zoster and postherpetic 
neuralgia for prevention trials: adaptation of the brief pain inventory. Journal of Pain, 5, 344-56. 
CROEN, K. D., OSTROVE, J. M., DRAGOVIC, L. J. & STRAUS, S. E. (1988) Patterns of gene 
expression and sites of latency in human nerve ganglia are different for varicella-zoster and 
herpes simplex viruses. Proceedings of the National Academy of Sciences of the United States 
of America, 85, 9773-7. 
DAVIES, L., COSSINS, L., BOWSHER, D. & DRUMMOND, M. (1994) The cost of treatment for post-
herpetic neuralgia in the UK. Pharmacoeconomics, 6, 142-8. 
DAVISON, A. J. & SCOTT, J. E. (1986) The complete DNA sequence of varicella-zoster virus. Journal 
of General Virology, 67, 1759-816. 
DE MORAGAS, J. M. & KIERLAND, R. R. (1957) The outcome of patients with herpes zoster. Archives 
of Dermatology, 2, 193-6. 
DE REGGE, N., FAVOREEL, H. W., GEENEN, K. & NAUWYNCK, H. J. (2006a) A homologous in vitro 
model to study interactions between alphaherpesviruses and trigeminal ganglion neurons. 
Veterinary Microbiology, 113, 251-5. 
DE REGGE, N., NAUWYNCK, H. J., GEENEN, K., KRUMMENACHER, C., COHEN, G. H., 
EISENBERG, R. J., METTENLEITER, T. C. & FAVOREEL, H. W. (2006b) Alpha-herpesvirus 
glycoprotein D interaction with sensory neurons triggers formation of varicosities that serve as 
virus exit sites. Journal of Cell Biology, 174, 267-75. 
DEBRUS, S., SADZOT-DELVAUX, C., NIKKELS, A. F., PIETTE, J. & RENTIER, B. (1995) Varicella-
zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during 
latency. Journal of Virology, 69, 3240-5. 
DEFECHEREUX, P., DEBRUS, S., BAUDOUX, L., RENTIER, B. & PIETTE, J. (1997) Varicella-zoster 
virus open reading frame 4 encodes an immediate-early protein with posttranscriptional 
regulatory properties. Journal of Virology, 71, 7073-9. 
DEFECHEREUX, P., DEBRUS, S., BAUDOUX, L., SCHOONBROODT, S., MERVILLE, M. P., 
RENTIER, B. & PIETTE, J. (1996) Intracellular distribution of the ORF4 gene product of 
varicella-zoster virus is influenced by the IE62 protein. Journal of General Virology, 77, 1505-
13. 
DEVLIN, M. E., GILDEN, D. H., MAHALINGAM, R., DUELAND, A. N. & COHRS, R. (1992) Peripheral 
blood mononuclear cells of the elderly contain varicella-zoster virus DNA. Journal of Infectious 
Diseases, 165, 619-22. 
DIAZ, P. S., SMITH, S., HUNTER, E. & ARVIN, A. M. (1989) T lymphocyte cytotoxicity with natural 
varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. 
Journal of Immunology, 142, 636-41. 
DONAGHY, H., BOSNJAK, L., HARMAN, A. N., MARSDEN, V., TYRING, S. K., MENG, T.-C. & 
CUNNINGHAM, A. L. (2009) Role for plasmacytoid dendritic cells in the immune control of 
recurrent human herpes simplex virus infection. Journal of Virology, 83, 1952-61. 
DONG, X., STOTHARD, P., FORSYTHE, I. J. & WISHART, D. S. (2004) PlasMapper: a web server for 
drawing and auto-annotating plasmid maps. Nucleic Acids Research, 32, W660-4. 
 The University of Sydney 
- 162 - 
DOUEK, D. C., BRENCHLEY, J. M., BETTS, M. R., AMBROZAK, D. R., J, H. B., OKAMOTO, Y., 
CASAZZA, J. P., KURUPPU, J., KUNSTMAN, K., WOLINSKY, S., GROSSMAN, Z., DYBUL, 
M., OXENIUS, A., PRICE, D. A., CONNORS, M. & KOUP, R. A. (2002) HIV preferentially 
infects HIV-specific CD4+ T cells. Nature, 417, 95-8. 
DRAKE, R., VOGL, A. W. & MITCHELL, A. W. M. (2009) Gray's Anatomy for Students Philadelphia, 
Churchill Livingstone Elsevier. 
DUBEY, L., STEINBERG, S. P., LARUSSA, P., OH, P. & GERSHON, A. A. (1988) Western blot 
analysis of antibody to varicella-zoster virus. Journal of Infectious Diseases, 157, 882-8. 
DUELAND, A. N., RANNEBERG-NILSEN, T. & DEGRE, M. (1995) Detection of latent varicella zoster 
virus DNA and human gene sequences in human trigeminal ganglia by in situ amplification 
combined with in situ hybridization. Archives of Virology, 140, 2055-66. 
DUUS, K. M. & GROSE, C. (1996) Multiple regulatory effects of varicella-zoster virus (VZV) gL on 
trafficking patterns and fusogenic properties of VZV gH. Journal of Virology, 70, 8961-71. 
DUUS, K. M., HATFIELD, C. & GROSE, C. (1995) Cell surface expression and fusion by the varicella-
zoster virus gH:gL glycoprotein complex: analysis by laser scanning confocal microscopy. 
Virology, 210, 429-40. 
DWORKIN, R. H., CORBIN, A. E., YOUNG, J. P., JR., SHARMA, U., LAMOREAUX, L., 
BOCKBRADER, H., GAROFALO, E. A. & POOLE, R. M. (2003) Pregabalin for the treatment of 
postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology, 60, 1274-83. 
DWORKIN, R. H., GNANN, J. W., JR., OAKLANDER, A. L., RAJA, S. N., SCHMADER, K. E. & 
WHITLEY, R. J. (2008a) Diagnosis and assessment of pain associated with herpes zoster and 
postherpetic neuralgia. Journal of Pain, 9, S37-44. 
DWORKIN, R. H., O'CONNOR, A. B., BACKONJA, M., FARRAR, J. T., FINNERUP, N. B., JENSEN, T. 
S., KALSO, E. A., LOESER, J. D., MIASKOWSKI, C., NURMIKKO, T. J., PORTENOY, R. K., 
RICE, A. S. C., STACEY, B. R., TREEDE, R.-D., TURK, D. C. & WALLACE, M. S. (2007a) 
Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain, 
132, 237-51. 
DWORKIN, R. H., WHITE, R., O'CONNOR, A. B., BASER, O. & HAWKINS, K. (2007b) Healthcare costs 
of acute and chronic pain associated with a diagnosis of herpes zoster. Journal of the 
American Geriatrics Society, 55, 1168-75. 
DWORKIN, R. H., WHITE, R., O'CONNOR, A. B. & HAWKINS, K. (2008b) Health care expenditure 
burden of persisting herpes zoster pain. Pain Medicine, 9, 348-53. 
ECKER, J. R. & HYMAN, R. W. (1982) Varicella zoster virus DNA exists as two isomers. Proceedings of 
the National Academy of Sciences of the United States of America, 79, 156-60. 
EDMUNDS, W. J. & BRISSON, M. (2002) The effect of vaccination on the epidemiology of varicella 
zoster virus. Journal of Infection, 44, 211-9. 
EISFELD, A. J., YEE, M. B., ERAZO, A., ABENDROTH, A. & KINCHINGTON, P. R. (2007) 
Downregulation of class I major histocompatibility complex surface expression by varicella-
zoster virus involves open reading frame 66 protein kinase-dependent and -independent 
mechanisms. Journal of Virology, 81, 9034-49. 
ENGSTROM, R. E., JR., HOLLAND, G. N., MARGOLIS, T. P., MUCCIOLI, C., LINDLEY, J. I., 
BELFORT, R., JR., HOLLAND, S. P., JOHNSTON, W. H., WOLITZ, R. A. & KREIGER, A. E. 
(1994) The progressive outer retinal necrosis syndrome. A variant of necrotizing herpetic 
retinopathy in patients with AIDS. Ophthalmology, 101, 1488-502. 
 The University of Sydney 
- 163 - 
ERAZO, A., YEE, M. B., BANFIELD, B. W. & KINCHINGTON, P. R. (2011) The alphaherpesvirus 
US3/ORF66 protein kinases direct phosphorylation of the nuclear matrix protein matrin 3. 
Journal of Virology, 85, 568-81. 
ESHLEMAN, E., SHAHZAD, A. & COHRS, R. (2011) Varicella zoster virus latency. Future Virology, 6, 
341-355. 
ETZIONI, A., EIDENSCHENK, C., KATZ, R., BECK, R., CASANOVA, J. L. & POLLACK, S. (2005) Fatal 
varicella associated with selective natural killer cell deficiency. Journal of Pediatrics, 146, 423-
5. 
FAIRLEY, C. K. & MILLER, E. (1996) Varicella-zoster virus epidemiology--a changing scene? Journal of 
Infectious Diseases, 174 Suppl 3, S314-9. 
FAN, B. F. & OXYCONTIN TABLETS POSTMARKETING SURVEILLANCE STUDY GROUP, C. (2008) 
Postmarketing surveillance study of OxyContin tablets for relieving moderate to severe 
postherpetic neuralgia pain. Oncology, 74 Suppl 1, 66-71. 
FARAGE, M. A., MILLER, K. W., ELSNER, P. & MAIBACH, H. I. (2007) Structural characteristics of the 
aging skin: a review. Cutaneous & Ocular Toxicology, 26, 343-57. 
FITZGERALD-BOCARSLY, P. (1993) Human natural interferon-alpha producing cells. Pharmacology & 
Therapeutics, 60, 39-62. 
FLEISHER, G., HENRY, W., MCSORLEY, M., ARBETER, A. & PLOTKIN, S. (1981) Life-threatening 
complications of varicella. American Journal of Diseases of Children, 135, 896-9. 
FORGHANI, B., DUPUIS, K. W. & SCHMIDT, N. J. (1990a) Epitopes functional in neutralization of 
varicella-zoster virus. Journal of Clinical Microbiology, 28, 2500-6. 
FORGHANI, B., MAHALINGAM, R., VAFAI, A., HURST, J. W. & DUPUIS, K. W. (1990b) Monoclonal 
antibody to immediate early protein encoded by varicella-zoster virus gene 62. Virus Research, 
16, 195-210. 
GARRY, E. M., DELANEY, A., ANDERSON, H. A., SIRINATHSINGHJI, E. C., CLAPP, R. H., MARTIN, 
W. J., KINCHINGTON, P. R., KRAH, D. L., ABBADIE, C. & FLEETWOOD-WALKER, S. M. 
(2005) Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and 
behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking 
drugs. Pain, 118, 97-111. 
GARWEG, J. & BOHNKE, M. (1997) Varicella-zoster virus is strongly associated with atypical 
necrotizing herpetic retinopathies. Clinical Infectious Diseases, 24, 603-8. 
GAUTHIER, A., BREUER, J., CARRINGTON, D., MARTIN, M. & REMY, V. (2009) Epidemiology and 
cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiology & 
Infection, 137, 38-47. 
GEENEN, K., FAVOREEL, H. W. & NAUWYNCK, H. J. (2005) Higher resistance of porcine trigeminal 
ganglion neurons towards pseudorabies virus-induced cell death compared with other porcine 
cell types in vitro. Journal of General Virology, 86, 1251-60. 
GEHLING, M. & TRYBA, M. (2002) Comment on Rice ASC, Maton S, the Postherpetic Neuralgia Study 
Group (UK), gabapentin in postherpetic neuralgia: a randomized, double blind, placebo-
controlled study. Pain, 96, 410-1. 
GERSHON, A. A., GERSHON, M. D., BREUER, J., LEVIN, M., OAKLANDER, A. L. & GRIFFITHS, P. 
D. (2010) Advances in the understanding of the pathogenesis and epidemiology of herpes 
zoster. Journal of Clinical Virology, 48, S2-S7. 
 The University of Sydney 
- 164 - 
GERSHON, A. A., SHERMAN, D. L., ZHU, Z., GABEL, C. A., AMBRON, R. T. & GERSHON, M. D. 
(1994) Intracellular transport of newly synthesized varicella-zoster virus: final envelopment in 
the trans-Golgi network. Journal of Virology, 68, 6372-90. 
GERSHON, A. A. & STEINBERG, S. P. (1981) Antibody responses to varicella-zoster virus and the role 
of antibody in host defense. American Journal of the Medical Sciences, 282, 12-7. 
GILDEN, D., COHRS, R. J., MAHALINGAM, R. & NAGEL, M. A. (2010) Neurological disease produced 
by varicella zoster virus reactivation without rash. Current Topics in Microbiology and 
Immunology, 342, 243-53. 
GILDEN, D. H., BEINLICH, B. R., RUBINSTIEN, E. M., STOMMEL, E., SWENSON, R., RUBINSTEIN, 
D. & MAHALINGAM, R. (1994a) Varicella-zoster virus myelitis: an expanding spectrum. 
Neurology, 44, 1818-23. 
GILDEN, D. H., COHRS, R. J., HAYWARD, A. R., WELLISH, M. & MAHALINGAM, R. (2003) Chronic 
varicella-zoster virus ganglionitis - a possible cause of postherpetic neuralgia. Journal of 
Neurovirology, 9, 404-7. 
GILDEN, D. H., DEVLIN, M., WELLISH, M., MAHALINGHAM, R., HUFF, C., HAYWARD, A. & VAFAI, 
A. (1989) Persistence of varicella-zoster virus DNA in blood mononuclear cells of patients with 
varicella or zoster. Virus Genes, 2, 299-305. 
GILDEN, D. H., KLEINSCHMIDT-DEMASTERS, B. K., WELLISH, M., HEDLEY-WHYTE, E. T., 
RENTIER, B. & MAHALINGAM, R. (1996) Varicella zoster virus, a cause of waxing and waning 
vasculitis: the New England Journal of Medicine case 5-1995 revisited. Neurology, 47, 1441-6. 
GILDEN, D. H., ROZENMAN, Y., MURRAY, R., DEVLIN, M. & VAFAI, A. (1987) Detection of varicella-
zoster virus nucleic acid in neurons of normal human thoracic ganglia. Annals of Neurology, 
22, 377-80. 
GILDEN, D. H., VAFAI, A., SHTRAM, Y., BECKER, Y., DEVLIN, M. & WELLISH, M. (1983) Varicella-
zoster virus DNA in human sensory ganglia. Nature, 306, 478-80. 
GILDEN, D. H., WRIGHT, R. R., SCHNECK, S. A., GWALTNEY, J. M., JR. & MAHALINGAM, R. 
(1994b) Zoster sine herpete, a clinical variant. Annals of Neurology, 35, 530-3. 
GILLER, R. H., WINISTORFER, S. & GROSE, C. (1989) Cellular and humoral immunity to varicella 
zoster virus glycoproteins in immune and susceptible human subjects. Journal of Infectious 
Diseases, 160, 919-28. 
GINHOUX, F., COLLIN, M. P., BOGUNOVIC, M., ABEL, M., LEBOEUF, M., HELFT, J., OCHANDO, J., 
KISSENPFENNIG, A., MALISSEN, B., GRISOTTO, M., SNOECK, H., RANDOLPH, G. & 
MERAD, M. (2007) Blood-derived dermal langerin+ dendritic cells survey the skin in the steady 
state. Journal of Experimental Medicine, 204, 3133-46. 
GOMI, Y., SUNAMACHI, H., MORI, Y., NAGAIKE, K., TAKAHASHI, M. & YAMANISHI, K. (2002) 
Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental 
virus. Journal of Virology, 76, 11447-59. 
GOWRISHANKAR, K. (2008) Studies on infection of Varicella Zoster Virus in human ganglia. 
Department of Infectious Diseases and Immunology. Sydney, University of Sydney. 
GOWRISHANKAR, K., SLOBEDMAN, B., CUNNINGHAM, A. L., MIRANDA-SAKSENA, M., BOADLE, 
R. A. & ABENDROTH, A. (2007) Productive varicella-zoster virus infection of cultured intact 
human ganglia. Journal of Virology, 81, 6752-6. 
 The University of Sydney 
- 165 - 
GOWRISHANKAR, K., STEAIN, M., CUNNINGHAM, A. L., RODRIGUEZ, M., BLUMBERGS, P., 
SLOBEDMAN, B. & ABENDROTH, A. (2010) Characterization of the host immune response in 
human ganglia after herpes zoster. Journal of Virology, 84, 8861-70. 
GRACE, P. M., HUTCHINSON, M. R., BISHOP, A., SOMOGYI, A. A., MAYRHOFER, G. & ROLAN, P. 
E. (2011) Adoptive transfer of peripheral immune cells potentiates allodynia in a graded chronic 
constriction injury model of neuropathic pain. Brain, Behavior, & Immunity, 25, 503-13. 
GRANT, S., AITCHISON, T., HENDERSON, E., CHRISTIE, J., ZARE, S., MCMURRAY, J. & DARGIE, 
H. (1999) A comparison of the reproducibility and the sensitivity to change of visual analogue 
scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. Chest, 
116, 1208-17. 
GROSE, C. (1981) Variation on a theme by Fenner: the pathogenesis of chickenpox. Pediatrics, 68, 
735-7. 
GUESS, H. A., BROUGHTON, D. D., MELTON, L. J., 3RD & KURLAND, L. T. (1985) Epidemiology of 
herpes zoster in children and adolescents: a population-based study. Pediatrics, 76, 512-7. 
GUEX-CROSIER, Y., ROCHAT, C. & HERBORT, C. P. (1997) Necrotizing herpetic retinopathies. A 
spectrum of herpes virus-induced diseases determined by the immune state of the host. Ocular 
Immunology & Inflammation, 5, 259-65. 
GURIS, D., JUMAAN, A. O., MASCOLA, L., WATSON, B. M., ZHANG, J. X., CHAVES, S. S., 
GARGIULLO, P., PERELLA, D., CIVEN, R. & SEWARD, J. F. (2008) Changing varicella 
epidemiology in active surveillance sites--United States, 1995-2005. Journal of Infectious 
Diseases, 197 Suppl 2, S71-5. 
GUTZEIT, C., RAFTERY, M. J., PEISER, M., TISCHER, K. B., ULRICH, M., EBERHARDT, M., 
STOCKFLETH, E., GIESE, T., SAUERBREI, A., MORITA, C. T. & SCHONRICH, G. (2010) 
Identification of an important immunological difference between virulent varicella-zoster virus 
and its avirulent vaccine: viral disruption of dendritic cell instruction. Journal of Immunology, 
185, 488-97. 
HAANPAA, M., LAIPPALA, P. & NURMIKKO, T. (1999) Pain and somatosensory dysfunction in acute 
herpes zoster. Clinical Journal of Pain, 15, 78-84. 
HABERTHUR, K., KRAFT, A., ARNOLD, N., PARK, B., MEYER, C., ASQUITH, M., DEWANE, J. & 
MESSOUDI, I. (2013) Genome-wide analysis of T cell responses during acute and latent 
simian varicella virus infections in rhesus macaques. Journal of Virology, 87, 11751-11761. 
HALL, G. C., CARROLL, D. & MCQUAY, H. J. (2008) Primary care incidence and treatment of four 
neuropathic pain conditions: a descriptive study, 2002-2005. BMC Family Practice, 9, 26. 
HAMA, Y., SHIRAKI, K., YOSHIDA, Y., MARUYAMA, A., YASUDA, M., TSUDA, M., HONDA, M., 
TAKAHASHI, M., HIGUCHI, H., TAKASAKI, I., DAIKOKU, T. & TSUMOTO, T. (2010) Antibody 
to Varicella-Zoster Virus Immediate-Early Protein 62 Augments Allodynia in Zoster via Brain-
Derived Neurotrophic Factor. Journal of Virology, 84, 1616-1624. 
HAMBLETON, S. & GERSHON, A. A. (2005) Preventing varicella-zoster disease. Clinical Microbiology 
Reviews, 18, 70-80. 
HAMBLETON, S., STEINBERG, S. P., GERSHON, M. D. & GERSHON, A. (2007) Cholesterol 
Dependence of Varicella-Zoster Virion Entry into Target Cells. Journal of Virology, 81, 7548-58. 
HAN, J.-Y., HANSON, D. C. & WAY, S. S. (2011) Herpes zoster and meningitis due to reactivation of 
varicella vaccine virus in an immunocompetent child. Pediatric Infectious Disease, 30, 266-8. 
 The University of Sydney 
- 166 - 
HASNIE, F. S., BREUER, J., PARKER, S., WALLACE, V., BLACKBEARD, J., LEVER, I., 
KINCHINGTON, P. R., DICKENSON, A. H., PHEBY, T. & RICE, A. S. C. (2007) Further 
characterization of a rat model of varicella zoster virus-associated pain: Relationship between 
mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs. 
Neuroscience, 144, 1495-508. 
HATA, A., ZERBONI, L., SOMMER, M., KASPAR, A. A., CLAYBERGER, C., KRENSKY, A. M. & 
ARVIN, A. M. (2001) Granulysin blocks replication of varicella-zoster virus and triggers 
apoptosis of infected cells. Viral Immunology, 14, 125-33. 
HATO, N., KISAKI, H., HONDA, N., GYO, K., MURAKAMI, S. & YANAGIHARA, N. (2000) Ramsay Hunt 
syndrome in children. Annals of Neurology, 48, 254-6. 
HEAD, H. & CAMPBELL, A. W. (1900) The pathology of herpes zoster and its bearing on sensory 
localization. Brain, 23, 252-62. 
HEININGER, U. & SEWARD, J. F. (2006) Varicella. Lancet, 368, 1365-76. 
HELLER, K. N., GURER, C. & MUNZ, C. (2006) Virus-specific CD4+ T cells: ready for direct attack. 
Journal of Experimental Medicine, 203, 805-8. 
HICKLING, J. K., BORYSIEWICZ, L. K. & SISSONS, J. G. (1987) Varicella-zoster virus-specific 
cytotoxic T lymphocytes (Tc): detection and frequency analysis of HLA class I-restricted Tc in 
human peripheral blood. Journal of Virology, 61, 3463-9. 
HONESS, R. W. & ROIZMAN, B. (1974) Regulation of herpesvirus macromolecular synthesis. I. 
Cascade regulation of the synthesis of three groups of viral proteins. Journal of Virology, 14, 8-
19. 
HOOD, C., CUNNINGHAM, A. L., SLOBEDMAN, B., ARVIN, A. M., SOMMER, M. H., KINCHINGTON, 
P. R. & ABENDROTH, A. (2006) Varicella-zoster virus ORF63 inhibits apoptosis of primary 
human neurons. Journal of Virology, 80, 1025-31. 
HOOD, C., CUNNINGHAM, A. L., SLOBEDMAN, B., BOADLE, R. A. & ABENDROTH, A. (2003) 
Varicella-zoster virus-infected human sensory neurons are resistant to apoptosis, yet human 
foreskin fibroblasts are susceptible: evidence for a cell-type-specific apoptotic response. 
Journal of Virology, 77, 12852-64. 
HOPE-SIMPSON, R. E. (1965) The nature of Herpes Zoster: a long-term study and a new hypothesis. 
Proceedings of the Royal Society of Medicine, 58, 9-20. 
HOPE-SIMPSON, R. E. (1967) Herpes zoster in the elderly. Geriatrics, 22, 151-9. 
HOPE-SIMPSON, R. E. (1975) Postherpetic neuralgia. Journal of the Royal College of General 
Practitioners, 25, 571-5. 
HU, H. & COHEN, J. I. (2005) Varicella-zoster virus open reading frame 47 (ORF47) protein is critical 
for virus replication in dendritic cells and for spread to other cells. Virology, 337, 304-11. 
HUANG, Z., VAFAI, A., LEE, J., MAHALINGAM, R. & HAYWARD, A. R. (1992) Specific lysis of targets 
expressing varicella-zoster virus gpI or gpIV by CD4+ human T-cell clones. Journal of Virology, 
66, 2664-9. 
HUCH, J. H., CUNNINGHAM, A. L., ARVIN, A. M., NASR, N., SANTEGOETS, S. J. A. M., 
SLOBEDMAN, E., SLOBEDMAN, B. & ABENDROTH, A. (2010) Impact of varicella-zoster virus 
on dendritic cell subsets in human skin during natural infection. Journal of Virology, 84, 4060-
72. 
 The University of Sydney 
- 167 - 
HUKKANEN, V., MIKOLA, H., NYKANEN, M. & SYRJANEN, S. (1999) Herpes simplex virus type 1 
infection has two separate modes of spread in three-dimensional keratinocyte culture. Journal 
of General Virology, 80, 2149-55. 
HYMAN, R. W., ECKER, J. R. & TENSER, R. B. (1983) Varicella-zoster virus RNA in human trigeminal 
ganglia. Lancet, 322, 814-6. 
IHARA, T., STARR, S. E., ITO, M., DOUGLAS, S. D. & ARBETER, A. M. (1984) Human 
polymorphonuclear leukocyte-mediated cytotoxicity against varicella-zoster virus-infected 
fibroblasts. Journal of Virology, 51, 110-6. 
INOUE, H., MOTANI-SAITOH, H., SAKURADA, K., IKEGAYA, H., YAJIMA, D., HAYAKAWA, M., SATO, 
Y., OTSUKA, K., KOBAYASHI, K., NAGASAWA, S. & IWASE, H. (2010) Detection of varicella-
zoster virus DNA in 414 human trigeminal ganglia from cadavers by the polymerase chain 
reaction: a comparison of the detection rate of varicella-zoster virus and herpes simplex virus 
type 1. Journal of Medical Virology, 82, 345-9. 
ITO, M., MIZUTANI, K., KAMIYA, T., IHARA, T., KAMIYA, H., SAKURAI, M., SUGANO, T. & 
MATUMOTO, Y. (1993) Inhibition of varicella-zoster virus (VZV) glycoprotein expression by a 
human monoclonal antibody against VZV glycoprotein III. Journal of Infectious Diseases, 168, 
1256-9. 
IYER, S., MITTAL, M. K. & HODINKA, R. L. (2009) Herpes zoster and meningitis resulting from 
reactivation of varicella vaccine virus in an immunocompetent child. Annals of Emergency 
Medicine, 53, 792-5. 
JACKSON, S. M., WILLIAMS, M. L., FEINGOLD, K. R. & ELIAS, P. M. (1993) Pathobiology of the 
stratum corneum. Western Journal of Medicine, 158, 279-85. 
JACQUET, A., HAUMONT, M., CHELLUN, D., MASSAER, M., TUFARO, F., BOLLEN, A. & JACOBS, 
P. (1998) The varicella zoster virus glycoprotein B (gB) plays a role in virus binding to cell 
surface heparan sulfate proteoglycans. Virus Research, 53, 197-207. 
JANTSCH, J., SCHMIDT, B., BARDUTZKY, J., BOGDAN, C., ECKARDT, K.-U. & RAFF, U. (2011) 
Lethal varicella-zoster virus reactivation without skin lesions following renal transplantation. 
Nephrology Dialysis Transplantation, 26, 365-8. 
JENKINS, D. E., REDMAN, R. L., LAM, E. M., LIU, C., LIN, I. & ARVIN, A. M. (1998) Interleukin (IL)-10, 
IL-12, and interferon-gamma production in primary and memory immune responses to 
varicella-zoster virus. Journal of Infectious Diseases, 178, 940-8. 
JOHNSON, R. W. (2009) Herpes Zoster and Postherpetic Neuralgia: a review of the effects of 
vaccination. Aging-Clinical & Experimental Research, 21, 236-43. 
JOHNSON, R. W., BOUHASSIRA, D., KASSIANOS, G., LEPLEGE, A., SCHMADER, K. E. & WEINKE, 
T. (2010) The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC 
Medicine, 8, 37. 
JONES, J. O. & ARVIN, A. M. (2006) Inhibition of the NF-kappaB pathway by varicella-zoster virus in 
vitro and in human epidermal cells in vivo. Journal of Virology, 80, 5113-24. 
JUNG, B. F., JOHNSON, R. W., GRIFFIN, D. R. J. & DWORKIN, R. H. (2004) Risk factors for 
postherpetic neuralgia in patients with herpes zoster. Neurology, 62, 1545-51. 
KANDEL, E. R., SCHWARTZ, J. H. & JESSELL, T. M. (2000) Principles of Neural Science, New York, 
McGraw-Hill. 
KENNEDY, P. G., GRINFELD, E. & BELL, J. E. (2000) Varicella-zoster virus gene expression in latently 
infected and explanted human ganglia. Journal of Virology, 74, 11893-8. 
 The University of Sydney 
- 168 - 
KENNEDY, P. G., GRINFELD, E. & GOW, J. W. (1998) Latent varicella-zoster virus is located 
predominantly in neurons in human trigeminal ganglia. Proceedings of the National Academy 
of Sciences of the United States of America, 95, 4658-62. 
KENNEDY, P. G., GRINFELD, E. & GOW, J. W. (1999) Latent Varicella-zoster virus in human dorsal 
root ganglia. Virology, 258, 451-4. 
KENNEDY, P. G. E. (2002) Key issues in varicella-zoster virus latency. Journal of Neurovirology, 8 
Suppl 2, 80-4. 
KENT, J. R., KANG, W., MILLER, C. G. & FRASER, N. W. (2003) Herpes simplex virus latency-
associated transcript gene function. Journal of Neurovirology, 9, 285-90. 
KENYON, T. K. & GROSE, C. (2009) VZV ORF47 serine protein kinase and its viral substrates. Current 
Topics in Microbiology & Immunology, 342, 99-111. 
KHANDAKER, G., MARSHALL, H., PEADON, E., ZURYNSKI, Y., BURGNER, D., BUTTERY, J., GOLD, 
M., NISSEN, M., ELLIOTT, E. J., BURGESS, M. A. & BOOY, R. (2011) Congenital and 
neonatal varicella: impact of the national varicella vacination programme in Australia. Archives 
of Disease in Childhood, 96, 453-456. 
KIM, Y. H., LEE, C. J., LEE, S. C., HUH, J., NAHM, F. S., KIM, H. Z. & LEE, M. K. (2008) Effect of 
pulsed radiofrequency for postherpetic neuralgia. Acta Anaesthesiologica Scandinavica, 52, 
1140-3. 
KIMURA, H., STRAUS, S. E. & WILLIAMS, R. K. (1997) Varicella-zoster virus glycoproteins E and I 
expressed in insect cells form a heterodimer that requires the N-terminal domain of 
glycoprotein I. Virology, 233, 382-91. 
KINCHINGTON, P. R., BOOKEY, D. & TURSE, S. E. (1995) The transcriptional regulatory proteins 
encoded by varicella-zoster virus open reading frames (ORFs) 4 and 63, but not ORF 61, are 
associated with purified virus particles. Journal of Virology, 69, 4274-82. 
KINCHINGTON, P. R. & COHEN, J. I. (2000) Viral proteins. IN ARVIN, A. M. & GERSHON, A. A. (Eds.) 
Varicella Zoster Virus: Virology and Clinical Management. Cambridge, Cambridge University 
Press. 
KINCHINGTON, P. R., FITE, K. & TURSE, S. E. (2000) Nuclear accumulation of IE62, the varicella-
zoster virus (VZV) major transcriptional regulatory protein, is inhibited by phosphorylation 
mediated by the VZV open reading frame 66 protein kinase. Journal of Virology, 74, 2265-77. 
KINCHINGTON, P. R., HOUGLAND, J. K., ARVIN, A. M., RUYECHAN, W. T. & HAY, J. (1992) The 
varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. 
Journal of Virology, 66, 359-66. 
KINCHINGTON, P. R., INCHAUSPE, G., SUBAK-SHARPE, J. H., ROBEY, F., HAY, J. & RUYECHAN, 
W. T. (1988) Identification and characterization of a varicella-zoster virus DNA-binding protein 
by using antisera directed against a predicted synthetic oligopeptide. Journal of Virology, 62, 
802-9. 
KINCHINGTON, P. R., LING, P., PENSIERO, M., MOSS, B., RUYECHAN, W. T. & HAY, J. (1990) The 
glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a 
vaccine strain (Oka). Journal of Virology, 64, 4540-8. 
KOST, R. G. & STRAUS, S. E. (1996) Postherpetic neuralgia--pathogenesis, treatment, and prevention. 
New England Journal of Medicine, 335, 32-42. 
KRUEGER, G. G. & STINGL, G. (1989) Immunology/inflammation of the skin--a 50-year perspective. 
Journal of Investigative Dermatology, 92, 32S-51S. 
 The University of Sydney 
- 169 - 
KRUSZEWSKI, S. P., PACZYNSKI, R. P. & KAHN, D. A. (2009) Gabapentin-induced delirium and 
dependence. Journal of Psychiatric Practice, 15, 314-9. 
KU, C.-C., PADILLA, J. A., GROSE, C., BUTCHER, E. C. & ARVIN, A. M. (2002) Tropism of varicella-
zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and 
skin homing markers. Journal of Virology, 76, 11425-33. 
KU, C.-C., ZERBONI, L., ITO, H., GRAHAM, B. S., WALLACE, M. & ARVIN, A. M. (2004) Varicella-
zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell 
interferon-alpha. Journal of Experimental Medicine, 200, 917-25. 
KUNKEL, E. J. & BUTCHER, E. C. (2003) Plasma-cell homing. Nature Reviews, Immunology. 3, 822-9. 
KWAN, W.-H., NAVARRO-SANCHEZ, E., DUMORTIER, H., DECOSSAS, M., VACHON, H., DOS 
SANTOS, F. B., FRIDMAN, H., W, REY, F. A., HARRIS, E., DESPRES, P. & MUELLER, C. G. 
(2008) Dermal-type macrophages expressing CD209/DC-SIGN show inherent resistance to 
dengue virus growth. PLoS Neglected Tropical Diseases, 2, e311. 
LABUZ, D., SCHREITER, A., SCHMIDT, Y., BRACK, A. & MACHELSKA, H. (2010) T lymphocytes 
containing beta-endorphin ameliorate mechanical hypersensitivity following nerve injury. Brain, 
Behavior, & Immunity, 24, 1045-53. 
LAGUARDIA, J. J., COHRS, R. J. & GILDEN, D. H. (1999) Prevalence of varicella-zoster virus DNA in 
dissociated human trigeminal ganglion neurons and nonneuronal cells. Journal of Virology, 73, 
8571-7. 
LAGUARDIA, J. J. & GILDEN, D. H. (2001) Varicella-zoster virus: a re-emerging infection. Journal of 
Investigative Dermatology, Symposium Proceedings. 6, 183-7. 
LANDAIS, E., SAULQUIN, X. & HOUSSAINT, E. (2005) The human T cell immune response to Epstein-
Barr virus. International Journal of Developmental Biology, 49, 285-92. 
LARUSSA, P. S., GERSHON, A. A., STEINBERG, S. P. & CHARTRAND, S. A. (1990) Antibodies to 
varicella-zoster virus glycoproteins I, II, and III in leukemic and healthy children. Journal of 
Infectious Diseases, 162, 627-33. 
LEUNG, J., HARPAZ, R., MOLINARI, N.-A., JUMAAN, A. & ZHOU, F. (2011) Herpes zoster incidence 
among insured persons in the United States, 1993-2006: evaluation of impact of varicella 
vaccination. Clinical Infectious Diseases, 52, 332-40. 
LEVIN, M. J., CAI, G.-Y., MANCHAK, M. D. & PIZER, L. I. (2003) Varicella-zoster virus DNA in cells 
isolated from human trigeminal ganglia. Journal of Virology, 77, 6979-87. 
LI, Q., ALI, M. A. & COHEN, J. I. (2006) Insulin degrading enzyme is a cellular receptor mediating 
varicella-zoster virus infection and cell-to-cell spread. Cell, 127, 305-16. 
LI, Q., CHEN, N., YANG, J., ZHOU, M., ZHOU, D., ZHANG, Q. & HE, L. (2009) Antiviral treatment for 
preventing postherpetic neuralgia. Cochrane Database of Systematic Reviews, CD006866. 
LI, Q., KROGMANN, T., ALI, M. A., TANG, W.-J. & COHEN, J. I. (2007) The amino terminus of 
varicella-zoster virus (VZV) glycoprotein E is required for binding to insulin-degrading enzyme, 
a VZV receptor. Journal of Virology, 81, 8525-32. 
LIEDGENS, H., HERTEL, N., GABRIEL, A., NUIJTEN, M., DAKIN, H., MITCHELL, S. & NAUTRUP, B. 
P. (2008) Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with 
gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective. Clinical 
Drug Investigation, 28, 583-601. 
 The University of Sydney 
- 170 - 
LIONNET, F., PULIK, M., GENET, P., PETITDIDIER, C., DAVOUS, P., LEBON, P. & ROZENBERG, F. 
(1996) Myelitis due to varicella-zoster virus in two patients with AIDS: successful treatment with 
acyclovir. Clinical Infectious Diseases, 22, 138-40. 
LITWIN, V., JACKSON, W. & GROSE, C. (1992) Receptor properties of two varicella-zoster virus 
glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI. Journal of 
Virology, 66, 3643-51. 
LOW, P. A. & DOTSON, R. M. (1998) Symptomatic treatment of painful neuropathy. JAMA, 280, 1863-
4. 
LUNGU, O., ANNUNZIATO, P. W., GERSHON, A., STAUGAITIS, S. M., JOSEFSON, D., LARUSSA, P. 
& SILVERSTEIN, S. J. (1995) Reactivated and latent varicella-zoster virus in human dorsal 
root ganglia. Proceedings of the National Academy of Sciences of the United States of 
America, 92, 10980-4. 
LUNGU, O., PANAGIOTIDIS, C. A., ANNUNZIATO, P. W., GERSHON, A. A. & SILVERSTEIN, S. J. 
(1998) Aberrant intracellular localization of Varicella-Zoster virus regulatory proteins during 
latency. Proceedings of the National Academy of Sciences of the United States of America, 95, 
7080-5. 
LYNCH, J. M., KENYON, T. K., GROSE, C., HAY, J. & RUYECHAN, W. T. (2002) Physical and 
functional interaction between the varicella zoster virus IE63 and IE62 proteins. Virology, 302, 
71-82. 
MACHELSKA, H. (2011) Dual peripheral actions of immune cells in neuropathic pain. Archivum 
Immunologiae et Therapiae Experimentalis, 59, 11-24. 
MACINTYRE, C. R., CHU, C. P. & BURGESS, M. A. (2003) Use of hospitalization and pharmaceutical 
prescribing data to compare the prevaccination burden of varicella and herpes zoster in 
Australia. Epidemiology & Infection, 131, 675-82. 
MAHALINGAM, R., CABIRAC, G., WELLISH, M., GILDEN, D. & VAFAI, A. (1990) In-vitro synthesis of 
functional varicella zoster and herpes simplex viral thymidine kinase. Virus Genes, 4, 105-20. 
MAHALINGAM, R., LASHER, R., WELLISH, M., COHRS, R. J. & GILDEN, D. H. (1998) Localization of 
varicella-zoster virus gene 21 protein in virus-infected cells in culture. Journal of Virology, 72, 
6832-7. 
MAHALINGAM, R., WELLISH, M., COHRS, R., DEBRUS, S., PIETTE, J., RENTIER, B. & GILDEN, D. 
H. (1996) Expression of protein encoded by varicella-zoster virus open reading frame 63 in 
latently infected human ganglionic neurons. Proceedings of the National Academy of Sciences 
of the United States of America, 93, 2122-4. 
MAHALINGAM, R., WELLISH, M., LEDERER, D., FORGHANI, B., COHRS, R. & GILDEN, D. (1993) 
Quantitation of latent varicella-zoster virus DNA in human trigeminal ganglia by polymerase 
chain reaction. Journal of Virology, 67, 2381-4. 
MALAVIGE, G. N., JONES, L., KAMALADASA, S. D., WIJEWICKRAMA, A., SENEVIRATNE, S. L., 
BLACK, A. P. & OGG, G. S. (2010) Natural killer cells during primary varicella zoster virus 
infection. Journal of Infection, 61, 190-2. 
MALLORY, S., SOMMER, M. & ARVIN, A. M. (1997) Mutational analysis of the role of glycoprotein I in 
varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking. 
Journal of Virology, 71, 8279-88. 
MANDAL, B. K., MUKHERJEE, P. P., MURPHY, C., MUKHERJEE, R. & NAIK, T. (1998) Adult 
susceptibility to varicella in the tropics is a rural phenomenon due to the lack of previous 
exposure. Journal of Infectious Diseases, 178 Suppl 1, S52-4. 
 The University of Sydney 
- 171 - 
MANIAN, F. A., KINDRED, M. & FULLING, K. H. (1995) Chronic varicella-zoster virus myelitis without 
cutaneous eruption in a patient with AIDS: report of a fatal case. Clinical Infectious Diseases, 
21, 986-8. 
MARESOVA, L., PASIEKA, T. J., HOMAN, E., GERDAY, E. & GROSE, C. (2005) Incorporation of three 
endocytosed varicella-zoster virus glycoproteins, gE, gH, and gB, into the virion envelope. 
Journal of Virology, 79, 997-1007. 
MARKUS, A., GRIGORYAN, S., SLOUTSKIN, A., YEE, M. B., ZHU, H., YANG, I. H., THAKOR, N. V., 
SARID, R., KINCHINGTON, P. R. & GOLDSTEIN, R. S. (2011) Varicella-zoster virus (VZV) 
infection of neurons derived from human embryonic stem cells: direct demonstration of axonal 
infection, transport of VZV, and productive neuronal infection. Journal of Virology, 85, 6220-33. 
MCINTYRE, P., GIDDING, H., GILMOUR, R., LAWRENCE, G., HULL, B., HORBY, P., WANG, H., 
ANDREWS, R., BURGESS, M. & NATIONAL CENTRE FOR IMMUNISATION RESEARCH 
AND SURVEILLANCE OF VACCINE PREVENTABLE, D. (2002) Vaccine preventable 
diseases and vaccination coverage in Australia, 1999 to 2000. Communicable Diseases 
Intelligence, Suppl, i-xi. 
MCKENDRICK, M. W., OGAN, P. & CARE, C. C. (2009) A 9 year follow up of post herpetic neuralgia 
and predisposing factors in elderly patients following herpes zoster. Journal of Infection, 59, 
416-20. 
MCMILLAN, D. J., KAY, J. & MILLS, J. S. (1997) Characterization of the proteinase specified by 
varicella-zoster virus gene 33. Journal of General Virology, 78, 2153-7. 
MEHTA, S. K., TYRING, S. K., GILDEN, D. H., COHRS, R. J., LEAL, M. J., CASTRO, V. A., 
FEIVESON, A. H., OTT, C. M. & PIERSON, D. L. (2008) Varicella-zoster virus in the saliva of 
patients with herpes zoster. Journal of Infectious Diseases, 197, 654-7. 
MEIER, J. L., HOLMAN, R. P., CROEN, K. D., SMIALEK, J. E. & STRAUS, S. E. (1993) Varicella-zoster 
virus transcription in human trigeminal ganglia. Virology, 193, 193-200. 
MILLER, R. J., JUNG, H., BHANGOO, S. K. & WHITE, F. A. (2009) Cytokine and chemokine regulation 
of sensory neuron function. Handbook of Experimental Pharmacology, 194, 417-49. 
MO, C., LEE, J., SOMMER, M., GROSE, C. & ARVIN, A. M. (2002) The requirement of varicella zoster 
virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma 
cells. Virology, 304, 176-86. 
MO, C., SCHNEEBERGER, E. E. & ARVIN, A. M. (2000) Glycoprotein E of varicella-zoster virus 
enhances cell-cell contact in polarized epithelial cells. Journal of Virology, 74, 11377-87. 
MO, C., SUEN, J., SOMMER, M. & ARVIN, A. (1999) Characterization of Varicella-Zoster virus 
glycoprotein K (open reading frame 5) and its role in virus growth. Journal of Virology, 73, 
4197-207. 
MOFFAT, J., ITO, H., SOMMER, M., TAYLOR, S. & ARVIN, A. M. (2002) Glycoprotein I of varicella-
zoster virus is required for viral replication in skin and T cells. Journal of Virology, 76, 8468-71. 
MOFFAT, J. F., KU, C.-C., ZERBONI, L., SOMMER, M. & ARVIN, A. (2007) VZV: pathogenesis and the 
disease consequences of primary infection. IN ARVIN, A., CAMPADELLI-FIUME, G., 
MOCARSKI, E., MOORE, P. S., ROIZMAN, B., WHITLEY, R. & YAMANISHI, K. (Eds.) Human 
Herpesviruses: Biology, Therapy and Immunoprophylaxis. Cambridge, Cambridge University 
Press. 
MOFFAT, J. F., STEIN, M. D., KANESHIMA, H. & ARVIN, A. M. (1995) Tropism of varicella-zoster virus 
for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. Journal of 
Virology, 69, 5236-42. 
 The University of Sydney 
- 172 - 
MOFFAT, J. F., ZERBONI, L., KINCHINGTON, P. R., GROSE, C., KANESHIMA, H. & ARVIN, A. M. 
(1998a) Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein 
C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. Journal of Virology, 72, 
965-74. 
MOFFAT, J. F., ZERBONI, L., SOMMER, M. H., HEINEMAN, T. C., COHEN, J. I., KANESHIMA, H. & 
ARVIN, A. M. (1998b) The ORF47 and ORF66 putative protein kinases of varicella-zoster virus 
determine tropism for human T cells and skin in the SCID-hu mouse. Proceedings of the 
National Academy of Sciences of the United States of America, 95, 11969-74. 
MONTALVO, E. A., PARMLEY, R. T. & GROSE, C. (1985) Structural analysis of the varicella-zoster 
virus gp98-gp62 complex: posttranslational addition of N-linked and O-linked oligosaccharide 
moieties. Journal of Virology, 53, 761-70. 
MOORE, K. L. & DALLEY, A. F. (1999) Clinically oriented anatomy, Philadelphia, Lippincott Williams & 
Wilkins. 
MORGAN, M. & NATHWANI, D. (1992) Facial palsy and infection: the unfolding story. Clinical Infectious 
Diseases, 14, 263-71. 
MORIUCHI, H., MORIUCHI, M., STRAUS, S. E. & COHEN, J. I. (1993) Varicella-zoster virus open 
reading frame 10 protein, the herpes simplex virus VP16 homolog, transactivates herpesvirus 
immediate-early gene promoters. Journal of Virology, 67, 2739-46. 
MORROW, G., SLOBEDMAN, B., CUNNINGHAM, A. L. & ABENDROTH, A. (2003) Varicella-zoster 
virus productively infects mature dendritic cells and alters their immune function. Journal of 
Virology, 77, 4950-9. 
MUELLER, M., WACKER, K., RINGELSTEIN, E. B., HICKEY, W. F., IMAI, Y. & KIEFER, R. (2001) 
Rapid response of identified resident endoneurial macrophages to nerve injury. American 
Journal of Pathology, 159, 2187-97. 
MUELLER, N. H., GILDEN, D. H., COHRS, R. J., MAHALINGAM, R. & NAGEL, M. A. (2008) Varicella 
zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. 
Neurologic Clinics, 26, 675-97. 
MURAKAMI, S., HONDA, N., MIZOBUCHI, M., NAKASHIRO, Y., HATO, N. & GYO, K. (1998) Rapid 
diagnosis of varicella zoster virus infection in acute facial palsy. Neurology, 51, 1202-5. 
MURAKI, R., IWASAKI, T., SATA, T., SATO, Y. & KURATA, T. (1996) Hair follicle involvement in herpes 
zoster: pathway of viral spread from ganglia to skin. Virchows Archiv, 428, 275-80. 
MURATA, K.-Y., MIWA, H. & KONDO, T. (2010) Polyneuritis cranialis caused by varicella zoster virus in 
the absence of rash. Neurology, 74, 85-6. 
NAGEL, M. A., CHOE, A., TRAKTINSKIY, I., CORDERY-COTTER, R., GILDEN, D. & COHRS, R. J. 
(2011) Varicella-zoster virus transcriptome in latently infected human ganglia. Journal of 
Virology, 85, 2276-87. 
NAGEL, M. A., GILDEN, D., SHADE, T., GAO, B. & COHRS, R. J. (2009) Rapid and sensitive detection 
of 68 unique varicella zoster virus gene transcripts in five multiplex reverse transcription-
polymerase chain reactions. Journal of Virological Methods, 157, 62-8. 
NAJAFZADEH, M., MARRA, C. A., GALANIS, E. & PATRICK, D. M. (2009) Cost effectiveness of 
herpes zoster vaccine in Canada. Pharmacoeconomics, 27, 991-1004. 
NARAYAN, R. (2009) Biomedical Materials, Chapel Hill, Springer. 
 The University of Sydney 
- 173 - 
NCBI (2013) TIA1 - cytotoxic granule-associated RNA binding protein [ Homo sapiens (human) ]. 
NESTLE, F. O., DI MEGLIO, P., QIN, J.-Z. & NICKOLOFF, B. J. (2009) Skin immune sentinels in health 
and disease. Nature Reviews, Immunology. 9, 679-91. 
NIKKELS, A. F., DEBRUS, S., SADZOT-DELVAUX, C., PIETTE, J., DELVENNE, P., RENTIER, B. & 
PIERARD, G. E. (1993) Comparative immunohistochemical study of herpes simplex and 
varicella-zoster infections. Virchows Archiv - A, Pathological Anatomy & Histopathology, 422, 
121-6. 
NIKKELS, A. F., DEBRUS, S., SADZOT-DELVAUX, C., PIETTE, J., RENTIER, B. & PIERARD, G. E. 
(1995a) Immunohistochemical identification of varicella-zoster virus gene 63-encoded protein 
(IE63) and late (gE) protein on smears and cutaneous biopsies: implications for diagnostic use. 
Journal of Medical Virology, 47, 342-7. 
NIKKELS, A. F., DEBRUS, S., SADZOT-DELVAUX, C., PIETTE, J., RENTIER, B. & PIERARD, G. E. 
(1995b) Localization of varicella-zoster virus nucleic acids and proteins in human skin. 
Neurology, 45, S47-9. 
NIKKELS, A. F., SADZOT-DELVAUX, C. & PIERARD, G. E. (2004) Absence of intercellular adhesion 
molecule 1 expression in varicella zoster virus-infected keratinocytes during herpes zoster: 
another immune evasion strategy? American Journal of Dermatopathology, 26, 27-32. 
OAKLANDER, A. L. (2008) Mechanisms of Pain and Itch Caused by Herpes Zoster (Shingles). Journal 
of Pain, 9, 10-18. 
OAKLANDER, A. L., BOWSHER, D., GALER, B., HAANPAA, M. & JENSEN, M. P. (2003) Herpes 
zoster itch: preliminary epidemiologic data. Journal of Pain, 4, 338-43. 
OAKLANDER, A. L., COHEN, S. P. & RAJU, S. V. Y. (2002) Intractable postherpetic itch and cutaneous 
deafferentation after facial shingles. Pain, 96, 9-12. 
OAKLANDER, A. L., ROMANS, K., HORASEK, S., STOCKS, A., HAUER, P. & MEYER, R. A. (1998) 
Unilateral postherpetic neuralgia is associated with bilateral sensory neuron damage. Annals of 
Neurology, 44, 789-95. 
OOI, P. L., GOH, K. T., DORAISINGHAM, S. & LING, A. E. (1992) Prevalence of varicella-zoster virus 
infection in Singapore. Southeast Asian Journal of Tropical Medicine & Public Health, 23, 22-5. 
OXMAN, M. N. (2000) Clinical Manifestations of herpes zoster. IN ARVIN, A. M. & GERSHON, A. A. 
(Eds.) Varicella Zoster Virus Virology and Clinical Management. Cambridge, Cambridge 
University Press. 
OXMAN, M. N. (2009) Herpes zoster pathogenesis and cell-mediated immunity and 
immunosenescence. Journal of the American Osteopathic Association, 109, S13-7. 
OXMAN, M. N., LEVIN, M. J., JOHNSON, G. R., SCHMADER, K. E., STRAUS, S. E., GELB, L. D., 
ARBEIT, R. D., SIMBERKOFF, M. S., GERSHON, A. A., DAVIS, L. E., WEINBERG, A., 
BOARDMAN, K. D., WILLIAMS, H. M., ZHANG, J. H., PEDUZZI, P. N., BEISEL, C. E., 
MORRISON, V. A., GUATELLI, J. C., BROOKS, P. A., KAUFFMAN, C. A., PACHUCKI, C. T., 
NEUZIL, K. M., BETTS, R. F., WRIGHT, P. F., GRIFFIN, M. R., BRUNELL, P., SOTO, N. E., 
MARQUES, A. R., KEAY, S. K., GOODMAN, R. P., COTTON, D. J., GNANN, J. W., JR., 
LOUTIT, J., HOLODNIY, M., KEITEL, W. A., CRAWFORD, G. E., YEH, S. S., LOBO, Z., 
TONEY, J. F., GREENBERG, R. N., KELLER, P. M., HARBECKE, R., HAYWARD, A. R., 
IRWIN, M. R., KYRIAKIDES, T. C., CHAN, C. Y., CHAN, I. S. F., WANG, W. W. B., 
ANNUNZIATO, P. W., SILBER, J. L. & SHINGLES PREVENTION STUDY, G. (2005) A 
vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England 
Journal of Medicine, 352, 2271-84. 
 The University of Sydney 
- 174 - 
OZAKI, T., KAJITA, Y., NAMAZUE, J. & YAMANISHI, K. (1996) Isolation of varicella-zoster virus from 
vesicles in children with varicella. Journal of Medical Virology, 48, 326-8. 
PAPPAGALLO, M., OAKLANDER, A. L., QUATRANO-PIACENTINI, A. L., CLARK, M. R. & RAJA, S. N. 
(2000) Heterogenous patterns of sensory dysfunction in postherpetic neuralgia suggest 
multiple pathophysiologic mechanisms. Anesthesiology, 92, 691-8. 
PASIEKA, T. J., MARESOVA, L., SHIRAKI, K. & GROSE, C. (2004) Regulation of varicella-zoster virus-
induced cell-to-cell fusion by the endocytosis-competent glycoproteins gH and gE. Journal of 
Virology, 78, 2884-96. 
PELLETT, P. E. & ROIZMAN, B. (2007) Herpesviridae. IN KNIPE, D. M. & HOWLEY, P. (Eds.) Fields 
Virology. Philadelphia, Lippincott Williams & Wilkins. 
PEREIRA, R. A., TSCHARKE, D. C. & SIMMONS, A. (1994) Upregulation of class I major 
histocompatibility complex gene expression in primary sensory neurons, satellite cells, and 
Schwann cells of mice in response to acute but not latent herpes simplex virus infection in vivo. 
Journal of Experimental Medicine, 180, 841-50. 
PERRIN, F. E., LACROIX, S., AVIL√©S-TRIGUEROS, M. & DAVID, S. (2005) Involvement of monocyte 
chemoattractant protein-1, macrophage inflammatory protein-1 alpha and interleukin-1 beta in 
Wallerian degeneration. Brain, 128, 854-866. 
PETERSEN, K. L., RICE, F. L., FARHADI, M., REDA, H. & ROWBOTHAM, M. C. (2010) Natural history 
of cutaneous innervation following herpes zoster. Pain, 150, 75-82. 
PETERSEN, K. L., RICE, F. L., SUESS, F., BERRO, M. & ROWBOTHAM, M. C. (2002) Relief of post-
herpetic neuralgia by surgical removal of painful skin. Pain, 98, 119-26. 
PETERSEN, K. L. & ROWBOTHAM, M. C. (2007) Relief of post-herpetic neuralgia by surgical removal 
of painful skin: 5 years later. Pain, 131, 214-8. 
PETURSSON, G., HELGASON, S., GUDMUNDSSON, S. & SIGURDSSON, J. A. (1998) Herpes zoster 
in children and adolescents. Pediatric Infectious Disease, 17, 905-8. 
PIERSON, D. L., MEHTA, S. K., GILDEN, D., COHRS, R. J., NAGEL, M. A., SCHMID, D. S. & TYRING, 
S. K. (2011) Varicella zoster virus DNA at inoculation sites and in saliva after Zostavax 
immunization. Journal of Infectious Diseases, 203, 1542-5. 
POULIN, L. F., HENRI, S., DE BOVIS, B., DEVILARD, E., KISSENPFENNIG, A. & MALISSEN, B. 
(2007) The dermis contains langerin+ dendritic cells that develop and function independently of 
epidermal Langerhans cells. Journal of Experimental Medicine, 204, 3119-31. 
QUAN, D., HAMMACK, B. N., KITTELSON, J. & GILDEN, D. H. (2006) Improvement of postherpetic 
neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir. Archives of 
Neurology, 63, 940-2. 
QUINLIVAN, M., AYRES, K., RAN, H., MCELWAINE, S., LEEDHAM-GREEN, M., SCOTT, F. T., 
JOHNSON, R. & BREUER, J. (2007) Effect of Viral Load on the Outcome of Herpes Zoster. 
Journal of Clinical Microbiology, 45, 3909-14. 
QUINLIVAN, M., BREUER, J. & SCHMID, D. S. (2011) Molecular studies of the Oka varicella vaccine. 
Expert Review of Vaccines, 10, 1321-36. 
QUINLIVAN, M., HAWRAMI, K., BARRETT-MUIR, W., AABY, P., ARVIN, A., CHOW, V. T., JOHN, T. 
J., MATONDO, P., PEIRIS, M., POULSEN, A., SIQUEIRA, M., TAKAHASHI, M., TALUKDER, 
Y., YAMANISHI, K., LEEDHAM-GREEN, M., SCOTT, F. T., THOMAS, S. L. & BREUER, J. 
(2002) The molecular epidemiology of varicella-zoster virus: evidence for geographic 
segregation. Journal of Infectious Diseases, 186, 888-94. 
 The University of Sydney 
- 175 - 
QUINLIVAN, M. L., AYRES, K. L., KELLY, P. J., PARKER, S. P., SCOTT, F. T., JOHNSON, R. W., 
MAPLE, C. & BREUER, J. (2010) Persistence of varicella-zoster virus viraemia in patients with 
herpes zoster. Journal of Clinical Virology, In Press, Corrected Proof. 
RAGOZZINO, M. W., MELTON, L. J., 3RD, KURLAND, L. T., CHU, C. P. & PERRY, H. O. (1982) 
Population-based study of herpes zoster and its sequelae. Medicine, 61, 310-6. 
RAMON Y CAJAL, S. (1959) Degeneration & Regeneration of the Nervous System, New York, Hafner 
Pub. Co. 
RAPPOCCIOLO, G., PIAZZA, P., FULLER, C. L., REINHART, T. A., WATKINS, S. C., ROWE, D. T., 
JAIS, M., GUPTA, P. & RINALDO, C. R. (2006) DC-SIGN on B lymphocytes is required for 
transmission of HIV-1 to T lymphocytes. PLoS Pathogens, 2, e70. 
REDWINE, J. M., BUCHMEIER, M. J. & EVANS, C. F. (2001) In vivo expression of major 
histocompatibility complex molecules on oligodendrocytes and neurons during viral infection. 
American Journal of Pathology, 159, 1219-24. 
REES, J. L. (2004) The genetics of sun sensitivity in humans. American Journal of Human Genetics, 75, 
739-51. 
REICHELT, M., BRADY, J. & ARVIN, A. M. (2009) The replication cycle of varicella-zoster virus: 
analysis of the kinetics of viral protein expression, genome synthesis, and virion assembly at 
the single-cell level. Journal of Virology, 83, 3904-18. 
RICE, A. S., MATON, S. & POSTHERPETIC NEURALGIA STUDY, G. (2001) Gabapentin in 
postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain, 94, 215-24. 
RICKINSON, A. B. & MOSS, D. J. (1997) Human cytotoxic T lymphocyte responses to Epstein-Barr 
virus infection. Annual Review of Immunology, 15, 405-31. 
RODRIGUEZ, J. E., MONINGER, T. & GROSE, C. (1993) Entry and egress of varicella virus blocked by 
same anti-gH monoclonal antibody. Virology, 196, 840-4. 
RODRIGUEZ, M. (2010) (Personal communication). IN ABENDROTH, A. (Ed.) Sydney. 
ROIZMAN, B. (1979) The structure and isomerization of herpes simplex virus genomes. Cell, 16, 481-
94. 
ROIZMAN, B. & BAINES, J. (1991) The diversity and unity of Herpesviridae. Comparative Immunology, 
Microbiology & Infectious Diseases, 14, 63-79. 
ROMANI, N., CLAUSEN, B. E. & STOITZNER, P. (2010) Langerhans cells and more: langerin-
expressing dendritic cell subsets in the skin. Immunological Reviews, 234, 120-41. 
ROSENFELD, J., TAYLOR, C. L. & ATLAS, S. W. (1993) Myelitis following chickenpox: a case report. 
Neurology, 43, 1834-6. 
ROSS, M. H. & PAWLINA, W. (2003) Histology; a text and atlas, Philadelphia, Lippincott Williams & 
Wilkins. 
ROWBOTHAM, M., HARDEN, N., STACEY, B., BERNSTEIN, P. & MAGNUS-MILLER, L. (1998) 
Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA, 
280, 1837-42. 
ROWBOTHAM, M. C., YOSIPOVITCH, G., CONNOLLY, M. K., FINLAY, D., FORDE, G. & FIELDS, H. 
L. (1996) Cutaneous innervation density in the allodynic form of postherpetic neuralgia. 
Neurobiology of Disease, 3, 205-14. 
 The University of Sydney 
- 176 - 
SABATOWSKI, R., GALVEZ, R., CHERRY, D. A., JACQUOT, F., VINCENT, E., MAISONOBE, P., 
VERSAVEL, M. & STUDY, G. (2004) Pregabalin reduces pain and improves sleep and mood 
disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-
controlled clinical trial. Pain, 109, 26-35. 
SADAOKA, T., YANAGI, T., YAMANISHI, K. & MORI, Y. (2010) Characterization of the varicella-zoster 
virus ORF50 gene, which encodes glycoprotein M. Journal of Virology, 84, 3488-502. 
SALAZAR, R., RUSSMAN, A. N., NAGEL, M. A., COHRS, R. J., MAHALINGAM, R., SCHMID, D. S., 
KLEINSCHMIDT-DEMASTERS, B. K., VANEGMOND, E. M. & GILDEN, D. (2011) Varicella 
zoster virus ischemic optic neuropathy and subclinical temporal artery involvement. Archives of 
Neurology, 68, 517-20. 
SANTOS, R. A., HATFIELD, C. C., COLE, N. L., PADILLA, J. A., MOFFAT, J. F., ARVIN, A. M., 
RUYECHAN, W. T., HAY, J. & GROSE, C. (2000) Varicella-zoster virus gE escape mutant 
VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures 
and SCID-hu mice. Virology, 275, 306-17. 
SANTOS, R. A., PADILLA, J. A., HATFIELD, C. & GROSE, C. (1998) Antigenic variation of varicella 
zoster virus Fc receptor gE: loss of a major B cell epitope in the ectodomain. Virology, 249, 21-
31. 
SATO, B., ITO, H., HINCHLIFFE, S., SOMMER, M. H., ZERBONI, L. & ARVIN, A. M. (2003a) 
Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus 
immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin 
xenografts in the SCID-hu mouse in vivo. Journal of Virology, 77, 5607-20. 
SATO, B., SOMMER, M., ITO, H. & ARVIN, A. M. (2003b) Requirement of varicella-zoster virus 
immediate-early 4 protein for viral replication. Journal of Virology, 77, 12369-72. 
SATO, H., PESNICAK, L. & COHEN, J. I. (2003c) Varicella-zoster virus ORF47 protein kinase, which is 
required for replication in human T cells, and ORF66 protein kinase, which is expressed during 
latency, are dispensable for establishment of latency. Journal of Virology, 77, 11180-5. 
SCHAAP, A., FORTIN, J.-F., SOMMER, M., ZERBONI, L., STAMATIS, S., KU, C.-C., NOLAN, G. P. & 
ARVIN, A. M. (2005) T-cell tropism and the role of ORF66 protein in pathogenesis of varicella-
zoster virus infection. Journal of Virology, 79, 12921-33. 
SCHMADER, K. (2007) Herpes zoster and postherpetic neuralgia in older adults. Clinics in Geriatric 
Medicine, 23, 615-32. 
SCHON, F., MAYER, M. L. & KELLY, J. S. (1987) Pathogenesis of post-herpetic neuralgia. Lancet, 2, 
366-8. 
SEMIONOV, V. & SHVARTZMAN, P. (2008) Post herpetic itching--a treatment dilemma. Clinical Journal 
of Pain, 24, 366-8. 
SEN, N., SOMMER, M., CHE, X., WHITE, K., RUYECHAN, W. T. & ARVIN, A. M. (2010) Varicella-
zoster virus immediate-early protein 62 blocks interferon regulatory factor 3 (IRF3) 
phosphorylation at key serine residues: a novel mechanism of IRF3 inhibition among 
herpesviruses. Journal of Virology, 84, 9240-53. 
SHIRAKI, K., DAIKOKU, T., TAKEMOTO, M., YOSHIDA, Y., SUZUKI, K., AKAHORI, Y., OKUNO, T., 
KUROSAWA, Y. & ASANO, Y. (2011) Neutralizing Anti-gH Antibody of Varicella-Zoster Virus 
Modulates Distribution of gH and Induces Gene Regulation, Mimicking Latency. Journal of 
Virology, 85, 8172-8180. 
 The University of Sydney 
- 177 - 
SHUBAYEV, V. I., ANGERT, M., DOLKAS, J., CAMPANA, W. M., PALENSCAR, K. & MYERS, R. R. 
(2006) TNF-alpha-induced MMP-9 promotes macrophage recruitment into injured peripheral 
nerve. Molecular and Cellular Neuroscience, 31, 407-415. 
SIEGAL, F. P., KADOWAKI, N., SHODELL, M., FITZGERALD-BOCARSLY, P. A., SHAH, K., HO, S., 
ANTONENKO, S. & LIU, Y. J. (1999) The nature of the principal type 1 interferon-producing 
cells in human blood. Science, 284, 1835-7. 
SILVERSTEIN, S. J. & STRAUS, S. (2000) Pathogenesis of latency and reactivation. IN ARVIN, A. M. & 
GERSHON, A. A. (Eds.) Varicella Zoster Virus Virology and Clinical Management. Cambridge, 
Cambridge University Press. 
SINDRUP, S. H. & JENSEN, T. S. (1999) Efficacy of pharmacological treatments of neuropathic pain: 
an update and effect related to mechanism of drug action. Pain, 83, 389-400. 
SLOAN, E., HENRIQUEZ, R., KINCHINGTON, P. R., SLOBEDMAN, B. & ABENDROTH, A. (2012) 
Varicella-zoster virus inhibition of the NF-kB pathway during infection of human dendritic cells: 
role for open reading frame 61 as a modulator of NF-kB activity. Journal of Virology, 86, 1193-
202. 
SLOBEDMAN, B., CAO, J. Z., AVDIC, S., WEBSTER, B., MCALLERY, S., CHEUNG, A. K., TAN, J. C. 
& ABENDROTH, A. (2010) Human cytomegalovirus latent infection and associated viral gene 
expression. Future Microbiology, 5, 883-900. 
SMITH, F. P. (1978) Pathological studies of spinal nerve ganglia in relation to intractable intercostal 
pain. Surgical Neurology, 10, 50-3. 
SMITH, G. A., GROSS, S. P. & ENQUIST, L. W. (2001) Herpesviruses use bidirectional fast-axonal 
transport to spread in sensory neurons Proceedings of the National Academy of Sciences of 
the United States of America, 98, 3466-70. 
SMITH, J. S. & ROBINSON, N. J. (2002) Age-specific prevalence of infection with herpes simplex virus 
types 2 and 1: a global review. Journal of Infectious Diseases, 186 Suppl 1, S3-28. 
SMITH, R. F. & SMITH, T. F. (1989) Identification of new protein kinase-related genes in three 
herpesviruses, herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus. Journal of 
Virology, 63, 450-5. 
SOMMER, M. H., ZAGHA, E., SERRANO, O. K., KU, C. C., ZERBONI, L., BAIKER, A., SANTOS, R., 
SPENGLER, M., LYNCH, J., GROSE, C., RUYECHAN, W., HAY, J. & ARVIN, A. M. (2001) 
Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 
69, of varicella-zoster virus. Journal of Virology, 75, 8224-39. 
SOTIRIOU, E., APALLA, Z., PANAGIOTIDOU, D. & IOANNIDIS, D. (2009) Severe post-herpetic 
neuralgia successfully treated with botulinum toxin A: three case reports. Acta Dermato-
Venereologica, 89, 214-5. 
SOUSHI, S., OZAWA, H., MATSUHASHI, M., SHIMAZAKI, J., SAGA, U. & KURATA, T. (1988) 
Demonstration of varicella-zoster virus antigens in the vitreous aspirates of patients with acute 
retinal necrosis syndrome. Ophthalmology, 95, 1394-8. 
SPECK, S. H. & GANEM, D. (2010) Viral latency and its regulation: lessons from the gamma-
herpesviruses. Cell Host & Microbe, 8, 100-15. 
STACEY, B. R., DWORKIN, R. H., MURPHY, K., SHARMA, U., EMIR, B. & GRIESING, T. (2008) 
Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label 
trial. Pain Medicine, 9, 1202-8. 
STEAIN, M. & SUTHERLAND, J. (2013) Unpublished data. Sydney, The University of Sydney. 
 The University of Sydney 
- 178 - 
STEAIN, M., SUTHERLAND, J. P., RODRIGUEZ, M., CUNNINGHAM, A. L., SLOBEDMAN, B. & 
ABENDROTH, A. (2013) The Immune Response to Herpes Zoster in Human Ganglia: 
Evidence for Cytolytic CD8 T Lymphocyte Infiltration During Active Herpes Zoster. (in press). 
STEINER, I., KENNEDY, P. G. E. & PACHNER, A. R. (2007) The neurotropic herpes viruses: herpes 
simplex and varicella-zoster. Lancet Neurology, 6, 1015-28. 
STEVENSON, D., COLMAN, K. L. & DAVISON, A. J. (1994) Characterization of the putative protein 
kinases specified by varicella-zoster virus genes 47 and 66. Journal of General Virology, 75, 
317-26. 
STORLIE, J., CARPENTER, J. E., JACKSON, W. & GROSE, C. (2008a) Discordant varicella-zoster 
virus glycoprotein C expression and localization between cultured cells and human skin 
vesicles. Virology, 382, 171-81. 
STORLIE, J., MARESOVA, L., JACKSON, W. & GROSE, C. (2008b) Comparative analyses of the 9 
glycoprotein genes found in wild-type and vaccine strains of varicella-zoster virus. Journal of 
Infectious Diseases, 197 Suppl 2, S49-53. 
STOW, N. D., WEIR, H. M. & STOW, E. C. (1990) Analysis of the binding sites for the varicella-zoster 
virus gene 51 product within the viral origin of DNA replication. Virology, 177, 570-7. 
STRANGFELD, A., LISTING, J., HERZER, P., LIEBHABER, A., ROCKWITZ, K., RICHTER, C. & ZINK, 
A. (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha 
agents. JAMA, 301, 737-44. 
SUMIYAMA, D., KIKKAWA, E. F., KITA, Y. F., SHINAGAWA, H., MABUCHI, T., OZAWA, A. & INOKO, 
H. (2008) HLA alleles are associated with postherpetic neuralgia but not with herpes zoster. 
Tokai Journal of Experimental & Clinical Medicine, 33, 150-3. 
SUTHERLAND, J. P. (2008) Immune infiltration and viral antigen detection in human ganglia during 
post-herpetic neuralgia. Infectious Diseases and Immunology. Sydney, University of Sydney. 
TAKAHASHI, M., ASANO, Y., KAMIYA, H., BABA, K., OZAKI, T., OTSUKA, T. & YAMANISHI, K. (2008) 
Development of varicella vaccine. Journal of Infectious Diseases, 197 Suppl 2, S41-4. 
TAKAHASHI, M., OKUNO, Y., OTSUKA, T., OSAME, J. & TAKAMIZAWA, A. (1975) Development of a 
live attenuated varicella vaccine. Biken Journal, 18, 25-33. 
TAKAYAMA, M., TAKAYAMA, N., KAMEOKA, Y., HACHIMORI, K., KANEDA, K. & MINAMITANI, M. 
(1989) Comparative restriction endonuclease analysis of varicella-zoster virus clinical isolates. 
Medical Microbiology & Immunology, 178, 61-7. 
TAKAYAMA, N., YAMADA, H., KAKU, H. & MINAMITANI, M. (2000) Herpes zoster in 
immunocompetent and immunocompromised Japanese children. Pediatrics International, 42, 
275-9. 
TAN, J. C. H., BYLES, D., STANFORD, M. R., FRITH, P. A. & GRAHAM, E. M. (2001) Acute retinal 
necrosis in children caused by herpes simplex virus. Retina, 21, 344-7. 
TAYLOR, S. L. & MOFFAT, J. F. (2005) Replication of varicella-zoster virus in human skin organ 
culture. Journal of Virology, 79, 11501-6. 
TERADA, K., NIIZUMA, T., KAWANO, S., KATAOKA, N., AKISADA, T. & ORITA, Y. (1998) Detection of 
varicella-zoster virus DNA in peripheral mononuclear cells from patients with Ramsay Hunt 
syndrome or zoster sine herpete. Journal of Medical Virology, 56, 359-63. 
 The University of Sydney 
- 179 - 
THACKER, M. A., CLARK, A. K., MARCHAND, F. & MCMAHON, S. B. (2007) Pathophysiology of 
peripheral neuropathic pain: immune cells and molecules. Anesthesia & Analgesia, 105, 838-
47. 
THEIL, D., DERFUSS, T., PARIPOVIC, I., HERBERGER, S., MEINL, E., SCHUELER, O., STRUPP, M., 
ARBUSOW, V. & BRANDT, T. (2003) Latent herpesvirus infection in human trigeminal ganglia 
causes chronic immune response. American Journal of Pathology, 163, 2179-84. 
THOMPSON, W. S., CULBERTSON, W. W., SMIDDY, W. E., ROBERTSON, J. E. & ROSENBAUM, J. 
T. (1994) Acute retinal necrosis caused by reactivation of herpes simplex virus type 2. 
American Journal of Ophthalmology, 118, 205-11. 
THYREGOD, H. G., ROWBOTHAM, M. C., PETERS, M., POSSEHN, J., BERRO, M. & PETERSEN, K. 
L. (2007) Natural history of pain following herpes zoster. Pain, 128, 148-56. 
TIPPLES, G. A., STEPHENS, G. M., SHERLOCK, C., BOWLER, M., HOY, B., COOK, D. & GROSE, C. 
(2002) New variant of varicella-zoster virus. Emerging Infectious Diseases, 8, 1504-5. 
TOBIN, D. J. (2006) Biochemistry of human skin--our brain on the outside. Chemical Society Reviews, 
35, 52-67. 
TSENG, H. F., SMITH, N., MARCY, S. M., SY, L. S., CHAO, C. R. & JACOBSEN, S. J. (2010) Risk 
factors of herpes zoster among children immunized with varicella vaccine: results from a 
nested case-control study. Pediatric Infectious Disease, 29, 205-8. 
UMBACH, J. L., NAGEL, M. A., COHRS, R. J., GILDEN, D. H. & CULLEN, B. R. (2009) Analysis of 
human alphaherpesvirus microRNA expression in latently infected human trigeminal ganglia. 
Journal of Virology, 83, 10677-83. 
VAFAI, A., WELLISH, M. & GILDEN, D. H. (1988) Expression of varicella-zoster virus in blood 
mononuclear cells of patients with postherpetic neuralgia. Proceedings of the National 
Academy of Sciences of the United States of America, 85, 2767-70. 
VAFAI, A., WROBLEWSKA, Z. & GRAF, L. (1990) Antigenic cross-reaction between a varicella-zoster 
virus nucleocapsid protein encoded by gene 40 and a herpes simplex virus nucleocapsid 
protein. Virus Research, 15, 163-74. 
VAFAI, A., WROBLEWSKA, Z., WELLISH, M., GREEN, M. & GILDEN, D. (1984) Analysis of three late 
varicella-zoster virus proteins, a 125,000-molecular-weight protein and gp1 and gp3. Journal of 
Virology, 52, 953-9. 
VALASKATGIS, P., MACKLIN, E. A., SCHACHTER, S. C. & WAYNE, P. M. (2008) Possible effects of 
acupuncture on atrial fibrillation and post-herpetic neuralgia--a case report. Acupuncture in 
Medicine, 26, 51-6. 
VALLADEAU, J. & SAELAND, S. (2005) Cutaneous dendritic cells. . Seminars in Immunology, 17, 273-
83. 
VALLEJO, R., TILLEY, D. M., VOGEL, L. & BENYAMIN, R. (2010) The role of glia and the immune 
system in the development and maintenance of neuropathic pain. Pain Practice, 10, 167-84. 
VAN VELZEN, M., LAMAN, J. D., KLEINJAN, A., POOT, A., OSTERHAUS, A. D. M. E. & VERJANS, G. 
M. G. M. (2009) Neuron-interacting satellite glial cells in human trigeminal ganglia have an 
APC phenotype. Journal of Immunology, 183, 2456-61. 
VANDEVENNE, P., LEBRUN, M., EL MJIYAD, N., OTE, I., DI VALENTIN, E., HABRAKEN, Y., DORTU, 
E., PIETTE, J. & SADZOT-DELVAUX, C. (2011) The varicella-zoster virus ORF47 kinase 
interferes with host innate immune response by inhibiting the activation of IRF3. PLoS ONE, 6, 
e16870. 
 The University of Sydney 
- 180 - 
VERJANS, G. M. G. M., HINTZEN, R. Q., VAN DUN, J. M., POOT, A., MILIKAN, J. C., LAMAN, J. D., 
LANGERAK, A. W., KINCHINGTON, P. R. & OSTERHAUS, A. D. M. E. (2007) Selective 
retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. 
Proceedings of the National Academy of Sciences of the United States of America, 104, 3496-
501. 
VLECK, S. E., OLIVER, S. L., BRADY, J. J., BLAU, H. M., RAJAMANI, J., SOMMER, M. H. & ARVIN, A. 
M. (2011) Structure-function analysis of varicella-zoster virus glycoprotein H identifies domain-
specific roles for fusion and skin tropism. Proceedings of the National Academy of Sciences of 
the United States of America, 108, 18412-7. 
VLECK, S. E., OLIVER, S. L., REICHELT, M., RAJAMANI, J., ZERBONI, L., JONES, C., ZEHNDER, J., 
GROSE, C. & ARVIN, A. M. (2010) Anti-glycoprotein H antibody impairs the pathogenicity of 
varicella-zoster virus in skin xenografts in the SCID mouse model. Journal of Virology, 84, 141-
52. 
VOLMINK, J., LANCASTER, T., GRAY, S. & SILAGY, C. (1996) Treatments for postherpetic neuralgia--
a systematic review of randomized controlled trials. Family Practice, 13, 84-91. 
VOSSEN, M. T. M., GENT, M.-R., WEEL, J. F. L., DE JONG, M. D., VAN LIER, R. A. W. & KUIJPERS, 
T. W. (2004) Development of virus-specific CD4+ T cells on reexposure to Varicella-Zoster 
virus. Journal of Infectious Diseases, 190, 72-82. 
WANG, K., LAU, T. Y., MORALES, M., MONT, E. K. & STRAUS, S. E. (2005) Laser-capture 
microdissection: refining estimates of the quantity and distribution of latent herpes simplex 
virus 1 and varicella-zoster virus DNA in human trigeminal Ganglia at the single-cell level. 
Journal of Virology, 79, 14079-87. 
WANG, Z. H., GERSHON, M. D., LUNGU, O., ZHU, Z., MALLORY, S., ARVIN, A. M. & GERSHON, A. 
A. (2001) Essential role played by the C-terminal domain of glycoprotein I in envelopment of 
varicella-zoster virus in the trans-Golgi network: interactions of glycoproteins with tegument. 
Journal of Virology, 75, 323-40. 
WATSON, C. P. (1995) The treatment of postherpetic neuralgia. Neurology, 45, S58-60. 
WATSON, C. P. (1998) Postherpetic neuralgia: the importance of preventing this intractable end-stage 
disorder. Journal of Infectious Diseases, 178 Suppl 1, S91-4. 
WATSON, C. P., DECK, J. H., MORSHEAD, C., VAN DER KOOY, D. & EVANS, R. J. (1991) Post-
herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain, 44, 105-
17. 
WATSON, C. P., EVANS, R. J., WATT, V. R. & BIRKETT, N. (1988a) Post-herpetic neuralgia: 208 
cases. Pain, 35, 289-97. 
WATSON, C. P., MORSHEAD, C., VAN DER KOOY, D., DECK, J. & EVANS, R. J. (1988b) Post-
herpetic neuralgia: post-mortem analysis of a case. Pain, 34, 129-38. 
WEAVER, B. A. (2007) The burden of herpes zoster and postherpetic neuralgia in the United States. 
Journal of the American Osteopathic Association, 107, S2-7. 
WELLER, T. H. (1953) Serial propagation in vitro of agents producing inclusion bodies derived from 
varicella and herpes zoster. Proceedings of the Society for Experimental Biology & Medicine, 
83, 340-6. 
WHARTON, M. (1996) The epidemiology of varicella-zoster virus infections. Infectious Disease Clinics 
of North America, 10, 571-81. 
 The University of Sydney 
- 181 - 
WHITE, F. A., JUNG, H. & MILLER, R. J. (2007) Chemokines and the pathophysiology of neuropathic 
pain. Proceedings of the National Academy of Sciences of the United States of America, 104, 
20151-8. Epub 2007 Dec 14. 
WILSON, A., SHARP, M., KOROPCHAK, C. M., TING, S. F. & ARVIN, A. M. (1992) Subclinical 
varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster 
viral antigens after bone marrow transplantation. Journal of Infectious Diseases, 165, 119-26. 
WU, C. L., MARSH, A. & DWORKIN, R. H. (2000) The role of sympathetic nerve blocks in herpes zoster 
and postherpetic neuralgia. Pain, 87, 121-9. 
WU, C. L. & RAJA, S. N. (2008) An Update on the Treatment of Postherpetic Neuralgia. Journal of Pain, 
9, 19-30. 
WU, J. J., HUANG, D. B. & TYRING, S. K. (2006) Postherpetic poliosis. Archives of Dermatology, 142, 
250-1. 
YAMAGISHI, Y., SADAOKA, T., YOSHII, H., SOMBOONTHUM, P., IMAZAWA, T., NAGAIKE, K., 
OZONO, K., YAMANISHI, K. & MORI, Y. (2008) Varicella-zoster virus glycoprotein M homolog 
is glycosylated, is expressed on the viral envelope, and functions in virus cell-to-cell spread. 
Journal of Virology, 82, 795-804. 
YAWN, B. P., WOLLAN, P. C., KURLAND, M. J., ST SAUVER, J. L. & SADDIER, P. (2011) Herpes 
zoster recurrences more frequent than previously reported. Mayo Clinic Proceedings, 86, 88-
93. 
ZAK-PRELICH, M., MCKENZIE, R. C., SYSA-JEDRZEJOWSKA, A. & NORVAL, M. (2003) Local 
immune responses and systemic cytokine responses in zoster: relationship to the development 
of postherpetic neuralgia. Clinical & Experimental Immunology, 131, 318-23. 
ZERBONI, L., KU, C.-C., JONES, C. D., ZEHNDER, J. L. & ARVIN, A. M. (2005) Varicella-zoster virus 
infection of human dorsal root ganglia in vivo. Proceedings of the National Academy of 
Sciences of the United States of America, 102, 6490-5. 
ZERBONI, L., REICHELT, M., JONES, C. D., ZEHNDER, J. L., ITO, H. & ARVIN, A. M. (2007) Aberrant 
infection and persistence of varicella-zoster virus in human dorsal root ganglia in vivo in the 
absence of glycoprotein I. Proceedings of the National Academy of Sciences of the United 
States of America, 104, 14086-91. 
ZERBONI, L., SOBEL, R. A., LAI, M., TRIGLIA, R., STEAIN, M., ABENDROTH, A. & ARVIN, A. (2012) 
Apparent expression of varicella-zoster virus proteins in latency resulting from reactivity of 
murine and rabbit antibodies with human blood group A determinants in sensory neurons. 
Journal of Virology. 
ZERBONI, L., SOBEL, R. A., RAMACHANDRAN, V., RAJAMANI, J., RUYECHAN, W., ABENDROTH, 
A. & ARVIN, A. (2010) Expression of Varicella-Zoster Virus Immediate-Early Regulatory 
Protein IE63 in Neurons of Latently Infected Human Sensory Ganglia. Journal of Virology, 84, 
3421-3430. 
ZHANG, Y., COSYNS, M., LEVIN, M. J. & HAYWARD, A. R. (1994) Cytokine production in varicella 
zoster virus-stimulated limiting dilution lymphocyte cultures. Clinical & Experimental 
Immunology, 98, 128-33. 
ZHANG, Y., WHITE, C. J., LEVIN, M. & HAYWARD, A. (1995) Cytokine production in varicella-zoster 
virus-stimulated lymphocyte cultures. Neurology, 45, S38-40. 
ZHOU, L.-J., REN, W.-J., ZHONG, Y., YANG, T., WEI, X.-H., XIN, W.-J., LIU, C.-C., ZHOU, L.-H., LI, 
Y.-Y. & LIU, X.-G. (2010) Limited BDNF contributes to the failure of injury to skin afferents to 
produce a neuropathic pain condition. Pain, 148, 148-57. 
 The University of Sydney 
- 182 - 
ZHU, Z., GERSHON, M. D., AMBRON, R., GABEL, C. & GERSHON, A. A. (1995a) Infection of cells by 
varicella zoster virus: inhibition of viral entry by mannose 6-phosphate and heparin. 
Proceedings of the National Academy of Sciences of the United States of America, 92, 3546-
50. 
ZHU, Z., GERSHON, M. D., HAO, Y., AMBRON, R. T., GABEL, C. A. & GERSHON, A. A. (1995b) 
Envelopment of varicella-zoster virus: targeting of viral glycoproteins to the trans-Golgi 
network. Journal of Virology, 69, 7951-9. 
ZIN, C. S., NISSEN, L. M., SMITH, M. T., O'CALLAGHAN, J. P. & MOORE, B. J. (2008) An update on 
the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. 
CNS Drugs, 22, 417-42. 
ZOCHODNE, D. W., LEVY, D., ZWIERS, H., SUN, H., RUBIN, I., CHENG, C. & LAURITZEN, M. (1999) 
Evidence for nitric oxide and nitric oxide synthase activity in proximal stumps of transected 
peripheral nerves. Neuroscience, 91, 1515-1527. 
ZUO, Y., PERKINS, N. M., TRACEY, D. J. & GECZY, C. L. (2003) Inflammation and hyperalgesia 
induced by nerve injury in the rat: a key role of mast cells. Pain, 105, 467-79. 
 
 
  
 
Appendix 1 - Primer sensitivity testing for real-time PCR primers using 
plasmid constructs 
IE63-specic primers
Quantitation curve
Standard curve
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 Quantitation curve
Standard curve
Melt curve
 
 
gB-specic primers
gE-specic primers
Quantitation curve
Standard curve
Melt curve
 
 
 
Appendix 2
Patient 1
Patient 2
Immunofluorescent staining was performed on all samples using primary antibodies which detected  CD4+ T cells, CD8+ T cells, Langerhan cells, dermal dentritic cells and plasmacytoid dendritic cells (see 
Chapter 5). Immunofluorecent assay for using a primary antibody to detect CD3+ T cells was performed on some samples. Positive cells for each marker were counted, and the total surface of each area of tissue 
measured. Cell frequency per 100 000 um^2 was calculated,  and values ploted on the graphs shown. The column shows the median value, while the minimum and maximum counts are shown by the square and 
triangle respectively.
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